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Abstract 
 
The apicomplexan parasite Plasmodium is the causative agent of the devastating tropical 
disease, malaria. The World Health Organisation reported that in 2010 there were an 
estimated 219 million malaria cases and about 660,000 deaths. Sub-Saharan Africa is the 
worst affected, with 80% of malaria deaths and 90% of cases occurring in this area of the 
world. P. falciparum causes the most severe form of the illness and accounts for the 
majority of malaria deaths. Parasite resistance to antimalarials including the most effective 
drug, artemisinin, is becoming an increasing problem, thus research into new drug targets 
is vital. 
 
The pyruvate dehydrogenase complex (PDC) is one of the -ketoacid dehydrogenase 
complexes, which are involved in energy and amino acid metabolism. The PDC catalyses 
the transfer of the acetyl group from pyruvate to coenzyme A (CoA) to form acetyl-CoA. 
The complex comprises three enzymes; pyruvate dehydrogenase (E1), dihydrolipoamide 
acetyltransferase (E2) and dihydrolipoamide dehydrogenase (E3). E2 has a multi-domain 
structure where the C-terminal catalytic domains (CD) of several E2 subunits interact to 
form the core of the complex. This core is an icosahedral 60-mer in mammals, plants and 
Gram-positive bacteria and an octahedral 24-mer in Gram-negative bacteria. The N-
terminal part of E2 consists of the sub-unit binding domain (SBD) and 1 to 3 lipoyl-
domains (LD) creating the ‘swinging arm’ of the PDC, which facilitates substrate 
channelling. E1 (a heterotetramer) and E3 (a homodimer) bind to the SBD to form the 
functional PDC. 
 
In humans, PDC converts pyruvate to acetyl-CoA, which leads into the citric acid cycle 
located in the mitochondrion. P. falciparum PDC, however, is found only in the apicoplast 
and produces acetyl-CoA for fatty acid biosynthesis. Plasmodium PDC has recently been 
shown to be important for parasite progression from the asymptomatic liver stage to the 
symptomatic erythrocytic stage. Thus, inhibiting PDC could prevent development of 
malaria.  
 
This study focuses on the role of the PDC in P. falciparum blood stages and the 
identification and characterisation of structural and biochemical differences between 
parasite and human PDC that may be ultimately exploited for drug or vaccine 
development. 
 iii 
I have optimised the expression and purification of soluble recombinant mature-length P. 
falciparum (Pf) E2 (His-rPfE2m), truncated PfE2 consisting of the SBD and CD (His-
rPfE2bc) and mature-length apicoplast PfE3 (His-rPfaE3) to obtain mg amounts of protein 
for biochemical and structural analyses. Each of the recombinant proteins was catalytically 
active.  
 
Analytical ultracentrifugation (AUC) showed that His-rPfE2m forms the typical trimer 
building blocks required for the large E2 core formation. Sedimentation velocity (SV) 
experiments showed a main species with a sedimentation coefficient of 6.6 ± 0.1 S, which 
corresponded to a species consistent with the PfE2 trimer size observed in sedimentation 
equilibrium (SE) studies. However, no 24-mer or 60-mer core species were detected in SV 
experiments. SE analyses did show some larger molecular mass species ( 1.5 MDa), 
however, whether these represent a PfE2 core complex was inconclusive due to 
interference by aggregated protein in the sample. My conclusion from these data is that 
PfE2 may form a large core structure but that this is very unstable compared with E2 
multimers from other organisms, where the core complex is readily formed and 
maintained. Similar results were obtained from SV and SE analyses of His-rPfE2bc; only 
trimers are present.  
 
Small angle X-ray scattering (SAXS) was used to further analyse the trimer structure. The 
solution structure obtained for His-rPfE2bc revealed the linker between the SBD and the 
CD is extended and partially flexible. This conformation, which would allow SBD 
interaction with E1 and E3, is supported by cryo-electron microscopy images obtained by 
others for E2 from other organisms.  
 
AUC on His-rPfaE3 showed a main species with a sedimentation coefficient of 6.1 ± 0.1 S 
and SE analyses of the protein confirmed it to be a dimer as expected. These findings were 
further corroborated with the solution structure obtained using SAXS. 
 
Deletion of the PfE2 gene from P. falciparum was unsuccessful, as the correct gene locus 
was not targeted. This could be due to the gene being required for parasite survival in the 
blood stages. However, it could also be due to the difficulty of P. falciparum gene 
manipulation and hence, further attempts to delete PfE2 using different approaches will be 
required. The PfaE3 gene was successfully deleted, thus as shown in previous studies with 
murine malaria species, the gene is not essential in the human malaria parasite, P. 
falciparum. The PfaE3 deletion mutants did not show increased susceptibility to oxidative 
 iv 
stressors compared with the wild type strain, suggesting that PfaE3 does not play a role in 
defence against oxidative stress. However, the mutants were less susceptible to triclosan, 
an inhibitor of the fatty acid biosynthesis enzyme FabI. In addition, the mutant parasites 
maintained synchronicity over more than four replication cycles as opposed to WT 
parasites, which gradually lost synchronicity over this period of in vitro culture. Further 
work will need to be carried out to fully characterise the role of PfaE3 in P. falciparum. 
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Chapter 1  
Introduction 
 
 
1.1 The Plasmodium parasite  
 
The Plasmodium species are intracellular protozoan parasites of the phylum Apicomplexa, 
which also includes Toxoplasma, Cryptosporidium, and the important animal pathogens 
Babesia, Theileria and Eimeria (Feagin, 1994). These organisms possess an apical 
complex (hence the name Apicomplexa) comprising rhoptries, dense granules and 
micronemes, which are involved in parasite invasion into host cells and the formation of a 
parasitophorous vacuole. Another characteristic of Apicomplexa is a complex life cycle 
involving several hosts (Feagin, 1994).   
 
There are over 100 species of Plasmodium, however, of these only five can infect humans 
(Tuteja, 2007). These are Plasmodium falciparum, the causative agent of the most severe 
form of malaria and the highest number of malaria cases and deaths worldwide (WHO, 
2012). P. vivax, which is most widespread but seldom causes fatal illness (Mueller et al., 
2009) and the rarer P. ovale (Collins and Jeffery, 2005) and P. malariae (Collins and 
Jeffery, 2007). P. knowlesi, the simian parasite, has also been reported to infect humans in 
South-East Asia and has the ability to cause fatal disease (Cox-Singh et al., 2010; Cox-
Singh, 2012). Other species of interest are the bird parasites P. lophurae and P. 
gallinaceum and rodent malaria parasites P. berghei, P. yoelii, P. chabaudi and P. vinckei, 
which were used in research before in vitro culture of P. falciparum was developed in the 
1970s (Trager and Jensen, 1976). Since then, the use of bird parasites has declined, 
however, the rodent parasites are still extensively used as an in vivo disease model for 
malaria, as culture of the exo-erythrocytic liver stages of P. falciparum is still extremely 
difficult (Sherman, 2009b). Also the rodent malaria parasites are more amenable to genetic 
manipulation making them valuable tools in studying Plasmodium biology (Limenitakis 
and Soldati-Favre, 2001). 
 
Sequencing of the P. falciparum genome has taken research of the parasite into the 
postgenomic era. The genome is about 23 Mb, is organised into 14 chromosomes and has 
an unusually high A/T content of 80.6% (Gardner et al., 2002a). In addition, the parasite 
has a circular 35 kb plastidial genome (Wilson et al., 1996) and a 6 kb linear mitochondrial 
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genome (Sherman, 2009a). Around 5000 proteins are predicted to be encoded by the 
nuclear genome, 60% of which are hypothetical proteins without similarity to any known 
proteins (Gardner et al., 2002a). Protein expression is highly regulated as the expression 
patterns change frequently while the parasite progresses through the different forms in its 
life cycle (Bozdech et al., 2003). 
  
 
1.1.1 The vectors 
 
Around the turn of the 20th century Ronald Ross concluded that the mosquito was the 
vector for malaria. The conclusion was further developed by Giovanni Battista Grassi, who 
showed that it was the Anopheles mosquito that transmitted malaria (Sherman, 2005). 
There are 400 species of Anopheles mosquitoes of which ~60 are malaria vectors and of 
these about 30 are of importance to transmission (Tuteja, 2007). Anopheles gambiae is by 
far the most efficient malaria transmitter in sub-Saharan Africa (Collins and Hill, 2005). 
This is followed by A. arabiensis, which unlike A. gambiae, tolerates cooler and drier 
environments, thus extending malaria transmission further north and south and also into 
the drier seasons of the year (Collins and Hill, 2005). 
 
  
1.1.2 The life cycle 
 
The complex life cycle of Plasmodium (Figure 1-1) progresses from the sexual stages in 
female Anopheles mosquitoes to the asexual stages in the human host (Sherman, 2005). 
The two stages relevant to this study are the liver and intraerythrocytic stages.  
 
 
1.1.2.1 Liver stage 
 
Sporozoites residing in the mosquito salivary glands are injected into a human as the 
mosquito takes a blood meal. Typically about 20 sporozoites enter the human host and 
after migrating in the skin tissue for at least 30 min (Vanderberg and Frevert, 2004), they 
migrate towards the liver. Once in the sinusoid the sporozoites adhere to the endothelial 
cells, glide along the surface until they encounter hepatic macrophages called Kuppfer 
cells and traverse through these to get to hepatocytes (Frevert et al., 2005).  
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Figure 1-1. The malaria parasite life cycle. 
(A) Asexual life cycles in the human host. (B) Sexual and asexual stages in the mosquito vector. 
Sporozoites are injected into a human as the mosquito takes a blood meal. The sporozoites then 
invade hepatocytes and multiply asexually to form merozoites, which go on to infect erythrocytes. 
In the red blood cells the parasites go through another cycle of asexual replication, which consists 
of the ring, trophozoite and schizont stage and the development of merozoites. The released 
merozoites go on to infect new erythrocytes. Some merozoites undergo gametocytogenesis, to 
produce male and female gametes, which are ingested by the female mosquito. In the mosquito gut, 
the female macrogamete is fertilised by a male microgamete to form an ookinete, which migrates 
through the mosquito gut wall to form an oocyst. Asexual replication takes place in the oocyst to 
produce sporozoites. The oocyst bursts to release sporozoites, which migrate into the mosquito 
salivary glands to wait for the mosquito to take its next blood meal (Sherman, 2005). This figure 
was taken from Wirth (2002), with permission from Nature Publishing Group.   
 
 
For reasons not yet fully understood, the parasites traverse through several hepatocytes 
before invading one and initiating liver stage development (Mota et al., 2001). On 
invasion, the sporozoite forms a surrounding parasitophorous vacuole (PV) using the host 
plasma membrane, which protects the parasite from the cytoplasm of the host cell 
(Mikolajczak and Kappe, 2006). This is followed by de-differentiation of the sporozoite 
into the liver trophozoite, which takes 5-7 days in the human parasite (Mikolajczak and 
Kappe, 2006). During the intermediate growth phase, the parasite prepares to exploit the 
host cell for the following rapid growth phase, or schizogony, during which extensive 
DNA and organelle replication occurs to form merozoites (Lindner et al., 2012). In the late 
liver stages, the parasite grows larger than its host cell, the PV becomes damaged and 
degrades, which induces hepatocyte death and detachment from the surrounding tissue 
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(Sturm et al., 2006; Sturm et al., 2009). The merozoites are pushed into vacuoles called 
merosomes, which protrude from the hepatocyte into the sinusoids (Sturm et al., 2006). 
The merosomes are then passively transported in the blood to the heart and lungs, where 
the merosomes rupture and the merozoites enter the blood stream to initiate the 
erythrocytic stages of the life cycle (Baer et al., 2007).        
 
 
1.1.2.2 Intraerythrocytic stage 
 
Merozoites recognise surface receptors on erythrocytes to which the merozoite attaches 
and then re-orientates so that the apical end of the parasite is adjacent to the erythrocyte 
(Cowman and Crabb, 2006). A tight junction is formed and the parasite pushes into the 
erythrocyte while simultaneously shedding the surface coat of ligands required for invasion 
(Harris et al., 2005). In the final stage the parasite invades the erythrocyte and forms the 
PV (Cowman and Crabb, 2006). Once inside the red blood cell, asexual replication begins. 
The merozoite becomes a discoidal ring stage parasite, which grows into a highly 
metabolically active trophozoite (Bannister et al., 2000). The trophozoite grows and 
changes shape while consuming nutrients and haemoglobin from the host, resulting in 
extensive remodelling of the erythocyte (Goldberg and Cowman, 2010). The PV grows to 
be adjacent to the host plasma membrane and towards the end of the trophozoite stage (28-
31 h after P. falciparum merozoite invasion) DNA replication is initiated (Arnot and Gull, 
1998). During the schizont stage the nucleus divides approximately 4 times to produce, in 
most cases, 16 merozoites (Bannister et al., 2000). The steps for egress of the merozoites 
from erythrocytes are initiated already soon after infection is established, as the parasite 
begins to destabilise the red blood cell membrane by incorporating plasmodial proteins 
into the submembraneous skeleton of the host cell (Wirth and Pradel, 2012). Several 
parasite proteases, including cysteine protease falcipain-2, aspartic protease plasmepsin II, 
subtilisin-like parasite protease PfSUB1, as well as the host protease erythrocyte-derived 
calpain-1, have been shown to be involved in parasite egress (Wirth and Pradel, 2012). 
PfSUB1 was shown to be released into the PV space from a secretory organelle called an 
exoneme (Yeoh et al., 2007), thus it is thought that the parasite proteases involved in 
egress would be contained in the exoneme until required (Wirth and Pradel, 2012). 
Following a yet unidentified signal for merozoite egress, the proteases are released and 
degrade the PV, which results in an intake of water from the erythrocyte leading to the 
rupture of the PV by an unknown mechanism (Glushakova et al., 2010; Wirth and Pradel, 
Chapter 1 Introduction 
 
 
5 
2012). Subsequently a protease independent pore formation occurs in the erythrocyte 
membrane which then curls outwards and turns inside out to propel the merozoites into the 
blood stream (Glushakova et al., 2010; Abkarian et al., 2011). Once in the bloodstream, 
the merozoites are short lived and take only about 60 seconds to invade the next host 
erythrocyte (Cowman and Crabb, 2006). In some cases, merozoites do not continue this 
cycle but undergo gametocytogenesis to produce female and male gametes, which are then 
ingested by the female mosquito as it takes a blood meal (Baker, 2010).  
 
The intraerythrocytic stage of the infection in humans varies in the time it takes to undergo 
intraerythrocytic schizogony. P. falciparum, P. vivax and P. ovale undergo the cycle in 48 
hours, while it takes 72 hours for P. malariae and 24 hours for P. knowlesi. It is this 
developmental stage that causes the symptoms of the disease and the release of merozoites 
at the end of the erythrocytic cycle coincides with fever, thus the names tertian, quartan 
and quotidian malaria, respectively (Grobusch and Kremsner, 2005).    
 
 
1.2 Malaria 
 
The name malaria comes from the assumption that malaria was spread by ‘mal’ aria’, or 
bad air from the swampy land that surrounded areas where the illness occurred (Tuteja, 
2007). Records of ‘autumnal fevers’ in texts from South Asia and China dating back to 
1500 to 800 BCE, give some clue to the antiquity of the disease (Packard, 2007). The 
disease, originating from Africa, also moved north into Europe. While P. falciparum did 
not reproduce well in the northern climate, P. vivax and P. malariae did, even as far as 
northern Russia. In the 17th century, in south-eastern England malaria was a significant 
source of morbidity and mortality and the disease had also made its way to the “New 
World”, as early settlers migrated to America (Packard, 2007). The arrival of P. falciparum 
malaria onto the continent is thought to be coincident with the arrival of slaves brought 
from Africa (Packard, 2007).  
 
Today, malaria is a tropical disease. Europe and North America were able to eradicate the 
illness following an increase in the socio-economic status of these countries pushed 
forward by development of agricultural methods, improved hygiene, better housing to 
protect from the mosquito vectors and access to the antimalarial quinine (Packard, 2007). 
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As these developments have lagged behind in Africa, Asia and South America, the illness 
has become almost solely a tropical blight (Packard, 2007). 
 
General symptoms of malaria are the periodic fever stated above, as well as headache, 
fatigue and malaise, musculoskeletal pain, nausea, vomiting and in some cases diarrhoea 
(Grobusch and Kremsner, 2005). Falciparum malaria accounts for 93% of malaria cases 
(Fig. 1-2) as well as the majority of deaths worldwide (WHO, 2012). P. falciparum is the 
deadliest of the malaria parasites as it is most likely to cause severe disease. This is 
characterised by malarial anaemia, acidosis and the development of cerebral malaria, 
which are the three primary causes of death in patients (Grobusch and Kremsner, 2005). 
 
 
 
 
Figure 1-2. Global distribution of P. falciparum malaria cases. 
Countries coloured in light grey do not have malaria. Figure taken from the Global Malaria Mapper 
created by Medicines for Malaria Venture and the WHO Global Malaria Programme from data 
obtained from the WHO World Malaria Report, 2012 (http://www.worldmalariareport.org/). Taken 
with permission from the World Health Organisation.  
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The World Health Organisation (WHO, 2012) reports that globally in 2010 there were an 
estimated 219 million malaria cases and about 660,000 deaths. Sub-Saharan Africa is by 
far the worst affected with 80% of cases and 90% of deaths in this region. Children under 
the age of five are especially at risk as 85% of the deaths occur in this age group. Malaria 
accounts for 20% of all childhood deaths. Pregnant women are also at high risk of 
infection, which can result in complications in the pregnancy and even death of the mother 
and child. Half the world’s population is at risk of acquiring the illness. Malaria’s gravity 
does not end at loss of life, but the economic loss due to periods of illness and post-
infection complications is estimated to be £8.3 billion a year (WHO, 2009). This is a 
substantial loss to the affected countries as their populations are already generally poor. As 
poverty and malaria tend to exacerbate each other, eradication of the illness will require 
not only efficient antimalarials to combat the symptoms and prevent deaths but other 
control measures and socio-economical development of these countries (Packard, 2007).  
 
 
1.2.1 Treatment and disease control 
 
Cinchona bark was effectively used as an antimalarial in ancient times (Packard, 2007). 
Quinine, the active agent in the bark, was later used to treat malaria and was widely used in 
Britain and North America in the eradication of the disease. The quinine derivative, 
chloroquine, was very effective and cheap, thus widely used, however, parasite resistance 
to the drug has made it largely ineffective especially in Africa and Asia (Fig. 1-3). Other 
antimalarial drugs include other quinine derivatives such as mefloquine and primaquine, 
the antifolate drug sulfadoxine-pyrimethamine and the naphthalene derivative atovaquone 
(White, 2008). However, resistance to these is also increasing (WHO, 2010).  
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Figure 1-3. P. falciparum resistance to the commonly used antimalarials (WHO, 2005).  
Taken from the World Malaria Report (2005) with permission from the World Health 
Organisation. 
 
 
Drugs based on artemisinin, which is derived from the plant Artemisia annua, remain 
extremely effective, although parasite resistance has been reported in some countries in 
South-East Asia (WHO, 2012). To reduce the occurrence of resistance, artemisinin 
combination therapy (ACT) is the recommended first-line therapy. Unfortunately, most of 
those who would require ACT do not receive it due to its high cost (White, 2008). For 
example, a course of sulfadoxine-pyrimethamine in Kenya costs $0.38 whereas a course of 
Coartem ACT treatment is $7.60 (Packard, 2007). No vaccine against malaria is yet 
available.  
 
The increase in resistance to antimalarials creates an urgent need for research to identify 
and validate new drug targets, so that combination therapy can be used for future treatment 
and prophylaxis. Drugs alone will not eliminate malaria, and it is likely that eradication of 
the disease will require a combined effort of effective drug treatment, vector control 
methods and socio-economic development of the endemic countries. However, as White 
(2008) reviews, if we lose the current effective drugs, which at the moment are mainly just 
the artemisinin based drugs, the successful control and elimination of malaria will become 
impossible.  
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1.3 The Plasmodium apicoplast 
 
The apicoplast was already seen on microscope images of avian Plasmodium parasites in 
the 1960’s. At the time it was called a ‘spherical body’ and it was shown to be closely 
associated with mitochondria (Aikawa, 1966; Hepler et al., 1966, Fig. 1-4). A circular 10.3 
m DNA was shown in electron micrographs following sub-cellular fractionation of P. 
lophurae and was presumed to be mitochondrial (Kilejian, 1975). Subsequent studies 
showed the presence of the circular ~10-12 m and ~ 35 kb DNA in a wide range of 
apicomplexan parasites including P. falciparum, however, for decades the genome was 
incorrectly thought to be mitochondrial (Dore et al., 1983; Borst et al., 1984; Williamson 
et al., 1985; Gardner et al., 1988). A second linear 6kb DNA was also discovered, which 
was later shown to be the real mitochondrial genome (Vaidya and Arasu, 1987; Vaidya et 
al., 1989; Feagin et al., 1991). It was not until the 1990’s when the enigma of the circular 
35 kb DNA in the parasite was solved. Inconsistencies of the genome with those of  
 
 
 
Figure 1-4. The close association of the mitochondrion and apicoplast shown in different 
intra-erythrocytic stages of P. falciparum.  
(A) budding merozoite, (B) young ring, (C) young trophozoite. p, apicoplast; m) mitochondrion; 
mt) subpellicular microtubules; n) nucleus. Figure taken from Hopkins et al. (1999) with 
permission from Elsevier. 
 
 
mitochondrial origin prompted suggestions of a chloroplast ancestry (Gardner et al., 1991; 
Wilson et al., 1991). Wilson et al. (1992) showed the 6 kb and 35 kb DNAs to localise to  
different sub-cellular fractions. This was followed by studies showing the 35 kb DNA to 
have features in common with plastid genomes (Williamson et al., 1994). Finally, in 1996, 
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Wilson and colleagues published the complete gene map of the P. falciparum apicoplast 
DNA, which opened research into the exciting new organelle. 
 
The general consensus today is that the apicoplast is of secondary endosymbiont origin, 
where the parasite has engulfed another eukaryote, most likely a single-celled red algae, 
which was a primary endosymbiont that obtained a plastid from a cyanobacterium (Botte et 
al., 2011; van Dooren and Striepen, 2013). Because of the prokaryotic origin of the 
apicoplast, many of the enzymes and metabolic pathways in the organelle are bacterial, 
thus making it a pool of potential novel drug targets (Qidwai and Khan, 2012; Goodman 
and McFadden, 2013).  
 
Apart from Cryptosporidium, all apicomplexan parasites studied so far contain an 
apicoplast (Ralph et al., 2004). The organelle has four membranes, associates closely with 
the mitochondrion throughout the parasite’s life-cycle (Hopkins et al., 1999) and is 
essential for parasite survival (Fichera and Roos, 1997; Sullivan et al., 2000). The 35 kb 
genome has a high A/T content of 86.9% and encodes mainly housekeeping proteins 
involved with translation and transcription of genes (Wilson et al., 1996). In addition, 
nuclear encoded proteins are targeted to the apicoplast by N-terminal leader sequences. 
Each bipartite leader sequence consists of a hydrophobic 16-34 amino acid signal peptide 
(SP) and a 30-42 amino acid transit peptide (TP) with a positive charge and a high lysine 
and asparagine content (Waller et al., 1998). The signal peptide targets the proteins to the 
endomembrane system, namely the endoplasmic reticulum, where it is cleaved off to 
expose the TP (Waller et al., 2000). This targets the protein to the apicoplast, via a poorly 
understood mechanism where vesicles containing the proteins bud from the ER and fuse 
with the outer membrane of the apicoplast (Deponte et al., 2012). Following transport 
across the apicoplast membranes, the TP is cleaved off to reveal the functional mature 
protein (Deponte et al., 2012). Bioinformatic tools, which detect these leader sequences, 
have been used to predict that over 540 nuclear encoded proteins are targeted to the 
apicoplast (Ralph et al., 2004).  
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1.3.1 Apicoplast metabolic pathways  
 
Several metabolic pathways have been shown to localise to the apicoplast, including type 
II fatty acid biosynthesis (FAS II) (Waller et al., 1998), non-mevalonate isoprenoid 
biosynthesis, synthesis of iron-sulphur clusters (Ralph et al., 2004), lipoic acid 
biosynthesis (Wrenger and Müller, 2004) and part of the haem biosynthesis pathway (Sato 
et al., 2004; Okada, 2009). The FAS II pathway and the lipoic acid biosynthesis pathways 
are of most relevance to this study and will be further discussed. 
  
 
1.3.1.1 The fatty acid biosynthetic pathway 
 
Until the turn of the 21st century it was thought that Plasmodium lacked the ability to 
synthesise fatty acids de novo and acquired the molecules solely by scavenging from the 
host red blood cell (Rock, 1971; Rock et al., 1971; Holz, 1977; Holz et al., 1977; Vial and 
Ancelin, 1992). However, Waller et al. (2000) showed that the parasite possessed nuclear 
encoded fatty-acid biosynthesis enzymes that were targeted to the recently discovered 
apicoplast. These enzymes included the acyl carrier protein (ACP), -ketoacyl-ACP 
synthase III (FabH) and -hydroxyl-ACP dehydratase (FabZ). This pathway requires 
acetyl-coenzyme A (acetyl-CoA) and/or malonyl-CoA, which enter a cycle of several 
consecutive elongations of acyl chains (Waller et al., 2003, Fig. 1-5).  
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Figure 1-5. P. falciparum FAS II pathway.  
Acetyl-CoA and/or malonyl-CoA feed into the several cycles of acyl chain elongation catalysed by 
FabH, FabG, FabZ, FabI and FabB/F. Products of FAS II include lipoic acid, free fatty acids such 
as oleic acid, phosphatidic acid and fatty acyl CoA. Substrates and intermediates in black, final 
products in brown boxes, enzymes in blue circles. ACCase, acetyl-CoA carboxylase; acetyl CoA, 
acetyl coenzyme A; ACP, acyl carrier protein; ACT1, glycerol-3-phosphate acyltransferase; ACT2, 
1-acyl-glycerol-3-phosphate acyltransferase; FabB/F, β-ketoacyl ACP synthase I/II; FabD, 
malonyl-CoA transacylase; FabG, β-ketoacyl ACP reductase; FabH, β-keto-ACP synthase III; 
FabI, enoyl-ACP reductase; FabZ, β-hydroxyacyl-ACP dehydratase; FatA, acyl-ACP thioesterase; 
G3P, glyceraldehyde 3 phosphate; GpdA, glycerol-3-phosphate dehydrogenase; LipA, lipoic acid 
synthase; LipB, lipoate protein ligase; LPA, lysophosphatidic acid; NAD+/NADH, nicotinamide 
adenosine; PA, phosphatidic acid; PDC, pyruvate dehydrogenase complex; SAD, stearoyl-ACP 
desaturase; C8, octanoic acid; C18, strearic acid; C16, palmitic acid; C18:1, oleic acid. Diagram 
adapted from Ralph et al. (2004).  
 
 
The FAS II pathway is catalysed by seven separate enzymes, whereas the type I FAS 
pathway found in animals, including humans, posesses a large multifunctional fatty acid 
synthase complex (Waller et al., 2003).  The biochemical confirmation of the apicoplast 
FAS II was achieved by Surolia and Surolia (2001) as they showed 14C labelled acetate- 
and malonyl-CoA incorporation into fatty acids both in vivo and in vitro. Additionally, 
bioinformatic analyses of apicoplast proteins have shown that all FAS enzymes exist in 
Plasmodium (Waller et al., 1998; Waller et al., 2000; McLeod et al., 2001; Surolia and 
Surolia, 2001). 
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Fatty acids are required as precursors for several functions in the parasite such as 
biological membrane biogenesis and production of protein membrane anchors (Vaughan et 
al., 2009). In addition, free fatty acids may be synthesised and transported out of the 
apicoplast possibly into the endoplasmic reticulum (Ralph et al., 2004). Importantly, the 
FAS II pathway is essential for production of the pyruvate dehydrogenase complex (PDC) 
co-factor lipoic acid. The octanoyl-group from octanoyl-ACP, produced by the FASII 
pathway, is transferred by N-octanoyltransferase (LipB) to the lipoyl-domain of E2. This is 
followed by the addition of sulphurs to positions 6 and 8 of the octanoyl moiety by lipoic 
acid synthase (LipA) to form the fully functioning PDC (Storm and Müller, 2012). 
 
As the P. falciparum mitochondrion does not synthesise the lipoic acid required for -keto 
acid dehydrogenase complexes, but scavenges it from outside the organelle, it was 
suggested that lipoic acid is transported from the apicoplast to the mitochondrion. This 
would free the parasite from relying on a host supply of the co-factor (Wrenger and 
Müller, 2004). However, this hypothesis was disregarded after Crawford et al. (2006), 
showed that inhibition of apicoplast fatty acid biosynthesis in Toxoplasma gondii did not 
affect lipoylation of the mitochondrial proteins. Allary et al. (2007) and Günther et al. 
(2007) also showed that the mitochondrion had its own specific lipoic acid scavenging 
mechanism independent of the apicoplast de novo lipoic acid synthesis.  
 
It was thought for almost a decade that FAS II was essential for P. falciparum during its 
intra-erythrocytic cycle as studies using FAS II pathway inhibitors inhibited parasite 
growth in vitro (Surolia and Surolia, 2001; Waller et al., 2003). However, several groups 
showed that the enzymes involved in fatty acid biosynthesis are dispensable during 
intraerythrocytic development of rodent malaria species (Yu et al., 2008a; Vaughan et al., 
2009). Nevertheless, it is has been shown that FAS II is essential for the development of 
the liver stages, since the majority of FAS II deficient parasites failed to form exo-
erythrocytic merozoites and thus could not initiate the blood stage infection. This is 
discussed in more detail in section 1.4.7.1. 

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1.4 -Keto acid dehydrogenase complexes (KADCs) 

KADCs are a group of multienzyme complexes that are usually found in the 
mitochondrion and are involved in energy and amino acid metabolism by catalysing the 
irreversible oxidative decarboxylation of -keto acids. This group consists of the pyruvate 
dehydrogenase complex (PDC), the -ketoglutarate dehydrogenase complex (KGDC) and 
the branced-chain -keto acid dehydrogenase complex (BCKDC). These are composed of 
three enzymes (E1, E2, E3) that catalyse similar reactions and function in close proximity 
to each other in a highly co-ordinated way to ensure correct substrate channelling (de Kok 
et al., 1998; Mooney et al., 2002).  
 
Research into these large complexes started in the 1940 and 1950s with the isolation and 
characterisation of the ‘acetate replacing factor’ or ‘pyruvate oxidation factor’ i.e. -lipoic 
acid, which is one of the essential co-factors of KADCs (Reed, 2001). Studies continued 
with the isolation and characterisation of PDC, KGDC and the BCKDC in the 1950s-1970s 
mainly by isolating the complexes from bacteria and yeast. The availability of molecular 
genetics methods from the 1980s onwards made it possible to clone, mutate and 
overexpress these proteins. This enabled research to be taken to the next level to acquire a 
better understanding of these carefully co-ordinated enzyme complexes.  
 
 
1.4.1 The -ketoglutarate dehydrogenase complex   
 
The KGDC is located in the mitochondrion and is part of the tricarboxylic acid (TCA) 
cycle where it catalyses the irreversible decarboxylation of -ketoglutarate to yield CO2, 
succinyl-CoA and NADH (Tretter and Adam-Vizi, 2005). It is highly regulated and is the 
rate-limiting enzyme of the TCA cycle. The overall reaction is  
 
-ketoglutarate + CoA-SH + NAD+  succinyl-CoA + CO2 + NADH + H+     (1.1) 
 
The kE1 enzyme, -ketoglutarate decarboxylase, catalyses the oxidative decarboxylation 
of -ketoglutarate by transferring the succinyl-group to the thiamine pyrophosphate (TPP) 
cofactor, releasing CO2. The succinyl moiety is subsequently transferred onto the lipoic 
acid co-factor of kE2, the dihydrolipoamide succinyltransferase (kE2). This is followed by 
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the kE2 transfer of the succinyl-group to CoA to form succinyl-CoA, which is then used 
for the subsequent reactions in the TCA cycle or is used for heme biosynthesis (van 
Dooren et al., 2006). The E3 is not specific to the KGDC but is also used by the other 
KADCs in the mitochondrion as well.   
 
The mammalian KGDC has a molecular mass of 2 MDa, which is similar to that of the 
plant complex, which is 1.7 MDa. P. falciparum homologues of each of the KGDC 
enzymes exist and are likely to be targeted to the mitochondrion. kE2 and the E3 
component have been shown experimentally to be targeted to the mitochondrion 
(McMillan et al., 2005). The kE1 is a homodimer (Tretter and Adam-Vizi, 2005), while the 
bacterial kE2 is an octahedral 24-mer (Knapp et al., 1998). The P. falciparum kE1 derived 
amino acid sequence has 39% and kE2 derived amino acid sequence 42% identity to the 
human gene (McMillan et al., 2005).  
 
KGDC is regulated by negative feedback inhibition by its products succinyl-CoA and 
NADH (Smith et al., 1974) and not by reversible phosphorylation of the E1 enzyme as 
with the PDC and BCKDC. It has also been shown that Ca2+ levels influence KGDC 
activity by lowering the apparent Km of kE1 for -ketoglutarate (McCormack and Denton, 
1979).  
 
KGDC is easily targeted by reactive oxygen species (ROS), potentially due to the large 
amounts of suphydryl groups and tyrosines required for its activity (Starkov, 2013). Thus, 
ROS can cause decreased activity of the enzyme, which has been observed in 
neurodegenerative diseases such as Alzheimer’s, Parkinson’s and Huntington’s disease 
(Starkov, 2013).  
 
 
1.4.2 The branced-chain -keto acid dehydrogenase complex  
 
The BCKDC is involved in the catabolism of the amino acids isoleucine, leucine and 
valine (Brosnan and Brosnan, 2006). These amino acids are the most hydrophobic of the 
amino acids, thus playing a crucial role in globular and membrane proteins as well as in 
coiled-coil -helices found in proteins such as myosin, keratin, fibrinogen and some 
transcription factors (Brosnan and Brosnan, 2006). A defect in the BCKDC interrupts the 
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catabolism of these amino acids resulting in their accumulation, which leads to maple 
syrup urine disease, a severe genetic disorder that can be fatal (Aevarsson et al., 2000).  
The first step of branched-chain amino acid catabolism is catalysed by the branched-chain 
amino acid transaminase (BCAT), which converts isoleucine, valine and leucine to the 
respective -keto acids -keto--methylvalerate, -ketoisovalerate and -ketoisocaproic 
acid (Brosnan and Brosnan, 2006). The BCKDC catalyses the second step, where the 
aforementioned -keto acid substrates are converted to acyl-CoA products -
methylbutyryl-CoA, isobutyryl-CoA and isovalyryl-CoA respectively. These products can 
then be converted to acetyl-CoA and/or succinyl-CoA for use in the TCA cycle (Ward et 
al., 1999; Holecek, 2002). The overall reaction is as follows 
 
branched chain -keto acid + CoA-SH + NAD+   
   succinyl/acetyl-CoA + CO2 + NADH + H
+    (1.2) 
 
As with KGDC, the BCKDC consists of three enzymes, homologues of which have been 
shown in P. falciparum and are likely to be localised to the mitochondrion (McMillan et 
al., 2005). The branched chain -keto acid decarboxylase (bE1) is composed of two - and 
-subunit dimers forming a heterotetramer. Regulation of the complex by phosphorylation 
and dephosphorylation is carried out by a branched chain -keto acid dehydrogenase 
kinase and phosphatase at conserved serine residues in the bE1 enzyme (Odessey, 1982).  
 
The P. falciparum bE1 and bE1 have 49% and 61% amino acid sequence identity to the 
human protein, whereas the bE2 gene showed 34% identity (McMillan et al., 2005).  The 
dihydrolipoamide acetyltransferase (bE2) in mammals forms an octahedral 24-mer, and the 
E3 is again the same one shared with the other KADCs. The P. falciparum bE2 has been 
shown to be lipoylated during the intraerythrocytic stages, suggesting bE2 and possibly the 
whole complex is active (Allary et al., 2007; Günther et al., 2007). The role of the BCKDC 
in P. falciparum is unclear as the parasite lacks the gene encoding BCAT, thus the 
complex is not likely to be involved in the degradation of branch-chained amino acids 
(Seeber et al., 2008; Storm and Müller, 2012). The BCKDC has been shown to be able to 
also catabolise pyruvate to acetyl-CoA (Pettit et al., 1978; Heath et al., 2007) thus it has 
been proposed that the P. falciparum BCKDC in the absence of a PDC could be the source 
of acetyl-CoA in the mitochondrion (Seeber et al., 2008).  
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1.4.3 The pyruvate dehydrogenase complex 
 
The PDC catalyses the conversion of pyruvate, the final end product of glycolysis, to 
acetyl-CoA which then enters the TCA cycle (Fig. 1-6) (de Kok et al., 1998). The equation 
for this reaction is  
 
pyruvate + CoA-SH + NAD+  acetyl-CoA + CO2 + NADH + H+  (1.3) 
 
 
 
 
Figure 1-6. The reactions catalysed by the PDC.  
(1) Oxidative decarboxylation of pyruvate by E1, (2) transfer of acetyl group from thiamine 
pyrophosphate (TPP) to lipoamide, (3) Acetylation of coenzyme A (CoA) by E2, (4) reoxidation of 
lipoamide by E3, (5) final electron transfer to NAD+ yielding NADH + H+. Diagram adapted from 
Mattevi et al. (1992a). 
 
 
Regulation of the PDC in mammals is by reversible phosphorylation by pyruvate 
dehydrogenase kinase (PDK) and phosphatase (PDP). In addition, there is negative 
feedback inhibition by the products acetyl-CoA and NADH, while the presence of the 
substrates CoA, NAD+, pyruvate as well as insulin and Ca2+ activate the PDC (Patel and 
Korotchkina, 2001). There are no PDK or PDP homologues in P. falciparum, thus 
regulation is likely to be by product inhibition, as in plants and bacteria where the 
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NAD+/NADH and acetyl-CoA/CoA-SH ratios regulate the activity of the complex (de Kok 
et al., 1998; Mooney et al., 2002). 
 
Genetic defects of the E1 subunit are most common, although mutations may occur in 
each of the enzymes of the PDC as well as the eukaryotic E3 binding protein (E3BP) (Patel 
et al., 2012). Common symptoms of PDC deficiency include lactic acidosis and 
neurological and neuromuscular degeneration (Patel et al., 2012). Another disease 
associated with the PDC is primary biliary chirrosis, an autoimmune liver disease, which is 
caused by anti-mitochondrial antibodies targeting mainly the lipoylated inner lipoyl 
domain of E2 (Hirschfield and Gershwin, 2013).  
 
 
1.4.3.1 Pyruvate decarboxylase (E1) 
 
The E1 of eukaryotes and Gram-positive bacteria is a heterotetramer composed of two 
subunits, E1α and E1β (Fig. 1-7), whereas in Gram-negative bacteria, the enzyme is a 
homodimer (Pei et al., 2008).  
 
 
 
Figure 1-7.  Human E1 structure  
The heterotetramer E1 contains several domains. The PP-domain and PYR-domain are involved in 
tetramer and active site formation, while the C-domain binds the sub-unit binding domain (SBD) of 
E2 (Ciszak et al., 2003; PDB entry 1NI4). Mg2+ shown as red spheres. Figure adapted from Ciszak 
et al., 2003. 
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The E1subunit contains what is termed the PP-domain, which is involved in binding the 
pyrophosphate of TPP and Mg2+, another cofactor of the protein (Ciszak et al., 2003). The 
E1 subunit forms two domains; the PYR-domain, which binds the aminopyrimidine ring 
of TPP, and the C-domain, which is involved in interactions with E2 (Ciszak et al., 2003; 
Frank et al., 2005). The α2β2-heterotetramer is formed predominantly by hydrophobic 
interactions between the PP and PYR domains as well as more flexible interactions due to 
shared binding of TPP (Ciszak et al., 2003).  
 
E1 transfers the acetyl-group from the -keto acid to TPP, concurrently releasing CO2 
(Fig. 1-8A). This enzyme confers substrate specificity to the PDC. The reaction catalysed 
by E1 takes place in two sequential reactions, thus it displays “ping-pong” kinetics (Pei et 
al., 2008). In the first reaction, the acetyl group from pyruvate is transferred to TPP via a 
decarboxylation reaction to form the intermediate enamine-TPP. Subsequently, reductive 
acetylation takes place where the acetyl group is transferred onto one of the sulphurs on the 
lipoamide moiety of E2 to form S-acetyldihydrolipoamide-E2, while the other sulphur is 
reduced.  
 
 
A       B 
   
 
Figure 1-8. E1 reaction and active site 
(A) The E1 reaction takes place in two steps; (1) the oxidative decarboxylation of pyruvate to form 
enamine-TPP and (2) the reductive transfer of the acetyl group to the lipoamide moiety of E2. (B) 
The active site of G. stearothermophilus E1 bound with the enamine-TPP analogue, 3-deazaTPP 
(3-DTPP, in black), pyruvate (cyan) and Mg2+ (red sphere). Residues in red are involved in the 
active site of E1, see text for description. Figure adapted from Pei et al., 2008.(PDB entry 3DV0).     
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Each E1 protein has two active sites, which are formed at the interface of the PP and PYR 
domains (Ciszak et al., 2003; Pei et al., 2008). Important residues in the active site include 
Glu59 (numbering based on the Geobacillus stearothermophilus E1), which initiates the 
proton transfer required to activate TPP, Phe85 and Tyr102 are important in enamine-
TPP binding, His128 interacts with pyruvate and His271 is involved in the reductive 
acetylation of the E2 lipoamide moiety (Pei et al., 2008, Fig. 1-8B)         
 
 
1.4.3.2 Dihydrolipoamide acetyltransferase (E2) 
 
PDC E2 has a multidomain structure consisting of 1-3 lipoyl-domains (LD) at the N-
terminus, followed by an E1/E3 sub-unit binding domain (SBD), and the catalytic domain 
(CD) at the C- terminus (Fig. 1-9A). The domains are linked together by 20-40 amino acid 
flexible linkers. E2 forms the so-called ‘swinging arm’ of PDC, which allows substrate 
channelling between E1, E2 and E3 (Perham and Reche, 1998). Eukaryotic E2 cores are 
formed with an additional protein, the E3 binding protein (E3BP), which has a multi-
domain structure similar to that of E2, however, it is not catalytically active as it lacks a 
conserved histidine residue required for activity (Fig. 1-9B).  
 
 A 
 
 
 
B 
        
 
Figure 1-9. E2 multidomain structure 
(A) E2 and (B) the E3 binding protein found only in eukaryotes. LD, lipoyl domain; SBD, sub-unit 
binding domain. Adapted from de Kok et al. (1998). 
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The lipoyl-domains contain a lysine residue, to which the co-factor lipoic acid binds via an 
amide linkage (de Kok et al., 1998). The catalytic domain forms the core structure of the 
protein complex. PDC E2 can form into either a dodecahedral 60-mer as in humans, Gram-
positive bacteria and plants or an octahedral 24-mer as in Gram-negative bacteria (Mattevi 
et al., 1992a; Izard et al., 1999; Mooney et al., 1999; Yu et al., 2008b, Fig. 1-10). PDC E2 
monomers form a tightly bound trimer involving 48 hydrogen-bonds (16 per monomer), 
several van der Waals interactions and loops that extend over the surface of the 
neighbouring monomer (Mattevi et al., 1992a). Conversely, the interactions involved in the 
large core formation are much weaker. A C-terminal 310-helix forms a “ball” that inserts 
into a socket formed by residues in a monomer of the neighbouring trimer resulting in four 
hydrogen bonds (2 bonds per ball and socket) (Mattevi et al., 1992a).  
 
 
A       B 
    
 
Figure 1-10. The core structure of PDC E2 
(A) Icosahedral 60-mer PDC E2 core from G. stearothermophilus (formerly called Bacillus 
stearothermophilus, PDB entry 1B5S, Izard et al., 1999). (B) Octahedral 24-mer PDC E2 core 
form Azotobacter vinelandii (PDB entry 1EAA, Mattevi et al., 1993a).  
 
 
E2 catalyses the transfer of the acetyl group from S-acetyldihydrolipoamide to coenzyme 
A (CoA) producing acetyl-CoA (Fig. 1-11A). The sulphide carrying the acetyl group is 
reduced in the process. The active site is formed in the junction of two monomers. As an 
example, the active site residues in A. vinelandii are His610’, Asn614’ on one monomer 
(denoted from hereafter with the prime symbol) and Ser558 and Asp508 on the other 
monomer (Mattevi et al., 1993a, Fig. 1-11B). In the inactive catalytic site Asp508 forms a 
hydrogen bond with Asn614’ side chain preventing CoA from entering (Mattevi et al., 
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1993a). Upon reduced CoA binding, Asn614’ rotates and forms a hydrogen bond with 
His610’ to allow the panthenine arm to enter the active site (Fig. 1-11C). This is followed 
by the E2 catalytic reaction where His610’ extracts a hydrogen from the sulphydryl group 
of CoA (Mattevi et al., 1993a, Hendle et al., 1995). The sulphur then attacks the carbonyl 
carbon of the S-acetyldihydrolipoamide acetyl group forming a tetrahedral intermediate, 
which is stabilised by a hydrogen bond to Ser558 (Mattevi et al., 1993a, Hendle et al., 
1995). The previously extracted hydrogen on His610’ reduces the sulphur atom bound to 
the acetyl group, thus releasing acetyl-CoA and reduced dihydrolipoamide (Mattevi et al., 
1993a, Hendle et al., 1995). Asn614’ then rotates back to form a hydrogen bond with 
Asp508 to close the active site channel (Mattevi et al., 1993a).  
 
 
A        B 
  
 
C              D 
 
       
Figure 1-11.  E2 reaction and active site 
(A) E2 transfer of the acetyl group from S-acetyldihydrolipoamide to reduced CoA results in the 
formation of acetyl-CoA and the reduction of the lipoamide moiety of E2. (B) The active site of A. 
vinelandii E2 showing the “closed” conformation where Asn614’ and Asp508 are involved in a 
hydrogen bond (dashed line) (PDB entry 1EAA, Mattevi et al., 1993a). (C) The “open” 
conformation where Asn614’ and His610’ are involved in a hydrogen bond upon CoA binding 
(PDB entry 1EAD, Mattevi et al., 1993a). (D) Co-crystallisation of E2 with dihydrolipoicacid 
(DHLA) showed the involvement of Asn424 in binding the co-factor (PDB entry 1EAE, Mattevi et 
al., 1993a). Figures B-D adapted from Mattevi et al. (1993a).   
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A 30 Å channel at the interface of each of the E2 monomers forms the active site. The 
substrate CoA enters the active site from inside the core, while S-acetyldihydrolipoamide, 
is swung by the extended arm to the outer opening of the channel (Mattevi et al., 1992a). 
The adenosine 3’phosphate moiety of CoA anchors the molecule to the protein allowing 
the movement of the panthenine arm (Fig. 1-11C), while dihydrolipoicacid (DHLA) 
binding involves a hydrogen bond with Asn424 (Fig. 1-11D) (Mattevi et al., 1993a).  
 
 
1.4.3.3 Dihydrolipoamide dehydrogenase (E3) 
 
E3 is a flavoprotein disulphide oxidoreductase, a group of proteins characterised by the 
requirement for the co-factor flavin adenine dinucleotide (FAD) (Perham et al., 1996). E3 
also requires the co-factor nicotinamide adenine dinucleotide (NAD+). For the formation of 
the active site E3 requires a homodimeric structure, which is highly conserved in bacteria, 
yeast and humans (Mattevi et al., 1991; Mattevi et al., 1993b; Toyoda et al., 1998; 
Brautigam et al., 2005, Fig. 1-12).  
 
 
 
Figure 1-12. Structure of human E3  
The FAD domain is in green, the NAD domain in blue, the central domain in purple and the 
interface domain in orange. FAD (magenta) and NAD (black) are shown as sticks. (PDB 
entry1ZMD, Brautigam et al., 2005). 
  
 
A monomer of E3 has four domains. The residue numbers stated here are as reported for 
the human E3 by Brautigam et al. (2005). The largest domain is the FAD-binding domain 
formed by residues 1-149. The other three domains are the NAD+-binding domain 
(residues 150-282), the central domain (residues 283-350) and the interface domain 
(residues 351-474). In addition to its role in the catalytic activity of E3, FAD binding is 
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required for the correct folding of the protein (Lindsay et al., 2000). Thus, it is 
unsurprising that there are several residues forming a total of 22 hydrogen bonds to bind 
the co-factor to the enzyme (Mattevi et al., 1991).  
 
The E2 reaction leaves the sulphurs of the lipoamide cofactor reduced and these are re-
oxidised by E3 to regenerate the co-factor for subsequent cycles of catalysis and to form 
NADH. E3 catalyses the oxidisation of the dihydrolipoamide moiety via two subsequent 
reactions, thus like E1, E3 exhibitis “ping-pong” kinetics (Fig. 1-13A).  
 
 
   A  
 
 
B      C 
 
 
Figure 1-13. E3 reaction and active site  
(A) E3 ping-pong kinetics. The first reaction (1) transfers a hydride ion from reduced 
dihydrolipoamide-E2 to FAD. The second reaction (2) transfers the hydride to NAD+ forming 
NADH + H+. (B) The human E3 active site residues and co-factors, see text for description. (C) 
Conformational change of NAD+ (blue) NADH (light blue) upon active site formation. The 
conformation of the isoalloxazine ring while NAD+ or NADH is bound is shown in magenta and 
light magenta, respectively. Figures adapted from Brautigam et al. (2005).  
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A hydride ion from the reduced lipoamide is transferred via a histidine residue onto a 
cysteine of the E3 active site disulphide. The cysteine forms a charge transfer complex 
with the isoalloxazine of FAD. NAD+ then interacts with the isoalloxazine, facilitating the 
final transfer of the hydride to form NADH + H+ (Mattevi et al., 1991; Brautigam et al., 
2005). 
 
The catalytic site involves a disulphide (formed by Cys45 and Cys50), His452’ from the 
second monomer, which is held in the correct conformation by Glu455’, and the 
isoalloxazine of FAD (Fig. 1-13B). NAD+ is also present, however, it is not permanently 
bound to the active site. NAD+ binding involves seven hydrogen bonds and there is a 
conformational change in the position of the nicotinamide ring during catalysis (Brautigam 
et al., 2005, Fig. 1-13C). Following the formation of the charge-transfer complex by one of 
the active site cysteines and the FAD isoalloxazine on the si-side, the nicotinamide ring is 
aligned with isoalloxazine on the re-side to allow the transfer of the hyride (Brautigam et 
al., 2005). The resulting NADH is bound to E3 by 12 hydrogen bonds (Brautigam et al., 
2005). Dimer formation involves nine hydrogen bonds, six of which are between residues 
in the interface domain and three in the FAD domain (Mattevi et al., 1991). Residues 
involved in binding the SBD of E2 or the E3BP are also located in the interface domain.      
 
 
1.4.3.4 The P. falciparum pyruvate dehydrogenase complex  
 
P. falciparum is unusual in that the sole PDC is located in the apicoplast and not in the 
mitochondrion, as in humans and other eukaryotes (Foth et al., 2005) or as in plants where 
a PDC is found in both the mitochondrion and plastid (Mooney et al., 2002).  
 
The P. falciparum PDC E1 enzyme is an 22 heterotetramer. The E1 subunit 
(PlasmoDB: PF11_0256, www.plasmodb.org) is encoded on chromosome 11, the gene is 
1824 bp and translates into a 608 amino acid protein with a predicted size of 70.9 kDa 
(Foth et al., 2005; McMillan et al., 2005). The gene for the E1 subunit (PlasmoDB: 
PF14_0441), on the other hand, is located on chromosome 14, is 1248 bp and encodes a 
protein with 416 amino acids with an estimated molecular mass of 47.0 kDa (Foth et al., 
2005; McMillan et al., 2005). Amino acid sequence identity for E1and E1compared to 
the human equivalents are 32% and 35% respectively (McMillan, 2006). Both subunits 
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show the greatest amino acid identity (around 40-50%) to homologous proteins from 
cyanobacteria and red algae, which is consistent with the secondary endosymbiotic origin 
of the apicoplast (Foth et al., 2005; McMillan, 2006). Although the protein sequence 
identity to homologues from other organisms is low, the PDC E1 subunits do contain 
conserved residues required for activity (Foth et al., 2005).  
 
The P. falciparum  PDC E2 gene (PlasmoDB: PF10_0407) is 3192 bp, and it contains 10 
predicted introns and complementary DNA analysis shows the full enzyme coding 
sequence is 1923 bp and the predicted protein consists of 641 amino acids, with an 
estimated molecular mass of 73.9 kDa (McMillan, 2006). The PDC E2 protein contains 
two lipoyl-domains, a SBD and a catalytic domain with conserved residues required for the 
acetylation reaction.  
 
McMillan et al. (2005) showed that there are two E3 enzymes encoded by the nuclear 
genome of P. falciparum, and that one of these is targeted to the mitochondrion, the other 
to the apicoplast. The apicoplast PDC E3 gene (aE3) (PlasmoDB_PF08_0066) is located 
on chromosome 8, is 2001 bp and encodes a protein of 667 amino acids with a theoretical 
molecular mass of 75.6 kDa (McMillan, 2006). This differs from the mitochondrial E3 
(mE3), which has a predicted molecular mass of 57.2 kDa, and is encoded by a 1539 bp 
gene (PlasmoDB: PFL1550w) on chromosome 12. The aE3 enzyme shows greatest 
sequence identity with cyanobacteria and plants, whereas the mE3 is similar to protists, 
Dictyostelium, plant and fungi homologues. This is unsurprising because of the different 
origins of the apicoplast and mitochondrion and in fact the aE3 and mE3 have an amino 
acid sequence identity of only 20%. Both proteins, however, do contain the conserved 
FAD, NADH, central and interface domains and the active site redox active cysteines 
(McMillan, 2006). 
 
A recent study on the rodent parasite, P. yoelii, showed that the PDC is essential in the 
liver stage of the parasite. Deletion of E1 and aE3 did not affect blood stage or mosquito 
stage parasite growth or development (Pei et al., 2010). However, E1 and aE3 were 
essential for the progression of the parasites from the liver stage to the infective blood 
stage in mice. Further investigation of E1 deletion mutants showed that specifically the 
late liver stages were affected. The mutants had growth and nuclear division defects and 
did not develop into mature schizonts and exo-erythrocytic merozoites (Pei et al., 2010). 
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Also, the mutant parasites did not express merozoite surface protein 1 (MSP1), which is 
required for invasion of erythrocytes (Pei et al., 2010). Comparable results were obtained 
with parasites lacking genes encoding proteins involved in FAS II, suggesting the major 
role of the PDC is to provide acetyl-CoA for FAS II (Yu et al., 2008a; Vaughan et al., 
2009). In P. berghei and P. falciparum, FabI deletion did not affect blood stage parasites 
but the gene was important for development of P. berghei liver stage merozoites and FabI 
deletion resulted in reduced infectivity of mice (Yu et al., 2008a). This effect was more 
pronounced in P. yoelii, where FabB/F and FabZ null mutants were shown to be unable to 
form exo-erythrocytic merozoites or to lead to a blood stage infection of mice (Vaughan et 
al., 2009). Similar to the P. berghei study, FabB/F and FabZ were not required for 
erythrocytic stage growth or development in P. yoelii (Vaughan et al., 2009). Deletion of 
the protein N-octanoyltransferase (LipB) also showed results similar to PDC and FASII 
mutant parasites. LipB is involved in producing the active form of E2 as it transfers the 
octanoyl-group from octanoyl-ACP, produced by the FASII pathway, to the lipoyl-
domains of E2. This is followed by the addition of sulphurs to positions 6 and 8 of the 
octanoyl moiety by lipoic acid synthase (LipA). LipB was shown to not be essential for the 
blood stage growth and development of P. falciparum (Günther et al., 2007). Deletion of 
the protein from P. berghei also showed it was not required for blood or mosquito stage 
growth. The P. falciparum LipB deletion mutants did, however, have a shorter cell cycle 
(Günther et al., 2007), a phenotype that was not seen in the P. berghei mutants (Falkard et 
al., 2013). Again, LipB was essential for successful late-stage liver development and the P. 
berghei mutant parasites had a reduced ability to infect mice erythrocytes (Falkard et al., 
2013). The reduced infectivity was likely to be due to residual lipoylation of PDC E2 
(Falkard et al., 2013), which could possibly be carried out by lipoic acid protein ligase-like 
protein (LplA2), a protein shown to be targeted to both the mitochondrion and apicoplast 
(Günther et al., 2007). Together, these studies show that a functional PDC and FAS II are 
very important for the progression of the parasite from the asymptomatic liver stage to the 
symptomatic blood stage. Thus, the PDC could be a potential target for the development of 
prophylactic drugs or vaccines.    
 
Even though the aforementioned studies suggest that the PDC is not required in the 
erythrocytic stages of Plasmodium, reverse transcriptase-PCR and western blotting have 
shown that the genes encoding the three subunits of PDC are expressed in P. falciparum 
during this stage (Foth et al., 2005; McMillan et al., 2005). RNA-seq data (available at 
www.plasmodb.org) show that the proteins are expressed at very low levels during the 
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intraerythrocytic cycle, however, higher levels are seen in late gametocytes and ookinetes 
(Bartfai et al. 2010; Lopez-Barragan et al., 2011). In addition it was shown that PDC E2 is 
lipoylated and thus likely to be catalytically active during blood stage development 
(Günther et al., 2007). Because the PDC is expressed, questions arise as to whether the 
enzyme has another role in the parasite. For example, E2 and E3 may play a role in redox 
regulation via the covalently attached lipoyl-group on E2 and the NADH/NAD+ cycling 
carried out by E3. Free lipoic acid is a potent antioxidant with therapeutic potential. The 
reduced/oxidised lipoic acid redox couple has metal chelating properties, can scavenge 
reactive oxygen species (ROS), regenerate other antioxidants such as vitamin C, vitamin E 
and glutathione and also plays a role in repair of oxidatively damaged proteins (Biewenga 
et al., 1997). Therapeutical lipoic acid has been suggested for aging, cancer and diabetes 
(Goraca et al., 2011). Protein bound lipoic acids may also have a role outside their function 
as acetyl/succinyl transferases in the KADC complexes. In Mycobacterium tuberculosis, 
peroxiredoxin alkyl hydroperoxide reductase (AhpC) is linked to the E2 enzyme of the 
KGDC complex and E3 via a thioredoxin-like protein (AhpD) to form a NADH-dependent 
peroxidase and peroxynitrite reductase (Bryk et al., 2002). This complex is important in M. 
tuberculosis defence against oxidative and nitrosative stress exerted by the host cells 
following an immune response to the bacterium. Also, the presence of several lipoylated 
domains on E2, all of which are not required for sufficient catalytic activity (Dave et al., 
1995; Guest et al., 1997), suggests that the lipoic acid moieties may interact with other 
molecules in the surrounding environment (Bunik, 2003). E3 has several redox active 
roles. It has been implicated in NADH-dependent scavenging of nitric oxide (Igamberdiev 
et al., 2004) and reduction of ubiquinone to the antioxidant ubiquinol (Olsson et al., 1999; 
Xia et al., 2001). E3 has also been shown to protect the mammalian E2-E3 binding protein 
core from lipid peroxidation products (Korotchkina et al., 2001). Thus, one of the aims of 
this part of the project was to investigate, whether the P. falciparum PDC could play a role 
in oxidative stress encountered by the parasite.     
 
Another important factor is that acetyl-CoA is not only required for metabolic pathways 
but it is also a major source of acetyl groups for protein acetylation (Xing and Poirier, 
2012). Acetylation has traditionally been associated with histones but recently it has been 
discovered to also be involved in a vast range of functions outside the nucleus and has 
been realised to be an important post-translational modification comparable to 
phosphorylation (Norris et al., 2009). Acetylation occurs at least in humans, plants and 
bacteria (Choudhary et al., 2009; Jones and O'Connor, 2011; Xing and Poirier, 2012). 
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Acetyl-CoA plays a role in three types of acetylation including O-acetylation, the addition 
of an acetyl group to the hydroxyl group of an internal serine or threonine, and N-
acetylation, the addition of an acetyl group to the N-terminal amino acid of a protein (Xing 
and Poirier, 2012). The most common form is N-acetylation, in which an acetyl group is 
added to the side-chain amino group of an internal lysine, thus also called lysine 
acetylation (Xing and Poirier, 2012). This acetylation is reversible and mediated by lysine 
acetyl transferases (KATs) and lysine deacetylases (KDACs) (Xing and Poirier, 2012). 
Thousands of proteins were found to be acetylated in human cells and acetylation-
mediated networks were involved in RNA splicing, DNA damage repair, the cell cycle, 
nuclear transport and actin cytoskeleton remodelling (Choudhary et al., 2009). Acetylated 
proteins also play a role in other cellular processes such as proteolysis, vesicular 
trafficking, endocytosis and autophagy, stress response and even some kinases and 
phosphatases are acetylated (Choudhary et al., 2009; Jones and O'Connor, 2011; Xing and 
Poirier, 2012). P. falciparum has been shown to encode at least four KATs as well as 
several KDACs and histone deacetylases (HDACs) (Miao et al., 2010; Miao et al., 2013). 
Acetylation in P. falciparum has mainly been studied in context of histone acetylation 
(Miao et al., 2006; Goyal et al., 2012) and potential drug candidates against parasite 
HDACs have been researched (Wheatley et al., 2010; Marfurt et al., 2011). There are also 
reports of N-acetylation of P. falciparum exported proteins and actin (Schmitz et al., 
2005; Chang et al., 2008).  A recent study has been carried out on P. falciparum lysine 
acetylation, which identified 230 proteins that were acetylated (Miao et al., 2013). Most of 
these proteins were cytosolic (n = 167) but ten were shown to be plastidial (Miao et al., 
2013). The P. falciparum acetylated proteins are mainly involved in translation, 
transcription, metabolism and chaperones and not as much in replication, invasion and 
structural functions (Miao et al., 2013). Clearly as acetylation is very important in the 
parasite and because acetyl-CoA is a major contributor of acetyl-groups, the role of the 
PDC in producing acetyl-CoA for acetylation would be an appealing perspective to study 
in P. falciparum.   
 
In conclusion, because the mutation of the PDC has been shown to inhibit egress of 
parasites from hepatocytes, thus preventing the initiation of the symptomatic 
intraerythrocytic cycle, the PDC could be a potential new target for prophylactic drugs and 
vaccines. This warrants further investigation into the structure and function of the P. 
falciparum PDC to determine whether there are any differences between the parasite and 
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human PDC, which could be exploited for drug development. In addition, studying the role 
of the PDC in the intraerythrocytic stages of P. falciparum will be very interesting to 
further understand how the parasite functions.      
 
 
1.5 Aims of the project 
 
The specific questions this project will address are: 
 
a. What are the structures and stoichiometries of the P. falciparum PDC components? 
b. What are the kinetic properties of the enzymes? 
c. Are there any biochemical and structural differences in the P. falciparum PDC 
compared with the human complex that are exploitable for future drug 
development? 
d. Is the PDC required for P. falciparum blood stage development? 
 
Hypotheses 
1. The P. falciparum PDC differs biochemically from the human PDC. 
2. The P. falciparum PDC differs structurally from the human PDC. 
3. The P. falciparum PDC is not essential for the parasite blood stage development. 
 
Testing these hypotheses will demonstrate drug target suitability of the P. falciparum PDC. 
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1.6 Introduction to biophysical techniques 
 
1.6.1 Analytical ultracentrifugation (AUC) 
 
In 1924, Theodor Svedberg built his first successful analytical ultracentrifuge (van Holde 
and Hansen, 1998). At a time when proteins were thought to be merely aggregated colloids 
of small molecules, his first studies on haemoglobin were monumental in protein research 
(Rosenfeld, 1982). By performing sedimentation equilibrium (SE) experiments, Svedberg 
and Fahraeus (1926) showed that the molecular mass of haemoglobin was 68,000 Da, 
which was exactly four times the minimum molecular mass (16,700 Da) estimated for the 
protein based on its iron content. For the first time it was shown that proteins were in fact 
specific molecules with large molecular masses that formed organised macromolecules 
rather than the previously thought aggregated clusters of small particles. Svedberg then 
went on to develop an oil turbine ultracentrifuge, which was capable of producing rotor 
speeds fast enough to measure sedimenting boundaries, thus developing sedimentation 
velocity (SV) analysis (Svedberg and Nichols, 1927). The first SV experiment was also 
carried out on haemoglobin and corroborated the SE results, showing a homogenous 
sample with a molecular mass of 68 kDa (Svedberg and Nichols, 1927).  
 
The development of the more powerful Spinco Model E analytical ultracentrifuge made 
AUC a popular method to study not only protein but also other molecules such as DNA 
(Bauer and Pickels, 1937). In the late 1970’s, however, the use of AUC almost stopped 
completely as the Spinco Model E became outdated and cheaper, easier methods such as 
gel filtration and gel electrophoresis were developed and were used to approximate protein 
molecular mass and stoichiometry (van Holde and Hansen, 1998). The next major 
development was not until 1992, when Beckman-Coulter (Palo Alto, USA) introduced the 
much-improved XL-A analytical ultracentrifuge with scanning absorption optics and 
digital data acquisition, followed by the XL-I in 1996, which has both absorption and 
Rayleigh interference optics that can be used at the same time (Schuster and Toedt, 1996; 
van Holde and Hansen, 1998). The development of more powerful computers and software 
also facilitated faster analysis of data (van Holde and Hansen, 1998). Following these 
developments AUC has yet again become a powerful tool in biomedical research.   
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AUC has several applications in biological research. First of all, it is an unrivalled method 
of directly determining the precise molecular mass of any molecule in their near native 
state in solution without relying on calibration standards (Ralston, 1993). Secondly, sample 
purity can be examined using AUC. SV analysis shows how many species there are and 
how much of each there is in a sample and SE analysis can be then used to determine the 
molecular mass of each species (Ralston, 1993). In addition, sedimentation analyses can be 
used to study associating systems. The change in molecular mass following complex 
formation or dissociation can be measured and the strength of the interaction can be 
calculated (Ralston, 1993). Other applications include determining the thermodynamic 
non-ideality of a solution, measuring conformational changes of proteins and ligand 
binding studies (Ralston, 1993).   
 
 
1.6.1.1 Theory for sedimentation of particles  
 
There are three forces acting on sedimenting particles (Fig. 1-14). The following is the 
description of the mechanical model of sedimentation as described in Ralston, (1993). 
 
 
 
 
Figure 1-14. Forces acting on sedimenting particles 
When centrifugal force (constant velocity) is applied to a molecule the sedimentation force (Fs) is 
opposed by the frictional force (Ff) and buoyancy (Fb). Figure adapted from Ralston, (1993). 
 
 
The sedimenting, or gravitational, force, Fs, depends on the mass of the particle m, and its 
linear acceleration, which in a rotating system is defined as the squared angular velocity (in 
radians per second) 2, multiplied by the distance from the centre of rotation (r) 
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     (1.4) 
 
where m is derived from the molar mass M of the molecule (g/mol) and Avogadro’s 
number N (6.023 x 1023 /mol). A second force, buoyancy, Fb, acts in the opposite direction 
of sedimentation and which is given by Archimedes’ principle ‘the buoyancy of a body in 
liquid equals the weight of the liquid in a volume equal to the volume of the body’ 
(Serdyuk et al., 2007a). Thus, Fb is defined as 
 
      (1.5) 
 
where 2r is the linear acceleration of the particle (the minus in -m0 denotes the opposite 
direction of Fb compared with Fs) and m0 is  
  
         (1.6) 
 
where  is the partial specific volume (ml/g) of the particle and  the density of the liquid 
(g/ml) in which the particle is immersed. The partial specific volume is defined as the 
change in volume when 1 gram of a molecule is solubilised.  
 
When the density of the particle is greater than the density of the liquid, the particle will 
start sedimenting towards the bottom of the cell. The velocity, u, will initially for a fraction 
of time increase the further away it moves along the radius from the centre of rotation. The 
viscosity of the liquid will cause friction and affect the velocity. Frictional force, Ff, is the 
third force affecting sedimentation and is defined as   
 
    fuF f       (1.7) 
 
where f is the frictional coefficient and the minus indicates the opposite direction of Ff 
compared with Fs. The frictional coefficient depends on the shape and size of the 
sedimenting molecule; f for smooth and compact spheres is smaller than for bulky and 
elongated particles.  
 

Fs  m
2r 
M
N
 2r

Fb  m0
2r

m0  mv 
M
N
v

v
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When the three forces come into equilibrium (usually in less than 10-6 s) constant velocity 
is achieved 
     
         (1.8) 
 
        (1.9) 
 
which can be rearranged to 
  
        (1.10) 
 
This is further rearranged so that the experimental parameters are on the left and the 
molecular parameters on the right (Serdyuk et al., 2007a) 
 
         (1.11) 
  
As sedimenting particles move toward the bottom of the cell, diffusion of the particles 
occurs, which broadens the boundary. The rate of the spreading boundary is determined as 
the diffusion coefficient, D, and depends on the size of the molecules  
  
          (1.12) 
 
where R is the gas constant, T the absolute temperature and N Avogadro’s number. Adding 
the diffusion constant to the equation determining the sedimentation coefficient, gives 
Svedberg’s equation (Lebowitz et al., 2002): 
 
        (1.13) 
 
From this we can determine the sedimentation coefficient, s, which is the ratio of the 
velocity of the particle to its centrifugal acceleration (u/2r). The dimensions of s are 
seconds. The sedimentation coefficient for biological molecules are around 1-100 x 10-13 s, 

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N
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
s 
u
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
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
D 
RT
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
MD(1 v)
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thus the basic unit is 10-13 s and is called a Svedberg unit (S) in acknowledgment of 
Theodor Svedberg’s work in AUC. Molecules of different shapes and sizes will move at 
different velocities when centrifuged and will thus have different sedimentation 
coefficients.  
 
To be able to compare sedimentation coefficients from different experiments conducted at 
different temperatures and in differing buffers, the experimental values (sT,B) are converted 
to s20,w, i.e. standard values at 20C in water (w):  
    
        (1.14) 
 
where T is experimental temperature and B is the experimental buffer conditions,  is 
viscosity of water or buffer (Poise),  is the partial specific volume (ml/g) of the studied 
protein and  the density of water or buffer (g/ml) (Lebowitz et al., 2002).   
 
 
1.6.1.2 AUC experiment: instrumentation and optics   
 
For an AUC experiment, a protein sample and the reference buffer are loaded into a double 
sector centrepiece flanked by optical-grade quartz or sapphire windows. This is placed into 
a metal housing and the cell is placed into an anodised titanium rotor. The samples are 
centrifuged at 3,000 to 60,000 rpm in a vacuum chamber, designed to decrease frictional 
heating and aerodynamic turbulence. The Beckman Coulter (Palo Alto, USA) Optima XL-I 
analytical ultracentrifuge uses both absorbance and Rayleigh interference optics. Data in 
this thesis were mainly collected using the absorbance optics. The absorbance optics 
operate at wavelengths ranging from 190 – 800 nm (Fig. 1-15). For experiments on 
proteins, the absorbance can be set to 280 nm to detect the aromatic side chains of amino 
acids or 230 nm, the wavelength absorbed by the peptide bonds (Ralston, 1993). Rayleigh 
interference optics produce fringe patterns, which arise from light passing slower though 
the sample compared with the reference buffer. The difference in the refractive index of 
the sample and reference buffer, which is proportional to the concentration difference, 
causes a vertical shift in the fringe pattern in the area of the sedimenting protein boundary 
(Ralston, 1993). The absorbance optics are valuable for measuring low concentrations of  

s20,w  sT ,B
T ,B
20,w






(1 v)20,w
(1 vp)T ,B

v
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Figure 1-15. Absorbance optical system 
A schematic of the absorbance optical system of the Beckman Optima XL-A analytical 
ultracentrifuge. The optics works the same way in the Beckman Optima XL-I analytical 
ultracentrifuge used in this study. The xenon lamp (1) flashes each time a measurement is taken. 
The light is directed via a monochromator (2), which contains a torroidal diffraction grating (2a) 
that selects the correct wavelength and collimates the light. The incident light detector (2b) in the 
monochromator measures and normalises the intensity of each flash of light before it reaches the 
sample. (3) The light is focused to 1/3 of the cell sector depth. The 2 nm slit (4) moves beneath the 
sample cell to allow measurements at different radial positions. The photomultiplier tube (5) 
measures the intensity of the light during a scan. Figure taken from Ralston (1993), with 
permission from Beckman Coulter. 
 
 
proteins because to keep within the linear range of Beer’s Law, absorbance of the sample 
should not exceed 1.0 (Schirf and Planken, 2008). Rayleigh interference is useful when 
measuring high concentrations of proteins when the absorbance would be too high, and 
also for substances that do not absorb light, for example polysaccharides (Schirf and 
Planken, 2008).  
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1.6.1.3 Sedimentation velocity (SV)   
 
In a SV experiment samples are centrifuged at 3,000 – 49,000 rpm depending on the size 
of the protein. Large macromolecules need to be centrifuged at lower speeds to be able to 
monitor their movement; at high speed the protein would sediment too fast. Likewise small 
molecules need higher speeds to force sedimentation. It is the movement of the boundary 
region (Fig. 1-16), which is monitored and recorded for analysis.  
 
 
A      B 
 
 
Figure 1-16. Sedimenting boundaries in a SV experiment 
(A) Diagram showing the AUC sample cell and one recorded fringe profile. (B) The boundary 
region moves as the proteins sediment and, in the simplest analysis, this movement is used to 
obtain the sedimentation coefficient. Figures taken from Ralston (1993), with permission from 
Beckman Coulter. 
  
 
The Lamm equation is used for direct modelling of the movement of sedimenting 
boundaries. The Lamm equation is a partial differential, which describes the sedimentation 
and diffusion of the boundary of a monodisperse solution in a sector shaped cell (Schuck et 
al., 2002)   
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Figure 2. Double-sector centerpiece. The sample solution is placed in one
sector, and a sample of the solvent in dialysis equilibrium with the sample
is placed in the reference sector. The reference sector is usually filled
slightly more than the sample sector, so that the reference meniscus does
not obscure the sample profile.
In equilibrium experiments, the time required to attain equilibrium
within a specified tolerance is decreased for shorter column lengths of
solution; i.e., when the distance from the meniscus to the cell bottom is
only 1 to 3 mm, rather than the 12 mm or so for a full sector. Considerable
savings of time can be achieved by examining 3 samples at once in 6-
channel centerpieces, in which 3 channels hol  3 different samples, and the
3 channels on the other side hold the respective dialyzed solvents
(Yphantis, 1964). For even more rapid attainment of equilibrium, 1-mm
solution lengths may be used (Arakawa et al., 1991; Van Holde and
Baldwin, 1958).
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where  is the concentration of the sedimenting particle, r the radial position in the sector 
shaped cell and t time. The first part of the equation in the brackets describes diffusion (D) 
and the second part sedimentation (s) of the particle. In this thesis, the programme SEDFIT 
(Schuck, 2000; Schuck et al., 2002) was used to obtain the sedimentation coefficient of 
proteins. Amongst other models, this programme generates the differential concentration 
distribution c(s) using the solution of the Lamm equation to model the experimental 
absorbance or interference profiles with the following equation (Schuck et al., 2002) 
 
    (1.16) 
 
where a(r,t) is the experimental sedimentation profile, c(s) is the concentration distribution 
of sedimentation coefficients between s and s+ds, (s,D(s),r,t) is the solution of the Lamm 
equation and  is error. By integrating the area under the peaks the weight-average 
sedimentation coefficient can be determined for each species in a sample. This analysis 
does not require prior knowledge of how many species are present in the sample and is not 
constrained in how many species it can fit. Thus c(s) analysis was used to determine 
sedimentation coefficients in this thesis.    
 
 
1.6.1.4 Sedimentation equilibrium (SE)  
 
During an SE experiment molecules are centrifuged at lower speeds than in an SV 
experiment. The lower centrifugal speed allows diffusion of the protein to oppose the 
sedimentation force (Lebowitz et al., 2002). Following centrifugation for one or two days 
(dependent on molecular mass) these two processes reach equilibrium and the protein 
forms a concentration gradient in which no net movement of molecules occurs (Fig. 1-17). 
The equilibrium distribution is dependent on the molecular mass of the protein, thus its 
mass can be determined from SE data (Ralston, 1993).  
 

a(r,t)  c(s)(s,D(s),r,t)ds
Chapter 1 Introduction 
 
 
39 
         
 
Figure 1-17. Sedimentation equilibrium experiment 
The opposing forces, sedimentation and diffusion, act on proteins until a concentration gradient is 
achieved where no net movement is observed. The steepness of the gradient curve depends on the 
size of the protein; large proteins will pack towards the bottom of the cell resulting in steep curves 
(black) and vice versa for smaller proteins (blue). The length of the arrows denotes the increasing 
sedimentation force and diffusion, which occurs towards the base of the cell. Figure adapted from 
Ralston, 1993.  
 
 
Sedimentation is proportional to 2r and r increases towards the bottom of the cell, thus 
the sedimentation force increases towards the bottom of the cell (Ralston, 1993). 
Therefore, there must be a higher degree of diffusion at the bottom of the cell to counteract 
the sedimentation force. Diffusion is dependent on the concentration gradient, thus the 
protein concentration increases towards the bottom of the cell (Ralston, 1993). For an ideal 
non-associating single species the following equation can be used to determine the 
molecular mass (M) from the concentration gradient 
 
        (1.17) 
 
where c is the concentration of the protein (Ralston, 1993). Thus, for a single ideally 
sedimenting species at equilibrium a slope proportional to the molecular mass can be 
obtained by plotting the log concentration against the radius squared (Ralston, 1993). 
 
For a mixture of non-interacting ideal species the following equation can be used 
(Lebowitz et al., 2002) 
 
  
   (1.18)
 

M 
2RT
(1 v) 2

d(lnc)
dr2

a(r)  cn,0ndexp
n

Mn (1 vn)
2
2RT
(r2  r0
2)






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where a(r) is the measured signal as a function of the radial position, cn,0 is the molar 
concentration of species n at position r0, Mn is the molecular mass,  is the partial specific 
volume, n is the molar extinction coefficient, d is the optical path length of the sector (1.2 
cm), and  is the baseline offset, which compensates small imperfections due to cell 
assembly, data acquisition and differences between protein sample and buffer (Lebowitz et 
al., 2002). SE data were analysed using the programme SEDPHAT (Schuck, 2003; Vistica 
et al., 2004), which uses the above equations amongst others to fit the experimental data. 
Analyses in this thesis were carried out using the single species non-interacting discrete 
species model to obtain the apparent whole-cell weight average molecular mass (Mw,app). A 
two or three species non-interacting discrete species model analysis was used to determine 
the molecular mass of each of the species in samples.  
 
While the equilibrium distribution is dependent on the molecular mass of an ideal single 
species protein, thermodynamic non-ideality due to elongated shape and/or the charge 
carried by proteins can complicate SE analysis (Ralston, 1993). This will affect the 
excluded volume of proteins, which for ideal globular proteins will be smaller than for 
non-ideal proteins, which in turn will affect how the molecules pack towards the base of 
the cell during an SE experiment. Decreasing Mw,app values as the concentration of the 
protein increases is indicative of thermodynamic non-ideality (Ralston, 1993). The 
magnitude of non-ideality can be determined from the second virial coefficient, which can 
be determined using the equation 
 
          (1.19) 
 
where B is the second virial coefficient (Ralston, 1993). Higher B values indicate greater 
thermodynamic non-ideality.  
 
 
 
 
 
 
 

v n

Mapp 
M
(1 BMc)
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1.6.2 Small angle X-ray scattering  
 
Small angle X-ray scattering (SAXS) was first developed by André Guinier in the late 
1930’s when he showed that X-ray scattering by particles at low angles contained shape 
and size information (Serdyuk et al., 2007b). SAXS has been used to study biomolecules 
in solution since the 1960’s with major advances in the 1970’s with the development of 
brighter synchrotron radiation (Svergun, 2007). Today, third-generation synchrotrons 
allow scattering from molecules with very short exposure times (seconds or less) to limit 
radiation damage to samples (Svergun, 2007). The major challenge in SAXS remains the 
accurate analysis of the low resolution data to obtain high quality three-dimensional 
structural information (Svergun, 2007). 
   
SAXS is a very useful tool to study proteins and other macromolecules such as DNA and 
RNA in their native state in solution. Recent advances in instrumentation and software for 
data analysis have enabled SAXS data to be used to obtain information about protein 
quaternary structure and flexibility, acquire low resolution (10 - 20 Å) ab initio models and 
calculate theoretical scattering curves for known crystal structures or homology models 
(Mertens and Svergun, 2010). The amount of protein required for an experiment depends 
on the synchrotron used. At second-generation beamlines, such as DORIS III at the 
European Molecular Biology Laboratory (EMBL)/Deutsches Elektronen-Synchrotron 
(DESY), Hamburg, Germany, 1-2 mg of protein is required. At third-generation 
synchrotrons, such as PETRA III (also at DESY), measurements can now be done on as 
little as 30 g of protein. The sample does need to be of high quality, ideally homogenous 
and not aggregate in solution for best results (Mertens and Svergun, 2010). Virtually any 
size of protein can be studied ranging from small 1-10 kDa polypeptides to large MDa 
viral capsids and sample environment effects (pH, salt concentration, temperature, addition 
of ligands, co-factors and other proteins) can easily be measured (Mertens and Svergun, 
2010). In cases where crystal structures cannot be obtained, SAXS provides important 
structural information. SAXS based solution structure envelopes can also be compared 
with crystal structures to see whether the native state of the protein is retained following 
crystallisation. The more advanced programmes available can also model missing 
structures, protein flexibility and oligomeric mixtures of proteins (Petoukhov et al., 2012). 
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1.6.2.1 SAXS instrumentation 
 
SAXS experiments were carried out at the X33 beamline at the EMBL/DESY, Hamburg, 
Germany. The beamline has since been decommissioned, however, X33 was a bending 
magnet beamline on the DORIS III storage ring, which operated at beam currents of 100 - 
140 mA with an X-ray wavelength of 0.15 nm and an electron energy of 4.5 GeV. The 
beam was directed through several slits and an X-ray mirror, which focused the beam and 
eliminated stray scattering (Roessle et al., 2007, Fig. 1-18). The beam was then passed 
through the sample and the data were collected on a 2D photon counting Pilatus 1M-W 
pixel X-ray detector positioned 2.6 m from the sample (Blanchet et al., 2012). The raw 
data were then fed into an automated SAXS data processing pipline (Petoukhov et al., 
2007) for analysis of results as described in section 2.7.4.  
                                                                 
 
 
 
Figure 1-18. SAXS beamline 
The beam passes though a primary slit (PS), the monochromator (Mono) and the first of several 
secondary slits (SS1) and is then focussed with the X-ray mirror. Before the beam is directed into 
the sample, parasitic scattering is eliminated with three more slits (SS2-4), two of which are in the 
experimental hutch. Scattering data can then be collected on a wide-angle X-ray scattering detector 
(WAXS) or a SAXS detector. The beam quality is monitored at several points (BM1-3). Figure 
taken from Roessle et al., 2007 with permission from the International Union of Crystallography 
(IUCr).   
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1.6.2.2 Theory of SAXS 
 
The scattering of X-rays by particles described here is based on the molecules being at 
infinite dilution, i.e. in conditions where no interparticle interactions take place. A 
schematic of SAXS is shown in Fig. 1-19. 
 
 
 
Figure 1.19. Scattering of X-rays in SAXS  
Schematic representation of a SAXS experiment where the incident X-rays (s0) are scattered (s1) by 
macromolecules in solution at an angle of 2. This results in the scattering vector s=s1-s0. Figure 
adapted from Mertens and Svergun, 2010.  
 
 
At infinite dilution all the scattered particles are identical and will have the same isotropic 
scattering amplitude (Serdyuk et al., 2007c; Mertens and Svergun, 2010). The scattering 
intensity (I(s)) is the sum of the scattering from all the particles (N) in the solution taking 
into account the different orientation of each particle (Serdyuk et al., 2007c). 
 
    
2
)()( sFNsI      (1.20) 
 
where s is the scattering vector given by s=s1-s0 and its magnitude is  (where 
2is the angle between the incident and scattering beam, and  is the wavelength, Fig. 1-
19) and N is the number of particles in the solution. The latter part of the equation is 
explained as follows. A wave that has been scattered by a single particle is expressed as a 
function of the scattering vector (Serdyuk et al., 2007c) 
  
       (1.21) 
 

4 sin() /

F(s)  f j exp(is rj )
j

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where fj is the scattering amplitude and rj the position of atom j. The scattering intensity is 
the wave amplitude squared (Serdyuk et al., 2007c)      
          (1.22)  
 
As each particle in the solution will scatter X-rays at different orientations, the  
brackets in equation 1.21 denote the averaged orientation of the particles (Serdyuk et al., 
2007c). The scattering intensity of proteins in solution also depends on the amount of 
protein in the solute, which is taken into account with the excess scattering length density, 
p(r), the difference between the electron density of the protein and the solute (Mertens 
and Svergun, 2010). Thus the final recorded scattering intensity, I(s), is  
 
        (1.23) 
 
where  denotes scattering intensity over all orientations and A(s) is the Fourier 
transformation of the excess scattering length density (Mertens and Svergun, 2010). 
Finally, the buffer scattering is subtracted from this to obtain the I(s) for the protein in the 
solution, which can then be analysed (Mertens and Svergun, 2010). 
 
 
1.6.2.3 Analysis of SAXS data 
 
SAXS experiments involve exposing the sample and reference buffer to X-rays, the 
scattering of which is collected with a specific SAXS detector (Fig. 1-18). Following data 
collection, primary analysis of the scattering data yields parameters that can then be used 
to obtain ab initio models of the studied protein. The ATSAS software developed by the 
Biological Small Angle Scattering Group lead by Dimitri Svergun is an advanced 
programme package that can be used to analyse all aspects of SAXS data (Petoukhov et 
al., 2012). PRIMUS is used for initial data reduction and processing such as buffer 
subtraction to obtain the final scattering curve (Fig. 1-20A & C). Guinier analysis can be 
carried out to determine forward scattering intensity at zero scattering angle, I(0), and the 
radius of gyration, Rg (Mertens and Svergun, 2010). The Guinier-plot is a good way of 
evaluating sample quality. A non-linear plot with increasing intensity at low angles is 
indicative of aggregation while decreasing intensity at low angles suggests inter-particle 
repulsion (Fig. 1-20B) (Mertens and Svergun, 2010).  

I(s)  F(s)
2
  
...

I(s)  I(s)

 A(s)A(s)

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Figure 1-20. Examples of SAXS data curves  
The figure shows (A) scattering curves and (B) Guinier plots for samples of BSA. The data in red 
(1) are an example of an aggregated sample, in black (2) an ideal sample resulting in good data and 
in blue (3) a sample showing inter-particle interaction. (C) The scattering curve and (D) the Kratky 
plot for lysozyme. The data in black (1) are from folded lysozyme, in red (2) partially unfolded 
lysozyme (in 8 M urea), data in blue (3) are also from partially unfolded lysozyme (at 90C) and in 
green (4) the lysozyme is completely unfolded (in 8 M urea at 90C). This figure was taken from 
Mertens and Svergun (2010) with permission from Elsevier. 
 
  
The molecular mass (M) of the studied protein can be determined using its forward 
scattering intensity, I(0), and that of a control protein with a known molecular mass, such 
as BSA 
         (1.24) 
  
PRIMUS can also be used to obtain the mass of a protein from the hydrated particle 
volume, or the Porod volume, which is 1.5-2 times the molecular mass in kDa (Mertens 
and Svergun, 2010). The folding state of the protein of interest can be determined with the 
Kratky plot (Fig. 1-19D, Doniach, 2001). Globular folded proteins will have a bell shaped 

M  MBSA 
[I(0) /c]protein
[I(0) /c]BSA
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curve at low angles. With unfolded proteins the curve continuously increases and partially 
folded proteins or muti-domain proteins with linkers give curves between these two.   
 
The programme GNOM (Svergun, 1992) can be used to obtain the maximum dimension 
parameter, Dmax, of a protein (Fig. 1-21). This is also an alternative method of obtaining 
the I(0) and Rg in real space (Mertens and Svergun, 2010). These parameters are 
determined from the distance distribution function, p(r), where r is the distance between 
pairs of scattering electrons within a molecule (Serdyuk et al., 2007c). The p(r) is an 
indirect Fourier transformation of the scattering intensity (Mertens and Svergun, 2010) 
 
        (1.25) 
 
where the integral over 0 -  is the Dmax value (Serdyuk et al., 2007c). The output file 
generated by GNOM containing the above information can then be used for ab initio 
modelling. 
 
 
 
 
Figure 1-21. The scattering curve and p(r) profiles for various molecules 
The scattering curve and distance distribution function for several different shapes calculated from 
bead models shown above the plots. This figure was taken from Mertens and Svergun (2010) with 
permission from Elsevier. 

p(r) 
r2
2 2
s2
0

 I(s)
sinsr
sr
ds
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1.6.2.4 Ab initio modelling of SAXS data  
 
Ab initio modelling of proteins in this study was carried out using DAMMIF (Franke and 
Svergun, 2009). The programme uses spheres, or dummy atoms, to model the scattering 
envelope using a simulated annealing method as described for the original widely used 
programme DAMMIN (Svergun, 1999). DAMMIN fills a search volume (a sphere with a 
radius (R) equal to half the maximum particle size (Dmax) with densely packed spheres with 
a radius of r0 << R, which are either assigned to the particle or solvent. A random dummy 
atom model (DAM) is formed and the scattering curve for that model is calculated and 
compared with the experimental data. To form a DAM representative of the experimental 
particle, a single solvent dummy atom is then chosen at random and assigned to be part of 
the particle. The scattering curve of the new DAM is calculated, compared with the 
experimental scattering data and penalties are implemented to take into account that for the 
final model all the dummy atoms must be interconnected. If the chosen sphere makes the 
DAM disconnected, the dummy atom is rejected from the model, likewise if connectivity 
is maintained the dummy atom is kept in the model. This is continued one sphere at a time 
until a satisfactory fit to the experimental data is reached. Calculating the scattering 
amplitudes for each potential model before accepting or rejecting the change made is very 
CPU intensive, thus DAMMIF (the F denoting fast) was developed, which is 25-40 times 
faster than DAMMIN (Franke and Svergun, 2009).  DAMMIF calculates the connectivity 
of a randomly selected sphere to the particle first before moving forward to calculate the 
scattering amplitudes. Also while DAMMIN completely randomises which beads are in 
particle and solvent phase within the search volume, DAMMIF starts with an isometric 
particle with a radius of gyration (Rg) determined from the experimental data, which 
reduces the amount of intermediate DAMs that need to be processed. In addition, 
DAMMIF was programmed to include an unlimited search volume. In DAMMIN, the 
initial search volume is defined before starting and this cannot be changed while the 
programme is running. This can lead to artefacts in cases where a sphere chosen for the 
particle phase is close to the border of the search volume. As the programme will not allow 
the DAM to extend past the borders, effects like artificial bending of the models can occur. 
DAMMIF has taken this into account by not limiting the search volume. If a dummy atom 
assigned to the particle is near the border, a new solvent phase bead is added to allow 
expansion and to make sure that solvent beads always surround the particle beads. 
Throughout modelling the structural similarity of the generated models is monitored using 
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normalised spatial discrepancy (NSD) and the model Rg. Higher NSD values indicate 
higher model flexibility. 
 
Ab initio modelling of flexible proteins cannot be done with DAMMIF, which is 
appropriate for macromolecules with more rigid structures. Flexible proteins can be 
modelled using the Ensemble Optimisation Method (EOM) (Bernado et al., 2007; 
Petoukhov et al., 2012). The programme can be used to model intrinsically unfolded 
proteins or multi-domain proteins with flexible linkers. The method is based on the 
assumption that the flexible protein can be in an average number of conformations, which 
represent the experimental data. The programme first generates a pool containing a large 
number of conformations (the default is 10,000), which cover the experimental 
configurational space. From this, a genetic algorithm is used to assign the appropriate 
models to subsets to generate an ensemble of models that fit the experimental data. The 
Dmax and Rg of the ensemble are determined and these can then be compared with the 
respective values obtained for the pool. The more variation there is in the Dmax and Rg 
values of the ensemble, the more flexible a protein is. Likewise, if the ensemble values lie 
within a tight peak compared with the pool, the protein is rigid. Representative structural 
envelope models are also generated for the ensemble. However, care must be taken not to 
over interpret the models as they are based on given crystal structures or homology models 
and, due to the flexibility of a protein, any of the given models may be as correct as 
another.    
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Chapter 2  
Materials and methods 
 
2.1 Chemicals, reagents and kits  
    
Agilent Technologies StrataClone PCR Cloning Kit 
Amersham   Autoradiography film 
Applied Biosystems POROS® PEEK™ 4.6 mm x 100 mm 1.7 ml column, 
POROS® MC 20 µm Self Pack® Media 
BD Biosciences  Mouse monoclonal anti-His-antibody 
BDH    Saponin 
Bio-Rad Bradford protein assay reagent, Econo-Pac® chromatography 
columns, Gene pulser electroporation cuvette (0.2 cm), 
Precision plus dual colour protein standard 
Blood Transfusion Service Human full blood  
BOC  Malaria culture gas (5% CO2, 1% O2, 94% N2)   
Eurogentec  Oligonucleotides 
Fisher Scientific 10x Phosphate buffered saline (PBS), ammonium 
persulphate, glycerol, low absorbance imizadole, Tris-base 
GE Healthcare Amersham Hybond-N+ nylon membrane, CDP Star 
detection solution, Gene Images AlkPhos Direct Labelling 
kit, GSTrap FF 1 ml column, HiLoad™ 16/60 Superdex 200 
gel filtration column, HiPrep 26/60 Sephacryl S-400 HR gel 
filtration column, HisTrap FF 1 ml column, Hyperfilm ECL, 
PD-10 desalting columns, PreScission Protease, Vivaspin™ 
sample concentrators  
GENEART AG* E. coli codon optimised gene synthesis (*from 2010 
onwards: GeneArt® Gene Synthesis, Life Technologies) 
Jacobus Pharmaceuticals WR99210 
Kodak  X-ray film 
Life Technologies Accuprime™ Pfx SuperMix, SybrSafe, Albumax, NuPAGE 
Bis/Tris 10% polyacrylamide gels, NuPAGE® MES SDS 
Running Buffer, Ultrapure™ agarose, Ultrapure™ low 
melting point agarose  
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Melford 1,10-phenanthroline, ampicillin, benzamidine, dithiothreitol 
(DTT), E-64, isopropyl β-D-thio-galactopyranoside (IPTG), 
leupeptin, -nicotinamide adenine dinucleotide (NAD+), 
reduced -nicotinamide adenine dinucleotide (NADH), 
proteinase K 
Millipore Aquacide II, Immobilon western chemiluminescent HRP 
substrate, Millex®-HV PVDF 0.45 m syringe filters 
Nalgene  1.0 ml cryotubes 
New England Biolabs 1 kb DNA ladder, all restriction enzymes and their buffers, 
blue gel loading dye (6x), T4 DNA ligase 
Novagen   BugBuster™ protein extraction reagent, benzonase 
PAA The Cell Culture Gentamycin, RPMI 1640 (with 25 mM HEPES and L- 
Company glutamine) 
Promega   pGEM-T-Easy Vector System I 
Qiagen Qiaquick gel extraction kit, Qiaquick PCR purification kit, 
Qiaprep spin DNA maxiprep kit, Qiaprep spin DNA 
miniprep kit, Ni-NTA agarose  
Roche    DNase 
Sigma 5-bromo-4-chloro-3-inodlyl--D-galactopyranoside (X-Gal), 
acrylamide/bisacrylamide 29:1, alcohol dehydrogenase, 
apoferritin, bovine serum albumin (BSA), butanol, 
chloramphenicol, coenzyme A, dextran blue, 
dihydrolipoamide, D-sorbitol, flavin adenine dinucleotide 
(FAD), glycine, hypoxanthine, kanamycin sulphate, 
lipoamide, lithium potassium acetyl phosphate, lysozyme, 
pepstatin A, phenol:chloroform:isoamyl alcohol 25:24:1, 
phenylmethanesulphonyl fluoride, phosphotransacetylase, 
Ponceau S, N,N,N’,N’-tetramethylethylenediamine 
(TEMED), thryoglobulin 
Takara TaKaRa Ex Taq™ polymerase (+ Mg2+ free buffer)  
Thermo Scientific GelCode Blue Safe Stain, Restore western blot stripping 
Buffer, SnakeSkin® 10 K MWCO 16 mm dry dialysis tubing  
VWR Giemsa stain 
Whatman   Protan® nitrocellulose membrane 
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2.2 Equipment 
  
Beckman Coulter  Avanti J-26 XP centrifuge with rotors JA25.50 and JSP F10, 
Optima analytical ultracentrifuge XL-I with An-60 Ti 4 and 
An-50 Ti 8 hole rotors, AUC sample cell parts: 12 mm Epon 
charcoal-filled double sector centrepieces, sapphire 
windows, gaskets, screws and housing  
Bio-Rad Agarose gel tanks, GelDoc 2000, Trans-Blot® SD Semi-Dry 
transfer cell  
Clare Chemical Research  DarkReader transilluminator 
Constant Systems   One shot cell disrupter  
Eppendorf  Microcentrifuge 5415D with rotor F45-24-11, 
microcentrifuge 5415R with rotor F45-24-11 
Fisher Scientific AccuSpin™ MicroR refrigerated microcentrifuge with 
biocontainment rotor 13-100-515, agarose gel tanks 
GE Healthcare   ÄKTApurifier, UNICORN 5.1 software  
G Storm   PCR machine 
Grant     Heat block QBT2 
Heidolph   Titramax 100 shaker 
IKA    VXR basic Vibrax® with test tube insert 
Kuehner   Shaking incubator ISF-1-W 
Life Technologies  Xcell Surelock™ Mini-cell apparatus 
Perkin Elmer  Wallac 1450 MicroBeta Trilux liquid scintillation & 
luminescence counter, printed filter mat A 
Sanyo    CO2 incubator MCO-18A1C 
Scientific Industries  Genie 2 Vortex mixer 
Sciquip    Sigma 6K 15 centrifuge with rotors 11150 and 12500 
Shimadzu   UV-2501 spectrophotometer 
Thermo Scientific NanoDrop 1000 spectrophotometer, Heraeus Megafuge 16R 
with rotor 750033629 
Tom Tech Harvester 96™ Mach III 
UVP    HS-1000 hybridization oven and UV crosslinker 
Wolf Laboratories  Galaxy S CO2 incubator 
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2.3 Buffers, solutions, media 
 
2.3.1 DNA analysis 
 
1x TAE    40 mM Tris-acetate, 1 mM EDTA, pH 8.0 
6x DNA loading dye 0.25% (w/v) bromophenol blue, 0.25% (w/v) orange-
G, 0.25% (w/v) xylene cyanol FF, 40% (w/v) sucrose 
20x SSC     300 mM trisodium citrate, 3 M NaCl, pH 7-8 
Colony cracking lysis buffer 20% (w/v) sucrose, 0.5 M NaOH, 0.3 M KCl,     
0.025 M EDTA, 1.25% SDS 
Southern blot hybridisation buffer Gene images AlkPhos hybridization buffer, 0.5 M 
NaCl, 4% (w/v) blocking reagent 
Southern primary wash buffer 2 M Urea, 150 mM NaCl, 1 mM MgCl2, 50 mM 
sodium phosphate pH 7.0, 0.1% (w/v) SDS, 0.2% 
(w/v) blocking reagent 
Southern secondary wash buffer 50 mM Tris-base, 100 mM NaCl, 2 mM MgCl2  
TE      10 mM Tris-HCl, 1 mM EDTA, pH 8.0 
X-Gal stock solution 2% (w/v) 5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside (X-Gal) in dimethylformamide 
 
 
2.3.2 Protein analysis 
 
6x SDS loading dye 62.5 mM Tris-HCl pH 6.8, 2% (w/v) SDS, 10% (v/v) 
glycerol, 0.001% (w/v) bromophenol blue, 5% (v/v) 
mercaptoethanol 
Resolving gel 375 mM Tris-HCl, pH 8.9, 0.1% (w/v) SDS, 10% 
(v/v) acrylamide 
Stacking gel 122 mM Tris-HCl, pH 6.7, 0.1% (w/v) SDS, 5% 
(v/v) acrylamide 
Towbin buffer 25 mM Tris, 192 mM glycine, 20% (v/v) methanol 
pH 8.3 
Tris/glycine resolving buffer  25 mM Tris, 192 mM glycine, 0.1% SDS, pH 8.3
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2.3.3 Protein purification 
 
Table 2-1. Buffers used for purification of recombinant proteins  
Purification method Buffer name Buffer composition 
HisTrap FF HisTrap binding buffer  20 mM sodium phosphate, 300 mM NaCl, 20 mM imidazole, pH 7.4  
  HisTrap buffer A 20 mM sodium phosphate, 300 mM NaCl, pH 7.4  
  
HisTrap buffer B1  
(His-rPfE2m) 
20 mM sodium phosphate, 300 mM NaCl, 1 M imidazole, pH 7.4  
  
HisTrap buffer B2  
(His-rPfE2bc) 
20 mM sodium phosphate, 150 mM NaCl, 2 M imidazole, pH 7.4  
POROS  POROS binding buffer 50 mM potassium phosphate, 150 mM NaCl, 0.1 mM EDTA, 10 mM imidazole, pH 8.0 
  POROS buffer A 50 mM potassium phosphate, 150 mM NaCl, 0.1 mM EDTA, pH 8.0 
  POROS buffer B 50 mM potassium phosphate, 150 mM NaCl, 0.1 mM EDTA, 1 M imidazole, pH 8.0 
Ni-NTA Qiagen lysis buffer 50 mM sodium phosphate, 300 mM NaCl, 10 mM imidazole, pH 8.0 
  Qiagen wash buffer 1 50 mM sodium phosphate, 300 mM NaCl, 20 mM imidazole, pH 8.0 
  Qiagen wash buffer 2 50 mM sodium phosphate, 300 mM NaCl, 50 mM imidazole, pH 8.0 
  Qiagen elution buffer 50 mM sodium phosphate, 300 mM NaCl, 250 mM imidazole, pH 8.0 
GSTrap GSTrap binding buffer 1x PBS (140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.3) 
  GSTrap elution buffer 50 mM Tris-HCl, 10 mM reduced glutathione, pH 8.0 
  PreScission cleavage buffer 50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol, pH 7.0 
Gel filtration PEBS150 50 mM potassium phosphate, 150 mM NaCl, 2 mM EDTA, pH 7.4 
  PEBS150 + glycerol + DTT 50 mM potassium phosphate, 250 mM NaCl, 2 mM EDTA, 0.1% glycerol, 5 mM DTT, pH 7.4 
  PEBS250 50 mM potassium phosphate, 250 mM NaCl, 2 mM EDTA, pH 7.4 
Column maintenance Stripping buffer 1 M NaCl, 50 mM EDTA, pH 8.0 
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2.3.4 Bacterial culture 
 
Ampicillin    100 mg/ml in dH2O  
Chloramphenicol   34 mg/ml in 100% ethanol 
Kanamycin    50 mg/ml in dH2O 
Luria Bertani (LB) medium 10 g/L tryptone, 5 g/L yeast extract, 5 g/L NaCl 
LB agar    15 g/L agar into LB medium 
Super optimal broth with catabolite  
repression (SOC) medium  20 g/L tryptone, 5 g/L yeast extract, 10 mM NaCl, 
2.5 mM KCl, 10 mM MgCl, 10 mM MgSO4, 20 mM 
glucose   
Terrific Broth (TB) medium 12 g/L tryptone, 24 g/L yeast extract, 0.4% glycerol, 
9.4 g/L K2HPO4, 2.2 g/L KH2PO4, pH 7.2   
Tfb I 100 mM RbCl, 50 mM MnCl2, 30 mM potassium 
acetate, 10 mM CaCl2, 5% (v/v) glycerol   
Tfb II 10 mM MOPS, 10 mM RbCl, 75 mM CaCl2, 15% 
(v/v) glycerol  
 
 
2.3.5 Parasite culture  
 
5-fluorocytosine (5-FC)  4 mM 5-FC in dH2O 
Blood wash medium  16.37 g/L RPMI 1640 (with 25 mM HEPES and L-
glutamine), 0.1% (w/v) sodium bicarbonate, 10 mM 
glucose, 20 M hypoxanthine, 20 g/ml gentamycin, 
pH 7.4    
Complete RPMI 1640 medium Blood wash medium with 0.5% (w/v) Albumax II 
Cytomix 120 mM KCl, 0.15 mM CaCl2, 2 mM EGTA, 5 mM 
MgCl2, 10 mM potassium phosphate, pH 7.6, 25 mM 
HEPES, pH 7.6   
IC50 medium    Complete RPMI 1640 medium without hypoxanthine 
Freezing solution   PBS with 30% (v/v) glycerol 
Sorbitol solution 5% (w/v) sorbitol in 10 mM potassium phosphate, 
pH 7.2 
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Thawing solution 1   12% (w/v) NaCl 
Thawing solution 2   1.8% (w/v) NaCl 
Thawing solution 3   0.9% (w/v) sodium chloride, 0.2% (w/v) glucose 
WR99210    Stock solution: 20 mM in dimethylsulphoxide 
     Working solution: 20 M in blood wash medium 
 
 
2.4 Vectors, primers, constructs, bacterial and P. falciparum strains, 
antibodies 
 
2.4.1 Vectors  
 
Vectors used in this study were for cloning, protein expression and P. falciparum gene 
knockout.  
 
Table 2-2. Vectors and their selectable markers, use and source 
Vector Selectable marker Use  Source 
pGEM-T-Easy  ampicillin cloning Promega 
pSC-B-amp/kan ampicillin/kanamycin cloning 
Agilent 
Technologies 
pET-15b                  
(N-terminal His-tag) 
ampicillin 
protein 
expression 
GENEART AG 
pGEX-6P-1             
(N-terminal GST-tag) 
ampicillin 
protein 
expression 
GE Healthcare 
pCC-1 Ampicillin/human 
dehydrofolate reductase 
(hdhfr)/Saccharomyces 
cerevisiae cytosine 
deaminase and uracil 
phosphoribosyl transferase 
chimera 
P. falciparum 
gene 
knockout 
Maier et al., 2006 
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2.4.2 Primers 
 
Table 2-3. Primers used in this study 
Construct Name of primer Direction Primer sequence 
His-rPfE2bc (pET-15b) 
PfE2 binding 
domain fwd GCGC CATATG GAA ATG GTT CTG CCG AGC (NdeI) 
  
PfE2 catalytic 
domain rev GCGC GGATCC TTA TTA CAG AAA GAT CTT CAT GAT GTC C (BamHI) 
GST-rPfE2c (pGEX-6P-1) 
PfE2 catalytic 
domain fwd GCGC GGATCC AAA ACC GTT GAT ATG ACC AAT ATC C (BamHI) 
  
PfE2 catalytic 
domain rev GCGC CTCGAG TTA TTA CAG AAA GAT CTT CAT GAT GTC C (XhoI) 
pCC1 PfE2 knockout 
construct pCC PfE2 5'  fwd GAGC CCGCGG AGT TTT AAC TAC AGA GGA AAA CGA AAA TAT G (SacII) 
 pCC PfE2 5'  rev GAGC CTTAAG GGC AAC TTC TTT GTC TAA ATC TAC GAA C (AflII) 
 pCCPfE2 3'  fwd GAGC GAATTC CCT TTT ATA GAA ACA GGA AAA CAC CC (EcoRI) 
  pCCPfE2 3'  rev GAGC CCATGG CGC ATT TTA CAA ACC TTC CAT TC (NcoI) 
pCC1 PfaE3 knockout 
construct pCC PfaE3 5' fwd GAGC ACTAGT CTT AAC GTC GTT ACT CTA ATT TGG TTA TC (SpeI) 
 pCC PfaE3 5' rev GAGC CTTAAG GCG CTT TGC TTG GTA TAC AGC C (AflII) 
 pCC PfaE3 3' fwd GAGC GAATTC GCA CAC ACA GCA TCA TAT CAA G (EcoRI) 
  pCC PfaE3 3' rev GAGC CCTAGG TTA GTG AGT TCT TAT TTT TGA TAT AGA (AvrII) 
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2.4.3 Constructs 
 
Table 2-4. The insert, vector and purpose of the constructs used in this study 
 
2.4.4 Chemically competent bacterial strains 
 
Table 2-5. The genotype, use and source of chemically competent cells used in this study  
Chemically competent cells Genotype Use Source 
DH5 
F- Φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 hsdR17  
(rK
-, mK
+) phoA supE44 λ– thi-1 gyrA96 relA1 cloning Life Technologies 
StrataClone SoloPack 
Competent Cells F- Φ80lacZΔM15 recA1 endA1 (rK-) tonA (StrepR) cloning Promega 
BLR(DE3)  F- ompT hsdSB (rB
- mB
-) gal dcm (DE3) ∆(srl-recA)306::Tn10 (TetR) protein expression Novagen 
Rosetta™ 2(DE3)pLysS F- ompT hsdSB (rB
- mB
-) gal dcm (DE3) pLysSRARE* (CamR) protein expression Merck Millipore 
BL21 Star™(DE3) F- ompT hsdSB (rB
- mB
-) gal dcm (DE3) rne131  protein expression Life Technologies 
NovaBlue(DE3) 
endA1 hsdR17(rK
- mK
+) supE44 thi-1 recA1 gyrA96 relA1 lac (DE3)  
F'[proA+B+ lacI Z∆M15::Tn10] (TetR) protein expression Novagen 
*contains tRNA genes argU, argW, ileX, glyT, leuW, proL, metT, thrT, tyrU, and thrU. Rare codons AGG, AGA, AUA, CUA, CCC, and GGA are supplemented. 
Name Insert Vector Purpose 
His-rPfE2m E. coli codon optimised mature length PfE2, amino acids 51 - 640 pET-15b protein expression 
His-rPfE2bc E. coli codon optimised binding and catalytic domain of PfE2, amino acids 356 - 640  pET-15b protein expression 
GST-rPfE2c  E. coli codon optimised catalytic domain of PfE2, amino acids 429 - 640 pGEX-6P-1 protein expression 
His-rPfaE3-pET-15b E. coli codon optimised mature length apicoplast PfaE3, amino acids 101 - 667 pET-15b protein expression 
His-rPfaE3 Native mature PfaE3, amino acids 111 - 667 pQE30 protein expression 
pCC1 PfE2 5' flank (nucleotides 685-1190) and 3 ' flank (nucleotides 2119-2626) of PfE2 pCC1 knockout of PfE2 
pCC1 PfaE3 5' flank (nucleotides 37-526) and 3 ' flank (nucleotides 1456-2001) of PfaE3 pCC1 knockout of PfaE3 
Chapter 2 Materials and Methods 
 
 
 
58 
2.4.5 P. falciparum strains  
 
D10  Papua New Guinea  
3D7  The Netherlands 
 
 
2.4.6 Antibodies 
 
Antibodies in this thesis were used for western blot analyses. 
 
Table 2-6. Antibodies and their dilutions and sources 
Antibody Raised in 
Dilution for western 
blot Source 
Primary antibodies       
-His mouse 1:25000 BD Biosciences 
-GST rabbit 1:50000 GE Healthcare 
-LA rabbit 1:10000 Eurogentec 
Secondary antibodies       
-mouse IgG (H+L) HRP 
conjugate N/A 1:10000 Promega 
-rabbit IgG (H+L) HRP 
conjugate N/A 1:10000 Promega 
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2.5 Molecular biology methods  
 
2.5.1 Polymerase Chain Reaction (PCR) 
 
2.5.1.1 PCR of inserts for recombinant protein expression constructs 
 
For production of the His-rPfE2bc and GST-rPfE2c inserts (Table 2-4), 1 l of each primer 
(final concentration 0.4 M) and 1 l of the template were added to 22 l of AccuPrime™ 
Pfx SuperMix. The template used for the reaction was E. coli codon optimized His-rPfE2m 
construct (Table 2-4). The products from this reaction are blunt ended.  
 
The PCR conditions used were:  
 
Step 1  94°C, 4 min 
Step 2  94°C, 30 s 
Step 3  55 – 45°C, 30 s (touchdown method)  
Step 4  68°C, 1 min  
Repeat steps 2 - 4 for 35 cycles 
Step 5   68°C, 10 min  
Step 6  storage at 10°C  
 
 
2.5.1.2 PCR of inserts for P. falciparum gene knockout  
 
For double-crossover gene knockout, ~500 bp fragments homologous to the 5’ and 3’ ends 
of PfE2 and apicoplast PfE3 (PfaE3) were generated. For the PfE2 5’ and 3’ flanks and 
PfaE3 5’ flank (Table 2-4) AccuPrime™ Pfx SuperMix was used as described above. P. 
falciparum genomic DNA was used as template.  
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The PCR conditions were: 
 
Step 1   94°C, 4 min 
Step 2  94°C, 30 s 
Step 3  48.5°C, 30 s  
Setp 4  68°C, 1 min 
Repeat steps 2 – 4 for 35 cycles 
Step 5  68°C, 10 min  
Step 6  storage at 10°C  
 
 
The PfaE3 3’ flank (Table 2-4) was amplified using TaKaRa Ex Taq™ Polymerase. The 50 
l reaction mix consisted of 1.25 U of TaKaRa Ex Taq™ Polymerase, 0.2 mM of each 
dNTP, <500 ng genomic DNA template, 0.3 M of each primer in 1x Ex Taq™ buffer. The 
products from this PCR method contain TA overhangs. 
 
The PCR conditions were: 
 
Step 1   94°C, 4 min 
Step 2  94°C, 30 s 
Step 3  52°C, 1 min 
Setp 4  68°C, 1 min 
Repeat steps 2 – 4 for 35 cycles 
Step 5  68°C, 10 min  
Step 6  storage at 10°C  
 
 
2.5.2 Cloning 
 
2.5.2.1 Cloning recombinant protein expression constructs into intermediate vector 
 
The PCR products for His-rPfE2bc and GST-rPfE2c constructs, generated in section 
2.5.1.1, were purified using the Qiaquick PCR purification kit, as per manuafacturers 
instructions. The blunt ended fragments were then cloned into the intermediate vector  
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pSC-B-amp/kan (Fig. 2-1) using the StrataClone Blunt PCR Cloning Kit. The StrataClone 
Blunt Vector Mix contains two blunt-ended vector arms with covalently bound 
topoisomerase I on one end and a loxP recognition site on the other. The PCR fragment is 
ligated into the vector arms via the topoisomerase I. This intermediate is transformed into 
competent bacteria that transiently express Cre recombinase, which then mediates the 
recombination of the two loxP sites to form a circular plasmid. The ligation mixture 
contained the following components in order of addition: 3 l StrataClone Blunt Cloning 
Buffer, 2 l PCR product (5-50 ng) and 1 l StrataClone Blunt Vector Mix. The ligation 
mix was incubated at room temperature overnight and then stored at 4°C until 
transformation in the afternoon.  
 
 
                                 
Figure 2-1. Vector map of pSC-B-amp/kan 
The pSC-B-amp/kan vector contains amipcillin (AmpR 1268-2125 bp) and kanamycin (KanR 465-
1256 bp) resistance cassettes. The multiple cloning site (MCS 57-197 bp, green) contains the PCR 
product insertion site at base pair 123, which is flanked by EcoRI restriction sites, which can be 
used to perform diagnostic digests after ligation. The multiple cloning site (MCS) is in the middle 
of the -galactosidase -fragment coding sequence (lacZ’ 1-354 bp), which allows  blue-white 
colony screening in the presence of X-Gal. The lacZ’ is under the control of the lac promoter (lacP 
4153-4272 bp). The pUC origin of replication (pUC ori 3264-3931 bp) is present. <loxp> (2690-
2723 bp) denotes where the two loxP recognition sites have been recombined to form the circular 
plasmid.    
 
 
StrataClone SoloPack competent cells (Table 2-5) were transformed as described in section 
2.5.4. As the template used for the PCR of His-rPfE2bc and GST-rPfE2c inserts was a 
plasmid containing an ampicillin (Amp) resistance cassette, the transformation mix was 
grown on plates containing kanamycin (Kan) to prevent any carryover of template plasmid. 
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Blue-white colour screening was used to select colonies positive for the plasmid containing 
an insert. A total of 40 l of 2% (v/v) X-Gal (section 2.3.1) was spread onto Luria 
Bertani/kanamycin (LB/Kan) agar plates and allowed to dry before spreading the ligation 
mix. Colonies containing the plasmid (white colonies) were then screened using the colony 
cracking method (section 2.5.5). This was followed by plasmid mini preparations from 
selected colonies (section 2.5.6) and a restriction digest analysis (section 2.5.7) with EcoRI 
(Fig. 2-1). The sequence of plasmids displaying the correct restriction digest profile was 
determined (Source BioScience, LifeSciences) before the insert was subcloned into the 
final destination vector.  
  
 
2.5.2.2 Cloning recombinant protein expression constructs into final vectors 
 
The His-rPfE2bc and GST-rPfE2c inserts were excised from the intermediate pSC-B-
amp/kan vector using the appropriate restriction enzymes (NdeI/BamHI and BamHI/XhoI, 
respectively). The final vectors pET-15b (Fig 2-2) and pGEX-6P-1 (Fig 2-3), respectively, 
were digested with the same enzymes to allow directional cloning of the inserts.  
 
                
 
 
Figure 2-2. Vector map of pET-15b 
The pET-15b cloning/expression region (green) contains an N-terminal His-Tag™ (362-380 bp) 
followed by a thrombin cleavage site (336-353 bp) and the MCS (319-335 bp) with NdeI, XhoI and 
BamHI restriction sites. Expression is controlled by the T7lac promoter (436-469 bp), which in 
turn is repressed by lacI (LacI 866-1945 bp) for induction of protein expression with IPTG. The T7 
terminator (213-259 bp) is found after the MCS. The plasmid contains the pBR322 origin of 
replication (pBR322 3882-4501 bp) and has an ampicillin resistance cassette (AmpR 4643-5500 
bp). 
Chapter 2 Materials and Methods 
 
 
 
63 
 
       
 
Figure 2-3. Vector map of pGEX-6P-1  
The pGEX-6P-1 vector has an N-terminal GST-Tag™ (258-992 bp) followed by a PreScission™ 
Protease cleavage site (PreScission 918 - 938bp) and the MCS (943-979 bp, blue) with BamHI, 
EcoRI, SmaI, SalI, XhoI and NotI restriction sites. Expression is controlled by the tac promoter 
(Ptac 184-212 bp), which in turn is repressed by lacI (LacI 3324-4415 bp). The plasmid contains 
the pBR322 origin of replication (pBR322 2407-3026 bp) and has an ampicillin resistance cassette 
(AmpR 1392-2252 bp). 
 
 
Digestion reactions (50 l) contained 9 l of either insert of vector (~ 3 g), 1 l of each 
restriction enzyme, 5 l of the appropriate NEB buffer and 34 l of dH2O. The mix was 
incubated for 4-5 h at 37°C after which the digested DNA was separated on 1 % (w/v) 
Ultrapure™ low melting point agarose. The insert and vector were excised and extracted 
from the gel as described in section 2.5.9.  
 
Ligation of the inserts into the vectors was carried out using T4 DNA ligase (New England 
Biolabs). Two ligations for each vector/insert pair were prepared with varying amounts of 
insert. The ligation mix contained 3 l of vector, 6 or 12 l of insert, 1 l of T4 DNA 
ligase, 2 l of 10 x T4 DNA ligase buffer and was made up to 20 l with dH2O. Ligation 
was carried out overnight at room temperature. In the morning the mixtures were 
transferred into storage at 4°C and transformation into DH5 chemically competent cells 
(Table 2-5) was carried out in the afternoon as described in section 2.5.4 using 
LB/ampicillin (LB/Amp) agar plates. Restriction digests (section 2.5.7) were carried out to 
determine transformed colonies, and plasmid with the correct restriction digest profiles was 
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sequenced (Source BioScience, LifeSciences) before subsequent use in recombinant 
protein expression.  
 
 
2.5.2.3 Cloning PfE2 and PfaE3 knockout constructs into intermediate vectors 
 
The PfE2 5’ and 3’ flanks and PfaE3 5’ flanks were cloned into the pSC-B-amp/kan 
intermediate vector as above (section 2.5.2.1). PCR of PfaE3 3’ was carried out using 
TaKaRa Ex Taq™ Polymerase (section 2.5.1.2), which creates TA overhangs; therefore the 
PCR fragments were subcloned into the pGEM®-T Easy Vector (Fig. 2-4) using the 
pGEM®-T Easy Vector System kit (Promega).  
 
 
 
 
 
Figure 2-4. Vector map of pGEM®-T Easy Vector 
The MCS (10-128 bp) for the pGEM®-T Easy Vector is located within the -galactosidase -
fragment coding sequence (lacZ’ 166-395, 2836-2996 bp). The MCS is flanked by EcoRI 
restriction sites, which can be used to cut the PCR fragment out with a single digest. The vector has 
an ampicillin resistance cassette (AmpR 1337-2197 bp) and a pUC origin (523-1190 bp). 
 
 
The ligation reaction (10 l) contained 5 l 2x Rapid Ligation Buffer, 1 l pGEM®-T Easy 
Vector, ~80 ng purified PCR product and 1 l T4 DNA ligase. The mixture was incubated 
overnight at room temperature. In the morning the ligations were transferred into storage at 
4°C and transformation into DH5 chemically competent cells (Table 2-5) was carried out 
in the afternoon. Blue/white selection was carried out on LB/Amp agar plates 
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supplemented with 0.5 mM isopropyl β-D-thio-galactopyranoside (IPTG) and 80 g/ml X-
Gal. Colony cracking (section 2.5.5) was carried out to screen colonies positive for 
plasmid, which was followed by restriction digest analysis (section 2.5.7) to determine 
which plasmid DNA to send for sequencing (The Sequencing Service, Dundee) before 
subcloning into final vector.  
 
 
2.5.2.4 Cloning PfE2 and PfaE3 knockout constructs into final vector 
 
Ligation of each flank into the final pCC-1 vector (Fig. 2-5) was carried out one at a time 
as described in section 2.5.2.2. For restriction enzymes used for each flank see Table 2-3. 
The 5’ flank was cloned first into the pCC-1 vector. This was then sequenced (The 
Sequencing Service, Dundee) before inserting the 3’ flank into the same vector. A final 
sequencing of the finished construct was carried out before transfection into P. falciparum.  
 
    
 
 
Figure 2-5. Vector map of pCC-1 
The pCC-1 vector contains multiple cloning sites at 2856-2888 bp and 5014-5048 bp. The fragment 
corresponding to the 5’ flank of the gene of interest is cloned into the former using the restriction 
sites SacII, SpeI or AflII. The 3’ fragment is inserted into the second MCS using EcoRI, NcoI or 
AvrII restriction sites. pCC-1 includes the ampicillin resistance cassette (AmpR 5492-6352 bp) for 
selection in E. coli during cloning. For positive selection of parasites harbouring transfected 
plasmid, the vector contains a human dehydrofolate reductase (hdhfr 3881-4442 bp) resistance 
cassette under the control of the P. falciparum calmodulin promoter (PfCAM 5’ 2890-3874 bp). At 
the 3’ end the P. falciparum histidine rich protein II 3’ UTR (PfhrpII 449-5015 bp) is present. For 
negative selection of parasites with plasmid integration into the genome, the vector contains the S. 
cerevisiae cytosine deaminase (cyd) gene as a bifunctional chimeric protein with S. cerevisiae 
uracil phosphoribosyl transferase (cyd 886-2007 bp) under the control of the P. falciparum heat 
shock protein 86 promoter with the P. berghei dhfr terminator (PbDT 3’ 9-853 bp) at the 3’ end.     
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2.5.3 Generation of chemically competent cells  
 
A 5 ml overnight culture was incubated at 37ºC with shaking at 200 rpm. This was used to 
inoculate 500 ml (1/1000 dilution of overnight culture) of LB medium and the bacteria 
were grown at 37ºC with shaking at 200 rpm until mid–log phase (OD600 = 0.5 – 0.6). The 
culture was then cooled on ice for 15 min and the bacteria harvested by centrifugation at 
4000 g for 10 min at 4ºC. The bacterial pellet was resuspended in 30 ml Tfb I and 
incubated on ice for 15 min. The cells were then spun down at 4000 g for 5 min, the 
supernatant was removed and the bacteria resuspended in 6 ml Tfb II. The now chemically 
competent cells were flash frozen in dry ice in 50 l aliquots in 1 ml tubes and stored at  
-80ºC.  
 
 
2.5.4 Transformation of chemically competent cells  
 
A total of 1 l of plasmid or 2-5 l of ligation mixture was added to a 50 l aliquot of 
chemically competent E. coli, which had been thawed on ice. The mixture was incubated 
for 20 min on ice, after which the cells were heat shocked in a 42ºC water bath for 45 s to 
induce insertion of DNA into the bacteria. The mixture was immediately cooled on ice for 
2 min, which was followed by addition of 250 l of SOC medium (section 2.3.4) pre-
warmed to 37ºC. The mix was incubated at 37ºC with shaking at 200 rpm for 1 h to allow 
recovery of bacteria, after which aliquots of 50 l and 200 l were spread onto LB agar 
plates containing the appropriate antibiotic and any possible additive (IPTG/X-Gal) 
required for a cloning step (section 2.5.2). For chemically competent cells used for cloning 
and for protein expression see Table 2-5. 
 
 
2.5.5 Colony cracking 
 
This method, as described by Barnes (1977), is an easy way to screen a large number of 
colonies for the presence of plasmid DNA containing an insert. It is based on the differing 
migration of bacterial DNA compared with plasmid DNA with and without insert. On each 
occasion, 17 positive colonies (white) and 3 negative control colonies (blue) from a blue-
white colony screening plate containing 2% (v/v) X-Gal were tested. Each colony was 
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transferred onto an agar plate with a grid reference (LB/Kan with X-Gal as in section 
2.5.2.1, or LB/Amp with IPTG and X-Gal as in section 2.5.2.3), and then resuspended in 
20 l colony cracking lysis buffer (section 2.3.1). This was then incubated at 55°C for 30 
min after which each suspension was mixed for 30 s to shear genomic DNA. A total of 4 l 
DNA loading dye (New England Biolabs) was added and the mixtures were vortexed again 
for 30 s. The samples were centrifuged for 1 min at 16,000 g to pellet any cell debris. The 
DNA in the samples was then separated on a 0.8% agarose gel at 50 V for several hours 
and the the electrophoretic mobility of DNA isolated from potential positive colonies 
(white) and the DNA isolated from negative controls (blue colonies) was compared . 
Plasmid DNA bands were visible between the E. coli genomic DNA (20 – 30 kb) and the 
low molecular mass (~500 bp) RNA.  
 
 
2.5.6 Purification of plasmid DNA from bacteria 
 
Depending on the amount of plasmid DNA to be isolated, two different methods were 
used. Both methods involve lysis of bacteria using SDS, precipitation of bacterial proteins 
and DNA with alkaline solution and purification of DNA using silica columns.  
 
For small-scale purification of plasmid DNA (generally for 10 - 30 g DNA) the Qiaprep 
Spin Miniprep Kit (Qiagen) was used. A single colony from a bacterial transformation was 
used to inoculate 2-10 ml LB medium with the appropriate antibiotic. The cultures were 
grown overnight at 37ºC with shaking at 200 rpm. The bacteria were harvested by 
centrifugation at 16,000 g for 3 min and DNA purified as per manufacturer’s instructions. 
Elution of DNA from the silica column was performed with 30 - 50 l of distilled water 
(dH2O).  
 
The Qiaprep Spin Maxiprep Kit (Qiagen) was used for large-scale purification (~ 0.7 mg 
DNA). Overnight pre-cultures were prepared by inoculating 2 ml of LB/Amp with a single 
colony from a transformation reaction and grown at 37ºC with constant shaking at 200 
rpm. This was used to inoculate 500 ml of TB/Amp, and the bacteria were grown overnight 
at 37ºC with shaking at 200 rpm. The bacteria were harvested by centrifugation at 4000 g 
for 15 min and the plasmid purified as described in the manufacturer’s instructions. 
Precipitated DNA was redissolved in 200 l of TE buffer (section 2.3.1).  
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2.5.7 Restriction endonuclease digests 
 
Restriction endonuclease digests were performed using enzymes and their appropriate 
buffers from New England Biolabs. Digests were carried out in a 37ºC incubator to avoid 
loss of any sample due to evaporation. For restriction digests of plasmid, 2 - 6 l of 
plasmid purification was digested for 1.5 - 2 h before electrophoresis. Digestion of 
genomic DNA (2 - 2.5 g) was carried out overnight.  
 
 
2.5.8 Agarose gel electrophoresis  
 
For separation of digested DNA fragments, agarose gel electrophoresis was used. Agarose 
(0.8-1% w/v) was dissolved in 1x TAE buffer (section 2.3.1) and 0.5 g/ml of Sybr Safe 
was added. Electrophoresis of DNA samples mixed with 6x DNA loading dye was carried 
out in 1x TAE buffer at 5-10 V/cm. A 1 kb DNA ladder was run next to the samples to 
determine the sizes of DNA fragments. DNA was visualised by taking a picture with a UV 
illuminator (GelDoc 2000, BioRad).   
 
 
2.5.9 Gel extraction  
 
For extraction of DNA from gels, low melting point agarose was used to separate the DNA 
fragments. A DarkReader transilluminator (Clare Chemical Companies) was used to 
visualise the DNA and a scalpel was used to cut the fragments out, trimming off as much 
of the surrounding gel as possible. The QIAQuick Gel Extraction Kit (Qiagen) was used to 
extract the DNA as per manufacturer’s instructions. DNA was eluted in 30 - 50 l of 
dH2O.   
 
 
2.5.10 Determining DNA concentration 
 
DNA concentrations were determined spectrally at 260 nm using a NanoDrop 1000 
operated with ND-1000 V.3.7.0 software (Thermo Scientific). The A260nm:A280nm and 
A230nm:A260nm ratios, respectively were recorded to determine purity of the DNA. 
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2.5.11 Southern blot 
 
Southern blots were performed to determine the genotype of P. falciparum mutant and 
wild-type lines. A total of 2 – 2.5 g of genomic DNA and 0.2 ng of the plasmid used for 
transfection were digested at 37ºC overnight with appropriate restriction enzymes in a 30 
l reaction volume. The digested DNA was mixed with 6x DNA loading buffer and 
separated on 0.8% agarose gel. The initial current was set at 100 V for 10 min to allow 
DNA to enter the gel, which was followed by separation of digested DNA at 40 – 50 V for 
 - 6 h. A 1 kb DNA ladder was included on both sides of the gel. Following separation, 
the gel, with a fluorescent ruler next to it, was photographed so that migration distances of 
DNA fragments could be determined in relation to the DNA standards on either side of the 
gel. The gel was soaked in 250 ml 0.25 M HCl for 10 min followed by 2 x 10 min wash 
with dH2O. A further 2 x 15 min incubation in 250 ml of 0.4 M NaOH was carried out. 
Transfer of DNA to a Hybond-N+ nylon membrane (GE Healthcare) was performed 
overnight in a sandwich as shown in Figure 2-6.  
 
 
 
Figure 2-6. Southern blotting apparatus 
Transfer of DNA to a Hybond-N+ nylon membrane was carried out using capillary blotting where 
the membrane is placed between the gel and absorbent paper towels to draw the 0.4 M NaOH 
through the gel using capillary action.  
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Following transfer of DNA, the wells were marked with a pencil and the membrane was 
washed in 2x SSC buffer (section 3.2.1) for 10 min and air-dried. The DNA was then fixed 
onto the membrane by UV cross-linking (254 nm) at 700 x 100 J/cm2).  
 
The probes used to detect DNA fragments were either gene specific, or specific for the 
selectable markers of the pCC-1 plasmid (Fig. 2-5). The probes were generated by PCR or 
isolated by restriction digest from the pCC-1 transfection plasmid and labelled using the 
Gene Images AlkPhos Direct Labelling kit (GE Heathcare) as instructed by the 
manufacturer. The membrane was incubated overnight at 60ºC in hybridisation buffer 
(section 2.3.1) with the labelled probes. The membranes were then washed 3 x 15 min with 
50 ml primary wash buffer (section 2.3.1) at 60ºC followed by 2 x 10 min with 100 ml 
secondary wash buffer (section 2.3.1) at room temperature. To visualise the probes, the 
membrane was incubated for 5 min with CDP Star detection solution (GE Healthcare) 
followed by exposure of the membrane to autoradiography film for 30 – 90 min 
(Amersham).   
 
 
2.5.12 Stripping a Southern blot membrane 
 
To strip a Southern blot membrane for re-probing, the membrane was incubated in 0.5% 
SDS for 1 h at 60ºC. The membrane was then washed twice in 2x SSC buffer (section 
2.3.1) for 10 min and air-dried before incubation with the new probe as described above.  
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2.6 Biochemical methods 
 
2.6.1 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
 
The Novex® NuPAGE® electrophoresis system (Life Technologies) was used for SDS-
PAGE. For expression trials, gels were self-made and consisted of a 5% polyacrylamide 
stacking gel and 10% polyacrylamide resolving gel (for gel mix compositions see 2.3.2). To 
make the SDS-PAGE gels, 20 l of ammonium persulphate (20% w/v) (Fisher Scientific) 
and 6 l of N,N,N’,N’-tetramethylethylenediamine (TEMED) (Sigma) were added to 
polymerise 6 ml of the resolving gel mix, which was poured into a Novex® 1 mm cassette 
(Life Technologies). A ~1 cm layer of butanol (Sigma) was added to ensure that the top of 
the resolving gel was level and to remove any air bubbles; the gel was left to polymerise for 
30 min. The butanol was then washed off with dH2O and 2 ml of stacking gel was mixed 
with 10 l of ammonium persulphate and 3 l of TEMED before it was poured on top of the 
separation gel. An appropriate comb was inserted immediately and the gel was allowed to 
set for at least 30 min before use. The gels were run in a Xcell Surelock™ Mini-cell apparatus 
with Tris/glycine resolving buffer (section 2.3.2) at a constant current of 20 mA until the 
protein had migrated through the stacking gel into the resolving gel. After this, the current 
was increased to 40 mA. During protein purification, pre-cast NuPAGE Bis/Tris 10% 
polyacrylamide gels were used with 1x NuPAGE® MES SDS Running Buffer (Life 
Technologies) as this combination allowed faster resolving of proteins between purification 
steps at a constant voltage of 200 V. Protein samples were prepared by denaturing for 10 
min at 100ºC in 1x SDS loading dye (section 2.3.2). Following separation the gels were 
stained in GelCode Blue Safe Stain (Thermo Scientific) for 30 min to 1 h and washed in 
dH2O for 2-3 h to destain.   
 
 
2.6.2 Western blot analyses  
 
A Trans-Blot® SD Semi-Dry Transfer Cell from Bio-Rad was used to transfer protein onto 
Protan nitrocellulose membrane (Whatman) according to manufacturer’s instructions. 
Transfer was in a down-ward direction in a sandwich made up of five pieces of Whatman 
paper soaked in Towbin buffer (section 2.3.2) on the top followed by the SDS-PAGE gel, 
nitrocellulose membrane and another five Whatman paper pieces all soaked in Towbin 
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buffer. A fixed voltage of 20 V was applied, while the transfer time varied between 40 – 75 
min, depending on the size of the protein and number of gels being transferred. The 
membranes were then stained with Ponceau S (Sigma) to confirm protein transfer and the 
lanes were marked with a pencil. Following removal of the Ponceau S with repeated 
washing with PBS containing 0.1% (v/v) Tween 20 (PBS/Tween20) the membrane was 
blocked on a shaker for either 1 h at room temperature or overnight at 4ºC in 5% (w/v) 
skimmed milk in PBS. After blocking, membranes were washed 3 x 10 min in 
PBS/Tween20. The membrane was then incubated for 1 h with shaking in primary 
antibody at the required dilution (Table 2-6) in 2% skimmed milk in PBS/Tween20. The 
membrane was again washed for 3 x 10 min in PBS/Tween20 and incubated for another 1 
h in secondary antibody at the appropriate dilution (Table 2-6) in 2% skimmed milk in 
PBS/Tween20. Following the final 3 x 10 min wash in PBS/Tween20, the horseradish 
peroxidase (HRP) conjugated secondary antibodies were detected with Immobilon Western 
Chemiluminescent HRP Substrate (Millipore) and visualised by exposing blots to X-ray 
films (Kodak).  
 
 
2.6.3 Stripping a western blot  
  
To strip a western blot for analysis with another antibody, the membrane was first washed 
for 5 min in PBS and then sealed into a plastic bag with 10 ml of Restore western blot 
stripping buffer (Thermo Scientific) and incubated at 37ºC for 30 min. The membrane was 
washed for 5 min in PBS/Tween20 before resuming with blocking, washing and re-probing 
the membrane as described above (section 2.6.2). 
  
 
2.6.4 Recombinant protein test expressions  
 
To obtain the most favourable expression conditions small-scale expression trials were 
carried out. Single colonies were inoculated into 2 ml of LB/Amp medium and grown 
overnight at 37ºC with shaking at 200 rpm. A total of 50 l of the overnight culture was 
added to 50 ml of LB/Amp medium and the cultures were grown at 37ºC with shaking at 
220 rpm until mid–log phase (OD600nm = 0.5 – 0.6). The cultures were then placed into 
incubators at various temperatures (15ºC, 18ºC, 25ºC, 30ºC and 37ºC) and expression was 
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induced with 0.5 – 5 mM of IPTG. For analysis of protein expression, 1 ml samples of the 
cultures were taken before induction (0 h) and after 1 – 4 h expression and after overnight 
expression. The samples were centrifuged at 16,000 g for 3 min to remove the medium and 
the pellets were stored at -20ºC awaiting further analysis.   
 
 
2.6.5 BugBuster protein extraction 
 
To extract the protein from the test expression experiment, the pellets were resuspended in 
100 l of BugBuster protein extraction reagent (Novagen), which contains a proprietary 
mixture of non-ionic detergents that disrupt bacterial cells without denaturing the protein. 
To degrade DNA and RNA, 0.5 l benzonase (Novagen) was added and to prevent protein 
degradation protease inhibitors were added at the following final concentrations; 20 M 
leupeptin, 2 M pepstatin A, 1 mM phenylmethanesulphonyl fluoride (PMSF), 1 mM 
benzamidine, 2 M 1,10-phenanthroline and 10 M E-64. The samples were incubated at 
room temperature for 15 min with shaking at 1500 rpm (VXR basic Vibrax® with test tube 
insert, IKA) and centrifuged for 15 min at 16,000 g at 4ºC. The supernatant, which 
contained the soluble protein fraction, was transferred into a new 1 ml tube and the 
remaining pellet was resuspended in 100 l of PBS with the above protease inhibitors. A 
15 l aliquot of the supernatant and 2 l aliquot of the resuspended pellet were mixed with 
1 x SDS loading dye, denatured at 100ºC for 10 min, separated by SDS-PAGE and 
analysed by western blotting.   
 
 
2.6.6 Large-scale recombinant protein expression 
 
Recombinant proteins were expressed in E. coli. Strains, temperature and time of 
expression and the amount of IPTG used for induction were optimised and are described in 
Table 2-7. Recombinant protein expression with a colony from a glycerol stock was poor, 
thus each time a freshly transformed bacterial colony was used to inoculate a 10 ml 
LB/Amp starter culture, which was incubated overnight at 37ºC with shaking at 220 rpm. 
For each expression batch, 8 x 500 ml of TB/Amp medium were inoculated with 1 ml of 
the overnight culture. The bacteria were grown at 37ºC with shaking at 220 rpm to an 
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OD600nm of 0.6-0.8, after which the cultures were cooled to the optimum temperature for 
expression of each construct before induction with 0.5 - 1 mM IPTG. The cultures were  
Table 2-7.  Large-scale expression conditions 
The host E. coli strain, temperature, time and concentration of IPTG used for induction of each 
construct. Also shown are the buffers in which the harvested bacterial pellets were resuspended 
(Table 2-1 for buffer compositions).  
 
Construct  Host E. coli 
Temp 
ºC Time 
[IPTG] 
(mM) 
Resuspension 
buffer 
His-rPfE2m 
Rosetta™ 
2(DE3)pLysS 18 overnight 0.5 
POROS binding 
buffer 
His-rPfE2bc BLR(DE3) 25 overnight 1 
HisTrap binding 
buffer 
GST-rPfE2c BLR(DE3) 18 overnight 1 GST binding buffer 
His-rPfaE3 NovaBlue(DE3) 30 overnight 1 Qiagen lysis buffer 
 
 
then incubated overnight at the appropriate temperature with constant shaking at 220 rpm. 
Bacteria were harvested by centrifugation at 3000 g for 15 min at 4ºC. The pellets were 
resuspended in the appropriate buffer required for the purification method to be used 
(Table. 2-7). Protease inhibitors (20 M leupeptin, 2 M pepstatin A, 1 mM PMSF, 1 mM 
benzamidine, 2 M 1,10-phenanthroline and E-64 10 M) were added to the resuspended 
pellets and stored at -20ºC until purification. For His-rPfaE3 overexpression, flavin 
adenine dinucleotide (FAD) was added to a final concentration of 100 M. 
 
 
2.6.7 Protein extraction for purification 
 
Bacterial pellets were defrosted at room temperature and 50 g/ml lysozyme (Sigma) was 
added to lyse bacterial cell walls, 1 g/ml of DNase (Roche) was added to degrade DNA 
and RNA, and to prevent protein degradation, protease inhibitors (20 M leupeptin, 2 M 
pepstatin A, 1 mM PMSF, 1 mM benzamidine, 2 M 1,10-phenanthroline and 10 M E-
64) were also added. The mixture was incubated on ice for 30 min after which the OneShot 
(PSI) programme set to 15 kpsi on the OneShot Cell Disrupter was used to disrupt the 
bacteria. The lysate was centrifuged at 48,000 g for 1 h, and filtered through a 45 m 
Millex®-HV PVDF syringe filter (Millipore) before use in various purification columns. 
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2.6.8 Recombinant protein purification 
 
Recombinant protein was purified on an ÄKTApurifier controlled by UNICORN 5.1 
software (both GE Healthcare). Programmes were set on the UNICORN software to load, 
wash and elute protein from the column. All buffers used are listed in Table 2-1. The 
buffers, dH2O and 20% ethanol were passed though a 0.22 m filter and degassed for at 
least 30 min before use.  
 
 
2.6.8.1 Nickel HisTrapFF 
 
HisTrap FF columns are packed with Ni Sepharose 6 Fast Flow medium, which contains 
90 m highly cross-linked agarose beads with a chelating group to bind metal ions. The 
column was used at a flow rate of 1 ml/min. On its first use, to prepare a 1 ml HisTrap FF 
(GE Healthcare) column charged with Ni2+ for purification, the column was washed with 
10 column volumes (CV) of dH2O and equilibrated with 5 CV of HisTrap binding buffer. 
When the column was reused, binding capacity was maintained by washing the HisTrap FF 
with 10 CV of dH2O, stripping the metal ions with 10 CV of Stripping buffer followed by a 
wash with 10 CV of HisTrap binding buffer followed by 10 CV of dH2O. The column was 
then recharged with 0.5 ml 0.1 M NiSO4, washed with 5 CV of dH2O and equilibrated with 
5 CV of HisTrap binding buffer before use. A total of 15 ml of filtered protein lysate was 
loaded onto the column and the flow-through collected into a separate tube. HisTrap buffer 
A (no imidazole) and buffer B1 and B2 (1 and 2 M imidazole, respectively) were mixed by 
the ÄKTApurifier to obtain the required imidazole concentration for each wash and elution 
step. An initial 2 CV wash with 10 mM imidazole was followed by a second wash for 5 – 
10 CV with 40 mM imidazole. Elution was either with a step-wise increase in imidazole 
concentration (100 mM, 400 mM and 1 M) as for His-rPfE2m or by a linear imidazole 
concentration gradient (40 mM - 2 M) as for His-rPfE2bc. The wash and elution steps were 
collected in 1 ml fractions and were analysed by SDS-PAGE and western blot along with 
the flow-through. All the samples were stored at 4ºC. After purification the column was 
washed with 10 CV of dH2O and 10 CV of 20% ethanol in which it was stored in at room 
temperature.   
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2.6.8.2 Zinc POROS® PEEK™ MC 
  
A POROS® PEEK™ 1.7 ml column was manually packed in-house with POROS® MC 20 
µm Self Pack® Media using the ÄKTApurifier. The column was stripped of metal ions 
prior to each purification with 10 CV of Stripping buffer, washed with 10 CV of dH2O and 
re-charged with 30 CV of 0.25 M ZnSO4. This was followed by a 10 CV wash with dH2O 
followed by 10 CV of 0.25 M NaCl to remove any ionically bound metals. To improve 
selectivity and binding, the column was saturated with imidazole (5 CV of POROS buffer 
B with 1 M imidazole). This displaces water molecules on the metal interaction sites with 
the elution agent, resulting in a reduction in binding strength, which improves selectivity. 
The final step was to equilibrate the column with 10 CV of POROS binding buffer (10 mM 
imidazole). The column preparation steps were carried out at a flow rate of 10 ml/min, 
while the following purification steps were performed at 5 ml/ml. Protein lysate was 
filtered and 15 ml loaded onto the column and the flow-through collected for analysis. 
POROS Buffer A (no imidazole) and Buffer B (1 M imidazole) were mixed by the 
ÄKTApurifier to obtain the required imidazole concentration for each wash and elution 
step. A preliminary 5 CV wash with 10 mM imidazole was followed by elution of protein 
with a step-wise increase in imidazole concentration (100 mM, 500 mM and 1 M). Elution 
fractions (1.7 ml) were collected, and together with the flow-through analysed by SDS-
PAGE and western blot. Following purification the column was washed with 10 CV of 
dH2O followed by 10 CV of 20% ethanol in which it was stored in at room temperature.   
 
 
2.6.8.3 Ni-NTA batch purification 
 
His-rPfaE3 was purified using a batch purification method with Ni2+- nitrilotriacetic acid 
(Ni-NTA) agarose (Qiagen). Filtered bacterial lysate was incubated with 1 ml of 50% Ni-
NTA resin per litre of bacterial culture for 1 h at 4ºC with rotation on a blood wheel. The 
mix was then poured into an Econo-Pac® chromatography column (Bio-Rad) and the flow-
through was collected by gravity flow. The Ni-NTA resin was washed twice with 4 ml of 
Qiagen wash buffer 1 (20 mM imidazole) and once with 4 ml of Qiagen wash buffer 2 (50 
mM imidazole). His-rPfaE3 was eluted from the Ni-NTA beads with 1 ml aliquots of 
Qiagen elution buffer (250 mM imidazole) and collected by gravity flow. The flow-
through, wash and elution fractions were stored at 4ºC and analysed by SDS-PAGE and 
western blot. The Ni-NTA agarose was not reused for subsequent purifications. 
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2.6.8.4 GSTrap FF 
 
For purification of GST-rPfE2c, GE Healthcare GSTrap FF 1 ml columns were used. The 
column is made of polypropylene with glutathione bound via a 10-carbon linker arm. 
Glutathione is the substrate for GST, thus it will bind GST-tagged proteins. Elution is 
achieved by displacing the GST-tagged protein with buffer containing reduced glutathione. 
The column was equilibrated with 5 CV of GSTrap binding buffer at a flow rate of 1 
ml/min. A total of 10 ml of filtered protein lysate was loaded onto the column at a flow 
rate of 0.2 ml/min to maximise the interaction time between the GST-tag and the 
glutathione-coated beads, as the binding kinetics are slow. The flow-through was collected 
into a separate tube. The column was washed with 10 CV of GSTrap binding buffer 
followed by elution of GST-rPfE2c with GSTrap elution buffer (10 mM reduced 
glutathione). The wash and elution steps were collected as 1 ml fractions. The flow-
through, wash and elution fractions were analysed by SDS-PAGE and western blotting.  
 
 
2.6.8.5 GST-tag removal 
 
The GST-tag on pGEX-6P-1 was cleaved using PreScission Protease (GE Heathcare). 
Cleavage was attempted both on eluted GST-rPfE2c and while the recombinant protein 
was still bound to the GSTrap column. For the former method, the reduced glutathione in 
the eluted GST-rPfE2c was removed by buffer exchange into PreScission cleavage buffer 
using a PD-10 column (GE Healthcare). The protein was incubated overnight at 4ºC with 
30 l (60 U) of PreScission Protease and loaded back onto an equilibrated GSTrap column 
to separate the GST-tag free protein. The GST molecule and PreScission protease should 
bind onto the column and the recombinant protein elute in the flow-through. For on-
column cleavage of the tag, GST-rPfE2c was not eluted from the GSTrap column. Instead 
following loading of protein, the column was washed with 10 CV of PreScission cleavage 
buffer. The PreScission protease (30 l (60 U) in 970 l PreScission cleavage buffer) was 
loaded onto the column using a syringe and the column incubated overnight at 4ºC. A 
syringe was used to elute the cleaved recombinant protein in 3 x 1 ml fractions of 
PreScission cleavage buffer. All fractions were analysed using SDS-PAGE and western 
blotting.  
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2.6.8.6 Gel filtration 
 
Gel filtration was carried out with HiLoad™ 16/60 Superdex 200 and HiPrep 26/60 
Sephacryl S-400 HR gel filtration columns at 4ºC. The columns were washed with 2 CV 
dH2O and equilibrated with 2 CV of the appropriate buffer (Table 2-1). A maximum 
volume of 5 ml and 10 ml of protein was applied to the Superdex 200 and Sephacryl S-400 
columns, respectively. Elution was carried out with 1.5 CV of the appropriate buffer at a 
flow rate of 0.75 ml/min for the Superdex 200 column and 1.3 ml/min for the Sephacryl S-
400 column. Elutions were collected in 1 ml fractions. Following purification, the columns 
were washed with 2 CV dH2O and 3 CV 20% ethanol in which they were stored in at 4ºC. 
Standards of known molecular mass were separated on both columns to generate a 
standard curve from which the molecular masses of the recombinant proteins could be 
estimated. The standards used were dextran blue (2 MDa, 0.6 mg/ml), thyroglobulin (669 
kDa, 2.5 mg/ml), apoferritin (440 kDa, 2.5 mg/ml), alcohol dehydrogenase (150 kDa, 2.5 
mg/ml) and bovine serum albumin (66 kDa, 2.5 mg/ml). 
 
 
2.6.9 Determination of protein concentration 
 
Protein concentrations were determined using the Bradford assay with bovine serum 
albumin as a standard (Bradford, 1976) using the 5 x Bio-Rad assay reagent. One part 
assay reagent was added to four parts of standard protein at concentrations ranging from 
0.01 mg/ml to 1 mg/ml and the absorbance was measured at 595 nm. The unknown 
concentration of recombinant protein was calculated from a standard curve generated with 
the known concentrations of BSA. Concentration of the recombinant proteins was also 
determined spectrally at 280 nm with a NanoDrop 1000 operated with ND-1000 V.3.7.0 
software (Thermo Scientific) and using the appropriate extinction coefficient (His-rPfE2m 
= 22 015 M-1 cm-1, His-rPfE2bc = 46 488 M-1 cm-1, His-rPfaE3 = 44 950 M-1 cm-1 
calculated from the amino acid composition using PROTPARAM (Gasteiger et al., 2005, 
http://web.expasy.org/protparam/). 
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2.6.10 Concentrating recombinant protein 
 
Concentration of recombinant protein was carried out either with 2 ml Vivaspin™ sample 
concentrators (GE Healthcare) with a 30 kDa molecular mass cut-off or with Aquacide II 
(Millipore). The concentrators were spun at speeds appropriate to the centrifuge rotor used 
(4000 g for the swing out rotor) until the desired concentration of protein was obtained. 
Aquacide II was used as an alternative method for concentrating His-rPfE2m, which bound 
onto the membrane of Vivaspin™ concentrators. Aquacide is a sodium salt of 
carboxymethylcellulose, which absorbs water and can thus be used to remove water from 
protein samples in dialysis tubing.  
 
 
2.6.11 Buffer exchange using a PD-10 column 
 
PD-10 desalting columns (GE Healthcare) were used for buffer exchange of protein 
samples. The column was equilibrated with 25 ml of the desired final buffer after which a 
maximum of 2.5 ml of the sample was added to the column. The flow-though was 
discarded and the protein was eluted with 3.5 ml of the required buffer and collected in 1 
ml fractions. The protein was usually found in the second and third fraction.  
  
 
2.6.12 Dialysis 
 
Following concentration with Aquacide II the protein sample was dialysed into the 
required buffer. Sample was placed into SnakeSkin® 10 K MWCO 16 mm dry dialysis 
tubing and dialysed in 1000x volume of the sample overnight at 4ºC. 
 
 
2.6.13 E2 activity assay 
 
The activity of His-rPfE2m and His-rPfE2bc was assayed as described by Yang et al. 
(1997) with modifications. The assay couples the production of acetyl-CoA with the 
reverse reaction catalysed by E2. The reaction was followed by measuring the increase in 
absorbance at 240 nm due to production of 8-acetyl-dihydrolipoamide, in a UV-2501 
spectrophotometer (Shimadzu). The reaction was carried out at 25ºC in 100 mM Tris-HCl, 
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1 mM EDTA, pH 7.4 with 1 mM acetyl-phosphate and 2 units of phosphotransacetylase. 
The amounts of coenzyme-A (CoA), dihydrolipoamide and His-rPfE2m or His-rPfE2bc 
were varied depending on the parameters analysed. To obtain a steady starting absorbance 
reading, His-rPfE2m and His-rPfE2bc were added last into the reaction mix, because all 
the other components absorb light at 240 nm.   
 
For measuring the activity of various concentrations of His-rPfE2m, 0.3 – 2 g of protein 
was used. For all other assays 1 – 2 g of His-rPfE2m or His-rPfE2bc was added to the 
reaction. To determine the Km and vmax for CoA, dihydrolipoamide was kept constant at 1 
mM, while the concentration of CoA was varied between 1 M – 50 M. To measure the 
optimal amount of dihydrolipoamide required for the assay, CoA was kept constant at 10 
M and dihydrolipoamide was varied between 0.1 – 5.0 mM. 
 
 
2.6.14 E3 activity assays 
 
Both the forward and reverse reaction of E3 was assayed to determine the kinetic 
parameters of His-rPfaE3 as described by McMillan et al. (2005). The production or 
consumption of NADH was measured at 340 nm in UV-2501 spectrophotometer 
(Shimadzu). 
 
 
2.6.14.1 Forward reaction 
 
The substrates for the forward reaction are dihydrolipoamide and NAD+. The reaction was 
performed in 50 mM potassium phosphate, 1 mM EDTA, pH 8 with 1 g of His-rPfaE3 at 
25ºC. Dihydrolipoamide (Sigma) was freshly prepared as a 60 mM stock with 100% 
ethanol and NAD+ was prepared with reaction buffer as a 10 mM stock solution. The Km 
and vmax for dihydrolipoamide were determined by keeping NAD
+ constant at 2 mM and 
varying the concentration of dihydrolipoamide between 50 M and 2 mM. Likewise for 
the kinetic parameters for NAD+, dihydrolipoamide was kept constant at 2 mM and NAD+ 
varied between 62.5 M and 2 mM.  
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2.6.14.2 Reverse reaction  
 
The substrates for the reverse reaction are lipoamide and NADH. The reaction was 
performed in 50 mM potassium phosphate, 1 mM EDTA, pH 7, at 25ºC with 1 g of His-
rPfaE3. Lipoamide (Sigma) was freshly prepared with 100% ethanol as a 60 mM stock, 
which required heating at 37ºC and repeated vortexing to dissolve. NADH was prepared in 
reaction buffer as a 10 mM stock solution. To determine the Km and vmax for lipoamide the 
concentration of NADH was kept constant at 200 M and lipoamide was varied between 
50 M and 4 mM. For the kinetic parameters for NADH, lipoamide was kept constant at 2 
mM and NADH was varied between 10 M and 200 M.   
 
 
2.7 Biophysical methods 
 
2.7.1 Protein partial specific volume and buffer density and viscosity calculations  
 
SEDNTERP (Laue et al., 1992) (http://bitcwiki.sr.unh.edu/index.php/Main_Page) was 
used to calculate the partial specific volume ( ) of each recombinant protein from their 
amino acid compositions (Table 2-8). Also the density () and viscosity () of each buffer 
used for AUC experiments was calculated (Table 2-9).  
 
 
Table 2-8. Calculated recombinant protein partial specific volumes at 4ºC and 20ºC.  
   (ml/g) 
Protein 4ºC 20ºC 
His-rPfE2m 0.7338 0.7406 
His-rPfE2bc 0.7356 0.7424 
His-rPfaE3 0.7317 0.7385 
 
 

v

v
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Table 2-9. Buffer parameters used for analysis of AUC data.  
The composition of buffers PEBS150, PEBS250 and PEBS150+glycerol+DTT can be seen in 
Table 2-1. The composition of the other buffers is the same as PEBS150 and PEBS250 – the 
number at the end denotes the concentration of NaCl (mM) in the buffer. 
Buffer Density (, g/ml) Viscosity (, cPoise) 
PEBS0 1.00774 1.5985 
PEBS10 1.00815 1.6022 
PEBS50 1.00981 1.6073 
PEBS100 1.01188 1.6141 
PEBS150 1.01394 1.5670 
PEBS250 1.01804 1.6354 
PEBS500 1.02821 1.6820 
PEBS1000 1.04815 1.7496 
PEBS150+glycerol+DTT 1.01414 1.5670 
 
 
2.7.2 Sedimentation velocity (SV) 
 
Sedimentation velocity experiments were carried out using a Beckman Coulter Optima 
XL-I analytical ultracentrifuge (Palo Alto, USA) with an An-50 Ti 8-hole or An-60 Ti 4-
hole rotor. Samples and reference buffers (360 l) were loaded into double sector 12 mm 
path length centrepieces made of charcoal-filled Epon. The rotor with the cells was placed 
in the centrifuge and cooled under vacuum for several hours until the experimental 
temperature, 4ºC, was reached. Samples were spun at 3,000 or 49,000 rpm depending on 
the anticipated size of the protein in the sample. Both absorbance and interference optics 
were used to record data over a radial range of 6.0 – 7.25 cm. For absorbance data a radial 
step size of 0.002 cm was used and for interference optics the laser delay and fringe 
contrast and brightness at the experimental speed was adjusted before the run to obtain 
high quality fringes. A cell was scanned every 4 or 8 min depending on whether the 4- or 
8-hole rotor was used. A total of 200 scans were taken. SEDFIT (Schuck, 2000; Schuck et 
al., 2002) (http://www.analyticalultracentrifugation.com/default.htm) was used to 
determine the number of species in the sample and to obtain the sedimentation coefficients 
using the continuous distribution c(s) Lamm equation model (section 1.6.1.3). Firstly, the 
meniscus, cell bottom and range of data to fit were determined. Following this the 
parameters for the analysis were defined. The resolution of the curve was set to 200 and 
the range of sedimentation coefficients to be shown were set at 0.1-10 S after confirming 
no larger species were observed. The frictional ratio was not fixed. The appropriate partial 
specific volume, buffer density and viscosity were defined as shown in Table 2-8 and 2-9. 
The other parameters were kept at default values. The obtained sedimentation coefficients 
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were then standardised to s20,w values as described in section 1.6.1.1 and plotted against 
protein concentration to obtain the sedimentation coefficient at infinite dilution (s ) from 
the y-intercept. Data from absorbance optics were of higher quality throughout, thus only 
absorbance data were used for the final analyses presented in this thesis.  
 
 
2.7.3 Sedimentation equilibrium (SE) 
 
Sedimentation equilibrium experiments were carried out using a Beckman Coulter Optima 
XL-I analytical ultracentrifuge (Palo Alto, USA) with an An-50 Ti 8-hole or An-60 Ti 4-
hole rotor. A total of 80 l of sample and reference buffer were loaded into double sector 
12 mm path length, charcoal-filled, Epon centrepieces. The samples were centrifuged at 
4ºC at a range of speeds depending on the protein size anticipated from sedimentation 
coefficients (Table 2-10).  
 
 
   Table 2-10. Speeds used for SE experiments 
Protein Speed (rpm) 
His-rPfE2m 12,000 
His-rPfE2bc 35,000 
His-rPfaE3 17,000 
 
 
Ten scans, using absorbance and interference optics, were recorded over a radial range of 
6.8 – 7.25 cm and were taken 3 h apart following a 3 h initial delay. WinMATCH 
(www.biotech.uconn/edu/auf/) was used to confirm that equilibrium had been reached in 
the sample, which was when no significant change in the root mean square deviation (rmsd 
< 0.1 x 10-2) was measured. SE data were analysed using SEDPHAT (Schuck, 2003; 
Vistica et al., 2004) (http://www.analyticalultracentrifugation.com/sedphat/sedphat.htm). 
To obtain the apparent whole-cell weight average molecular mass, Mw,app, single fit 
analysis with one species was carried out for each sample. The model also allows fitting of 
up to four species, which was used to determine the molecular masses of all the species 
present in the samples. The user defined experimental parameters were the partial specific 
volume, buffer density and viscosity and shown in Table 2-8 and 2-9, and the experimental 
temperature. The meniscus, cell bottom and range of data to fit were determined before 
analysis. M w,app was plotted against protein concentration and from the y-intercept the 

20,w
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whole-cell average molecular mass at infinite dilution, M ,  was determined. The species 
analysis with mass conservation constraints model was used to further analyse His-
rPfE2m. This model allows defining the concentration and molecular mass of a specific 
species in a sample to aid determination of the correct molecular mass of another species.  
 
 
2.7.4 Small angle X-ray scattering (SAXS) 
 
Small angle X-ray scattering experiments were carried out at the EMBL/DESY), Hamburg, 
beamline X33. The beamline has been recently decommissioned, however, X33 was a 
bending magnet beamline in the DORIS III storage ring, which operates at beam currents 
of 100 - 140 mA with an X-ray wavelength of 0.15 nm and an electron energy of 4.5 GeV. 
The samples were measured at various concentrations in a vacuum cell with mica windows 
at 10ºC. The beamline had an automated sample changer allowing 8 samples and up to 3 
buffers to be measured without interruption. The sample to detector distance was 2.7 m at 
which the resolution of the SAXS data is s = 0.06 – 6 nm-1, (momentum transfer s = 4 sin 
()/, where 2 is the scattering angle and  is the X-ray wavelength). Data were collected 
with a 2D photon counting Pilatus 1M-W pixel X-ray detector, which was calibrated with a 
standard sample of ~ 5 mg/ml of BSA prior to measuring experimental samples. The 
exposure time of the sample to the X-rays was 15 s and 8 frames were taken for each 
sample, which took approximately 2 minutes per sample. The raw data were fed into the 
automated SAXS data processing pipline (Petoukhov et al., 2007) for initial averaging of 
sample data frames and buffer subtractions. The ATSAS 2.5 programme suite (Petoukhov 
et al., 2012) (http://www.embl-hamburg.de/biosaxs/software.html) was used for all 
processing and analysis of SAXS data. PRIMUS (Konarev et al., 2003) was used to assess 
the data for aggregation and to obtain the Guinier range and Kratky plot (section 1.6.2.3). 
The processed scattering curve was then used for determination of the p(r) distance 
distribution function and the maximum dimensions (Dmax) using GNOM (Svergun, 1992). 
Rg was determined both from the Guinier approximation and from GNOM, while the 
molecular wmass of the samples were calculated from the Porod volume determined from 
the GNOM processed file using DATPOROD (Petoukhov et al., 2007).   
 
 

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2.8 Bioinformatics and computational methods 
 
2.8.1 Amino acid sequence alignments 
 
Amino acid sequences were aligned using the multiple sequence alignment tool ClustalW2 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/) (Larkin et al., 2007; Goujon et al., 2010). For 
all alignments default parameters were used.  
 
 
2.8.2 Homology modelling 
  
Homology modelling was carried out using the I-TASSER server for protein structure and 
function predictions (http://zhanglab.ccmb.med.umich.edu/I-TASSER/) (Zhang, 2008; Roy 
et al., 2010). The amino acid sequences of proteins were submitted in FASTA format and 
default parameters were chosen. I-TASSER generates several models in PDB (Brookhaven 
Protein Data Bank) format, which are given a ‘C-score’ based on how good the prediction 
is. The C-score ranges from -5 to 2 and the closer the value was to 2, the better the 
prediction was and the model was chosen for use in subsequent applications.    
 
 
2.8.3 Ab initio modelling of SAXS data  
 
Ab initio modelling of proteins was carried out using DAMMIF (Franke and Svergun, 
2009). The programme uses spheres, or dummy atoms, to model the scattering envelope 
using a simulated annealing method (Svergun, 1999) (section 1.6.2.4). DAMMIF was used 
on the ATSAS online server (http://www.embl-hamburg.de/biosaxs/atsas-
online/dammif.php) (Petoukhov et al., 2007) with the input file being the p(r) distance 
distribution file generated by GNOM (section 2.7.4). The search volume was in nm3 units, 
the P2 and P3 symmetry parameter was given for His-rPfaE3 and His-rPfE2bc, 
respectively. The programme was asked to run 20 times to obtain 20 models. Usually, 
generated models are clustered and averaged to obtain the final representative ab initio 
model. The online version of DAMMIF automatically does this; it groups the models it has 
generated into clusters based on their similarity using DAMCLUST (Kelley et al., 1996; 
Petoukhov et al., 2012). The models within these clusters are subsequently analysed by 
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DAMAVER (Volkov and Svergun, 2003) to obtain the representative model i.e. the model 
with the lowest average normalised spatial discrepancy (NSD) value (section 2.8.5). 
 
Ab initio modelling of flexible proteins cannot be done with DAMMIF, which is 
appropriate for macromolecules with more rigid structures. To model His-rPfE2bc better 
the Ensemble Optimisation Method (EOM) was used (Bernado et al., 2007; Petoukhov et 
al., 2012). The programme can be used to model intrinsically unfolded proteins or multi-
domain proteins with flexible linkers. The method is based on the assumption that the 
flexible protein can be in an average number of conformations, which represent the 
experimental data (section 1.6.2.4). The programme first generates a pool containing a 
large number of possible conformations (the default is 10,000), which cover the 
experimental configurational space. From this, a genetic algorithm is used to divide the 
appropriate models into subsets to generate an ensemble of models, which fit the 
experimental data. The flexibility of His-rPfE2bc arises from the 31 amino acid linker 
between the E1/E3 subunit binding domain (SBD) and the catalytic domain (CD). The files 
given to EOM in order of input were (1) a .seq file with the amino acid sequence of the 
whole protein, (2) the PDB file for the BD in monomeric form, (3) the PDB file for the CD 
in trimeric form, and (4) the experimental scattering curve .dat file. EOM was run with 
default parameters, apart from specifying P3 symmetry and fixing the position of the CD 
trimer to only allow movement of the linker and SBD to generate the models. A chi 
squared value (2) determined how well the ensemble fit the experimental data. 
   
 
2.8.4 Superimposition of ab initio models and homology models 
 
Superimposition of the high-resolution homology models with the low-resolution 
scattering envelopes generated by ab initio modelling was done using the programme 
SUPCOMB (Kozin and Svergun, 2001). The programme can also superimpose low-
resolution models with each other.  SUPCOMB matches models by treating them as 
ensembles of points in three-dimensional space. Superimposition is done by minimising 
the dissimilarity measure, called the normalised spatial discrepancy (NSD), of the models. 
The alignment is started from the inertia-axis followed by minimisation of the NSD, where 
the minimal distance value between one point in the first model and all points in the second 
model is determined. This is then repeated vice versa with points in the second model. 
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These values are then added and normalised against the average distances between the 
neighbouring points for the two models to obtain a final NSD value, which is an indicator 
of how similar the models are (Koch et al., 2003). Generally, NSD values of around one 
indicate that the two models are similar. Default values for programme parameters were 
used when running the programme.     
 
 
2.8.5 Hydrodynamic modelling 
 
US-SOMO (Rai et al., 2005; Brookes et al., 2010a; Brookes et al., 2010b) was used to 
calculate the hydrodynamic parameters of the various homology and ab initio models 
obtained. For the calculations, each amino acid of the homology models is represented by 
two beads; one for the main chain component and the other for the side-chain. The 
volumes of the beads are determined by the atoms in the residue and by any water 
molecules bound onto them to account for protein hydration in solution (Brookes et al., 
2010b). The position of the beads corresponds to the residues they represent and any 
overlap is removed because the hydrodynamic interaction tensor is not valid for 
overlapping beads of differing radii. From the PBD files of the models, US-SOMO 
calculates, among other parameters, the estimated sedimentation and frictional coefficients 
and Rg, which can then be compared with the experimental data.    
 
The hydrodynamic parameters of the EOM models were computed with the same bead 
modelling procedure as above. The DAMMIF models, however, were first processed using 
the AtoB ‘grid’ method (Byron, 1997) in order to remove the slight overlap between the 
constituent monomers at the dimer interface. In this method a cuboid with the dimensions 
of a molecule is created and divided into cubes, which in this case had dimensions of 5 Å. 
To create the hydrodynamic bead model a sphere with a radius proportional to the mass 
contained in the cube is then placed at the cube's centre of gravity (Byron, 2008).     
 
Discrete molecular dynamics (DMD) (Dokholyan et al., 1998; Ding and Dokholyan, 2006) 
simulations were carried out to model flexible sequences in homology models. The 
programme generates several models with possible conformations of the flexible region. 
The static regions were defined and default parameters were used apart from changing the 
temperature to 1 kcal/mol/kB, extending the run time to 50000 and the pdb output timestep 
was set to 1000 to create 50 pdb model files. The simulation was carried out on the Alamo 
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cluster via the University of Texas Health Sciences Centre at San Antonio. The models 
were then submitted into US-SOMO to compute the hydrodynamic parameters.  
 
 
2.9 P. falciparum culture 
 
2.9.1 Culture of P. falciparum erythrocytic stages 
 
P. falciparum was cultured as described by Trager and Jensen, (1976). All work was 
carried out in a containment level 3 culture suite. All solutions and media were filter 
sterilised (0.2 µm filters) prior to use. Parasites were grown at 37ºC in sterile tissue culture 
flasks in a gas atmosphere of 5% CO2, 1% O2 and 94% N2 or in a 5% CO2 incubator. 
Erythrocytes used for culture were separated from buffy coat by centrifugation at 600 g for 
15 min followed by at least 3 x 15 min washes (at 600 g) with blood wash medium (section 
2.3.5) until the supernatant was clear. The washed erythrocytes were stored at 4ºC and used 
for a maximum of 4 weeks. Parasites were grown in 5 or 10 ml of complete RPMI 1640 
medium (section 2.3.5) at 5% haematocrit.  For general maintenance, medium was changed 
every 24 h, without disturbing the erythrocyte layer. Parasitemia was monitored by 
examining Giemsa stained blood smears and was kept around 1 – 4% by regularly diluting 
the culture with fresh erythrocytes.  
 
 
2.9.2 Giemsa staining of blood smears  
 
Blood smears were made by spreading a small drop (5 to 10 µl) of erythrocytes onto a 
glass slide. The blood was allowed to dry and then fixed with 100% methanol for at least 
20 s. The slides were then stained for 5 -10 min in a 1:25 dilution of Giemsa stain (VWR) 
in H2O and excess stain washed off with water. The slides were air-dried and examined 
using a light microscope with a 100x oil immersion objective. To determine the 
parasitemia, the number of infected erythrocytes in 1000 red blood cells was determined.   
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2.9.3 Thawing P. falciparum 
 
Stabilates were taken from liquid nitrogen and thawed in the incubator at 37ºC. One tenth 
of the stabilate volume of thawing solution 1 (section 2.3.5) was slowly added while 
carefully mixing and the cell suspension was incubated at room temperature for 5 min. Ten 
times the original stabilate volume of thawing solution 2 (section 2.3.5) was added slowly 
while gently mixing and the suspension was incubated for another 5 min at room 
temperature. Finally, 10 times the original stabilate volume of thawing solution 3 (section 
2.3.5) was slowly added, mixed and incubated at room temperature for 5 min. The cell 
suspensions were centrifuged at 800 g for 5 min. The supernatant was carefully discarded 
and the parasites were transferred into a flask with 9.3 ml culture medium and 200 l fresh 
erythrocytes.  
 
 
2.9.4 Freezing P. falciparum stabilates 
 
To prepare three parasite stabilates, a 10 ml culture with at least 2% ring stage parasites 
was centrifuged at 800 g for 5 min at 4ºC and the medium was discarded. The erythrocytes 
were resuspended in 1x pellet volume of complete RPMI 1640 medium followed by 2 x 
pellet volume of cold freezing solution (PBS with 30% (v/v) glycerol). The mixture was 
aliquoted (600 l) into cryotubes and placed on ice for 15 min before transfer into liquid 
nitrogen.  
 
 
2.9.5 Synchronisation of P. falciparum cultures 
 
Sorbitol was used to synchronise ring-stage parasites as described by Lambros and 
Vanderberg, (1979). Cultures were centrifuged at room temperature at 800 g for 5 min. 
The medium was removed and the erythrocytes mixed with 5x pellet volumes of sorbitol 
(5% (w/v) in 10 mM potassium phosphate pH 7.2) and incubated for 5 min at 37ºC. The 
mixture was centrifuged again as above and the supernatant removed before returning the 
parasites into 10 ml of fresh pre-warmed (to 37ºC) complete RPMI 1640 medium.  
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2.9.6 Isolation of P. falciparum from erythrocytes 
 
To isolate DNA and protein from P. falciparum, large cultures (50 ml) were allowed to 
reach a parasitemia of ~ 10% and the parasites were freed from contaminating erythrocytes 
by saponin lysis. Approximately 5 – 10 ml of medium was aspirated from the flask and the 
erythrocytes were resuspended in the medium. Saponin (2% (w/v) in PBS) was added at a 
tenth of the remaining culture volume. For complete lysis of erythrocytes the cells were 
incubated on ice for 10 min and the parasites harvested by centrifugation at 1800 g for 10 
m in at 4ºC. The supernatant was removed and the parasite pellet washed twice by 
centrifugation as above in 10 ml cold PBS. The pellet was then resuspended in 1 ml cold 
PBS and transferred into a 1.5 ml tube and centrifuged at 2,300 g for 5 min. The 
supernatant was removed and the pellet was washed again in 1.5 ml cold PBS until the 
supernatant was clear. The parasite pellet was then used immediately for DNA extraction 
(section 2.9.7).  
 
 
2.9.7 DNA extraction from P. falciparum  
 
A phenol extraction method was used to isolate genomic DNA from P. falciparum. The 
isolated parasite pellet (usually 100 - 200 l), was resuspended in 50 mM Tris HCl, pH 
9.0, 0.2 M NaCl, 0.1 M EDTA and 1 mg/ml proteinase K by repeated pipetting. Finally, 
1% (w/v) SDS was carefully mixed in to prevent excessive foaming and the mixture was 
incubated overnight at 50ºC with rotation. The following morning, 1 ml of 
phenol/chloroform was added to the mixture and incubated at room temperature for 1 h 
with rotation. During this time, proteins were denatured due to the phenol/chloroform and 
were extracted into the organic solvent, while DNA stayed in the aqueous buffer. The 
aqueous layer was separated from the phenol/chloroform by centrifugation for 10 min at 
3000 g and the upper layer was carefully collected into a fresh tube with a Pasteur pipette. 
The phenol/chloroform extraction was repeated and the upper layer collected again. DNA 
was precipitated by addition of 1/30 sample volume of 3 M sodium acetate, pH 5 and 0.6x 
sample volume of isopropanol. The mixture was inverted several times and the precipitated 
DNA spooled out and dissolved in 200 l of TE buffer (section 2.3.1). 
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2.9.8 Transfection 
 
Transfection of P. falciparum was carried out on synchronised cultures (section 2.9.5) with 
4 – 7% ring stages (Crabb and Cowman, 1996; Crabb et al., 2004). The medium was 
removed from the culture and the remaining erythrocytes were resuspended in cytomix 
(section 2.3.5) and centrifuged at 400 g for 5 min at 4ºC. The supernatant was discarded. A 
total of 30 l of plasmid DNA (100 g) in sterile TE buffer was carefully mixed with 370 
l of cytomix and 200 l of the infected erythrocytes. Electroporation was carried out with 
a Gene Pulser Xcell electroporator (Bio-Rad) in 0.2 cm electroporation cuvettes (Bio-Rad) 
at 310 V and 950 F and measuring time constant values of 10 – 15 ms. The cells were 
then immediately transferred into 9 ml of pre-warmed (to 37ºC) complete RPMI 1640 
medium with 300 l uninfected erythrocytes. The culture medium was changed after 6 h 
and the drug WR99210 was added to the culture. All transfections were carried out in 
duplicate on two separate days to increase chances of a successful transfection. The 
medium in the cultures was changed every day for the first 8 days and then every second 
day until parasites appeared, which took 3 – 6 weeks. After this, the cultures were 
maintained daily and parasites were harvested, DNA extracted (section 2.9.7) and a 
Southern blot was carried out to confirm genotype of the transfectant parasites before 
starting drug selection for integration of plasmid (section 2.9.9). 
 
 
2.9.9 Gene knockout in P. falciparum 
 
Knockout of PfE2 and PfaE3 was attempted using the pCC-1 plasmid (section 2.5.2.4), 
which integrates into the genome by double cross-over recombination via the 5’ and 3’ end 
gene fragments cloned into the vector (Maier et al., 2006, Table 2-3). pCC-1 contains the 
human dehydrofolate reductase (hdhfr) gene for positive selection of trasfected parasites 
with the drug WR99210. Integration of the plasmid into the gene is forced by negative 
selection via the S. cerevisiae cytosine deaminase bifunctional chimera with  S. cerevisiae 
uracil phosphoribosyl transferase gene (cyd) found on the pCC-1 plasmid. This gene 
converts 5-fluorocytosine (5-FC) to 5-fluorouracil, which inhibits RNA synthesis and 
thymidylate synthase. Thus parasites with episomal pCC-1 plasmid will be killed. If double 
cross-over recombination of the plasmid occurs, the cyd gene is lost and only parasites 
with integration of the positive selectable  marker should survive in the culture.  
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Following confirmation of successful transfection of parasites by Southern blotting 
(section 2.5.11), Ancotil® (commercial name for 5-FC) was added to a final concentration 
of 1 M in addition to WR99210 (at 5 nM final concentration). 5-FC killed most parasites 
in the first few days, however, after 1-2 weeks the parasites re-emerged. Parasites were 
harvested and DNA was extracted (section 2.9.7) and analysed for integration of plasmid 
by Southern blotting. 
 
 
2.9.10 Cloning by limiting dilution  
 
To obtain clonal populations of parasites that had correct integration of the pCC-1 plasmid, 
cloning by limiting dilution was carried out. This involved diluting the culture in a 96-well 
microtitre plate to 0.25 parasites/well with medium containing appropriate drugs. The 
medium was changed every 5 days for 15 days after which the wells were checked for 
growth of parasites every 2-3 days by placing a drop of resuspended erythocytes onto a 
slide, staining it with Giemsa and examining it with a microscope (section 2.9.2). Once 
parasite growth was confirmed the culture volumes were increased and parasites were 
harvested and DNA was extracted (section 2.9.7) and analysed to determine the genotypes 
of the clones by Southern blotting (section 2.5.11).     
 
 
2.9.11 Growth assay 
 
To investigate any effect gene knockout had on parasite growth compared with the wild 
type, a growth assay was carried out as described by Sanders et al. (2006) with 
modifications. Synchronised cultures of rings (section 2.9.5) were diluted to 0.5% 
parasitemia and 5% haematocrit in 2 ml of medium. Each parasite line was assessed in 
triplicate. Every second day the cultures were diluted 1:5 with fresh erythrocytes. Blood 
smears of the cultures were made every day at the same time for 14 days. The parasitemia 
for each day was determined by counting the infected erythrocytes in 1000 cells (section 
2.9.2). Also, the cycle stage of the parasite lines was determined by counting 100 parasites 
and noting the presence of rings, trophozoites and schizonts.         
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2.9.12 Determination of IC50 values 
 
The incorporation of [3H]-hypoxanthine was used to determine IC50 values (Desjardins et 
al., 1979) for L-buthionine sulfoximine (BSO), paraquat and triclosan. The starting 
concentrations for the agents were 1.25 mM for BSO, 0.5 mM for paraquat and 0.4 mM for 
tricolsan. Synchronised ring stage cultures (section 2.9.5) were diluted to 0.5% 
parasitemia, 2% haematocrit, in IC50 medium (section 2.3.5). A serial dilution of the drug 
at 2 times the concentration to be tested was carried out in a 96-well microtitre plate 
leaving 100 l in each well. On addition of 100 l of the parasites, the final drug 
concentration was obtained. Uninfected erythrocytes and parasites incubated without the 
drug were included as controls. The microtitre plates were placed into a 5% CO2 incubator 
at 37ºC for 48 h. After 48 h, 100 l of medium was removed and 100 l of fresh medium 
with 5 Ci [3H]-hypoxanthine/ml was added. The plates were incubated for a further 24 h 
after which they were frozen at -20ºC. The wells were defrosted at room temperature for 2-
3 h before harvesting with a Harvester 96™ Mach III (TomTec) onto Printed Filter Mat A 
filter mats (Perkin Elmer). The filter mats were dried at 55ºC for 90 min and sealed into 
plastic sample bags. Following the addition of 4 ml of scintillation fluid, the decay was 
measured with a Wallac 1450 MicroBeta Trilux liquid scintillation counter (Perkin Elmer) 
for 1 min per well. IC50 values were calculated using the ‘log (inhibitor) versus response’ 
model in GraphPad Prism 5.0.  
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Chapter 3  
Expression and purification of recombinant P. falciparum 
dihydrolipoamide acetyltransferase and dihydrolipoamide 
dehydrogenase 
 
3.1 Dihydrolipoamide acetyltransferase 
 
3.1.1 Introduction 
 
Dihydrolipoamide acetyltransferase (E2) (EC 2.3.1.12) is an enzyme in the family of 
acyltransferases, which transfer non-amino-acyl groups (EC 2.3.1.-) using coenzyme A 
(CoA) as an acceptor. E2 catalyses the transfer of an acetyl group bound to the E1 cofactor 
thiamine pyrophosphate (TPP) to CoA, generating acetyl-CoA (Fig. 3-1). 
 
 
 
 
Figure 3-1. Reaction catalysed by E2 
(1) The acetyl group (blue) is transferred from E1 via the thiamine pyrophosphate (TPP) 
cofactor to the lipoamide moiety of E2 (green), forming 8-acetyl-dihydrolipoamide. (2) From 
here the acetyl group is further transferred onto CoA (red) to form acetyl-CoA (circled), in the 
process reducing the lipoamide moiety.  
 
 
P. falciparum E2 (PfE2) (PlasmoDB annotation PF3D7_1020800, www.plasmodb.org) is 
located on chromosome 10 of the P. falciparum genome. The gene is 3192 bp in length, 
contains 10 introns and 11 exons. Complementary DNA analysis shows the full-length 
protein is 1923 bp and consists of 640 amino acids, with an estimated molecular mass of 
73.9 kDa (McMillan, 2006). As the protein is located in the apicoplast (McMillan et al., 
2005), a signalling and transit peptide are present at the N-terminus of the protein. Using 
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subcellular localisation prediction programmes and alignments with E2 amino acid 
sequences from other organisms, the predicted start site of the mature PfE2 was estimated 
at Ser51 resulting in a 67.2 kDa protein (McMillan, 2006). 
 
The mature PfE2 contains two lipoyl-domains (LD), an E1/E3 subunit binding domain 
(SBD), and a catalytic domain (CD) separated by long flexible linkers (Fig. 1-9). The 
structure as well as the stochiometry of the PfE2 core are unknown. In humans, Gram-
positive bacteria and plant mitochondria E2 forms an icosahedral 60-mer, while in Gram-
negative bacteria the core is an octahedral 24-mer (Mattevi et al., 1992a; Izard et al., 1999; 
Mooney et al., 1999; Yu et al., 2008b). As the apicoplast is of red algal origin (Botte et al., 
2011), the hypothesis tested here was whether the PfE2 forms a 24-mer, which is 
significantly different to the human E2 oligomeric structure and may have implications in 
the drug discovery process.   
 
 
3.1.2  Aims 
 
The aims for this part of the project were to: 
 express recombinant P. falciparum E2 (rPfE2) in soluble form 
 purify rPfE2 
 determine the kinetic parameters of rPfE2 
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3.1.3 Results 
 
3.1.3.1 E2 amino acid alignments  
 
Amino acid alignments were performed using ClustalW2 (Larkin et al., 2007; Goujon et 
al. 2010). Jalview Version 2.8 (Waterhouse et al., 2009) was used to colour different 
groups of residues in the alignments. The N-terminal section of the proteins aligned poorly 
owing to the variation in number of lipoyl domains (LD) present in an organism. Homo 
sapiens and P. falciparum E2 and Arabidopsis thaliana mitochondrial E2 have two LDs, A. 
thaliana chloroplast and the cyanobacterium Synechocystis sp. PCC 6803 have one and 
Azotobacter vinelandii and E. coli E2 have three. Also the amino acids in the linkers vary 
greatly. Thus, to identify the conserved residues in the LDs, the sequences of those 
domains were aligned separately (Fig. 3-2). 
 
P. falciparum LD1 shared greatest sequence identity with the single Synechocystis sp. LD 
(51%) followed by the single A. thaliana chloroplast LD (48%) and shared higher identity 
with the eukaryotic domains (28-34%) than the bacterial domains (19-29%). P. falciparum 
LD2, however, shared little sequence identity with other LDs (21-28%). It had greatest 
sequence identity with the single Synechocystis sp. LD (28%) and the single A. thaliana 
chloroplast LD and mitochondrial LD1 (both 26%). All the domains contain the lysine 
residue required for lipoylation (in P. falciparum these are Lys93 and Lys223, 
respectively, all numberings based on the full-length PfE2 amino acid sequence, Fig. 3-2). 
The lysines are in the middle of a conserved DKA motif forming a sharp -turn in the 
domain structure essential for recognition of the lysine for lipoylation (Russell and Guest, 
1991; Dardel et al., 1993; Wallis and Perham, 1994). This motif is present in P.falciparum 
LD1, but in LD2 the sequence is DKS. The identity of the aspartic acid or alanine adjacent 
to the lysine is not crucial for lipoylation of the lysine as long as the -turn is preserved, 
however, recognition of the domain by E1 could be affected (Wallis and Perham, 1994). 
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Figure 3-2. Amino acid sequence alignment of E2 lipoyl domains (LD) from various 
organisms  
ClustalW2 alignments were coloured based on amino acid type using Jalview Version 2.8. Peach, 
aliphatic/hydrophobic residues (ILVAM); orange, aromatic residues (FWY); blue, positive residues 
(KRH); red, negative residues (DE); green, hydrophilic residues (STNQ); magenta, 
conformationally special residues (PG); bright yellow, cysteine (C). Highly conserved residues 
denoted with a star. Conserved motifs are boxed. At_mE2, A. thaliana mitochondrial E2; At_pE2, 
A. thaliana chloroplast E2; Av_E2, A. vinelandii E2; Ec_E2, E. coli E2; Gs_E2, G. 
stearothermophilus E2; Hu_E2, human E2; Pf_E2, PfE2, Sy_E2, Synechocystis sp E2. Number 
following LD denotes the domain number starting from the N-terminus.  
 
 
The eukaryotic E2 LDs, Synechocystis sp. and P. falciparum LD1 also contain the highly 
conserved P58S/ALSP/STM64 sequence (the subscript number denotes the amino acid 
number based on the full-length PfE2 amino acid sequence) (Neagle et al., 1989). This 
motif is not present in the bacterial sequence and interestingly is not found in P. falciparum 
LD2. In PfLD1, 15% of the residues were of a different amino acid type compared with the 
LDs from other organisms. The corresponding value for PfLD2 was 30%, thus showing 
poorer conservation of this domain.  
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The amino acid sequence identity of mature length PfE2 to other species was low, the 
highest being 34% with Synechocystis sp. followed by 29% identity with A. thaliana 
chloroplast E2 (Table 3-1).  
 
 
Organism Identity (%) 
Synechocystis sp. 34 
A. thaliana - chloroplast 29 
G. stearothermophilus 22 
A. thaliana - mitochondrion 22 
H. sapiens 21 
E. coli 19 
A. vinelandii 18 
          
Table 3-1. Amino acid identities of full-length PfE2 compared with E2 from other organisms 
 
 
The full-length E2 sequence alignments from various organisms are shown in two parts as 
the variation in linker lengths distorts alignment of the whole sequence. The LDs and 
linkers are aligned in Fig. 3-3 and the binding domain and catalytic domain in Fig. 3-4.  
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Figure 3-3. Amino acid sequence alignment of lipoyl domains and linkers from various 
organisms 
ClustalW2 alignments were coloured based on amino acid type using Jalview Version 2.8. Peach, 
aliphatic/hydrophobic residues (ILVAM); orange, aromatic residues (FWY); blue, positive residues 
(KRH); red, negative residues (DE); green, hydrophilic residues (STNQ); magenta, 
conformationally special residues (PG); bright yellow, cysteine (C). Conserved motifs are boxed. 
At_mE2, A. thaliana mitochondrial E2; At_pE2, A. thaliana chloroplast E2; Av_E2, A. vinelandii 
E2; Ec_E2, E. coli E2; Gs_E2, G. stearothermophilus E2; Hu_E2, human E2; Pf_E2, PfE2, Sy_E2, 
Synechocystis sp E2.  
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Figure 3-4. Amino acid sequence alignment of E2 binding domain and catalytic domain from 
various organisms  
ClustalW2 alignments were coloured based on amino acid type using Jalview Version 2.8. Peach, 
aliphatic/hydrophobic residues (ILVAM); orange, aromatic residues (FWY); blue, positive residues 
(KRH); red, negative residues (DE); green, hydrophilic residues (STNQ); magenta, 
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conformationally special residues (PG); bright yellow, cysteine (C). Conserved proline in SBD 
denoted with a star. Conserved motifs are boxed. Active site residues denoted with a diamond 
shape. At_mE2, A. thaliana mitochondrial E2; At_pE2, A. thaliana chloroplast E2; Av_E2, A. 
vinelandii E2; Ec_E2, E. coli E2; Gs_E2, G. stearothermophilus E2; Hu_E2, human E2; Pf_E2, 
PfE2, Sy_E2, Synechocystis sp E2.  
 
 
While human E2 is rich in small and hydrophobic amino acids (proline 10.3%, alanine  
9.5%, leucine 8.0% and valine 8.0%), in PfE2 the basic amino acid lysine is the most 
abundant (13.2%) followed by hydrophobic isoleucine (9.1%) and leucine (8.9%) and the 
amides glutamine (9.1%) and asparagine (8.9%). The amino acid profiles in the domains of 
P. falciparum and human E2 are similar with leucine (10.6% and 9.1% in P. falciparum 
and human domains, respectively), isoleucine (9.8% and 8.6%) and lysine (7.7% and 
12.3%) being the most abundant residues. PfE2 domains do contain, however, more 
asparagine (8.0% in P. falciparum, 2.9% in human domains). The starkest difference 
between the two proteins is found in the linkers, which in human E2 are high in proline 
(27.1%) and alanine (17.1%), whereas in the PfE2 linkers, glutamine (18.3%), lysine 
(15.6%) and asparagine (11.8%) are the most abundant. The sizes of the domains are all 
similar, however, there are differences in linker lengths especially in the one between the 
second lipoyl domain and the binding domain. This linker is very long (96 amino acids) in 
PfE2 compared with 40-59 amino acids in the other organisms. 
 
In the binding domain, important conserved residues include Pro359 (the numbering is 
based on the P. falciparum full-length sequence, Fig. 3-4), which promotes the formation 
of the first helix that interacts with E3 (Mande et al., 1996). There is also a GRV/L/I 
domain thought to be important for the stability and function of the binding domain 
(Mande et al., 1996), however, P. falciparum lacks the glycine and has an asparagine at 
this place instead (Asn382). This is unfavourable for the conformation of the domain, as a 
side chain in this position would protrude and could interfere with the recognition of the 
E3 binding residue (Arg383) by E3 (Kalia et al., 1993). Also, the other residue involved in 
E3 binding is normally a positively charged arginine or lysine, but in P. falciparum this is 
an uncharged serine (Ser362).   
 
In the catalytic domain there is a D611HRXXD/N/YG617 motif (the subscript number 
denotes the amino acid number based on the full-length PfE2 amino acid sequence, Fig. 3-
4), which forms part of the active site and is conserved throughout species (Mooney et al., 
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1999). The P. falciparum and A. thaliana chloroplast E2 have the same motif as 
Synechocystis sp. E2 (DHRXXYG), which is interesting as the apicoplast and chloroplast 
are of cyanobacterial ancestry. In A. vinelandii the motif is DHRXXNG and in the other 
organisms DHRXXDG. The active site of the catalytic domain in P. falciparum is formed 
by the residues Ser561, His612, Tyr616. The histidine is highly conserved and is present in 
all organisms and the Tyr616 varies as mentioned in the above motif. Apart from G. 
stearothermophilus, Ser561 is also conserved.  
 
E2 sequences from other Plasmodium species were also aligned with ClustalW2 (Fig. 3-5). 
The non-human parasites, P. berghei, P. yoelii and P. chabaudi, aligned well as a group 
with identities ranging from 73-83%. The other two human infective Plasmodium species, 
P. vivax and P. knowlesi, also aligned well with each other, with 77% sequence identity. 
The two groups did not align well with each other with identities ranging between 49% to 
51%. PfE2 did not align as well with either group. The protein sequence had highest 
identity with E2 from P. yoelii (60%) followed by P. berghei and P. chabaudi  (both 57%) 
(Table 3-2). However, this was only slightly higher than PfE2 identity with P. knowlesi 
and P. vivax (both 54%). 
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Figure 3-5. Amino acid alignment of E2 from various Plasmodium species  
ClustalW2 alignments were coloured based on amino acid type using Jalview Version 2.8. Peach, 
aliphatic/hydrophobic residues (ILVAM); orange, aromatic residues (FWY); blue, positive residues 
(KRH); red, negative residues (DE); green, hydrophilic residues (STNQ); magenta, 
conformationally special residues (PG); bright yellow, cysteine (C). Conserved motifs are boxed. 
Active site residues denoted with a diamond shape. The start of each E2 construct used in this study 
is also shown. At_mE2, A. thaliana mitochondrial E2; At_pE2, A. thaliana chloroplast E2; Av_E2, 
A. vinelandii E2; Ec_E2, E. coli E2; Gs_E2, G. stearothermophilus E2; Hu_E2, human E2; Pf_E2, 
PfE2, Sy_E2, Synechocystis sp E2. 
 
 
Organism Identity (%) 
P. yoelii 60 
P. berghei 57 
P. chabaudi 57 
P. knowlesi 54 
P. vivax 54 
 
Table 3-2. Amino acid identities of PfE2 compared with PDC E2 from other Plasmodium 
species 
 
 
When further examining the sequence alignments, when a residue was not conserved, the 
PfE2 residue aligned 52% of the time with the non-human parasite sequence and 48% of 
the time with the human parasite sequence. Thus, PfE2 seemed to contain a mix of residues 
from both groups. In addition, on 23 occasions when the residues of all the other species 
aligned, PfE2 contained a different amino acid. This occurred less often in the other 
species (P. yoelii n = 11, P. chabaudi n = 6, P. knowlesi n = 6, P. berghei n = 1, P. yoelii n 
= 1).  
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While the domains are mostly highly preserved among all the Plasmodium species, 
differences can be seen in linker lengths. Most notably, P. yoelii has a very short linker 
between LD2 and the SBD (37 amino acids) compared with the other species (89-98 amino 
acids). Most of the conserved residues in each of the domains mentioned above are present 
in all the species. The asparagine instead of a glycine at Asn210 is conserved among the 
Plasmodium species. Interestingly, the binding domain is not as well conserved within the 
Plasmodium species as the domain is in other organisms. 
 
 
3.1.3.2 Generation of expression constructs 
 
On close inspection of the coding sequence for PfE2, multiple rare codons were observed. 
These could hinder expression of the Plasmodium protein in E. coli, thus codon 
optimisation of the full-length PfE2 with E. coli codon bias was carried out by GENEART 
AG (from 2010 onwards the company is known as GeneArt® Gene Synthesis, Life 
Technologies). Following gene synthesis, the company cloned both the full-length and the 
mature-length (starting at Ser51, Fig 3-5) PfE2 sequences into the expression vector pET-
15b, with a cleavable N-terminal 6 x His-tag, thus generating the constructs His-rPfE2f and 
His-rPfE2m, respectively.   
 
The codon optimised PfE2 sequence was also used as the template for generation of rPfE2 
constructs with only the binding domain and/or catalytic domain (see section 2.5.1.1, 
2.5.2.1 and 2.5.2.2 for generation of constructs). Protein amino acid sequence alignments 
(Fig. 3-3 and 3-4) and assessment of homology models (section 4.1.3.1) were used to 
determine the start residue for each domain. One of these constructs, His-rPfE2bc, 
consisted of amino acids 356-640 (Fig. 3-5), which contained the binding and catalytic 
domains and was cloned into pET-15b to include an N-terminal His-tag (this construct was 
generated by Jamie Whitelaw). The other, GST-rPfE2c, included only the catalytic domain 
(amino acids 429-640, Fig. 3-5) and was cloned into pGEX-6P-1 with a GST-tag at the N-
terminus.  
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3.1.3.3 Recombinant protein expression  
 
To find the most favourable conditions for expression of the various recombinant proteins, 
small-scale expression trials were set up. By varying the expression vector, temperature, 
time and IPTG concentration the parameters required for optimum expression yield and 
purity of the recombinant protein were determined. 
 
 
 
3.1.3.3.1 Expression of His-rPfE2m 
 
The initial trial to determine the optimal temperature for recombinant expression was 
carried out with His-rPfE2f because this construct was obtained from GENEART AG prior 
to the His-rPfE2m construct. The 76 kDa His-rPfE2f in pET-15b was transformed into 
BLR(DE3) E. coli. This host strain is a BL21 derivative that can stabilise the expression of 
target proteins with repetitive sequences, which is often the case for P. falciparum genes. 
Expression was tested at various time points at 18°C, 25°C, 30°C and 37°C (Fig. 3-6).  
 
 
A    B 
 
 
Figure 3-6. Western blot analysis of His-rPfE2f expression in BLR(DE3) E. coli  
Expression of rPfE2f in pET-15b was tested at 18°C, 25°C, 30°C and 37°C following induction 
with 1 mM IPTG. Samples of expression cultures were taken (A) before induction and (B) 3 h, 4 h 
and overnight (ON) after induction. Expression of His-rPfE2f was assessed by western blotting 
using an anti-His-tag antibody. Results for soluble fractions only are shown. Expression of His-
rPfE2f was tightly controlled as no recombinant protein was seen before induction. Recombinant, 
His-tagged protein of the expected size (76 kDa, arrow) was present on the blot with additional 
higher and lower molecular mass possibly corresponding to multimers of His-rPfE2f or degradation 
products of the recombinant protein, respectively.  
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At 30°C and 37°C very little or no soluble His-rPfE2f was detected, while at 25°C protein 
yield was high, however there was a lot of degradation and aggregation of the His-tagged 
protein. Expression at a lower temperature (18°C) for a shorter time (4 h) resulted in less 
degradation of the recombinant protein but a low yield. To avoid protein degradation, low 
temperatures were used in subsequent trials while attempting to improve yield. 
 
His-rPfE2m in pET-15b was transformed into BLR(DE3) E. coli and an expression trial 
with varying amounts of IPTG was carried out at 15°C and 18°C (Fig. 3-7). Slightly more 
protein was expressed at 18°C than at 15°C, probably due to differences in bacterial 
densities. Initially more degradation could be seen at 18°C, however, the difference was 
negligible after 2 h expression. The optimal IPTG concentration was deduced to be 0.5 
mM. Increasing the concentration of IPTG did not result in higher levels of recombinant 
protein, but appeared to result in a greater level of degradation. The leaky expression seen 
in the non-induced controls after 3 h expression was unexpected as pET-15b contains the 
T7lac promoter, which should efficiently prevent transcription by basal levels of T7 RNA 
polymerase. However, as His-rPfE2m was not toxic to the bacteria, the leaky expression 
was not such a concern. In all, expression of His-rPfE2m in BLR(DE3) E. coli was poor, as 
degradation could already be seen 1 h after induction.  
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A               D 
 
 
B               E 
 
 
C               F 
 
 
Figure 3-7. Western blot analysis of His-rPfE2m expression in BLR(DE3) E. coli 
The effect of various concentrations of IPTG (0 – 5 mM) on the expression of His-rPfE2m in pET-
15b was analysed at (A-C) 15°C and (D-F) 18°C. Samples of expression cultures were taken prior 
to induction (0 h) as well as after 1 – 4 h and overnight (ON) expression. Anti-His-tag antibody 
western blotting was used to assess the results; only soluble fractions are shown. His-rPfE2m 
resolved on the gel as a ~75 kDa protein (arrow) although the estimated molecular mass from the 
amino acid sequence is 70 kDa. No expression of His-rPfE2m was seen before induction (0 h). 
However, some leaky expression could be observed in the non-induced controls (0 mM IPTG) from 
3 h onwards. Increasing the concentration of IPTG past 0.5 mM only resulted in increased amounts 
of degradation products.  
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Although His-rPfE2m has an molecular mass of 70 kDa, the protein seemed to run at a 
larger 75 kDa size (Fig. 3-7), similar to rPfE2f-His (76 kDa, Fig. 3-6). However, when the 
two proteins were electrophoresed in adjacent wells in the same gel the slight size 
difference between the two was observed (Fig. 3-8). 
 
 
  
 
Figure 3-8. Size difference between His-rPfE2f and His-rPfE2m  
Samples taken after 1 h expression showed a small size difference between both insoluble (I) and 
soluble (S) fractions of rPfE2f-His (76 kDa) and His-rPfE2m (70 kDa) when resolved on the same 
gel. 
 
 
An expression trial of His-rPfE2m in pET-15b was also carried out in Rosetta™ 2 
(DE3)pLysS E. coli at 18°C (Fig. 3-9). This host E. coli contains additional plasmids 
encoding rare tRNAs. Expression of soluble His-rPfE2m without degradation products was 
seen up to 2 h, with degradation and aggregation increasing from 3 h onwards. 
Nevertheless, compared with BLR(DE3) (Fig. 3-7), more recombinant protein and less 
degradation was observed.  
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 A            B 
  
 
Figure 3-9. Western blot analysis of His-rPfE2m expression in Rosetta™ 2(DE3)pLysS E. coli 
Expression of His-rPfE2m in pET-15b in Rosetta™ 2(DE3)pLysS E. coli was tested at 18°C 
following induction with 0.5 mM IPTG. Samples of expression cultures were taken before 
induction (0 h) and after 1 - 4 h and overnight (ON) expression (A & B). Anti-His-tag antibody 
western blotting was used to analyse results. His-rPfE2m (arrow) was expressed in higher amounts 
in the insoluble fractions (I) compared with the soluble fractions (S). Degradation of His-rPfE2m 
can again be seen as expression time increases. 
 
 
In an attempt to decrease degradation of the recombinant protein, an expression trial was 
also carried out using BL21 Star™(DE3) E. coli. This line contains a mutated RNase E that 
cannot degrade mRNA, thus increasing its stability, hence the amount of full-length protein 
expressed should increase. The expression was, however, no better than with Rosetta™ 
2(DE3)pLysS (Fig. 3-10).   
 
 
 
 
Figure 3-10. Western blot analysis of His-rPfE2m expression BL21 Star™(DE3) E. coli 
Expression was tested at 18°C following induction with 0.5 mM IPTG. Samples of expression 
cultures were taken before induction (0 h) and after 1 h – 4 h and overnight (ON) expression. His-
rPfE2m (arrow) was detected by an anti-His-tag antibody western blot. Results were comparable 
with expression in Rosetta™ 2(DE3)pLysS E. coli.  
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Based on all the trials Rosetta™ 2(DE3)pLysS was chosen as the bacterial line for large-
scale expression of His-rPfE2m. Cultures were grown in Terriffic broth (TB), rather than 
Luria Bertani (LB) broth, as it allowed growth of bacteria to higher densities (OD600 nm = 
0.6 - 0.8) during the log phase before induction of protein expression and subsequently an 
increased amount of recombinant protein was obtained. Initially expression for only 2.5 h 
was chosen to avoid degradation and aggregation of His-rPfE2m. Following very low final 
yields of purified recombinant protein, higher yield of His-rPfE2m was chosen over 
degradation, and overnight expression of His-rPfE2m was carried out prior to purification 
of the protein used for all subsequent analyses. 
 
 
3.1.3.3.2 Expression of His-rPfE2bc 
 
His-rPfE2bc in pET-15b was transformed into BLR(DE3) and Rosetta™ 2(DE3)pLysS E. 
coli. No expression of soluble His-rPfE2bc was seen in Rosetta™ 2(DE3)pLysS E. coli. 
Expression using BLR(DE3) resulted in low levels of soluble protein with no degradation 
at temperatures under 30°C (Fig. 3-11). For large-scale purification, His-rPfE2bc was 
expressed for 18 h at 25°C in Terrific broth.  
 
 
A          B 
              
 
Figure 3-11. Western blot analysis of expression of His-rPfE2bc in pET-15b  
An expression trial of His-rPfE2bc in BLR(DE3) was carried out at 18°C, 25°C, 30°C and 37°C. 
Samples of expression cultures were taken (A) before induction (0 h), 14 h and (B) 18 h after 
induction of expression with 1 mM IPTG. The soluble fractions were analysed by anti-His-tag 
antibody western blotting. Expression of the 35 kDa rPfE2bc (arrow) was well controlled as no 
recombinant protein was seen at 0 h. Overall expression yield was low but largely free of 
degradation products. At 37°C rPfE2bc degraded.  
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3.1.3.3.3 Expression of GST-rPfE2c 
 
GST-rPfE2c was transformed into Rosetta™ 2(DE3)pLysS and BLR(DE3) E. coli. 
Expression trials at various temperatures (18°C, 25°C, 30°C and 37°C) resulted in very 
degraded expression in Rosetta™ 2(DE3)pLysS (Fig. 3-12A & B). Successful expression 
was achieved in BLR(DE3), in which overnight expression at 18°C resulted in the highest 
amounts of soluble GST-rPfE2c with minimal degradation (Fig. 3-12C-D). These 
conditions were chosen for large-scale expression.  
 
 
A            B 
 
 
C       D
 
 
Figure 3-12. Western blot analysis of expression of GST-rPfE2c in pET-15b  
Expression of GST-rPfE2c was trialled in two bacterial lines at 18°C, 25°C, 30°C and 37°C. 
Samples of expression cultures were taken before induction (0 h) and 1 – 4 h and overnight after 
induction with 1 mM IPTG. Soluble fractions were analysed by anti-His-tag antibody western 
blotting. (A & B) Expression in Rosetta™ 2(DE3)pLysS was leaky as some protein can be seen in 
the 0 h sample and large amounts of degradation can be seen. The GST-rPfE2c was expected to be 
52 kDa, however, it resolved as a lower molecular mass band at about 45 kDa (arrow). (C & D) 
Expression in BLR(DE3) was much cleaner and tightly controlled as no protein can be seen at 0 h. 
Again the 52 kDa GST-rPfE2c (arrow) resolved at a lower molecular mass. 
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3.1.3.4 Recombinant protein purification 
 
3.1.3.4.1 Purification of His-rPfE2m 
 
Initial purification of His-rPfE2m was carried out with nickel affinity chromatography 
using a 1 ml HisTrap FF column. Protein lysate from 4 L of His-rPfE2m culture expressed 
at 18°C for 2.5 h was loaded onto the column. A preliminary gradient elution (10 mM – 1 
M imidazole) of His-rPfE2m was used to determine the elution profile of the protein and 
any contaminants. Based on this, a step-wise increase in imidazole concentration was used 
to separate His-rPfE2m from contaminants eluting at concentrations up to 400 mM. His-
rPfE2m eluted in peak 3 and the fractions containing the highest amounts of the protein 
were pooled for further purification by gel filtration (Fig. 3-13A-C). Approximately 3 mg 
of His-rPfE2m was loaded onto a HiLoad™ 16/60 Superdex 200 gel filtration column, 
which allows separation of proteins up to 600 kDa. His-rPfE2m eluted as three species; a 
large molecular mass species in the void volume (≥600 kDa), and two others 
corresponding to 450 kDa and 170 kDa, respectively (Fig. 3-13D-G). Peak 4 (Fig. 3-13D) 
contained only very small molecular mass species (43 kDa), thus it was concluded not to 
be His-rPfE2m and was not analysed further. Lipoylation of His-rPfE2m was confirmed by 
western blot using anti-lipoic acid (-LA) antibody (Fig 3-13H). Interestingly, while the 
void volume peak contained least His-rPfE2m, this fraction showed the strongest -LA 
signal. This suggested that the protein in this peak was highly lipoylated and could thus be 
the correctly folded and assembled His-rPfE2m required for subsequent characterisation. 
However, the protein concentration was too low (0.02 – 0.03 mg/ml) for any structural 
analyses to be carried out successfully.  
A major cause of concern was an additional slightly lower molecular mass protein seen in 
gel filtration peak 2 (Fig. 3-13F, grey arrow). As this was not detected by -LA antibody, 
it was suspected to be an E.coli contaminant. Both protein bands in peak 2 and the band in 
peak 3 were excised and sent for identification using mass spectrometry (Proteomics Unit, 
University of Glasgow). Peak 3 was confirmed to be His-rPfE2m, however, no good match 
was obtained for the 75 kDa protein in peak 2 and the smaller protein was identified as an 
E.coli bifunctional UDP-glucuronic acid decarboxylase/UDP-4-amino-4-deoxy-L-
arabinose formyltransferase. Due to this contamination, purification using this method was 
not continued.  
Chapter 3 Expression and purification of recombinant P. falciparum dihydrolipoamide acetyltransferase 
and dihydrolipoamide dehydrogenase 
 
 
 
114 
A         B                C  
    
 
D         E 
 
    
  F       G        H 
 
 
Figure 3-13. Purification of His-rPfE2m with nickel affinity chromatography 
(A) Protein lysate was loaded onto a 1 ml HisTrap FF column. A step-wise increase in imidazole 
concentration (100 mM, 400 mM and 1 M) was used to obtain a good separation of contaminating 
proteins (peak 1 and 2) from His-rPfE2m (peak 3). (B) SDS-PAGE analysis shows a major protein 
of ~75 kDa (arrow) is present in peak 3. Numbers above lanes denote fractions. (C) Anti-His-tag 
antibody (-His) western blot verified that the ~75 kDa protein (arrow) corresponds to His-
rPfE2m. (D) Fractions 3 – 6 of the HisTrap FF peak 3 were pooled and further purified by gel 
filtration using a HiLoad™ 16/60 Superdex 200 column. (E) A standard curve for the above column 
was obtained to determine the size of the protein present in each peak (see section 2.6.8.6 for 
standards). Elution peak 1 corresponded to the void volume, peaks 2, 3 and 4 eluted at volumes 
corresponding to 450 kDa, 170 kDa and 43 kDa respectively. (F) SDS-PAGE showed that the first 
three peaks contained the 75 kDa His-rPfE2m (black arrow), but peak 2 also contained a slightly 
smaller size protein (grey arrow). (G) -His-tag antibody western blot confirmed the 75 kDa 
protein as His-rPfE2m (arrow). (H) Lipoylation of His-rPfE2m was confirmed (arrow) when the 
western blot shown in figure G was stripped and probed with anti-LA antibody (-LA).   
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Immobilised-metal affinity chromatography (IMAC) is based on the affinity of transition 
metal ions such as copper, nickel, zinc and cobalt to histidine and cysteine, and was first 
shown to be useful protein purification method in the 1970s (Block et al., 2009). Following 
this, His-tags for recombinant proteins were developed to improve binding of target 
proteins to metal ions bound on agarose beads. However, repeats of histidine residues in 
native expression host proteins can also bind the metal ions leading to contaminating 
proteins in the purification fractions, as seen with the above nickel HisTrap FF 
purification. The metal used in the purification can be altered to increase selectivity for the 
recombinant protein. The commonly used metals, in order of binding strength, are copper, 
nickel, zinc and cobalt. Because the E. coli contaminant seen in peak 2 of gel filtration 
(Fig. 3-13F) was binding strongly to nickel, zinc, which does not bind His-tagged proteins 
as strongly, was chosen for further purification.  
 
A POROS® PEEK™ metal affinity chromatography column loaded with ZnSO4 was used 
to bind His-rPfE2m from 6 L of culture expressed at 18°C for 2.5 h. His-rPfE2m eluted in 
one major peak at ~800 mM imidazole when a linear gradient was applied (Fig 3-14A-C). 
The fractions with the highest protein concentration were pooled and ~1 mg was loaded 
onto a HiPrep 26/60 Sephacryl S-400 HR gel filtration column. This column has a 
fractionation range from 20 kDa to 8 MDa, thus it was chosen for better resolution of the 
larger molecular mass His-rPfE2m species (≥600 kDa) that were present in the void 
volume of the HiLoad™ 16/60 Superdex 200 column (Fig. 3-13D). His-rPfE2m eluted in 
two peaks, the first after 193 ml, the second at 222 ml and the protein in both peaks was 
lipoylated (Fig. 3-14D-G).  
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Figure 3-14. Zinc POROS® PEEK™ purification of His-rPfE2m 
A) A POROS® PEEK™ metal affinity chromatography column loaded with ZnSO4 was used for 
further purification of His-rPfE2m. A linear imidazole gradient (40 mM – 1 M) was used to elute 
His-rPfE2m. (B) SDS-PAGE analysis shows the main protein present in peak 2 has a molecular 
mass of ~75 kDa (arrow). Numbers above lanes denote fractions. (C) Anti-His-tag antibody (-His) 
western blot analysis confirmed this to be His-rPfE2m (arrow) along with several degradation 
products. (D) Fractions 1 – 5 from the POROS® PEEK™ purification were pooled and further 
purified by gel filtration using a HiPrep 26/60 Sephacryl S-400 HR column. (E) A 75 kDa protein 
(arrow) was seen on SDS-PAGE of both gel filtration peaks. (F) The protein bands were verified to 
be His-rPfE2m (arrow) with -His-tag antibody western blot. (G) Both protein species were 
lipoylated as shown by an anti-lipoic acid antibody (-LA) western blot. 
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Due to technical difficulties in determining the void volume for this particular gel filtration 
column, the molecular mass of the protein species cannot be determined from the 
chromatogram. Because the Sephacryl S-400 separates proteins up to 8 MDa, the typical 
high molecular mass standard, dextran blue (2 MDa), was not large enough to determine 
the exact void volume. The appropriate void marker for this particular column used by its 
manufacturer, GE Healthcare, was proprietary and not available for purchase. An attempt 
to determine the void volume was made using 0.5 M latex beads, however, without a 
refractometer the elution of the beads could not be detected. Nevertheless, standards with 
known molecular masses were separated on the column. Dextran blue (2 MDa) eluted at 
100 ml, thryoglobulin (669 kDa) eluted at 186 ml, apoferritin (440 kDa) at 196 ml, alcohol 
dehydrogenase (150 kDa) at 217 ml and bovine serum albumin (66 kDa) eluted at 240 ml. 
From this, the molecular masses for the protein species in gel filtration peaks 1 and 2 (Fig. 
3-12D) could be estimated. Peak 1 eluted at 193 ml suggesting a molecular mass between 
440 - 700 kDa. Peak 2 eluted at 222 ml, which could correspond to a molecular mass 
between 70 - 150 kDa.    
 
Although His-rPfE2m purified after 2.5 h expression was very pure, the protein 
concentration obtained was very low; only 10 ml of protein at ~20 g/ml was obtained. 
Even after concentrating the protein extensively (from ~ 10 ml to 1ml), only up to 0.2 
mg/ml of His-rPfE2m could be obtained. Attempts to carry out analytical 
ultracentrifugation (AUC) to determine the oligomeric state of His-rPfE2m at such a low 
protein concentration were unsuccessful. Thus, the decision was made to choose protein 
yield over degradation products and subsequent purifications were carried out on His-
rPfE2m expressed for a longer period to increase protein yield. 
 
Protein lysate from 2 L of His-rPfE2m culture expressed at 18°C overnight was used for 
purification. Due to the high viscosity of the lysate, this was divided into 5 aliquots, which 
were each purified using a ZnSO4 POROS® PEEK
™ column. Initially a 10 mM – 1 M 
imidazole gradient elution was carried out and His-rPfE2m eluted as a doublet peak 
between 300 – 700 mM. To separate the two peaks, subsequent elutions were carried out 
using step-wise increments (Fig. 3-15A). Although on SDS-PAGE (Fig. 3-15B) both peaks 
seemed to contain the same proteins, only peak 1 was used in further purification as this 
contained most of the protein.  
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Figure 3-15. Purification of His-rPfE2m following overnight expression 
(A) Step-wise increase in imidazole concentration (100 mM, 500 mM and 1 M) was used to elute 
His-rPfE2m from the ZnSO4 POROS® PEEK™ column. (B) SDS-PAGE analysis showed the 75 
kDa His-rPfE2m (arrow) was mostly in peak 1. Numbers above lanes denote fractions. (C) 
Fractions 2 - 6 from the POROS® PEEK™ purification were pooled and purified by gel filtration 
using a HiPrep 26/60 Sephacryl S-400 HR column. (D) SDS-PAGE showed that His-rPfE2m 
appears to be present in all four peaks. (E) Anti-His-tag antibody (-His) western blot confirmed 
the presence of His-rPfE2m (black arrow) but also showed degradation products (grey arrows, 25 
and 37 kDa) and larger molecular mass bands (grey arrows, 210 and 280 kDa). (F) Anti-LA 
antibody (-LA) western blot confirmed lipoylation of His-rPfE2m (black arrow), the degradation 
products (grey arrows, 13, 37 and 60 kDa) and larger molecular mass bands (grey arrows, 210 and 
280 kDa). L, protein lystate; FT, flow-through; W, wash; P, protein loaded onto gel filtration 
column. 
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At this point in the purification, the total protein obtained from 0.4 L of culture was 2.5 mg 
compared with 1 mg from 6 L His-rPfE2m expressed for 2.5 h. The fractions with most 
His-rPfE2m from five separate purifications were pooled, concentrated and loaded onto the 
HiPrep 26/60 Sephacryl S-400 HR gel filtration column. His-rPfE2m eluted in four peaks, 
at 103 ml, 134 ml, 181 ml and 218 ml (Fig. 3-15C-D). As previously described, the 
molecular mass of each peak cannot be assigned accurately on the gel filtration column 
used. However, estimated molecular masses based on standards were ~ 2 MDa, >700 kDa, 
~ 700 kDa and ~150 kDa, respectively for peaks 1-4. The protein concentrations were 
0.08, 0.15, 0.64 and 0.25 mg/ml for each peak, respectively. For subsequent structural 
analyses His-rPfE2m from each peak was concentrated using aquacide, as the protein 
bound onto the membrane on spin columns (Vivaspin™ concentrators).   
 
Western blot analysis of His-rPfE2m in each peak using -His and -LA antibodies (Fig 
3-15E-F) showed protein bands larger than the monomer size, suggesting the presence of 
multimers, which were not disrupted in the process of denaturing the protein for the blots. 
The band sizes could correspond to a trimer (210 kDa) and possibly a tetramer (280 kDa) 
and even larger species (Fig. 3-15E-F). Several degradation products were also seen. A 60 
kDa degradation product was detected by the anti-lipoic acid antibody but not the anti-His-
tag antibody, suggesting the loss of the 2 kDa His-tag and part of the first lipoyl domain 
from this protein species. A second smaller product (~37 kDa) was detected by both the 
anti-lipoic and the anti-His-tag antibody, implying truncation of the protein nearer the 
catalytic domain. Finally a ~ 13 kDa band was detected only on the anti-lipoic acid western 
blot, which could correspond to a lipoyl domain in its own. Similar degradation products 
have been reported for full length human E2 (Yang et al., 1997).  
 
 
3.1.3.4.2 Purification of His-rPfE2bc  
 
Protein lysate from 2 L of His-rPfE2bc culture expressed at 25°C for 18 h was loaded onto 
a 1 ml nickel HisTrap FF column. In the preliminary purifications, elution was carried out 
with a linear imidazole gradient first up to 1 M and then to 1.5 M, but His-rPfE2bc did not 
elute within the gradient until the final concentration was increased to 2 M (Fig. 3-16A). 
His-rPfE2bc was present mainly in the latter fractions of peak 3 (Fig. 3-16B&C), which 
eluted at ~ 1.2 M imidazole.   
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Figure 3-16. Purification of His-rPfE2bc 
(A) His-rPfE2bc was eluted from the 1 ml HisTrap FF column using an imidazole gradient ranging 
from 100 mM to 2 M. (B) SDS-PAGE analysis showed that the largest amount of a 35 kDa protein 
(arrow) was purified in peak 3. (C) Anti-His-tag antibody western blot (-His) analysis confirmed 
the 35 kDa band as His-rPfE2bc (arrow) and showed fractions 2-4 of peak 3 to lack His-tagged 
degradation products. (D) Fractions 2 – 4 of peak 3 from seven separate purifications were pooled 
and further purified by gel filtration using a HiLoad™ 16/60 Superdex 200 column. His-rPfE2bc 
eluted in two poorly resolved peaks corresponding to 140 kDa and 68 kDa, respectively. For 
standard curve see Fig. 3-13E. (E) SDS-PAGE shows peak 1 contained the 35 kDa protein (arrow) 
and an additional protein at around 75 kDa  (arrow). (F) -His western blot confirmed the presence 
of His-rPfE2bc (arrow) and that the larger band (arrow) was also His-tagged. L, protein lystate; FT, 
flow-through 
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As these fractions were relatively free of contaminants, further optimisation of the elution 
was not carried out. Fractions from seven separate purifications were pooled, concentrated 
(~ 8 mg in 5 ml) and loaded onto the HiLoad™ 16/60 Superdex 200 gel filtration column. 
His-rPfE2bc eluted in two peaks corresponding to molecular masses of 140 kDa and 68 
kDa (Fig. 3-16D-F). While fractions in the second peak consisted of pure His-rPfE2bc, 
SDS-PAGE showed the fractions in the first peak to contain a larger molecular mass 
protein. The protein was also detected by anti-His-tag antibody western blot, suggesting it 
was a multimer of His-rPfE2bc that had not completely denatured during the SDS-PAGE 
protocol. The proteins in these two peaks were kept separate for subsequent analyses.  
 
Peak 1 contained ~ 2 mg of His-rPfE2bc in 11 fractions (11 ml). Peak 2 contained ~ 1 mg 
of His-rPfE2bc in 10 fractions (10 ml). Concentration of the proteins was attempted using 
Vivaspin™ concentrators and aquacide. Unfortunately, His-rPfE2bc was not stable at 
higher concentrations. This could already be seen during purification as ~ 8 mg of protein 
was loaded onto the gel filtration column but a total of only ~ 3 mg was collected in peak 1 
and 2 elution fractions. The elution profiles showed broad peaks at 110 – 115 ml, 
corresponding to 3 – 4 kDa, which could be degraded His-rPfE2bc. During concentration, 
precipitation of His-rPfE2bc was seen once 0.5 – 0.7 mg/ml was reached. The addition of 2 
mM EDTA and up to 5% glycerol or 5 mM DTT did not prevent aggregation or improve 
yield. Concentration of His-rPfE2bc was also attempted by re-loading fractions from gel 
filtration onto a 1 ml nickel HisTrap FF column. The eluted His-rPfE2bc was stable 
following elution in the presence of imidazole, however, following buffer exchange to 
remove imidazole, the protein aggregated. Regardless, the concentrations obtained (0.3 – 
0.5 mg/ml) were ultimately sufficient for biochemical and structural analyses of the 
protein. 
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3.1.3.4.3 Purification of GST-rPfE2c 
 
Protein lysate from 2 L of GST-rPfE2c expressed overnight at 18°C in BLR(DE3) was 
purified on a GSTrap FF column (GE Healthcare). Elution was carried out with 10 mM 
reduced glutathione and GST-rPfE2c eluted in one peak (Fig. 3-17A & B).  
 
 
A       B 
       
 
Figure 3-17. GSTrap purification of GST-rPfE2c  
(A) GST-rPfE2c eluted in one peak (consisting of two fractions) from a GSTrap FF column with 10 
mM reduced glutathione. (B) SDS-PAGE showed the presence of a 45 kDa protein (arrow) 
presumed to GST-rPfE2c in both fractions (numbered). L, protein lysate; FT, flow through. 
 
 
Cleavage of the GST-tag was attempted using PreScission Protease (GE Healthcare) 
(section 2.6.8.5). Cleavage was first tried on eluted GST-rPfE2c with overnight incubation 
of the protein with 60 U of PreScission Protease at 4ºC. Cleavage of the recombinant 
protein from the GST-tag was successful (Fig. 3-18A), however, separation of the cleaved 
rPfE2c was not (Fig. 3-18B & C). rPfE2c did not elute in the flow-through as it should but 
a large fraction of it was still bound onto the GSTrap FF column or interacted with the 
bound GST-tag. rPfE2c only eluted along with the GST-tag on addition of 10 mM reduced 
glutathione. On-column cleavage under the same conditions as above did not solve the 
problem. The cleaved rPfE2c and GST-tag could not be separated (Fig. 3-18D & E) thus, 
further studies with this construct were not continued.  
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Figure 3-18. Cleavage of GST-tag from GST-rPfE2c 
(A) Before cleavage with PreScission Protease, a large amount of a 45 kDa protein corresponding 
to the size of GST-rPfE2c can be seen. Following cleavage, only a small amount is left at 45 kDa 
as most of the protein has a mass of ~23 kDa. This size corresponds to both the cleaved rPfE2c and 
GST-tag. (B) SDS-PAGE of flow-though and elution fractions (numbered) following attempted 
purification of rPfE2c from the GST-tag. Very little 23 kDa protein is seen in the flow-though 
fractions. The elution fractions contain most of the protein. (C) Anti-GST-antibody western blot 
showing the presence of GST-tag in all fractions, thus confirming that rPfE2c and the GST-tag 
have not been well separated. The anti-GST-antibody is extremely sensitive, even at a dilution of 
1:50,000. (D) SDS-PAGE of on-column cleavage fractions (numbered). Again most of the 23 kDa 
protein is in the elution fractions. (E) An anti-GST-antibody western blot confirmed all fractions to 
still contain the GST-tag.   
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3.1.3.5 Kinetic analyses 
 
During transfer of the acetyl group from E1 to CoA to form acetyl-CoA an intermediate, 8-
acetyl-dihydrolipoamide, is formed which absorbs light at 240 nm. In the E2 activity assay, 
this reaction is reversed and coupled to the production of acetyl-CoA by 
phosphotransacetylase (PTA) (Fig. 3-19). Dihydrolipoic acic (DHLA) is added to reverse 
the reaction, as the lipoamide moiety on purified E2 would be in the oxidised form as 
required for the natural forward direction of the reaction. The increase in absorbance due to 
increasing quantities of the product 8-acetyl-dihydrolipoamide was measured at 240 nm. 
Activity is represented as Abs 240nm/min/mg as the extinction coefficient for 8-acetyl-
dihydrolipoamide cannot be determined precisely. This is because acetyl groups shuffle 
between sulphurs in acetylated dihydrolipoamide leading to a mixture of 8- and 6-acetyl 
dihydrolipoamide at a 3:1 ratio and also high levels of acetylation result in large amounts 
of a biacetyl derivative (O'Connor et al., 1982; Yang and Frey, 1986; Yang et al., 1997).    
 
 
 
 
Figure 3-19. The E2 activity assay 
PTA catalyses the formation of acetyl-CoA + Pi from acetyl-phosphate (Acetyl-P) and CoA. Upon 
addition of DHLA followed by E2, 8-acetyl-dihydrolipoamide + CoA is formed. CoA feeds back 
into the PTA reaction creating a cycle where acetyl-CoA is constantly produced. 
 
3.1.3.5.1 Activity of His-rPfE2m  
 
Before each set of activity measurements, the appropriate controls to test each substrate 
and enzyme were carried out to ensure the reaction was working (Fig. 3-20). Special care 
was taken with DHLA, which was tested between measurements as well, because it started 
to oxidise once exposed to air. When using DHLA stored at 4°C overnight, an unstable  
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Figure 3-20. Control reactions for the E2 activity assays  
To test the E2 activity assay, each component of the reaction was left out in turn and also heat 
inactivated (10 min at 100°C) His-rPfE2m was tested. No increase in absorbance with time can be 
seen until the reaction contains all components and His-rPfE2m.  
 
 
absorbance prior to addition of His-rPfE2m was observed. Thus, once a vial of DHLA was 
opened it was used for up to 8 h only to ensure the reaction was not compromised.  
 
The activity values for His-rPfE2m and His-rPfE2bc were obtained by determining the 
steady state kinetics following addition of the recombinant protein into the reaction 
mixture. The rate was measured from the linear curve at a position where the change in 
absorbance over time did not vary significantly.    
 
Activity of His-rPfE2m was first assayed by increasing the amount of protein while both 
CoA and DHLA were kept at saturation levels (50 M CoA, 1 mM DHLA). His-rPfE2m 
activity increased in a linear fashion when 0.2 - 1 g of protein was used (Fig. 3-21A). The 
pH optimum of His-rPfE2m was determined to be between pH 7 and 8 (Fig. 3-21B) and 
there seemed to be a threshold of 0.75 mM for the amount of DHLA required for activity 
(Fig. 3-21C).    
 
The activities of each of the His-rPfE2m forms purified by gel filtration (Fig. 3-15C) were 
comparable, with peak 1 being slightly less active than the other three (Table 3-3). Kinetic 
parameters (Fig. 3-21D and Table 3-4) were determined for peak 3, as this contained the 
most protein and was used for subsequent structural characterisation. 
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Figure 3-21. Activity of His-rPfE2m 
Each point represents the mean ± standard error of three independent measurements (unless 
otherwise stated). A total of 1 – 2 g of His-rPfE2m was used for each assay. (A) Activity of 
His-rPfE2m increased as the amounts of protein were increased (0.2 – 2 g). Only one 
measurement for each concentration was carried out for this data set. Both a linear (red) and 
non-linear (black) regression have been applied to the graph to show the linearity of the 
reaction up to 1 g of protein. (B) The optimum pH of His-rPfE2m was between pH 7 and 8. 
(C) The concentration of DHLA required in the reaction was determined by keeping CoA at 
10 M and varying the DHLA concentration (0.1 – 5 mM). (D) Michaelis-Menten kinetics of 
the His-rPfE2m reaction for CoA. DHLA was kept constant at 1 mM while the concentration 
of CoA was varied (2.5 – 50 M). The Km was 13.5 ± 0.9 M CoA and the vmax was 
determined as 110 ± 3 Abs 240nm/min/mg by fitting the Michaelis-Menten and Lineweaver 
Burk equations in GraphPad Prism 5 (GraphPad Software Inc.). The inset shows the double 
reciprocal Lineweaver-Burk plot of the data. 
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3.1.3.5.2 Activity of His-rPfE2bc 
 
Both forms of His-rPfE2bc purified by gel filtration (Fig. 3-16D) were active. Protein in 
peak 1 was slightly more active than in peak 2 (Table 3-3). The kinetic parameters of the 
two forms of His-rPfE2bc for the substrate CoA were determined by keeping the 
concentration of DHLA constant (1 mM) and varying the concentration of CoA (2.5 – 50 
M) (Fig. 3-22). The values can be seen in Table 3-4. 
    
   
  A       B 
 
  
Figure 3-22. Activity of His-rPfE2bc 
Each point represents the mean ± standard error of three independent measurements. A total of 
2 g of His-rPfE2bc was used for each assay.  (A) The Michaelis-Menten plot for His-rPfE2bc 
gel filtration peak 1. The kinetic parameters for CoA were: Km = 5.3 ± 0.6 M and vmax = 173 
± 5 Abs 240nm/min/mg. (B) The Michaelis-Menten plot for His-rPfE2bc gel filtration peak 2. 
The kinetic parameters for CoA were: Km = 4.8 ± 0.4 M and vmax = 144 ± 3 Abs 
240nm/min/mg. The insets in A and B show the double reciprocal Lineweaver-Burk plot of the 
data. Kinetic parameters were determined by fitting the Michaelis-Menten and Lineweaver 
Burk equations in GraphPad Prism 5 (GraphPad Software Inc.). 
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E2 source Abs240mn/min/mg 
P. falciparum, rPfE2m-His  
Gel filtration peak 1 20 ± 0.8 
peak 2 33 ± 0.4 
peak 3 30 ± 0.9 
peak 4 34 ± 0.4 
P. falciparum, rPfE2m-His  
Gel filtration peak 1 80 ± 4 
peak 2 75 ± 2 
P. falciparum, catalytic 
domain1 153.8 ± 16.2 
Human E22 19.4 ± 0.5 
Bovine E2-E3BP2 12.3 ± 0.3 
Maize mitochondrial PDC E23 191 
B. stearothermophilus4 7 
A. vinelandii mature -length5 79.4 
A. vinelandii catalytic domain6 117.9 
E. coli catalytic domain6 47.1 
 
Table 3-3. Comparison of E2 activities  
Activities of the various His-rPfE2m and His-rPfE2bc species purified by gel filtration (Fig. 3-15C 
and 3-16D, respectively). Values are the mean ± standard error of three independent measurements. 
For comparison the activities of E2 from other sources are added. 1Foth et al. (2005), 2Yang et al. 
(1997), 3Thelen et al. (1999), 4Lessard et al. (1998), 5 Hanemaaijer et al. (1989), 6Schulze et al. 
(1991b). 
 
 
E2 source vmax (Abs240mn/min/mg) Km (μM CoA ) 
P. falciparum, His-rPfE2m 110 ± 3  13.5 ± 0.9  
P. falciparum, His-rPfE2bc   
Gel filtration peak 1 173 ± 5  5.3 ± 0.6  
peak 2 144 ± 3  4.8 ± 0.4  
 
Table 3-4.  Comparison of kinetic parameters for CoA 
The kinetic parameters for each of the measured His-rPfE2m and His-rPfE2bc samples. Values are 
the mean ± standard error of three independent measurements. 
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3.2 Dihydrolipoamide dehydrogenase  
 
 
3.2.1 Introduction 
 
Dihydrolipoamide dehydrogenase (E3) (EC 1.8.1.4) is part of the oxidoreductase family  
of proteins, which act on a sulphur group of donors and use NAD+ or NADP+ as an 
electron acceptor (EC 1.8.1.-). E3 catalyses the final step of the PDC reaction; the 
oxidation of the reduced lipoyl moiety of E2 using NAD+ as the final electron acceptor 
(Fig. 3-23). For this reaction, E3 requires the cofactor flavin adenine dinucleotide (FAD) 
and redox disulphides to transfer the reducing equivalents from E2-bound 
dihydrolipoamide to NAD+ (Patel et al., 1995). The protein is a highly conserved 
homodimer (Mattevi et al., 1992b).   
 
  
 
 
Figure 3-23. Reaction catalysed by E3 
The reaction is a ping-pong mechanism characterised by two reactions. (1) E3 oxidises the E2 
dihydrolipoamide moiety while reducing the disulphides in E3. (2) E3 is oxidised by transferring 
an electrons to NAD+ and releasing a proton. 
 
 
The gene for apicoplast P. falciparum E3 (PfaE3) (PlasmoDB annotation PF3D7_0815900, 
www.plasmodb.org) is located on chromosome 8, is 2001 bp and encodes a 667 amino 
acid protein with a predicted molecular mass of 75.6 kDa (McMillan, 2006). P. falciparum 
has two distinct E3s. One localises to the apicoplast and is used by the PDC, while the 
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other is found in the mitochondrion and is shared by the other -ketoacid dehydrogenase 
complexes (KADHs) (McMillan et al., 2005). A similar situation is found in plants, in 
which the mitochondrion and the chloroplast have separate E3 proteins (Mooney et al., 
2002). The apicoplast PfaE3 showed the highest amino acid sequence identity with plant 
and cyanobacterial E3 (37 – 38%) E3 (McMillan, 2006).    
 
 
3.2.2 Aims 
 
The aims for this part of the project were to: 
 express recombinant P. falciparum E3 (rPfaE3) in soluble form 
 purify rPfaE3 
 determine the kinetic parameters of rPfaE3 
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3.2.3 Results 
 
3.2.3.1 Generation of expression constructs 
 
As for PfE2 the native coding sequence for PfaE3 contained several rare codons and in 
addition, Shine-Dalgarno-like sequences (GGAGGA) at 406 – 411 bp and 484 – 489 bp. 
Thus codon optimisation of the full-length PfaE3 was carried out by GENEART AG (from 
2010 onwards the company is known as GeneArt® Gene Synthesis, Life Technologies). 
Following gene synthesis, the company cloned the mature-length PfaE3 sequence (starting 
at Lys101) into the expression vector pET-15b, with a cleavable N-terminal 6 x His-tag 
producing the construct His-rPfaE3-pET-15b. The starting residue of the mature-length 
PfaE3, had been previously estimated by McMillan (2006). A construct with the first 120 
amino acids of PfaE3 fused to a GFP-tag with a predicted molecular mass of 42 kDa was 
transfected into P. falciparum. As the fusion protein was expressed in the parasite and 
transported into the apicoplast, the bipartite signal/transit peptide was cleaved. 
Immunoprecipitation was then carried out to isolate the fusion protein from the parasites 
and a 29 kDa GFP-tagged protein was observed. From this the deduction was made that the 
mature-length rPfaE3 started around Met110 (McMillan, 2006). However, as this was only 
an estimation of the start site, to make sure none of the mature-length protein residues were 
missed, the His-rPfaE3-pET-15b expression construct was started at Lys101.     
 
 
3.2.3.2 Recombinant His-rPfaE3 expression 
 
 
An attempt to express the codon optimised His-rPfaE3-pET-15b in Rosetta™ 2(DE3) E. 
coli at 30°C resulted in very small amounts of the 64 kDa protein in soluble form, which 
degraded 4 h following induction (Fig. 3-24A & B). Expression of the construct in 
BLR(DE3) or BL21 Star™(DE3) E. coli produced no soluble protein. Purification of His-
rPfaE3-pET-15b following expression at 37°C for 2 h, was unsuccessful as the protein did 
not bind the nickel affinity chromatography resin. The reason for the very low expression 
of soluble protein could have been the additional amino acids present at the beginning of 
the protein (K101-M110). These were likely to have been still part of the hydrophobic 
targeting peptide. Thus, a previously made construct (McMillan, 2006) containing the  
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Figure 3-24. Western blot analysis of expression of rPfaE3  
Expression of His-rPfaE3-pET-15b using Rosetta™ 2(DE3) E. coli was tested at 30°C following 
induction with 1 mM IPTG. Samples of expression cultures were taken (A) before induction at 0 h, 
after induction at 1 h, 2 h and (B) after 3 h, 4 h and overnight expression (ON). Both insoluble (I) 
and soluble (S) fractions were analysed with anti-His-tag antibody western blotting. A ~ 60 kDa 
protein (arrow) corresponding to His-rPfaE3-pET-15b could be seen. C) Expression of His-rPfaE3 
(in pQE30) using NovaBlue(DE3) E. coli at 30°C as previously described by McMillan (2006). 
Anti-His-tag antibody western blotting showed a small amount of soluble degradation-free His-
rPfaE3, with a mass of ~ 60 kDa, after overnight expression. 
 
 
native amino acid sequence of the mature-length rPfaE3, starting at Met110, in the vector 
pQE30 was used (construct name His-rPfaE3). An expression trial at 30°C in 
NovaBlue(DE3) E. coli showed expression only after overnight incubation (Fig. 3-24C), 
however, this was free of degradation products and the yield was greatly improved 
following large scale expression.  
 
 
3.2.3.3 Recombinant His-rPfaE3 purification 
 
Protein lysate from 1 L of His-rPfaE3-pQE30 culture expressed using NovaBlue(DE3) E. 
coli at 30°C overnight was incubated with 1 ml of Ni-NTA agarose. The mixture was 
poured into an empty column and the flow-through collected. The resin was washed two 
times with 20 mM imidazole, once with 50 mM imidazole and elution carried out with 250 
mM imidazole. His-rPfaE3 eluted mainly in the first elution fraction along with some 
degradation products (Fig. 3-25A & B).    
 
Fractions from two separate purifications were pooled and loaded onto a HiLoad™ 16/60 
Superdex 200 gel filtration column. His-rPfaE3 eluted in one peak corresponding to 
molecular mass of 140 kDa (Fig. 3-25C & D). The protein concentration in the peak was 
0.2 mg/ml. Concentration of the protein was carried out using aquacide (section 2.6.10). 
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Figure 3-25.  Ni-NTA batch purification of His-rPfaE3 
(A) SDS-PAGE of the flow-through (FT), wash and elution fractions. Numbers above the lanes 
denote fractions. In elution fraction 1, a ~ 60 kDa protein could be seen (arrow), which was 
confirmed to be His-rPfaE3 by anti-His-tag antibody western blot (B). (C) The first elution 
fractions of two Ni-NTA purifications were loaded onto a HiLoad™ 16/60 Superdex 200 column. 
His-rPfaE3 eluted in one peak corresponding to 140 kDa. For standard curve see Figure 3-13E.  (D) 
SDS-PAGE shows that peak 1 contained the purified His-rPfaE3. FT, flow through; P, pooled Ni-
NTA elutions; V, void volume. The SDS-PAGE and western blot in figures A & B were done by 
Jamie Whitelaw. 
 
 
3.2.3.4 Kinetic analyses 
 
The kinetic parameters of His-rPfaE3 forward and reverse reactions were assayed at 25°C 
using 1 g of protein as described in section 2.6.14. The change in absorbance at 340 nm 
due to reduction of NAD+ or oxidation of NADH, was monitored at 240 nm for the forward 
and reverse reactions, respectively. The Km and vmax for dihydrolipoamide (DHLA) were 
determined by keeping NAD+ constant at 2 mM and varying the concentration of DHLA 
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between 50 l and 2 l mM (Fig. 3-26A). For the kinetic parameters for NAD+, DHLA 
was kept constant at 2 mM and NAD+ varied between 62.5 and 2 mM (Fig. 3-26B).  
 
 
A           B 
 
 
C           D 
 
 
Figure 3-26. Activity of His-rPfaE3 
Each point represents the mean ± standard error of three independent measurements. The figures 
show the Michaelis-Menten plot for each substrate and the double reciprocal Lineweaver-Burk plot 
of the data as an inset. The Km and vmax for each substrate was determined by fitting the Michaelis-
Menten and Lineweaver Burk equations in GraphPad Prism 5 (GraphPad Software Inc.). (A) 
DHLA: Km = 1160 ± 105 M and vmax = 104 ± 5 mol/min/mg (B) NAD+: Km = 96 ± 12 M and 
vmax = 104 ± 5 mol/min/mg (C) Lipoamide: Km = 841 ± 97 M and vmax 91 ± 4 mol/min/mg (D) 
NADH: Km = 15 ± 2 M and vmax = 73 ± 2 mol/min/mg. 
 
 
To determine the Km and vmax for lipoamide the concentration of NADH was kept constant 
at 200 M and lipoamide was varied between 50 M and 4 mM (Fig. 3-26C). Finally for 
NADH kinetic parameters, lipoamide was kept constant at 2 mM and NADH was varied 
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between 10 M and 200 M (Fig. 3-26D). The kinetic parameters were comparable to E3 
from other species (Table 3-5). 
 
 
  His-rPfaE3 
P. falciparum 
mitochondrial 
E31 
Human 
E32 
Trypanosome 
E33 
Km DHLA 1160 ± 105 μM 146 ± 15 M 570 M 130 M 
Km NAD
+   96 ± 12 M 450 ± 30 M 290 M 600 M 
Km lipoamide 841 ± 97 M    870 ± 270 M 1010 M 800 M 
Km NADH 15 ± 2 M 21 ± 6 M 51 M  25 M 
 
Table 3-5. Comparison of the Km of E3 from various species  
His-rPfaE3 values are the mean ± standard error of three independent measurements. 1McMillan et 
al. (2005), 2Kim et al. (1991), 3Schöneck et al. (1997). 
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3.3 Summary 
 
 Full-length PfE2 had low sequence identity compared with PDC E2 from other 
organisms, especially at the N-terminus where there is great variation between the 
species due to different numbers of LDs. The linker regions also had low identity, 
for example, the human E2 linkers had high levels of alanine and proline whereas 
the PfE2 linkers were abundant in glycine, lysine and asparagine.  
 
 Regardless of the low amino acid sequence identity, PfE2 domains contain several 
important conserved residues. The LDs contain the lysine required for lipoylation 
(Lys93 and Lys 223), the SBD contains an arginine (Arg383) required for E3 
binding in other organisms, and the CD contains the conserved DHR motif with the 
histidine (His612) essential for activity. Some key residues in the PfE2 domains 
differ from the human counterparts and could thus be of interest in future studies. 
 
 The domains of various Plasmodium E2 are quite conserved, while differences are 
seen in the linkers. PfE2 did not have more sequence identity with the other human 
Plasmodium parasites nor the rodent species but seemed to be a mix of the two 
groups.  
 
 E. coli codon optimised mature-length PfE2 (His-rPfE2m) was expressed in 
Rosetta™ 2(DE3)pLysS E. coli at 18C overnight to obtain a final yield of 1.8 mg/L 
of baterial culture. His-rPfE2m was purified using ZnSO4 POROS
® PEEK™ column 
and gel filtration. The purified protein could be concentrated to 3.5 mg/ml. His-
rPfE2m was more active than human E2. 
 
 E. coli codon optimised truncated PfE2 comprising the SBD and CD (His-rPfE2bc) 
was expressed in BLR(DE3) E. coli at 25C overnight to obtain a final yield of  
0.25 mg/L of bacterial culture. The recombinant protein was purified using a 
HisTrap FF column and gel filtration. Concentration of His-rPfE2bc was difficult 
as the protein aggregated at above 0.7-0.8 mg/ml, thus His-rPfE2bc was only 
concentrated to 0.5 mg/ml. His-rPfE2bc was more active than His-rPfE2m. 
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 An attempt was made to purify a GST-tagged PfE2 CD (GST-rPfE2c). Cleavage of 
the tag from the recombinant protein was successful, however, the GST-tag could 
not be separated from rPfE2c. Thus no further work was done with this construct.  
 
 Native mature-length apicoplast PfE3 (His-rPfaE3) was expressed in 
NovaBlue(DE3) at 30C overnight. A final yield of 1.5 mg/L of bacterial culture 
was obtained. His-rPfaE3 was purified using the Ni-NTA batch purification method 
and could be concentrated to 2.9 mg/ml. The recombinant protein activity was 
comparable to that of E3 from other organisms.  
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Chapter 4  
Structural characterisation of recombinant P. falciparum 
dihydrolipoamide acetyltransferase and dihydrolipoamide 
dehydrogenase 
 
 
4.1 Dihydrolipoamide acetyltransferase 
 
4.1.1 Introduction 
 
E2 has a multidomain structure; PfE2 contains two lipoyl-domains (LD) at the N-terminus 
followed by an E1/E3 sub-unit binding domain (SBD), and a catalytic domain (CD) at the 
C- terminus, all separated by flexible linkers (Fig. 4-1). Three E2 monomers assemble into 
a tightly bound trimer. For example, in A. vinelandii trimer formation involves 66 residues 
per monomer and 48 hydrogen bonds (i.e. 16 hydrogen bonds per monomer) (Mattevi et 
al., 1992a; Mattevi et al., 1993a). The active sites are formed at the interface of each 
monomer. The interactions between the trimers to form the large E2 core are not as strong 
as the intra-trimer bonds. Core formation involves only a hydrophobic 310-helix “ball” at 
the C-terminus of the protein, which inserts into a hydrophobic “socket” and is kept in 
place by only two hydrogen bonds (Mattevi et al., 1992a; Izard et al., 1999). The E2 core 
is an icosahedral 60-mer in humans, Gram-positive bacteria and plant mitochondria, and an 
octahedral 24-mer in Gram-negative bacteria and the plant chloroplast (Mattevi et al., 
1992a; Izard et al., 1999; Mooney et al., 1999; Yu et al., 2008b). 
 
 
 
Figure 4-1. Multidomain structure of PfE2 
The linker between the two lipoyl-domains (LD) is 58 amino acids (aa), between the second LD 
and the E1/E3 sub-unit binding domain (SBD) 96 residues and between the SBD and catalytic 
domain (CD) 31 amino acids.   
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The structure and stochiometry of the Plasmodium E2 core are unknown. As the apicoplast 
is of red algal origin and a non-photosynthetic chloroplast-like organelle (Botte et al., 
2011), the hypothesis tested here was that PfE2 forms a 24-mer. Full-length E2 has not yet 
been crystallised, probably due to the flexible linkers. Thus, to obtain structural 
information on PfE2, other biophysical methods were utilised to obtain structural 
information. In this study, analytical ultracentrifugation (AUC) and small angle X-ray 
scattering (SAXS) were used to investigate the solution structure and stoichiometry of 
recombinant PfE2.  
 
 
4.1.2 Aims 
 
The aims for this part of the project were to: 
 determine the stoichiometry of the rPfE2 core 
 obtain a structural model of rPfE2 
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4.1.3 Results  
 
4.1.3.1 Homology modelling of P. falciparum E2 domains 
 
In the absence of a crystal structure for PfE2, homology modelling was carried out to 
obtain an indication of the PfE2 structure. The I-TASSER server for protein structure and 
function prediction was used for this (http://zhanglab.ccmb.med.umich.edu/I-TASSER/, 
Zhang, 2008; Roy et al., 2010, section 2.8.2). I-TASSER generates structural models using 
templates from proteins in the PDB database that have similar folds and secondary 
structures as those predicted from the submitted amino acid sequence (Zhang, 2008). Due 
to the flexible linkers between the domains, I-TASSER was unable to model the mature 
length protein (residues 51-640). Thus, the individual domains were modelled.  
 
The top three templates used for structure prediction of P. falciparum LD1 (PfLD1) were 
the LD from the human E3 binding protein (E3BP) (PDB entry 2DNC, no associated 
publication), LD2 from human E2 (PDB entry 1FYC, Howard et al., 1998), and the A. 
vinelandii -ketoglutarate dehydrogenase complex E2 LD (PDB entry 1GHK, Berg et al., 
1996). Only one model with a high C-score (1.22, on a scale of -5 to 2, where a higher 
score indicates a better model) was generated (Fig. 4-2A), suggesting PfLD1 is structurally 
very similar to that of other organisms (Fig. 4-2C). Root mean square deviations (rmsd) 
values showed PfLD1 to be most similar to human E3BP LD (0.9 Å), human E2 LD2 (1.0 
Å), A. vinelandii LD1 (1.3 Å), G. stearothermophilus LD (1.5 Å) and finally E. coli LD3 
(2.2 Å). For reference, two identical structures will have a rmsd of 0.   
 
Using the same templates as above, four I-TASSER models were obtained for PfLD2 with 
C-scores ranging from 0.52 to -3.26. The best model, i.e. the model with the highest C-
score, is shown in Fig. 4-2B. The amino acid sequence of PfLD2 is less conserved than 
that of PfLD1, however, the best model was still similar to PfLD1 (rmsd = 0.8 Å). PfLD2 
was most similar to the human E2 LD2 and A. vinelandii LD1 (rmsd for both = 1.1 Å). It 
was also more similar to the other bacterial structures than was PfLD1 (G. 
stearothermophilus LD rmsd: 1.1 Å, E. coli LD3 rmsd: 1.5 Å).  
 
In both the PfLD1 and PfLD2 models, the lysine residue (Lys93 and Lys223, numbering 
based on full-length PfE2 sequence) required for lipoylation of E2 is present in the same 
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loop as in E2 lipoyl-domains from other organisms. In the model for PfLD1, the side chain 
of Lys93 points into the domain itself, which would not be ideal for lipoylation. This is 
likely a limitation of the model, as the residues surrounding Lys93 are similar to those 
observed in E2 LDs from other species. Also, the amino acid sequence alignments by I-
TASSER of both P. falciparum LDs with their template sequences were the same as earlier 
alignments done with ClustalW2 (Fig. 3-2), with the lysines positioned within the same 
conserved DKA/S motif.     
 
A          B  
    
                PfLD1 model (1.22)     PfLD2 model (0.52) 
 
C 
              
Human LD21         A. vinelandii LD12        E. coli LD33   G. stearothermophilus  
                LD4          
 
Figure 4-2. Models for P. falciparum lipoyl-domains 
(A) I-TASSER generated only one model for PfLD1. (B) The best model for PfLD2. (C) NMR 
structures for lipoyl domains from other species. 1PDB entry 1FYC, Howard et al. (1998); 2PDB 
entry 1IYU, Berg et al. (1997); 3PDB entry 1QJO, Jones et al. (2000); 4PDB entry 1LAC, Dardel et 
al. (1993). C-scores of I-TASSER models are shown in parenthesis. Side chain of lysine residue 
required for lipoylation of E2 shown in red.  
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I-TASSER generated five models for the P. falciparum SBD (PfSBD) with C-scores of      
-0.16 to -2.61. The best model is shown in Fig. 4-3A. The top three templates used were 
the SBD of E. coli succinyltransferase from the -ketoglutarate dehydrogenase complex 
(PDB entry 2WXC, Neuweiler et al., 2009), Thermus thermophilus E2 (PDB entry 2EQ9, 
no associated publication) and human branched-chain -ketoacid dehydrogenase complex 
E2 (PDB entry 1ZWV, no associated publication). The resulting P. falciparum SBD model 
was, however, structurally most similar (rmsd=1.1 Å) to the human E3BP SBD (PDB entry 
2F60, Brautigam et al., 2006) and the SBD of the archaeum Pyrobaculum aerophilum E2 
(PDB entry 1W4I, Ferguson et al., 2005) (rmsd=1.2 Å). Alignment of the PfSBD amino 
acid sequence with those of the templates was the same as alignments done with 
ClustalW2 (Fig. 3-4). Interesting observations can be made when mapping onto the P. 
falciparum I-TASSER model the residues reported to be involved in E1 and E3 binding in 
G. stearothermophilus (Mande et al., 1996; Jung et al., 2003; Frank et al., 2005, Table 4-
1). Arg383, a residue key in binding both E1 and E3, is in a similar position on loop L2 in 
the P. falciparum model as in G. stearothermophilus (Fig. 4-3A & B). Preceding the 
arginine in G. stearothermophilus, is a glycine (Gly155, in yellow, Fig. 4-3B), which is 
conserved in other organisms apart from P. falciparum, which has an asparagine instead 
(Asn382, in yellow, Fig. 4-3A). Kalia et al. (1993) suggested the glycine to be conserved 
in all organisms, as side-chains from any other amino acids could interfere with 
recognition of the arginine by E3. However, this does not seem to be the case in the 
homology model of P. falciparum SBD as the side-chain of Asn382 points in the opposite 
direction to that of Arg383. A striking difference is seen in the residues on helix H1 
involved in both E1 and E3 binding. While G. stearothermophilus has Arg135 and Lys136, 
which have positively charged side-chains, P. falciparum has small, uncharged Ser362 and 
negatively charged Glu363 in these positions. This could suggest that a different set of 
residues are involved in the interaction between P. falciparum SBD and E1 and E3. 
Although the homology model was structurally similar to the SBD of the human E3BP 
(Fig. 4-3C), the residues involved in the interaction between the domain and E3 
(Brautigam et al., 2006; Ciszak et al., 2006) are very different (Table 4-2). There is no 
crystal structure showing the interaction between E1 and the human E2 SBD, however, 
mutagenesis studies suggest residues similar to those in G. stearothermophilus are 
involved (Korotchkina and Patel, 2008). This is very interesting because if there is a 
sufficient difference in the binding mechanism of E1 and/or E3 in P. falciparum PDC 
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compared with the human proteins, this could be exploitable for development of drugs that 
target the P. falciparum PDC.  
 
 
 
A       B   
   
 
         PfSBD model (-0.16)       G. stearothermophilus SBD 
 
   
 
 
C       
                                        
                          Human E3BP SBD 
 
     
Figure 4-3. Model of P. falciparum SBD  
(A) The best I-TASSER model for PfSBD, C-score is shown in parenthesis. (B) NMR structure for 
the G. stearothermophilus E1/E3BD, PDB entry 2PDD, Kalia et al. (1993). (C) Crystal structure of 
the SBD of human E3BP, PDB entry 2F60, Brautigam et al. (2006). Side chain residues in blue are 
those that interact with E3, in red with E1 and in purple those that interact with both E1 and E3. 
Residue in yellow is the highly conserved glycine in the SBD, which is an asparagine in P. 
falciparum. The residue positions in the P. falciparum I-TASSER model are based on the position 
of G. stearothermophilus residues reported to be involved in E1 and E3 binding.    
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  G. stearothermophilus P. falciparum model 
E1 binding only Ala130 Val357 
 Met131 Leu358 
 Pro132 Pro359 
   
E3 binding only Ser133 Ser360 
 Arg139 Arg366 
   
E1 and E3 binding  Arg135 Ser362 
 Lys136 Glu363 
  Arg156 Arg383 
 
Table 4-1. SBD residues involved in binding E1 and E3  
Shown are the G. stearothermophilus (Mande et al., 1996; Jung et al., 2003; Frank et al., 2005) and 
the respective residues in P. falciparum based on sequence alignments (section 3.1.3.1) and 
structural position in homology model. Identical residues in bold.   
 
 
  Human E3BP SBD PfE2 SBD model 
E3 binding Arg130 Met356 
 Ser132 Leu358 
 Pro133 Pro359 
 Ala134 Ser360 
 Arg136 Ser362 
 Asn137 Glu363 
 Glu140 Arg366 
 Pro154 Pro381 
 Ile157 Ile384 
 Lys160 Glu387 
  Glu161 Asp388 
 
Table 4-2. Residues involved in human E3BP SBD interaction with E3 
Human E3BP residues (Brautigam et al., 2006; Ciszak et al., 2006) and the respective residues in 
P. falciparum E2 SBD based on sequence alignments (section 3.1.3.1) and structural position in 
homology model. Apart from the charged amino acids, substitutions in the parasite SBD compared 
with the human E3BP SBD are not conserved. Identical residues in bold.  
 
 
 
 
 
 
 
Chapter 4 Structural characterisation of recombinant P. falciparum dihydrolipoamide  
acetyltransferase and dihydrolipoamide dehydrogenase 
 
 
 
145 
Four I-TASSER models were obtained for the P. falciparum CD (PfCD), however, only 
one model had a good C-score (1.54) and was used for further analyses (Figure 4-4). The 
top templates used for the modelling were the A. vinelandii CD (PDB entry 1EAF, Mattevi 
et al., 1993a) and human CD (PDB entry 3B8K, Yu et al., 2008b). The resulting homology 
model was more similar to G. stearothermophilus (rmsd = 1.7 Å) than A. vinelandii (rmsd 
= 2.4 Å) and human CD (rmsd = 2.5 Å). Superimposition of the P. falciparum CD model 
onto these structures showed more overall similarity with bacterial than with human 
structures (Fig. 4-5).  
 
 
    
 
     PfCD model (1.54) 
   
 
Figure 4-4. I-TASSER model for PfCD 
C-score is shown in parenthesis. Positions of active site residues are in red, residues involved in 
trimer formation are in green and in orange, residues involved in n-mer core formation. The 
positions of these residues are based on A. vinelandii and G. strearothermophilus structures 
(Mattevi et al., 1993a; Izard et al., 1999). 
 
 
 
 
 
A      B 
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Figure 4-5. Alignment of PfCD homology model (grey) with CD from other organisms 
(A) Alignment with cryo-electron microscopy based structure for human CD (pink, PDB entry 
3B8K, Yu et al., 2008b). (B) Alignment with CD crystal structures for A. vinelandii (light orange) 
and G. strearothermophilus (light blue), PDB entry IEAE, Mattevi et al. (1993a) and 1B5S, Izard 
et al. (1999), respectively. Positions of active site residues are in red, residues involved in trimer 
formation in green and in dark blue, residues involved in n-mer core formation.  
 
 
Based on the orientation of the A. vinelandii and G. stearothermophilus trimer crystal 
structures, the PfCD homology structure was modelled into a trimer to assess how the 
residues thought to be involved in trimer formation are positioned (Mattevi et al., 1993a; 
Izard et al., 1999). Alignment of the PfCD amino acid sequence with those of the templates 
was very similar to alignments done with ClustalW2 (Fig. 3-4). Conserved residues 
including the active site DHRXXD/N/YG motif as well as residues that could be involved 
in inter- and intratrimer bond formations were in the same positions in both alignments. As 
the overall structure of the P. falciparum homology model and bacterial CDs are very 
similar, the residues were mapped to analogous positions. There are four major points of 
interaction based on the A. vinelandii crystal structure. The residues in these areas are not 
conserved, however, they contain several polar, hydrophobic and charged amino acids, 
which could take part in interactions. On the outer surface of the trimer, in the middle, N-
terminal residues 405-410 (numbering based on full-length PfE2) of monomer A interact 
with residues 436-440 of monomer B helix H1. Towards the side, residues 418-424 of 
monomer A interact with residues 496-502 of monomer B (Fig. 4-6A). On the inner 
surface, which points towards the centre of the core complex, residues 594-600 form loops, 
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which reach over the neighbouring monomer surface (Fig 4-6B). Inside the monomer, 
residues 445-448 of monomer A interact with residues 568-572 of monomer C (Fig. 4-6C).  
 
A           B 
       
 
C          D                        
 
    
 
 
Figure 4-6. Model of PfCD trimer  
Each monomer is shown in a light colour (pink, light yellow, light blue). Residues involved in 
trimer interactions based those in A. vinelandii and G. strearothermophilus (Mattevi et al., 1993a; 
Izard et al., 1999) are in dark colours (red, orange, blue). (A) View of the trimer from above along 
the 3-fold axis. (B) Side view of model showing the loops reaching over the neighbouring 
monomer. (C) Inside view of the trimer showing interaction between two monomers (circled). (D) 
Active sites are formed at the interface of two monomers. Residues involved in catalytic activity 
are in red. Residue numbers shown are based on the full-length P. falciparum amino acid sequence. 
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The interactions in the human CD are similar apart from those in the N-terminal, as it is 
positioned differently (Yu et al., 2008b). The trimer model also shows the formation of the 
active sites in the interface of two monomers (Fig. 4-6D) as in other organisms.  
Finally, I analysed the potential interactions between the trimers to form the multimeric E2 
core. Based on the residues determined for A. vinelandii and G. strearothermophilus 
(Mattevi et al., 1992a; Izard et al., 1999), P. falciparum residues 635-640 form the 310-
helix “ball” at the C-terminus of one monomer in a trimer, could insert into the “socket” 
formed by residues Leu458, Val462, Ile529 and Tyr530 on the neighbouring trimer (Fig. 4-
7A & B).  
 
 A 
 
 
 B        C         
                         
 
Figure 4-7. Potential model of interaction between two PfE2 trimers 
Residues involved in inter-trimer interactions based on those known to be involved in trimer 
formation in A. vinelandii and G. strearothermophilus (Mattevi et al., 1992a; Izard et al., 1999). 
Residues involved are in dark blue and red. (A) View of two trimers from the inner surface facing 
the centre of the core. (B) The residues thought to be involved in inter-trimer bonds. (C) Hydrogen 
bonds could be formed between Phe639 and Ile 529, and Leu 640 and Tyr530.  
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The required hydrophobic nature of the residues involved is conserved. In A. vinelandii 
and G. strearothermophilus, the last two residues in the 310-helix form hydrogen bonds 
with residues at the N-terminus of helix H4 (Mattevi et al., 1992a; Izard et al., 1999). The 
hydrogen bonds are not formed by the side chains, instead they are between the main chain 
nitrogen and carbonyl oxygen (Mattevi et al., 1992a; Izard et al., 1999). Thus, the 
corresponding residues in P. falciparum, Phe639 and Leu640 at the C-terminus and Ile529 
and Tyr 530 in helix H4, could also form these bonds (Fig 4-7C).  
 
When comparing the sites involved in the inter-trimer interactions to the bacterial and 
human counterparts, the P. falciparum site is missing a residue, as helix H3 is shorter (Fig. 
4-8). The residues involved in the latter part of H3 in A. vinelandii, G. strearothermophilus 
and human CD structures are absent in P. falciparum as seen by both the ClustalW2 
alignments (Fig. 3-4) and I-TASSER alignment of PfCD with template structures. 
Interestingly, the ClustalW2 alignment (Fig. 3-4) also shows that A. thaliana chloroplast 
and Synechocystis sp. CD amino acid sequences also lack these residues.  
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 P. falciparum E2 model                  Human1 
 
                             
 
       A.vinelandii2                     G. stearothermophilus3  
 
Figure 4-8. Comparison of inter-trimer interaction sites in different organisms  
The P. falciparum helix H3 is shorter than that from other organisms, the missing part of the helix 
is circled. Residues involved in inter-trimer interactions in dark blue. 1PDB entry 3B8K, Yu et al. 
(2008b); 2PDB entry IEAE, Mattevi et al. (1993a); 3PDB entry 1B5S, Izard et al. (1999).  
 
 
Attempts were also made to model the protein in sections. Modelling the two LDs with 
their joining linker, and LD2 connected to the SBD were not successful. However, a model 
was obtained for the SBD linked to the CD. In the model the linker of one monomer 
reaches over the neighbouring monomer, just as in the CD homology model. The SBD then 
reaches back on top of its own monomer (Fig. 4-9). The residues in the linker, which may 
be involved in the trimer formation, are positioned the same way as in the CD model (Fig 
4-10). This arranges the SBD in an orientation where the residues that potentially interact 
with E1 and E3 face the surface of the trimer and would not be accessible to the other 
proteins. Movement from the linker would be required to orient the SBD correctly, 
however, there are only 8 – 10 residues between the SBD and the first residue in the linker, 
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which possibly interacts with the CD in trimer formation. The residues involved in trimer 
formation are based on crystal structures, thus it could be that in solution these interactions 
do not occur, or are transient.   
 
       
 
  
 
Figure 4-9. Homology models of the SBD linked to the CD 
Each monomer is shown in a light colour (pink, light orange, light blue). The corresponding linker 
and SBD are shown in red, orange and blue. The linker is shown as spheres. The His-tag of the His-
rPfE2bc construct is in grey.  
 
 
 
 
 
  
 
Figure 4-10. Orientation of the SBD in the PfE2 homolgy model 
The SBD is shown in blue. The residues and their side-chains that are potentially involved in E1/E3 
binding are in red. 
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4.1.3.2 Stoichiometryof His-rPfE2m 
 
4.1.3.2.1 Sedimentation coefficient of His-rPfE2m species purified by gel filtration 
 
To determine the stoichiometry of His-rPfE2m, AUC was carried out on each of the four 
species of His-rPfE2m purified by gel filtration (Fig. 3-15C). The reference buffer used 
was PEBS100 (Table 2.9) and the samples were initially spun at 49,000 rpm as the 
molecular masses of the species in the samples were unknown. This speed was appropriate 
for His-rPfE2m from peaks 3 and 4. However, peaks 1 and 2 comprised larger molecular 
mass species, thus in subsequent AUC analyses the samples were centrifuged at 3,000 rpm. 
For SEDFIT (Schuck, 2000; Schuck et al., 2002) analysis the following parameters were 
used: His-rPfE2m  = 0.7338 ml/g at 4ºC and 0.7406 ml/g at 20ºC; PEBS100  = 1.01188 
g/ml and  = 1.6141 cPoise (Table 2-8 and 2-9).   
 
His-rPfE2m which eluted at ~100 ml (peak 1) on the HiPrep 26/60 Sephacryl S-400 HR 
gel filtration column (Fig. 3-15C), was expected to have a large molecular mass, possibly 
corresponding to a large E2 core. Protein from two separate purifications was shown to 
contain very large species; one sample contained a single species with s20,w 100 S, the other 
comprised three species corresponding to 40 S, 100 S and 130 S (Fig 4-11). Unfortunately, 
these values are much larger than the sedimentation coefficient expected for an E2 core, as 
the sedimentation coefficient of a 24-mer core is 23 S (Willms et al., 1967) and of a 60-
mer is ~30 S (Vijayakrishnan et al., 2010). The finding that peak 1 contained mostly 
aggregates was supported by the observation that, when determining protein concentration 
spectrophotometrically by absorbance at 280 nm, much larger values (0.7 – 3.5 mg/ml) 
would be obtained than when using the Bradford method (0.2-0.8 mg/ml). Also the amount 
of protein seen on Coomassie blue or silver stained SDS-PAGE gels did not correspond to 
high protein concentrations. Large aggregates in a sample would scatter light and cause 
apparent higher absorbance values at 280 nm.  
 
His-rPfE2m in peak 2, which eluted at ~130 ml from the HiPrep 26/60 Sephacryl S-400 
HR gel filtration column, was always at a very low concentration. SV analysis on two 
separate occasions showed the samples were also mainly aggregated protein (Fig. 4-11).    
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Figure 4-11. SV analysis of His-rPfE2m peak 1 and 2  
c(s) analysis of the SV data was carried out using SEDFIT (Schuck, 2000; Schuck et al., 2002). 
Each sample was from a separate purification carried out 24 h prior to the start of the SV 
experiment. Only protein in peak 1 formed distinct species, however, s20,w values were extremely 
large, indicating that these samples contained only aggregated His-rPfE2m. Interpretation of the 
data for peak 2 was difficult, as the SV data could not be well described by distinct species even 
beyond s20,w 150 S. The data was analysed up to s20,w 200 S. 
 
 
His-rPfE2m in peak 3 (eluted at ~180 ml) or 4 (eluted at ~220 ml) did not form large 
complexes either. Peak 3 contained a species with s20,w 6.0 S while peak 4, consisted of 
approximately equal amounts of two species with s20,w 3.9 S and 6.1 S (Fig. 4-12). Because 
most of the active His-rPfE2m was found in peak 3 following purification, and the SV 
analysis showed the protein in this peak was also the purest, His-rPfE2m in peak 3 was 
taken as the representative sample of the protein for further analysis.   
 
      
Figure 4-12. SV analysis of His-rPfE2m peak 3 and 4  
c(s) analysis of the SV data was carried out using SEDFIT (Schuck, 2000; Schuck et al., 2002). 
His-rPfE2m peak 3 was homogenous whereas peak 4 contained roughly equal amounts of two 
species. Due to the very low concentration of peak 4 and thus, low absorbance at 280 nm, for this 
experiment only the absorbance optics were set at a wavelength of 225 nm.  
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4.1.3.2.2 The effect of buffer NaCl concentration on His-rPfE2m  
 
As initial SV analyses showed only aggregates and no large complex, experimental 
conditions which could affect the assembly of the E2 core were considered. NaCl is added 
to purification buffers to inhibit non-specific ionic interactions between proteins 
themselves, and also interactions between proteins and purification resins. As the 
interactions between the E2 trimers to form the large core are relatively weak, the effect of 
NaCl concentration on the stoichiometry of His-rPfE2m was tested. Following gel 
filtration, His-rPfE2m from peak 3 was dialysed against buffers with NaCl conentrations 
ranging from 0 to 1 M. These samples were then analysed by SV to observe the effect on 
the species present and the heterogeneity of the samples.  
 
SV was carried out at 49,000 rpm. The density and viscosity values for each of the buffers 
are listed in Table 2-9. NaCl concentration did not affect the formation of larger His-
rPfE2m complexes. SV analysis confirmed the presence of a main species of s20,w = 5.9 – 
6.6 S and a minor species of s20,w = 3.2 – 3.6 S (Fig 4-13). NaCl concentration did, 
however, have an effect on sample heterogeneity, which was taken into account for 
subsequent purifications. In buffers with 100, 250 and 500 mM NaCl, 63, 66 and 68% of 
the protein was found in the ~6.3 S peak, respectively, compared with only 38 – 49% with 
0 – 50 mM NaCl (Table 4-3). These samples also showed least aggregation (26-27% of 
sample) compared with the amount of aggregation seen with lower NaCl concentrations 
(40 - 52%). In 1 M NaCl, 60% of His-rPfE2m was in the ~6.3 S peak, but also more 
aggregation (36% of sample) could be seen. The amount of the minor ~ 3.4 S species 
stayed fairly constant (10 – 15%) in 0 – 100 mM NaCl, with slightly less (4-8%) found at 
higher NaCl concentrations. The sedimentation coefficient for His-rPfE2m in 0 – 250 mM 
NaCl was stable (6.4 – 6.6 S), while it decreased to 6.2 S in 500 mM and 5.9 S in 1 M 
NaCl. To keep the salt concentration at a level suitable for downstream applications (e.g. 
SAXS) while minimising heterogeneity of the sample and keeping the sedimentation 
coefficient in the stable range, buffer with 250 mM NaCl was used hereafter.  
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Figure 4-13. SV analysis of His-rPfE2m at various NaCl concentrations 
c(s) analysis of the SV data was carried out using SEDFIT (Schuck, 2000; Schuck et al., 2002).All 
samples showed the presence of a main peak (~6.3 S) and a minor peak (~3.4 S). 
 
     % of total protein sample  
[NaCl] (mM) [His-rPfE2m] (M) s20,w (S) ~3.4 S ~6.3 S Aggregate 
0 1.9 3.4 6.4 10 38 52 
10 2.0 3.5 6.6 15 42 43 
50 1.4 3.4 6.5 11 49 40 
100 1.9 3.3 6.4 10 63 27 
250 1.4 3.2 6.4 8 66 26 
500 1.4 3.2 6.2 6 68 26 
1000 1.4 3.6 5.9 4 60 36 
Table 4-3. Percentage of each species present in His-rPfE2m at various NaCl concentrations 
 
 
4.1.3.2.3 SV analysis of various concentrations of His-rPfE2m 
 
SV of His-rPfE2m over a concentration range of 4 – 17 M was carried out with PEBS250 
( = 1.01804 g/ml and  = 1.6354 cPoise; for buffer composition see table 2.1) as 
reference buffer. A main species (33 – 40% of sample) with s20,w 6.6 – 7.0 S and a minor 
10.2 – 10.6 S species (4-8% of sample) could be observed (Fig. 4-14A, Table 4-4). At the 
lowest concentration (4 M) a 2.5 S species (24% of sample) could be seen, which was 
most likely a degradation product. Regardless of optimising the sample buffer, aggregation 
(species with sedimentation coefficients over 40 S) could still be seen in increasing 
amounts as protein concentration was increased (Table 4-4). At the highest concentration 
(17 M) a total of 68% of the sample was aggregated, while at 4 M the percentage was 
only 32%. The s20,w values were plotted against His-rPfE2m concentration to obtain an 
infinite dilution sedimentation coefficient, which was s  6.6 ± 0.1 S (Fig 4-14B). 

20,w
0
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A             B 
         
Figure 4-14. SV analysis of various concentrations of His-rPfE2m 
c(s) analysis of the SV data was carried out using SEDFIT (Schuck, 2000; Schuck et al., 2002). (A) 
SV analysis of six different concentrations (4 – 17 M) of His-rPfE2m show the presence of a main 
species with an average s20,w 6.8 S and a minor ~10.4 S species. (B) His-rPfE2m s20,w for the main 
species was plotted against concentration to obtain the sedimentation coefficient at infinite dilution, 
which was s  6.6 ± 0.1 S. The experiment was carried out only once, thus, the error bars are the 
standard deviation shown as the square root of the central moment of the curve. 
 
    % of total protein sample 
His-rPfE2m (M)  s20,w (S) 2.5 S ~ 6.8 S  ~10.4 S Aggregate 
17  - 6.9    33  67 
14  - 7.0 10.3   33 4 63 
12  - 6.8 10.4   39 6 55 
10  - 6.7 10.5   40 6 54 
5  - 6.8 10.6   39 7 54 
4 2.5 6.6 10.2 24 37 8 31 
Table 4-4. Proportion of each of species present at a range of His-rPfE2m concentrations 
from c(s) analysis (Fig. 4-14) 
 
 
4.1.3.2.4 SE analysis of His-rPfE2m 
 
For sedimentation equlibrium analysis, various concentrations (4-17 M) of His-rPfE2m 
were centrifuged at 12,000 rpm. The speed was chosen based on the predicted trimer size 
(210 kDa) of His-rPfE2m, as the major species in the SV analyses was anticipated to be a 
trimer. Ten scans were taken every 3 h until the sample had reached equilibrium. The non-
interacting species analysis model in SEDPHAT (Vistica et al., 2004) was used to analyse 
the SE data. Data at each concentration were analysed separately. Analysis with a single 
species model resulted in very poor fits at all concentrations (Fig. 4-15A) indicating the 
presence of more than one species in the samples. The fits were improved when two 
species were modelled (Fig. 4-15B).  

20,w
0
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A 
 
B 
 
Figure 4-15. Analysis of His-rPfE2m SE data  
Absorbance data (dots) were fit by SEDPHAT (Vistica et al., 2004) using the non-interacting 
discrete species model. (A) Single species analysis resulted in poor fits (smooth line) with high Chi 
squared (1.3-10.9) and rmsd (0.005-0.165) values. (B) A two species analysis resulted in better fits 
(smooth line) with lower Chi squared (0.3-0.8) and rmsd (0.003-0.004) values. The red vertical line 
indicates the cell meniscus, the blue vertical line indicates the cell base and the green vertical lines 
denote the range of data that was analysed. Residual plots, which show the goodness of the fit, are 
shown beneath each graph for each concentration. 
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The highest concentration samples, 14 M and 17 M, contained a 193-195 kDa species, 
which accounted for 84-89% of the sample (Table 4-5). This species would correspond to a 
trimer of His-rPfE2m. The molecular mass of His-rPfE2m calculated from its amino acid 
sequence is 210 kDa, which is slightly higher than the experimental value, suggesting 
some degradation of the protein. 
 
 
His-rPfE2m (M) MM  % of sample 
17 195 kDa 84 
 1.53 MDa 16 
   
14 193 kDa 89 
 1.33 MDa 11 
   
10 253 kDa 28 
 2.07 MDa 72 
   
5 161 kDa 18 
 2.01 MDa 82 
   
4 287 kDa 42 
 3.70 MDa 58 
   
 
Table 4-5. Molecular mass (MM) of His-rPfE2m at various concentrations 
 
 
Interestingly, a larger 1.33 – 1.53 MDa species was also present making up 11-16% of the 
sample. A 24-mer of undegraded His-rPfE2m would have a molecular mass of 1.67 MDa. 
However, taking into account the degraded His-rPfE2m trimer mass of 193-195 kDa, a 24-
mer would be 1.54-1.56 MDa. These values fit well with the larger molecular mass species 
seen in the sample, suggesting that the larger species in the samples could be a 24-mer E2 
core complex. In SV experiments, however, no species with a sedimentaion coefficient that 
would correspond to the 24-mer size was seen. The E. coli E2 forms a 1.59 MDa 24-mer 
with a sedimentation coefficient of 23 S (Willms et al., 1967), thus a species with a similar 
sedimentation coefficient should have been seen.  
 
With decreasing sample concentration the molecular mass of the species increased and the 
main species in the samples had molecular masses of ~ 2 MDa and 3.7 MDa (Table 4-5). A 
2 MDa complex would correspond to about 30 His-rPfE2 monomers and 3.7 MDa would 
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be roughly a 60-mer. Again, species this size were not seen in SV analysis. The increase in 
molecular mass with decreasing concentration was evident when determining the apparent 
whole-cell weight average molecular mass (Mw,app). This was used to obtain the whole-cell 
weight average molecular mass at infinite dilution, , by plotting sample concentration 
vs Mw,app (Fig.4-16).  for His-rPfE2m was 1.54  0.32 MDa.  
 
    
Figure 4-16. Whole cell weight average molecular mass, , of His-rPfE2m 
Mw,app was plotted as a function of sample concentration and extrapolated to zero to obtain , 
which was 1.54  0.32 MDa.  
 
 
The increase in molecular mass with decreasing concentration is indicative of 
thermodynamic non-ideality of the protein in the sample. In this case, the non-ideality is 
most likely due to the elongated shape of His-rPfE2m. 
 
Because no 1.5 – 3.7 MDa species were observed in the SV experiments, an attempt was 
made to analyse the data with SEDPHAT (Vistica et al., 2004) using the species analysis 
with mass conservation constraints (Fig. 4-17). As the presence of a trimer is clear from 
both SE and SV analysis, this model was used to fix the trimer size (210 kDa) and amount 
(based on SV analysis) to try and fit the larger species better. The analysis, however, 
resulted in poor fits as is evident from the residual plots (Fig. 4-17) and Chi squared (0.7-
7.8) and rmsd (0.004-0.014) values. As seen in the SV analysis, the His-rPfE2m sample 
contained a lot of aggregates (sedimentation coefficients above 40 S), which are likely to 
complicate the interpretation of the SE data. Thus, further analyses on this set of data were 
not carried out.  
 

Mw
0

Mw
0

Mw
0

Mw
0
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Figure 4-17. Further analysis of His-rPfE2m larger molecular mass species 
Absorbance data (dots) were fit by SEDPHAT (Vistica et al., 2004) using a species analysis with 
mass conservation constrains model to obtain the fits (smooth line). The red vertical line indicates 
the cell meniscus, the blue vertical line indicates the cell base and the green vertical lines denote 
the range of data that was analysed. Residual plots are shown beneath each graph. 
 
 
4.1.3.3 Small angle X-ray scattering (SAXS) of His-rPfE2m 
    
SAXS was attempted on His-rPfE2m peak 1 and 3. Unfortunately, the scattering curves 
showed a steep increase at low angles (Fig 4-18, red circles), which is indicative of 
aggregation of the sample. Thus, no meaningful solution structure could be obtained for 
His-rPfE2m.  
 
    A            B 
 
Figure 4-18. Scattering curves for His-rPfE2m   
(A) Peak 1 and (B) peak 2. Scattering intensity is plotted against the scattering angle, s.  
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4.1.3.4 Stoichiometry of His-rPfE2bc 
 
4.1.3.4.1 SV analysis of His-rPfE2bc 
 
Both of the His-rPfE2bc forms purified by gel filtration (Fig. 3-16D) were analysed by 
AUC. The reference buffer used was PEBS150 (Table 2-1). The partial specific volumes of 
His-rPfE2bc used in SEDFIT (Schuck, 2000; Schuck et al., 2002) analysis were 0.7356 
ml/g at 4ºC and 0.7424 ml/g at 20ºC. PEBS150 parameters  = 1.01804 g/ml and  = 
1.6354 cPoise were used (Table 2-8 and 2-9).    
 
SV at various concentrations of His-rPfE2bc from gel filtration peak 1 (1 – 4 M) showed 
the samples to be homogenous with a single species of s20,w = 4.7 – 5.2 S (Fig. 4-19A). The 
protein was stable at these low concentrations, as no aggregates were seen in the sample. 
As already mentioned previously (section 3.1.3.4.2), the protein precipitated completely at 
concentrations above 7-8 M, hence no analyses could be carried out at higher 
concentrations. From the y intercept of a plot of His-rPfE2bc concentration vs s20,w, the 
infinite dilution sedimentation coefficient, s , was determined to be 4.5 ± 0.3 S (Fig 4-
19B).  
 
 
A         B
      
Figure 4-19. SV analysis for both forms of His-rPfE2bc purified by gel filtration  
(A) c(s) analysis with SEDFIT (Schuck, 2000; Schuck et al., 2002) for His-rPfE2bc from gel 
filtration peak 1 and peak 2. Only one species with an average s20,w 5.1 S was observed. (B) The 
s20,w of His-rPfE2bc from peak 1 was plotted against concentration to obtain the infinite dilution 
sedimentation coefficient, which was s

20,w
0
= 4.5 ± 0.3 S. The experiment was carried out only once, 
thus, the error bars are the standard deviation shown as the square root of the central moment of the 
curve. 
 

20,w
0
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His-rPfE2bc from gel filtration peak 2 had sedimentation coefficients (s20,w = 5.2 S and 5.5 
S) similar to those for peak 1 (Fig. 4-18A). Due to the very low concentration of this peak, 
only two samples of 2 M and 1 M were analysed, and therefore no s

20,w
0  value could be 
determined.  
 
 
4.1.3.4.2 SE analysis of His-rPfE2bc 
 
For SE analysis of His-rPfE2bc from peak 1, two concentrations (4 M and 2 M) were 
centrifuged at 35,000 rpm (based on trimer His-rPfE2bc size, 104 kDa) and 10 scans were 
taken every 3 h until equilibrium was reached. The non-interacting species analysis model 
in SEDPHAT (Vistica et al., 2004) was used to analyse the SE data. Good fits were 
obtained using a single species model resulting in molecular masses of 103 kDa and 108 
kDa for the 4 M and 2 M samples respectively (Fig. 4-20). This compared well with the 
molecular mass of 104 kDa calculated from the amino acid sequence for a His-rPfE2bc 
trimer. Two samples of His-rPfE2bc from peak 2 (2 M and 1 M) were also analysed, 
however, unfortunately the samples had degraded during the experiment.  
  
 
 
Figure 4-20. Analysis of His-rPfE2bc SE data  
Absorbance data (dots) were fit by with SEDPHAT (Vistica et al., 2004) using the non-interacting 
discrete single species model (smooth line). The red vertical line indicates the cell meniscus, the 
blue vertical line indicates the cell base and the green vertical lines denote the range of data that 
was analysed. Residual plots are shown beneath each graph for each concentration. 

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4.1.3.5 Solution structure of His-rPfE2bc 
 
4.1.3.5.1 Small-angle scattering of His-rPfE2bc  
 
SAXS measurements were carried out at the EMBL/DESY beamline X33. Homogeneity of 
protein samples was determined by an SV experiment before transport to the beamline. 
His-rPfE2bc in peak 1 consisted of a 4.8 S main species (88%, Fig. 4-21). A minor, 1.2 S 
species (12%) was also detected, which could have been a degradation product. Peak 2 
comprised two species, the 4.7 S major component (76%) and a 2.8 S species (24%, Fig. 4-
21).  
 
 
 
Figure 4-21. SV analysis of His-rPfE2bc samples prior to SAXS 
The concentration of both samples was 3 M. His-rPfE2bc in peak 1 was mostly homogenous, 
while peak 2 contained two species.   
 
 
Due to the instability of His-rPfE2bc at high concentrations, the samples were transported 
to the beamline at very low concentrations (0.4 – 0.5 M). The final concentrations of peak 
1 and 2 His-rPfE2bc used for SAXS measurements were 5 M and 3 M, respectively. As 
the concentration of the samples was still low, the data were very noisy and detail in the 
scattering data at high angles is very limited (Fig. 4-22), however, the data from low angles 
were of sufficient quality to provide some useful structural information. 
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A      B 
 
C      D 
 
Figure 4-22. SAXS curves for His-rPfE2bc  
(A) Curve for His-rPfE2bc in peak 1 with error bars and (B) without error bars. (C) Curve for His-
rPfE2bc in peak 1 with error bars and (D) without error bars. 
 
 
The linear Guinier region confirmed that there was no aggregation in the sample (Fig. 4-
23A & B) and the radius of gyration, Rg, was determined to be 43.1  0.4 Å and 33.7  0.2 
Å for peak 1 and 2, respectively. GNOM (Svergun, 1992) was used to determine the 
distance distribution function, p(r), from which the maximum dimension of the particle, 
Dmax, was determined to be 147 Å for peak 1 and 113 Å for peak 2 (Fig. 4-23C & D). The 
values of Rg estimated from GNOM were similar to those determined from the Guinier 
region; 45.2  0.4 Å for peak 1 and 34.8  0.5 Å for peak 2. The shape of the p(r) curve is 
suggestive of a particle with separated subunits (Fig. 1-21) as would be the case with His-
rPfE2bc.  
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A      B 
 
C      D 
 
   
Figure 4-23.  SAXS data analysis for His-rPfE2bc 
Guinier analysis of SAXS data aquired for His-rPfE2bc peak 1 (A) and peak 2 (B). The Rg was 
43.1 ± 0.4 Å for peak 1 and 33.7 ± 0.2 Å for peak 2. The I(0) was 38.2 ± 2.2 for peak 1 and 49.5 ± 
1.8 for peak 2. Distance distribution for peak 1 (C) and peak 2 (D). The Dmax for peak 1 was 147 Å 
and for peak 2, 113 Å.  
 
 
 
The Kratky plots do not show a bell-shaped curve characteristic of folded proteins, thus 
His-rPfE2bc could be unfolded (Fig. 4-24A & B). However, activity assays carried out on 
the samples before SAXS measurements showed the protein to be active, thus the protein 
may be merely partially unfolded. The molecular mass of His-rPfE2bc estimated by 
extrapolating the scattering intensity to zero angle, I(0) was 38 kDa and 49 kDa, for peak 1 
and peak 2 respectively. This would suggest the His-rPfE2bc sample to contain only 
monomer, however, the AUC data (Fig. 4-21) confirmed that in peak 1 88% of the sample 
has a sedimentation coefficient consistent with a trimer.  
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Figure 4-24.  Analysis of His-rPfE2bc folding 
Kratky plots for peak 1 (A) and peak 2 (B) indicative of partial unfolding of His-rPfE2bc.    
 
 
4.1.3.5.2 Ab initio modelling  
 
Ab initio modelling was attempted using DAMMIF (Franke and Svergun, 2009) on the 
ATSAS online server (http://www.embl-hamburg.de/biosaxs/atsas-online/dammif.php, 
Petoukhov et al., 2007, section 2.8.3). Using P3 symmetry, 20 ab initio models were 
generated, which were then clustered by DAMCLUST (Petoukhov et al., 2012). For His-
rPfE2bc peak 1, the models were clustered into eight groups of which seven contained a 
single model and one group had 13 models. The representative ab initio model of the large 
cluster is shown in Fig. 4-25A. The ab initio models can be further refined by averaging 
the models in a cluster with DAMAVER (Volkov and Svergun, 2003) and use DAMFILT 
(Volkov and Svergun, 2003) to obtain an averaged model (Fig. 4-25B). The model had a 
Rg of 45.5 Å and a Dmax of 159 Å and fit the simulated scattering curve generated by 
DAMMIF well (2 = 1.04, Fig. 4-26A). An optimal fit would have a Chi squared value of 
1.0. The DAMMIF generated scattering curve and fit were scaled and overlaid with the 
actual experimental scattering data and the simulated curve looks similar to the 
experimental data, thus adding to the validity of the ab initio model (Fig. 4-26B).  
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A       B  
                              
 
Figure 4-25. Ab initio model for peak 1 His-rPfE2bc  
(A) His-rPfE2bc peak 1 representative model from the largest DAMMIF cluster. (B) The averaged 
model for the largest cluster.  
 
 
A         B 
 
Figure 4-26. Fit of ab initio model for peak 1 His-rPfE2bc to scattering data  
(A) Fit of the representative model (red) to the simulated scattering curve (black) generated by 
DAMMIF. (C) Overlay of the simulated scattering curve (light blue) and the representative model 
fit (red) to the experimental scattering curve (black).  
 
 
The models in the other clusters were all similar in that the arms of the structure were 
oriented on the z-axis rather than the x/y-axis. These models had on average poorer fits to 
the simulated scattering curve (2 = 1.18) than the models in the largest cluster (average 2 
= 1.04). However, three of the models had Chi squared values ranging between 1.03 – 
1.05, a representative of these is shown in Fig. 4-27.  
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A         B 
              
Figure 4-27. Ab initio model from smaller cluster 
(A) One of the DAMMIF models in a smaller cluster. (B) Fit of the model (red) to the simulated 
scattering curve (black) (2 = 1.05). 
 
 
Modelling of SAXS data for His-rPfE2bc peak 2 with P3 symmetry resulted in seven 
clusters. The largest cluster comprised only eight models, the representative model and the 
fit to the simulated scattering curve (2 = 1.05) is shown in Fig. 4-28.   
   
 
 A      B 
          
Figure 4-28. Ab initio model for peak 2 His-rPfE2bc  
(A) His-rPfE2bc peak 2 representative model from the largest DAMMIF cluster. (B) Fit of the 
representative model (red) to the experimental scattering curve (black). 
 
 
The Rg of the model was 35 Å and the Dmax 115 Å. The models in this cluster were 
identical, thus no average model was generated. There was more variation in the ab initio 
models for His-rPfE2bc in peak 2. The six other clusters contained models that varied not 
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only between the clusters but within them as well. The fits of these models to the simulated 
scattering curve were also worse as the Chi squared values ranged between 1.10 - 1.29. 
The generation of several different DAMMIF models is indicative of unfolded protein, 
thus it is possible that the protein in this sample had denatured during transport to the 
synchrotron.    
 
To address the possibility of peak 2 His-rPfE2bc consisting of both the monomer and 
trimer species, as suggested by the SV experiment prior to SAXS measurements, the 
programme OLIGOMER (Petoukhov et al., 2012) was used. When providing monomer 
and dimer form factors, i.e. information about shape and size of the two conformations, the 
programme calculates the proportion of each species present in the sample. Both the I-
TASSER and ab initio models were used to obtain these values and in both cases, only the 
trimer species was present. Thus, although the DAMMIF models for the protein in this 
sample seems suspicious and might indicate unfolded protein, the OLIGOMER result 
would suggest that there is an at least partially folded trimer in the sample. His-rPfE2bc in 
peak 1 was also analysed using OLIGOMER and only trimer was present as well.  
 
The estimated molecular masses of the ab initio models determined by DAMMIF were 
very low, around 17 kDa, which is apparent from the models being very stringy and 
lacking the volume of the expected catalytic and binding domains. This could be due to the 
very low concentration of the samples resulting in the high noise-to-data ratio, especially at 
high angles. It could also be due to DAMMIF not being the ideal method for modelling 
flexible proteins. 
 
His-rPfE2bc is flexible due to the 31 amino acid linker between the binding domain and 
the catalytic domain. The ensemble optimisation method (EOM) (Bernado et al., 2007; 
Petoukhov et al., 2012) is a modelling programme for flexible proteins. Given a suitable 
starting model, EOM generates a pool of 10,000 conformations, which cover the 
experimental configurational space. From this, a genetic algorithm is used to generate an 
ensemble of models, which fit the experimental data. High-resolution structures are used as 
initial possible conformations for the ensemble. In this case, the I-TASSER models were 
used. The catalytic domain (CD) was fixed, while the linker and sub-unit binding domain 
(SBD) were allowed to adopt all sterically possible conformations. The simulation was 
performed three times. For peak 1, ensembles containing 16, 18 and 24 models in each 
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EOM simulation were generated. The ensembles fit the data well at low angles, but not at 
high angles, most likely due to the lack of structural information caused by the low 
concentration of the sample (Fig. 4-29A). The Chi squared value of the overall fit for all 
curves was 1.03. Modelling was also tried once using monomer symmetry, however, the fit 
of the ensemble was worse (2 = 1.09), especially at low angles (Fig. 4-29B). Thus, the 
presence of a trimer of His-rPfE2bc was further confirmed.  
 
 
A        B 
 
 
C         D 
 
Figure 4-29. EOM of His-rPfE2bc in peak 1  
(A) Fit of ensemble curves from three EOM simulations using trimer symmetry (red, dark blue and 
light blue) to the scattering curve (black). (B) Fit of ensemble curve from one EOM simulation 
using monomer symmetry (red) to the scattering curve (black). (C) Rg distributions of pool (black) 
and the average of three EOM simulations (red), with error shown as dashed line. (D) Dmax 
distributions of pool (black) and the average of three EOM simulations (red), with error shown as 
dashed line. 
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How flexible a protein is can be determined by plotting the Rg and the Dmax values of the 
pool and the ensembles. If the range of ensemble values is as wide as the pool, the protein 
is very flexible, if the ensemble values are very constrained the protein is less flexible. The 
Rg values for peak 1 ranged between 37.0 – 49.8 Å (average 46.2  0.3 Å, Fig. 4-29C) and 
the Dmax values between 108 - 186 Å (average 165  4 Å, Fig. 4-29D, Table 4-6).  
 
 
 Ensemble Pool 
  Range Average Range Average 
Peak 1     
Rg (Å) 37 - 50 46.2 ± 0.3 27 - 51 37.7 ± 0.02 
Dmax (Å) 108 - 186 165 ± 4 83 - 213 135.7 ± 0.1 
     
Peak 2     
Rg (Å) 34 - 58 45.7 ± 0.3 28 - 57 37.8 ± 0.03 
Dmax (Å) 100 - 218 166 ± 2 81 - 217 136 ± 0.2 
 
Table 4-6. EOM Rg and Dmax distribution for His-rPfE2bc 
 
 
The values for the pool ranged between a Rg of 27 – 51 Å (average 37.7  0.02 Å) and a 
Dmax of 83-210 (136  0.1 Å). An extended flexible protein would have an Rg distribution 
close to that of the pool (in this case 24 Å), while a rigid protein Rg distribution would be 
within a few angstroms around the average value (Bernado et al., 2007). The Rg 
distribution for His-rPfE2bc was ~13 Å, thus the protein is flexible to some degree but not 
completely unfolded. A similar conclusion can be made from the Dmax distribution. If His-
rPfE2bc were an extended unfolded protein, the variability in the Dmax range would be that 
of the pool (127 Å). The Dmax range for His-rPfE2bc was ~80 Å, thus the protein is not 
completely unfolded but is flexible. 
 
For His-rPfE2bc peak 2, EOM with trimer symmetry yielded a slightly poorer fit to the 
scattering data (2 = 1.04) than a simulation with monomer symmetry (2 = 1.01, Fig. 4-
30A & B). However, visual inspection of the curves shows the fit at low angles was better 
when modelling with trimer symmetry. The Rg and the Dmax values ranged between 34 – 58 
Å (average 45.7  0.3 Å) and 100 – 218 Å (average 166  2), respectively (Fig. 4-30C & 
D). The variation in the pool Rg and Dmax distribution was 29 Å and 136 Å, respectively. 
The Rg distribution for His-rPfE2bc peak 2 in this case was 24 Å, which makes it more 
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flexible than peak 1. The Dmax distribution, 118 Å, was also indicative of a much more 
unstructured protein.  
 
A      B 
  
 
C       D 
 
Figure 4-30. EOM of His-rPfE2bc in peak 2  
(A) Fit of ensemble curves from three EOM simulations using trimer symmetry (red, dark blue and 
light blue) to the scattering curve (black). (B) Fit of ensemble curve from three EOM simulations 
using monomer symmetry (red, dark blue and light blue) to the scattering curve (black). (C) Rg 
distributions of pool (black) and the average of three EOM simulations (red), with error shown as 
dashed line. (D) Dmax distributions of pool (black) and the average of three EOM simulations (red), 
with error shown as dashed line. 
 
 
EOM creates representative models for each of the ensembles. However, as the protein is 
flexible, any one model may not be the exact model for the protein. SAXS models are low 
resolution and because the EOM is carried out using high-resolution structures as 
templates, care must be taken not to over-interpret the resulting models. While the size 
distribution of an ensemble stays similar in repeat EOM simulations, the selected 
combinations of conformations can vary (Bernado et al., 2007). However, the 10 
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representative models generated for peak 1 His-rPfE2bc ensembles were of just two types 
(Fig. 4-31A&B).  
     
  
    A       B 
         
         
 
     C       D  
    
 
 
 
Figure 4-31. Representative models from EOM of peak 1 His-rPfE2bc 
(A) Group 1 contained 4 models, with an Rg range of 41.7 – 47.3 Å and a Dmax  range of 145 - 178 
Å. (B) Group 2 comprised 6 models with an Rg range of 42.6 – 54.6 Å and a Dmax  range of 119 – 
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156 Å. (C) Position of residues possibly involved in intra-trimer interaction in group 1 models and 
(D) group 2 models. The blue residues in the linker (light green) could interact with the blue 
residues on the CD (light orange). Likewise for the red residues. The SBD is shown in light blue.  
 
In one group of models the linker and the SBD point outwards on the x/y-axis (Fig. 4-31A) 
and in the other they point upwards on the z-axis (Fig. 4-31B). A similar grouping was 
seen with the DAMMIF models (Fig. 4-25 and 4-27A).  
 
The residues in the linker, which are thought to be involved in trimer formation, are shown 
in Fig 4-31C & D. When these residues were modelled into the His-rPfE2bc homology 
model, the SBD was oriented in a manner whereby it could not interact with E1 or E3 (Fig. 
4-9 and 4-10). As these residues are based on a rigid crystal structure, it could be that in 
solution these interactions do not occur, or are transient. The extended linker formation in 
these EOM models would allow movement of the SBD to interact with its subunits.   
 
As peak 2 His-rPfE2bc was much more flexible, the 10 models that were generated were 
unsurprisingly much more varied with the position and the degree of extension of the 
linker and SBD, thus the models could not be easily grouped. The Rg range of the models 
was very wide, 31.8 – 57.8 Å, as was the Dmax range, 106 – 203 Å. Because the outcome of 
every analysis on His-rPfE2bc in peak 2 was more ambiguous than the protein in peak 1, 
no further analyses were done on this.     
 
 
4.1.3.6 Hydrodynamic parameters of His-rPfE2bc 
 
US-SOMO (Rai et al., 2005; Brookes et al., 2010a; Brookes et al., 2010a) was used to 
calculate the sedimentation coefficient of the I-TASSER homology models and the EOM 
models. The I-TASSER model for His-rPfE2bc would have s

20,w
0  = 6.9 S, which is much 
larger than the experimental value for the protein in peak 1, which was 4.5 ± 0.3 S. This is 
due to the homology model being much more compact, thus it sediments faster. The 
computed s

20,w
0  for the EOM models (4.6 ± 0.1 S), correlates very well with the 
experimental value, giving further validation to the solution structure obtained for His-
rPfE2bc from the SAXS data.  
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4.2 Dihydrolipoamide dehydrogenase 
 
 
4.2.1 Introduction 
 
E3 is a highly conserved homodimer. This conformation is required for the formation of 
two active sites, which involve residues from both monomers (Mattevi et al., 1991; 
Mattevi et al., 1993a; Toyoda et al., 1998; Brautigam et al., 2005). A monomer of E3 has 
four domains; the FAD-binding domain, the NAD+ binding domain, the central domain 
and the interface domain. Dimer formation involves six hydrogen bonds between residues 
in the interface domain and three in the FAD domain (Mattevi et al., 1991).  
 
The mature length apicoplast PfE3 (PfaE3), which is 63 kDa, is on average 12 kDa larger 
than E3 in other species. It is also larger than its mitochondrial counterpart (PfmE3), which 
is 54 kDa. PfaE3 contains the conserved residues required for FAD and NAD+  binding, as 
well as all the active site residues (Cys165, Cys170, His646 and Glu651, McMillan, 2006). 
The structure of P. falciparum E3 is unknown, however, as the protein is highly conserved 
throughout various organisms, it is expected to be a structurally similar homodimer. As it 
was difficult to generate high quantities of His-rPfaE3 for crystallisation, the protein was 
characterised using AUC and SAXS.  
 
 
4.2.2 Aims 
 
The aims for this part of the project were to: 
- determine the oligomeric state of rPfaE3 
- obtain a structural model of rPfaE3 
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4.2.3 Results 
 
 
4.2.3.1 Homology modelling of P. falciparum E3  
 
The I-TASSER server for protein structure and function prediction was used to obtain a 
homology model for the recombinant expression construct His-rPfaE3 
(http://zhanglab.ccmb.med.umich.edu/I-TASSER/, Zhang, 2008; Roy et al., 2010, section 
2.8.2). The top three templates used for the modelling were the Pisum sativum glycine 
cleavage system E3 (PDB entry 1DXL, Faure et al., 2000), Sinorhizobium meliloti E3 
(PDB entry 3URH, no associated publication) and Sulfolobus soflataricus E3 (PDB entry 
3L8K, no associated publication). The best of the His-rPfaE3 models had a C-score of -
0.35 (Fig. 4-32A), while the other four models had scores ranging from -1.65 to -2.42. The 
His-tag (9 amino acids) was removed from the model for structural comparisons with E3 
from other organisms. The best model had most similarity to the human E3 (PDB entry 
1ZMC, Brautigam et al., 2005) with rmsd=1.1 Å, S. cerevisiae E3 (PDB entry 1YEH, 
Toyoda et al., 1998) rmsd=1.3 Å and T. cruzi E3 (PDB entry 2QAE, no associated 
publication) rmsd=1.4 Å. Similarity to A. vinelandii was the lowest with an rmsd of 2.2 Å 
(PDB entry 3LAD, Mattevi et al., 1991). For comparison, the human and yeast E3, which 
are very similar, have an rmsd of about 0.8 Å (Brautigam et al., 2005).  
 
 
A        B 
  
Figure 4-32. I-TASSER model of His-rPfaE3 and PfmE3 
The FAD domain is in green (residues 1-191), the NAD+ domain in blue (residues 193-334), the 
central domain in purple (residues 335-422) and the interface domain in orange (residues 423-557). 
(A) Homology model for His-rPfaE3, the His-tag is in red. (B) PfmE3 homology model. Residue 
numbers are those for the construct His-rPfaE3. 
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 An I-TASSER model was also generated for PfmE3. The best model had a C-score of 0.43 
(Fig. 4-32B), while the other four ranged from -0.89 to -1.82. In addition to the templates 
used for the His-rPfaE3 model, the P. falciparum thioredoxin reductase was also used as a 
template (PDB entry 4B1B, Boumis et al., 2012). E3 is part of the same protein family as 
thioredoxin reductase, thus some structural similarity would not be unexpected. Indeed, 
PfmE3 aligns with P. falciparum thioredoxin reductase to an rmsd of 2.5 Å, making it 
more similar to the reductase than to PfaE3 (rmsd = 3.2 Å). However, PfmE3 is 
structurally most similar to T. cruzi E3 followed by yeast, human and A.vinelandii E3 
(rmsd range 0.4-1.0 Å). PfmE3 is more similar to the E3 from other organisms than it is to 
PfaE3 (rmsd=1.3 Å). This could reflect the specificity of PfaE3 for the apicoplast PDC, as 
the other E3s are shared between the KADCs in the mitochondrion.   
 
The larger size of PfaE3 (63 kDa versus 50 – 54 kDa for other E3s) is accounted for by six 
larger loops (numbered 1-6 in Fig. 4-33). Alignment of the PfaE3 amino acid sequence 
with the I-TASSER template sequences shows gaps in the other organisms where the 
longer loops are present in P. falciparum. The loops do not contain any of the residues 
required for FAD or NAD+ binding or catalytic activity, which are conserved amongst 
various organisms. As the residues involved in dimer formation are not very conserved, 
some of the loops could be involved in this. Loop 1 in the FAD domain is in close 
proximity to the second monomer, as is loop 6 (Fig. 4-32), thus residues in these could be 
involved in dimer formation. The other loops are at the periphery of the protein and do not 
seem to come into contact with other domains. Finally, the active site residues are in very 
similar positions as in the other organisms, as would be expected (Fig. 4-34).  
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  FAD domain    NAD domain 
 
  
         Central domain   Interface domain 
 
Figure 4-33. PfaE3 homology model domains superimposed with corresponding human E3 
domains  
PfaE3 is shown in green human E3 in blue. The larger loops present in P. falciparum are circled 
and the residue numbers shown.  
 
 
A      B 
     
 
Figure 4-34. PfaE3 active site  
(A) PfaE3 was aligned with human E3 to obtain the potential positions of FAD and NAD+ in the P. 
falciparum I-TASSER model. The catalytic site comprises a disulphide (formed by Cys165 and 
Cys170), His646’ from the second monomer, which is held in the correct conformation by 
Glu651’, the isoalloxazine of FAD, and NAD+. (B) Human E3 active site. Figure adapted from 
Brautigam et al., (2005).  
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4.2.3.2 Stoichiometry of His-rPfaE3 
 
4.2.3.2.1 SV analysis of His-rPfaE3  
 
His-rPfaE3 was analysed over a range of concentrations (3 – 23 M) by SV. The reference 
buffer was PEBS250 (Table 2.1) and the density and viscosity values used for c(s) 
distribution analysis using SEDFIT (Schuck, 2000; Schuck et al., 2002) were  = 1.01804 
g/ml and  = 1.6354 cPoise, respectively. The partial specific volume of His-rPfaE3 is 
calculated to be 0.7317 ml/g at 4ºC and 0.7385 ml/g at 20ºC (Table 2-8 and 2-9). 
 
The samples consisted of a main species with s20,w = 6.0 – 6.1 S (68 – 94% of the sample) 
(Fig 4-35A and Table 4-7). A minor species (4 – 18%) of s20,w = 4.0 – 4.2 S  was also 
present at all concentrations. Some samples (5, 6 and 16 M) additionally contained a s20,w 
= 8.2 – 9.2 S species, albeit at a very low amounts (2 – 9%). No aggregation was seen, 
however, 1-13% of the sample was unaccounted for in the analysis (Table 4-7), which was 
most likely due to the degradation of His-rPfaE3. The sedimentation coefficient at infinite 
dilution was determined to be s  = 6.1 ± 0.1 S (Fig. 4-35B). 
 
 
A            B 
       
Figure 4-35. c(s) distribution analysis for a concentration range of His-rPfaE3 
(A) c(s) analysis of the SV data with SEDFIT (Schuck, 2000; Schuck et al., 2002) was carried out 
for His-rPfaE3 concentrations ranging from 3 to 23 M. A main species with an average s20,w of 6.1 
S and a minor ~4.1 S and ~8.8 S species can be observed. (B) A plot with His-rPfaE3 concentration 
vs s20,w was generated to obtain the sedimentation coefficient at infinite dilution, which was s  = 
6.1 ± 0.1 S. The experiment was only carried out once, thus, the error bars are the standard 
deviation shown as the square root of the central moment of the curve.  
 
 
 

20,w
0

20,w
0
Chapter 4 Structural characterisation of recombinant P. falciparum dihydrolipoamide  
acetyltransferase and dihydrolipoamide dehydrogenase 
 
 
 
180 
    % of total protein sample 
His-rPfaE3 [μM]   s20,w (S)   ~4.1 S ~ 6.1 S ~8.8 S Sample loss 
23 4.1 6.1  - 5 94  - 1 
16 4.2 6.2 9.2 4 90 4 2 
12 4.0 6.0  - 5 94  - 1 
6 4.2 6.1 8.9 11 84 2 4 
5 4.2 6.2 8.2 10 72 9 10 
3 4.1 6.1  - 18 68  - 13 
 
Table 4-7. Analysis of His-rPfaE3 sample composition from c(s) analysis (Fig. 4-34). 
 
 
4.2.3.2.2 SE analysis of His-rPfaE3  
 
For sedimentation equlibrium analysis, various concentrations (5-23 M) of His-rPfaE3 
were centrifuged at 17,000 rpm (the speed was based on the predicted dimer mass of His-
rPfaE3) and 10 scans were taken 3 hours apart until the sample had reached equilibrium. 
The data aquired at each concentration were analysed using the non-interacting species 
analysis model in SEDPHAT (Vistica et al., 2004, Fig. 4-36).  
 
        
Figure 4-36. Analysis of His-rPfaE3 SE data 
Interference data (dots, not visible in plot as the data are so well fit by the model) was analysed 
with SEDPHAT (Vistica et al., 2004) using the non-interacting single (1 sp) and three (3 sp) 
species model to obtain best fits (smooth line). The red vertical line indicates the cell meniscus, the 
blue vertical line indicates the cell base and the green vertical lines denote the range of data that 
was analysed. Residual plots are shown beneath each graph. 
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M MW (kDa) % of sample 
23 118 100 
   
16 117 100 
   
12 122 100 
   
6 123 66 
 62 11 
 233 23 
   
5 124 71 
 60 16 
 238 13 
 
Table 4-8. Molecular mass of His-rPfaE3 species at various concentrations as determined by 
SE.  
 
 
The main species at the two lowest concentrations (5 and 6 M) were 124 kDa and 123 
kDa, respectively, which are slightly smaller than the estimated 128 kDa dimer size of His-
rPfaE3 (Table 4-8). The samples also contained a larger 233 - 238 kDa species, which 
could be a tetramer. In addition, both contained a small amount of a 60 kDa or 62 kDa 
species. This would be the size of a slightly truncated monomer (monomer size of His-
rPfaE3 is 64 kDa). This would be in agreement with the SV data, which show a minor 
species with s20,w ~4.1 S and the observation of a slightly smaller protein seen both on 
SDS-PAGE and on an anti-His-tag antibody western blot following gel filtration of His-
rPfaE3. This would suggest that the His-rPfaE3 had been truncated at the C-terminus, thus 
preserving the N-terminal His-tag. Truncation at the C-terminus affects dimer stability. 
Deletion of just 14 amino acids from the C-terminus of A. vinelandii E3 has been reported 
to inactivate E3, decrease thermostability to almost that of a monomer and decrease FAD 
binding (Benen et al., 1992). FAD binding is required for correct folding of E3 (Lindsay et 
al., 2000), which, in turn, would affect dimer formation. A decrease from the estimated 
His-rPfaE3 monomer size 64 kDa to 60-62 kDa would mean the loss of 15-34 amino acids, 
which would most likely prevent dimerisation of the protein.  
 
The three higher concentration samples (12, 16 and 23 M) contained one species which 
was 122 kDa, 117 kDa and 118 kDa, respectively (Table 4-9). These molecular masses are 
lower than the anticipated dimer size (128 kDa), suggesting degradation of His-rPfaE3, 
however, possibly from the N-terminus rather than the C-terminus as above since the 
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protein has clearly dimerised. As the SE experiment required centrifuging the protein for 
several days, this could contribute to the degradation of the protein.  
 
 
4.2.3.3 Solution structure of His-rPfaE3 
 
4.2.3.3.1 Small-angle scattering of His-rPfaE3  
 
SAXS measurements were carried out at the EMBL/DESY beamline X33. His-rPfaE3 was 
purified two days before measurements and homogeneity was determined by SV analysis 
before and after measurements. A day before SAXS, His-rPfaE3 was homogenous with a 
single 6.3 S species (Fig. 4-37). Two days after SAXS, some of the protein had degraded 
resulting in a small amount (5%) of a 3.9 S species in addition to the main 6.1 S species. 
Protein activity was also confirmed on the day of purification.  
 
 
 
Figure 4-37. SV analysis of His-rPfaE3 before and after SAXS  
His-rPfaE3 was homogenous before SAXS but had degraded a little after measurements. The peak 
seen near 0 S is due to buffer. 
 
 
The final concentrations of His-rPfaE3 used for SAXS measurements were 9 M, 8 M, 6 
M, 5 M and 4 M. High angle data from the highest concentration and low angle data 
from the lowest concentration were merged and the resulting scattering curve was used for 
all subsequent analyses (Fig. 4-38A). The linear Guinier region confirmed that there was 
no aggregation in the sample (Fig. 4-38B) and the radius of gyration, Rg, was determined to 
be 39.5  0.3 Å.  
Chapter 4 Structural characterisation of recombinant P. falciparum dihydrolipoamide  
acetyltransferase and dihydrolipoamide dehydrogenase 
 
 
 
183 
A      B 
 
C      D 
   
Figure 4-38. His-rPfaE3 SAXS data analysis 
(A) Experimental SAXS curve. (B) Guinier region. The Rg was 39.5 ± 0.3 Å and the I(0) was 53.1 
± 0.7. (C) p(r) distribution function.The Dmax of His-rPfaE3 was 133 Å. (D) Kratky plot shows the 
protein is folded.    
 
 
GNOM (Svergun, 1992) was used to determine the distance distribution function, p(r), 
from which the maximum dimension of the particle, Dmax, was determined to be 133 Å 
(Fig. 4-38C). The Rg estimated from GNOM analysis, 37.8  0.04 Å was similar to that 
determined from the Guinier region. The bell shape of the p(r) curve has a short tail, 
indicative of a globular particle which is slightly elongated. The Kratky plot also shows a 
bell-shaped curve, which means His-rPfaE3 is folded (Fig. 4-38D).  
 
The molecular mass of His-rPfaE3 estimated by extrapolating the scattering intensity to 
zero angle, I(0) was 54 kDa. This would suggest that the sample was a monomer, however, 
the AUC data confirmed that His-rPfaE3 was largely dimeric at concentrations used. The 
estimation of molecular mass from I(0) is not always reliable. Another method of 
determining the mass of a particle from SAXS data is by dividing the excluded volume of 
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the particle by 1.5 - 2. Determination of the excluded volume directly from scatting data is 
difficult when the data at high angles are very noisy, as in this case. The programme 
DATPOROD (Petoukhov et al., 2012) can be used to determine the POROD volume from 
the p(r) distribution curve, which should improve accuracy. The POROD volume obtained 
was 188 nm3, which would put the molecular mass estimation of His-rPfaE3 between 94 - 
125 kDa, the average being 110 kDa. This would be closer to the dimer size of 128 kDa.  
 
  
4.2.3.3.2 Ab initio modelling of His-rPfaE3 
 
Ab initio modelling using P2 symmetry was carried out using DAMMIF (Franke and 
Svergun, 2009) on the ATSAS online server (http://www.embl-hamburg.de/biosaxs/atsas-
online/dammif.php, Petoukhov et al., 2007, section 2.8.3) to obtain 20 ab initio models, 
which were clustered by DAMCLUST (Petoukhov et al., 2012). The models clustered into 
three groups of which the largest contained 15 models. Closer inspection showed slightly 
different models had been clustered together, thus clustering was carried out again with the 
15 models. These were divided into two groups, one with seven and the other with eight 
models. The representative and the averaged model for both groups are shown in Fig. 4-
39A - D.  
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C         D 
         
          
 
Figure 4-39. DAMMIF models of His-rPfaE3  
Representative model of (A) group 1 and (B) group 2. Average model of (C) group 1 and (D) group 
2.    
 
 
Both representative models had Rg = 37.8 Å. The group one model Dmax was 146 Å (Fig. 4-
39A), and group two Dmax was 149 Å (Fig 4-39B). The molecular mass of the models was 
128 kDa and 127 kDa, for group one and two, respectively. Both models fit the 
experimental scattering data well with Chi squared values of 0.79 (Fig. 4-40A & B).  
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A         B 
 
Figure 4-40. Ab initio model fits to scattering data for His-rPfaE3 
Representative model of (A) group 1 and (B) group 2. Scattering curve (black), ab initio model fit 
(red).  
 
 
The averaged ab initio models were superimposed with the I-TASSER His-rPfaE3 dimer 
model using SUPCOMB (Kozin and Svergun, 2001, Fig. 4-41). The normalised spatial 
discrepancy (NSD) values (section 2.8.4) for both superimpositions were 0.95. For 
comparison, NSD values close to one indicate that the two models are highly similar.  
 
 
A       B 
          
 
   
 
Figure 4-41. Superposition of I-TASSER homology model with His-rPfaE3 ab initio model  
Average model of (A) group 1 and (B) group 2. FAD domain (green), NAD domain (blue), central 
domain (purple), interface domain (orange).   
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The His-rPfaE3 solution structure is more elongated than the I-TASSER model. The Dmax 
of the homology model dimer was 110 Å, while the maximum dimensions of the averaged 
solution envelopes were 139 - 144 Å. The NAD+ domains (blue) are partially outside the 
solution structure, while the homology model does not extend into the space neighbouring 
the N-terminus of the FAD (green) and central (purple) domains (Fig. 4-41).  
 
There are a few flexible regions in His-rPfaE3 (Fig. 4-42), as predicted by IUpred 
(Dosztanyi et al., 2005, http://iupred.enzim.hu/). The N-terminus of His-rPfaE3 contains a 
14-amino acid flexible peptide including the His-tag, which could extend into the adjacent 
empty space in the DAMMIF model (Fig. 4-43, green). A loop in the NAD+ domain 
extends outside the ab initio model (Fig. 4-43, blue). This is one of the longer loops in 
PfaE3 (loop 2, Fig. 4-33) and is also slightly flexible according to IUpred. In the central 
domain, another longer loop extends outside the DAMMIF model (Fig. 4-43, cyan). The 
other extended loops in PfaE3 (loops 1 and 4-6, Fig. 4-33) and a short flexible region (Fig. 
4-43, yellow) cluster adjacent to another unoccupied region of the solution structure. It is 
likely that these loops and flexible regions are not well modelled by the rigid ab initio 
approach, manifesting themselves as extended lobes in the model in order to best fit the 
data. Instead, these regions should be explicitly modelled as flexible entities. 
 
 
 
Figure 4-42. IUpred prediction of flexible regions in His-rPfaE3 
Values above 0.5 indicate flexibility. The flexible regions are residues 1-14, residues 300-315 in 
the NAD domain, and residues 483-487 in the interface domain (numbering according to His-
rPfaE3 construct).  
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Figure 4-43. Flexible and extended loops in relation to the ab initio model of His-rPfaE3 
Average model of (A) group 1 and (B) group 2. His-rPfaE3 N-terminus flexible region and His-tag 
is in green, PfaE3 extended loop 2 in the NAD+ domain is in blue and the central domain extended 
loop 3 in cyan. Loops 1 and 4-6 in the FAD, central and interface domain, respectively, cluster 
together (red). A shord flexible region is shown in yellow.   
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EOM (Bernado et al., 2007; Petoukhov et al., 2012) was carried out to assess whether the 
N-terminal flexible region with the His-tag could extend outwards to account for the empty 
space in the DAMMIF model. When changing the orientation of the His-rPfE3 homology 
model in the DAMMIF model, the His-tag does seem to account for some of the space 
adjacent to it (Fig. 4-44). US-SOMO DMD (Dokholyan et al., 1998; Ding and Dokholyan, 
2006) simulations resulted in similar movement of the flexible N-terminal region.  
 
 
A          B 
     
    
 
 
 
Figure 4-44. Modelling the flexible His-tag of His-rPfaE3 
Superposition of His-rPfaE3 EOM model with the flexible 14-amino acid N-terminal His-tag with 
the DAMMIF average model for (A) group 1 and (B) group 2. EOM modelling was carried out 
twice, thus the His-tag is shown in grey and magenta.  
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4.2.3.4 Hydrodynamic modelling of His-rPfaE3 
 
 
Using the programme US-SOMO (Rai et al., 2005; Brookes et al., 2010a; Brookes et al., 
2010b) the sedimentation coefficients were calculated for the I-TASSER homology models 
and the ab initio models. The computed sedimentation coefficients also support the 
conclusion that the His-rPfaE3 is more extended than the homology model. The I-TASSER 
dimer model has s = 7.4 S, which is much larger than the experimental average of 6.1 S. 
This would suggest that the homology model is more compact that the real protein, as 
compact molecules sediment faster. The estimated s  value for the DAM model was 6.8 
S, which is still higher than the experimental sedimentation coefficient for His-rPfaE3. The 
computed sedimentation coefficients for the His-rPfaE3 EOM models taking into account 
the flexible His-tag were 7.0 S. For the US-SOMO DMD models the sedimentation 
coefficients ranged from 7.0 to 7.3 S. Thus, the His-tag alone is not the source of the more 
elongated and less compact structure of His-rPfaE3.  
 
The calculated sedimentation coefficients for an I-TASSER monomer model and truncated 
monomers suggest that the monomer model itself is also more compact. The full length I-
TASSER monomer would have s  = 4.6 S, which is higher than the average 4.1 S peak 
observed in the experimental data, attributed to a small amount of monomer. From the 
molecular mass of the species, 60-62 kDa (as determined by SE analysis, section 
4.2.3.2.2), it can be deduced that this peak is the His-rPfaE3 monomer, which is truncated 
by 15-34 amino acids. The computed s  for an I-TASSER monomer with 34 amino 
acids missing from the C-terminus was 4.4 S. This is still slightly higher than the 
experimental value. To obtain an s  of 4.2 S, 60 amino acids would need to be removed 
from the I-TASSER model. However, the molecular mass would then drop to 53 kDa, 
which is smaller than the experimental values. Thus, the extended and less compact 
structure of His-rPfaE3 is not only due to how the dimer is assembled but is also 
influenced by the monomer structure of the protein. The truncation of the PfaE3 C-
terminus could be experimentally determined in the future by using mass spectrometry 
based methods to analyse the amino acid sequence of the C-terminus (Nakajima et al., 
2012a, Nakajima et al., 2012b). 
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4.3 Summary 
 
 
 Homology modelling using I-TASSER suggested that PfE2 LD, SBD and CD 
structures have similar features to those from other organisms. Interestingly, 
differences in key residues in the PfE2 SBD, which could be involved in E1 and E3 
binding, were revealed. The I-TASSER homology PfE2 CD was modelled into a 
trimer, which showed the potential inter-trimer interaction sites. The trimer models 
were also used to assess potential intra-trimer interactions required for large E2 core 
formation. This modelling suggested that interactions between the PfE2 trimers could 
be weaker than those in other organisms. 
 
 SV analyses of His-rPfE2m showed no large core complex. The main species had a 
sedimentation coefficient of 6.1 ± 0.1 S, which was confirmed to be a trimer by SE 
analysis. The molecular mass (193-195 kDa) in the highest concentration samples was 
slightly lower than that calculated for His-rPfE2m from its amino acid sequence (210 
kDa), which suggests some degradation of the protein. 
 
 SE analysis of His-rPfE2m showed the presence of larger molecular mass species (1.5 
– 3.7 MDa), which could be the E2 core complex. However, these species were not 
seen in SV analyses. Unfortunately, aggregates in the samples and thermodynamic 
non-ideality of the protein complicated the analyses of these species. Thus, the 
potential E2 core complex stoichiometry is inconclusive. 
 
 His-rPfE2bc only contained a trimer species in both SV and SE analysis. The protein 
had a sedimentation coefficient of 4.5 ± 0.3 S and a molecular mass of 104-108 kDa, 
which is consistent with the trimer size calculated from the amino acid sequence of 
His-rPfE2bc (104 kDa). 
 
 SAXS was carried out to obtain a solution structure of His-rPfE2bc. Low concentration 
of the protein made analsis challenging, however, EOM models of His-rPfE2bc fit the 
scattering data well at low angles (2 = 1.03). The models also had computed 
sedimentation coefficients (4.6 ± 0.1 S) that correlated well with the experimental 
values for His-rPfE2bc (4.5 ± 0.3 S).  
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 I-TASSER homology models of His-rPfaE3 showed the larger size of PfaE3 compared 
with E3 from other organisms to be due to longer loops between the conserved 
domains. 
 
 His-rPfaE3 is a dimer with a sedimentation coefficient of 6.1 ± 0.1 S and a molecular 
mass of 117-124 kDa, which is consistent with a slighty truncated protein as the 
molecular mass of His-rPfaE3 calculated from the amino acid sequence is 128 kDa. 
 
 The solution structure obtained for His-rPfaE3 using SAXS was more elongated than 
the homology model based on the crystal strucutres of other organisms. The computed 
sedimentation coefficient for the homology model (7.4 S) is much larger than the 
experimental value for His-rPfaE3 (6.1 ± 0.1 S). Surprisingly, the calculated 
sedimentation coefficient for the His-rPfaE3 DAMMIF model was still high (6.8 S) 
regardless of the more elongated structure.  
 
 Modelling the N-terminal flexible region including the His-tag did not significantly 
decrease the calculated sedimentation coefficient (7.0 S), thus the source of the more 
elongated shape is likely to be due to the long loops and flexible regions within the 
PfE3 structure.  
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Chapter 5 
P. falciparum dihydrolipoamide acetyltransferase and 
dihydrolipamide dehydrogenase gene deletion 
 
5.1 Introduction 
 
The PfE2 gene (PlasmoDB: PF3D7_1020800, www.plasmodb.org) is 3192 bp, however it 
contains 10 predicted introns and complementary DNA analysis showed the full protein 
encoding sequence is 1923 bp (McMillan, 2006). The gene is located on chromosome 10, 
which is 1.7 Mb and predicted to encode 403 proteins of the overall ~5300 coding genes in 
the P. falciparum genome (Gardner et al., 2002a; Gardner et al., 2002b). PfE2 is very A/T 
rich (78.6%) with the introns showing the characteristic higher A/T content than exons 
(87.5% and 72.9%, respectively) (McMillan, 2006). The 2001 bp PfaE3 (PlasmoDB 
annotation PF3D7_0815900, www.plasmodb.org) does not contain introns (McMillan, 
2006). It is located on chromosome 8, which is 1.3 Mb and encodes 312 proteins (Hall et 
al., 2002). PfaE3 has an A/T content of 74.7%.   
 
A recent study of the rodent parasite, P. yoelii, showed that the PDC is essential only in the 
liver stages of the parasites. E1 and aE3 were essential for the progression of the parasites 
from the liver stage to the infective blood stage in mice (Pei et al., 2010). Similarly, the 
type II fatty acid biosynthesis (FASII) pathway, for which PDC provides acetyl-CoA, was 
essential only for the liver stages (Yu et al., 2008a). Nevertheless, reverse transcriptase-
PCR and western blotting have shown that the genes are expressed in P. falciparum during 
the blood stages (Foth et al., 2005; McMillan et al., 2005). Even though the PDC may not 
be essential in the erythrocytic stages of P. falciparum, the proteins could still have a role 
in the growth and development of the parasite. The PDC enzymes could, for example, have 
a role in defence against oxidative stress via the reducing equivalents in the E2 and E3 
enzymes (section 1.4.3.4).   
 
Chapter 5 P. falciparum dihydrolipoamide acetyltransferase and dihydrolipamide dehydrogenase  
gene deletion 
 
 
 
194 
5.2 Aims 
 
The aims for this section of the project were to  
- Generate PfE2 and PfaE3 deletion mutants 
- Characterise the resulting ∆PfE2 and ∆PfaE3 parasite lines  
 Determine any effect of the deletion on the growth and development of blood 
stage parasites 
 Determine whether PfE2 or PfaE3 play a role in defence against oxidative stress 
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5.3 Results  
 
 
5.3.1 Cloning of pCC-1 PfE2 and PfaE3 knockout constructs 
 
pCC-1 and pCC-4 vectors were developed by Maier et al. (2006) for gene deletion by 
double cross-over recombination via the 5’ and 3’ flanks of the gene of interest using 
positive/negative drug selection. pCC-1 contains the human dihydrofolate reductase 
(hdhfr) gene and pCC-4 contains the blasticidin-S-deaminase (bsd) gene. These are used 
for positive selection of parasites containing the plasmid with WR99210 or Blasticidin-S-
HCl, respectively. Both vectors contain the S. cerevisiae cytosine deaminase (cyd) gene as 
a bifunctional chimeric protein with S. cerevisiae uracil phosphoribosyl transferase, which 
forces integration of the plasmid into the gene loci by negative drug selection using 5-
fluorocytosine (5-FC) (Maier et al., 2006). The cyd gene converts 5-FC to 5-fluorouracil, 
which inhibits RNA synthesis and thymidylate synthase, resulting in death of parasites 
with episomal pCC plasmid. When double cross-over recombination takes place, the target 
gene is replaced with either the hdhfr or bsd, but the cyd gene is lost (Fig. 5-1A & B). 
Therefore, only parasites with plasmid integration should survive in the presence of 5-FC.  
 
In this study, knockout constructs were made using the pCC-1 vector only (see section 
2.5.2.4). As the PfE2 gene sequence is extremely AT rich, there was difficulty finding 
optimum primer binding sites to produce the 5’ and 3’ end fragments for cloning. For the 
5’ end, a 506 bp fragment (nucleotides 685-1190) was generated, and for the 3’ end, a 508 
bp fragment (nucleotides 2119-2626) was produced. Although the resulting pCC1-PfE2 
construct would not replace the whole PfE2 gene, there would still be a deletion of 1941 bp 
from the centre of the 3192 bp gene. This would correspond to the loss of the protein from 
the second lipoyl domain onwards to the middle of the catalytic domain (Fig. 5-1A).  
 
For the pCC1-PfaE3 construct, a 490 bp fragment (nucleotides 37-526) and a 545 bp 
fragment (nucleotides 1456-2001) were generated for the 5’ and 3’ flanks, respectively. 
Successful integration of the pCC1-PfaE3 construct into the PfaE3 locus would delete the 
whole mature gene as the first 327 nucleotides are predicted to encode the signalling and 
transit peptides (Fig. 5-1B).     
 
Chapter 5 P. falciparum dihydrolipoamide acetyltransferase and dihydrolipamide dehydrogenase  
gene deletion 
 
 
 
196 
A 
 
 
   
  B 
 
 
 
Figure 5-1. Schematic diagram for pCC-1 vector mediated double cross-over gene 
replacement of PfE2 and PfE3.   
The numbers in parenthesis are nucleotide sequence numbers for each gene portion. Diagrams are 
not to scale. (A) The pCC1-∆PfE2 plasmid contained ~500 bp flanks consisting of nucleotides 685-
1190 at the 5’ end and nucleotides 2119-2626 at the 3’ end. If these flanks integrate into the 
corresponding sequences in the native gene, 1941 bp from the middle of the PfE2 gene (nucleotides 
1191-2118) are excised and replaced with the hdhfr selection marker. This deletion strategy leaves 
the start (nucleotides 1-684) and end (nucleotides 2627-3192) of PfE2 in place, however, the 
majority of the gene is excised. (B) The pCC1-∆PfE3 plasmid contained ~500 bp flanks consisting 
of 5’ nucleotides 37-526 and 3’ nucleotides 1456-2001. When these flanks integrate into 
corresponding sequences in the native gene, nucleotides 527-1455 are replaced with the hdhfr 
selection marker. This deletes the whole PfE3 gene as nucleotides 1-36 encode the transit peptide.  
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5.3.2 Generation of ∆PfE2 and ∆PfaE3 P. falciparum 
 
5.3.2.1 Positive/negative drug selection for P. falciparum with pCC1-∆PfE2 or pCC1-
PfaE3 integration 
 
The pCC1-∆PfE2 and pCC1-∆PfaE3 constructs were transfected in duplicate on two 
separate occasions into D10 and 3D7 parasite lines (section 2.9.8). The parasites were 
cultured with WR99210 for selection of transfectants and resistant parasites emerged after 
3-7 weeks. Genomic DNA was isolated from the parasites (section 2.9.6 and 2.9.7) and 
Southern blotting (section 2.5.11) was carried out to confirm the presence of episomal 
pCC1-∆PfE2 or pCC1-∆PfaE3. All the transfections were successful, apart from one 
transfection of 3D7 parasites with pCC1-∆PfE2, from which no resistant parasites 
emerged.  
 
Two of each construct/parasite line combination were chosen for further drug selection 
(section 2.9.9). Using 5-FC, negative drug selection pressure was applied to the cultures to 
force integration of the plasmids into their respective loci. 5-FC resistant parasites emerged 
in one pCC1-∆PfE2/D10 parasite line (D10pCC1-∆PfE2) and one pCC1-∆PfaE3/3D7 parasite 
line (3D7pCC1-∆PfaE3). DNA was harvested from these cultures and analysed for integration 
of plasmid by Southern blotting.   
 
For genotyping of D10pCC1-∆PfE2, gDNA was digested with HincII and BglI and initially 
probed for the PfE2 5’ cloning fragment sequence. The expected DNA fragment sizes are 
shown in Fig. 5-2A. An 8.7 kb band potentially corresponding to full integration could be 
seen along with the 7.5 kb wild type (WT) D10 band (Fig. 5-2B). No band corresponding 
to the plasmid (5.5 kb) was present but two additional faint bands (~2.2 kb and ~1.4 kb) 
could be seen. As these did not correspond to any of the expected band sizes (Fig. 5-2A), 
the blot was stripped and the gDNA re-probed for the cyd gene. In the event of correct 
integration, this gene is lost and no bands should be seen with this probe. The 5.5 kb 
plasmid band was not seen, however, the smaller 0.75 kb band was present in the potential 
PfE2 knockout line in addition to unidentified ~1.4 kb and 2.2 kb bands (Fig 5-2C), 
suggesting the presence of a population of parasites with incorrect integration of the 
plasmid. The hdhfr gene was also probed for, and only the 8.7 kb band corresponding to 
full integration was detected (Fig. 5-2D). In conclusion, at this stage these analyses 
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suggested that the D10pCC1-∆PfE2 line did not contain an episomal copy of the pCC1-PfE2 
plasmid and could be a mixture of parasites with both correct and incorrect integration of 
the plasmid. To obtain a homologous population of correctly integrated parasites, the line 
was subject to cloning by limited dilution (see section 5.3.2.2).  
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Figure 5-2. Southern blot analyses of pCC1-PfE2 integration into the P. falciparum D10 
genome following positive/negative drug selection 
(A) A schematic diagram (not to scale) of the expected DNA fragment sizes following digestion with 
HincII and BglI: (I) Endogenous gene: 7.5 kb fragment detectable with the PfE2 5’ cloning fragment 
probe (blue star); (II) pCC1-PfE2 plasmid; 5.5 kb fragment detectable with all the probes, and 0.75 
kb fragment detected only with the cyd probe (yellow star); (III) Integration: 8.7 kb fragment 
detectable by the PfE2 5’ cloning fragment and hdhfr probes (blue and pink stars, respectively). (B) 
D10pCC1-∆PfE2 gDNA (2.5 g) digested with HincII and BglI. A potential full integration band (8.7 kb) 
and the WT D10 band (7.5 kb) were seen. No plasmid band (5.5 kb) was present. Two faint 
unidentified bands (~2.2 kb and ~1.4 kb) were detected. (C) Probed for the cyd gene, the 0.75 kb cyd 
fragment was detected in the D10pCC1-∆PfE2 line. Also unidentified ~1.4 kb and 2.2 kb bands were 
present. (D) With a probe for the hdhfr, only a band corresponding to full integration (8.7 kb) could 
be seen.  
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The 3D7pCC1-∆PfaE3 gDNA was digested with HincII and probed for the PfaE3 5’ cloning 
fragment sequence. Only a 3.9 kb band corresponding to integration could be seen in the 
line, with no WT 3D7 or plasmid contamination (Fig. 5-3). Although the 3D7pCC1-∆PfaE3 
line seemed to have only a single population of integrated parasites, cloning by limiting 
dilution was also carried out to ensure a homogenous population.   
 
 
A      B 
   
 
Figure 5-3. Southern blot analysis of pCC1-∆PfaE3 integration into P. falciparum 3D7 
genome following positive/negative drug selection 
(A) A schematic representation (not to scale) of the expected band sizes following digestion with 
HincII. The PfaE3 5’ cloning fragment probe (blue star) was used to visualise DNA. (I) Digestion 
of the endogenous gene results in a 2.7 kb fragment. (II) Digestion of the pCC1-PfaE3 results in a 
7.8 kb fragment. (III) Following integration pCC1-PfaE3 plasmid, digestion with HincII results in 
a 3.9 kb fragment. (B) 3D7pCC1-∆PfaE3 gDNA (2.5 g) digested with HincII probed for the PfaE3 5’ 
cloning fragment sequence. Only a band corresponding to correct integration (3.9 kb) could be seen 
in the 3D7pCC1-∆PfaE3 line. No bands corresponding to WT 3D7 (2.7 kb) or pCC1-PfaE3 plasmid 
(7.8 kb) were present in this line.  
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5.3.2.2 Cloning of integrated P. falciparum lines by limited dilution 
 
To obtain homogenous populations of knockout parasites, cloning by limiting dilution was 
carried out (section 2.9.10). The D10pCC1-∆PfE2 and 3D7pCC1-∆PfaE3 lines were diluted to 0.25 
parasites/well in culture medium containing both WR99210 and 5-FC into two 96-well 
mictrotitre plates. After 3-4 weeks, 17 D10pCC1-∆PfE2 and 34 3D7pCC1-∆PfaE3 clonal lines had 
emerged. These were then bulked to larger cultures, stored in liquid nitrogen and genomic 
DNA was extracted for genotypic analysis.    
 
Genomic DNA of four clones of the potential PfE2 knockout parasite line D10pCC1-∆PfE2 
was digested with HincII and BglI and probed for the PfE2 5’ cloning fragment sequence. 
Three out of the four clones seemed to show the 8.7 kb band possibly corresponding to 
integration, however, the 7.5 kb WT band was still also present (Fig. 5-4). One of the 
clones had only the 7.5 kb WT band. In addition, the several unidentified bands were still 
seen casting doubt on whether the line was an actual PfE2 knockout line as was first 
thought.  
 
 
 
Figure 5-4. Southern blot analyses of potential clonal PfE2 knockout P. falciparum lines  
gDNA (2.5 g) from four clones (numbered 2, 6, 10 and 11 in order of emergence following 
limiting dilution) was digested with HincII and BglI and probed for the PfE2 5’ cloning fragment 
sequence. A possible intergration band (8.7 kb), the WT (7.5 kb) band and several unidentified 
bands were present in the potential knockout line. For expected fragment sizes see Fig. 5-2A.  
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A BsaI digest    B 
        
C SpeI and BglII digest  D 
      
 
Figure 5-5. Additional diagnostic Southern blot analyses of potential clonal PfE2 knockout P. 
falciparum lines 
(A) A digest with BsaI probed for the PfE2 5’ cloning fragment sequence showed only the WT 
3D7 band (3.5 kb) and two unidentified bands (~8 kb and ~9 kb). (B) A schematic diagram (not to 
scale) of the expected DNA fragment sizes following digestion with BsaI. The PfE2 5’ cloning 
fragment probe (blue star) was used to visualise DNA. (I) Endogenous gene: 3.5 kb fragment. (II) 
pCC1-PfE2: 8.5 kb fragment (III) Integration: 4.7 kb fragment. (C) A digest with SpeI and BglII 
and probed for the PfE2 5’ fragment sequence also showed no integration band (6.1 kb). Only WT 
D10 (4.9 kb) and an unidentified ~8 kb band were seen. (D) A schematic representation (not to 
scale) of the expected DNA fragment sizes following digestion with SpeI and BglII. The PfE2 5’ 
fragment probe (blue star) was used to visualise DNA. (I) Endogenous gene: 4.9 kb fragment. (II) 
pCC1-PfE2: 8.5 kb fragment. (III) Integration: 6.1 kb fragment. 
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To confirm the genotype, two additional digests were carried out on two of the clones. A 
digest with BsaI showed only the WT D10 band (3.5 kb) and two unidentified bands (~8 
kb and ~9 kb) (Fig. 5-5A). Correct integration would have produced a 4.7 kb band (Fig 5-
5B). A digest with SpeI and BglII showed similar results; there was no integration band 
(6.1 kb), only a WT D10 (4.9 kb) and an unidentified ~8 kb band (Fig. 5-5D&E). Thus, the 
conclusion was made that the pCC1-PfE2 plasmid had not targeted the PfE2 locus and no 
further work was carried out with the parasite line.  
 
Five 3D7pCC1-∆PfaE3 clonal lines were analysed by Southern blot (Fig. 5-6). The gDNA was 
digested with HincII and probed for the PfaE3 5’ cloning fragment as before. All five lines 
showed the presence of only the band corresponding to integration (3.9 kb), confirming 
these to be homogenous populations of PfaE3 knockout P. falciparum. 3D7pCC1-∆PfaE3 
clones number 16 and 32 were used for phenotypic studies.   
 
 
        
 
Figure 5-6. Southern blot analysis of 3D7pCC1-∆PfaE3 clonal lines 
gDNA (2.5 g) from five clones (numbered 16, 21, 25, 32 and 34 in order of emergence following 
limiting dilution) was analysed and confirmed to be homogenous PfaE3 knockout parasites as only 
the 3.9 kb integration fragment could be seen. The gDNA was digested with HincII and probed for 
the PfaE3 5’ cloning fragment sequence. For the expected fragment sizes see Fig. 5-3A.  
 
 
 
 
Chapter 5 P. falciparum dihydrolipoamide acetyltransferase and dihydrolipamide dehydrogenase  
gene deletion 
 
 
 
204 
5.3.3 3D7pCC1-∆PfaE3 growth assay 
 
To investigate the effect of the deletion of PfaE3 on parasite development, growth of the 
parasites was observed for 15 days (section 2.9.11). The 3D7pCC1-∆PfaE3 mutant showed 
impaired growth in erythrocytic stage parasites compared with the wild type parental strain 
(Fig. 5-7). This is contrary to P. yoelii, in which deletion of aE3 did not have an effect on 
parasite growth in the blood stages (Pei et al., 2010). The initial multiplication rate (i.e. 
how much the parasitemia increased after the first 48 h cycle) was 8.6 ± 0.4 for the WT 
3D7 compared with 6.4 ± 0.7 for 3D7pCC1-∆PfaE3 clone 34. The parasitemia of WT 3D7 
reached 12.2 ± 1.4 % on day 5, after which it steadily decreased until no parasites were 
observed in the culture on day 14. This suggests that the WT 3D7 reached its limiting 
parasitemia on day 5, after which parasite death started to occur. Such death of parasites 
was not observed in the 3D7pCC1-∆PfaE3 clones, where the parasitemia fluctuated between 
2.3 ± 0.5 % and 4.6 ± 0.2 % on the second day of each cycle throughout the experiment.   
 
 
        
Figure 5-7. Growth of 3D7pCC1-∆PfaE3 
Synchronised ring stage cultures (in triplicate) were diluted to 0.5 % parasitemia (day 1) and every 
second day the cultures were diluted 1:5 with fresh erythrocytes. Blood smears of the cultures were 
made every 24 h. Parasitemia was determined by counting the number of infected erythrocytes per 
1000 erythrocytes (section 2.9.2). The error bar denotes the standard error of the mean.  
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The cell cycle stage was also monitored (Fig. 5-8). As the cultures were synchronised on 
day 1 all the parasites were rings. On day 2 most parasites were in trophozoite stage. The 
WT 3D7 culture contained some schizonts (3 ± 1 %), while 3D7pCC1-∆PfaE3 clone 34 only 
had a small proportion of schizonts (0.7 ± 0.7 %). On day 3 following invasion, more rings 
had already progressed to trophozoite stage (24 ± 1.4 %) in WT 3D7 than in 3D7pCC1-∆PfaE3 
clone 34 (4.3 ± 0.7 %). These differences became more obvious in the next three cycles 
(days 3-8) before the WT 3D7 culture began dying. This would imply that progression of 
the 3D7pCC1-∆PfaE3 clone 34 through the cell cycle was slowed, thus resulting in the lower 
parasitemias observed during the growth experiment. Also the 3D7pCC1-∆PfaE3 clone stayed 
highly synchronous over a lengthy period of 7 days, while the WT 3D7 parasites lost their 
synchrony after just two cycles (4 days).   
 
 
Figure 5-8. Cell cycle stage of 3D7pCC1-∆PfaE3 compared with WT 3D7 
The cycle stage of the parasite lines (in triplicate) was determined by counting 100 parasites and 
noting the number of rings, trophozoites and schizonts present. The error bar denotes the standard 
error of the mean. Trophozoites containing several large vacuoles or those that were extremely 
dense were classed as unhealthy/dying trophozoites.  
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5.3.4 3D7pCC1-∆PfaE3 susceptibility to oxidative stressors and triclosan  
 
To begin investigation into the role PfaE3 may play during the erythrocytic stages, 
susceptibility of 3D7pCC1-∆PfaE3 to two different oxidative stressors and a drug thought to 
affect the FASII pathway was determined. L-buthionine sulfoximine (BSO) is a specific 
inhibitor of -glutamylcysteine synthase (-GCS), an enzyme in the glutathione synthesis 
pathway, which also affects P. falciparum growth (Griffith, 1982; Meierjohann et al., 
2002). Inhibiton of -GCS results in reduced levels of the important antioxidant 
glutathione, which is essential for blood stage parasite survival (Luersen et al., 2000; 
Patzewitz et al., 2012). Paraquat is a commonly used herbicide, which produces superoxide 
anions and oxidises cellular NADPH levels and causes lipid peroxidation (Suntres, 2002). 
Paraquat is also used experimentally, for example, to study responses to oxidative stress in 
P. falciparum (Komaki-Yasuda et al., 2003; Gallo et al., 2009). Susceptibillity to tricolsan, 
a broad-spectrum antimicrobial and anti-fungal agent, was also tested as it targets the FabI 
protein of FASII in bacteria (McMurry et al., 1998; Heath et al., 1999; Heath et al., 2000). 
Triclosan has also demostrated antiparasitic activity in Plasmodium and Trypanosoma 
(Surolia and Surolia, 2001; Perozzo et al., 2002; Paul et al., 2004; Yu et al., 2008a). 
However, the target of the drug in both parasites actually may not solely be the FabI 
enzyme in vitro, as was shown by Paul et al. (2004) in T. brucei and by Yu et al. (2008a) 
in P. falciparum and P. berghei.   
 
Following 48 h incubation of WT 3D7 and 3D7pCC1-∆PfaE3 clones 16 and 34 with BSO, 
paraquat or triclosan, the incorporation of [3H]-hypoxanthine was used to determine IC50 
values (section 2.9.12). No difference in IC50 values between WT 3D7 and the 3D7
pCC1-
∆PfaE3 clones was observed for BSO or paraquat (Fig. 5-9A & B). Interestingly, a 
significant difference (P< 0.001) was seen in susceptibility to triclosan. 3D7pCC1-∆PfaE3 
clones were more resistant to triclosan (for both clones IC50 = 14 ± 1 M) than WT 3D7 
(IC50 = 8 ± 1 M) (Fig. 5-9C). This is in contrast to the findings of Yu et al. (2008a), who 
showed that susceptibility of P. falciparum and P. berghei FabI deletion mutants to 
tricolsan did not differ from the WT parental strain. Due to time constrains, this experiment 
was only done once and thus needs to be repeated for further analysis.   
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Figure 5-9. IC50 analyses of 3D7pCC1-∆
PfaE3 clones 16 and 34 
Three technical replicates were set for each assay. The IC50 values are the mean ± standard error as 
determined using the log(inhibitor) vs response non-linear regression model in GraphPad Prism 5 
(GraphPad Software Inc.). (A) BSO had no differing effect on the 3D7pCC1-∆PfaE3 clones (IC50 = 82 
± 1 M and 79 ± 1 M clones 16 and 34, respectively) compared with WT 3D7 (IC50 = 82 ± 1 
M). (B) No effect was seen with paraquat (clone 16 IC50 = 12 ± 1 M, clone 34 IC50 15 ± 1 M, 
WT 3D7 IC50 20 ± 1 M ). (C) Triclosan IC50 for 3D7pCC1-∆PfaE3 clone 16 (14 ± 1 M) and 
clone 34 (14 ± 1 M) was significantly higher than for WT 3D7 (8 ± 1 M) (P< 0.001). The one-
way analysis of variance (ANOVA) was used to calculate the statistical significance (P< 0.05 
indicated signficance). 
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5.4 Summary  
 
 The attempt to delete PfE2 by double cross-over recombination using the pCC1 
plasmid was not successful. Southern blot analyses showed integration of the 
plasmid, however, the PfE2 loci was not targeted.  
 
 PfaE3 was successfully deleted in the 3D7 P. falciparum strain via double cross-
over recombination using the pCC1 plasmid. Clonal lines homogenous for the 
mutation were obtained and named 3D7pCC1-∆PfaE3.  
 
 3D7pCC1-∆PfaE3 mutants showed a slightly impaired growth compared with WT 3D7 
in the erythrocytic stages of the life cycle. The lack of PfaE3 resulted in parasites 
that stayed highly synchronous compared with WT 3D7 parasties.   
 
 Deletion of PfaE3 had no effect on the susceptibility of the parasites to the 
oxidative stressors BSO or paraquat, however, the 3D7pCC1-∆PfaE3 clones were more 
resistant to triclosan than the 3D7 wild type.   
 
 209 
Chapter 6  
Discussion  
 
 
This study investigated the malaria parasite PDC, which is unusual in that it is only found 
in the apicoplast, the plastid-like organelle found in most apicomplexan parasites (Foth et 
al., 2005; McMillan et al., 2005). Unlike the mammalian PDC, which is located in the 
mitochondrion and produces acetyl-CoA for the citric acid cycle, the Plasmodium PDC 
produces acetyl-CoA for fatty acid biosynthesis. The PDC has been shown to be essential 
for liver stage parasites, as mutants lacking the E1 and E3 enzymes did not egress from 
hepatocytes and thus, could not elicit the intraerythrocytic stages of the malaria infection 
(Pei et al., 2010). As the blood stages of the parasite life cycle cause the symptoms of 
malaria, the PDC could be a potential prophylactic drug target or vaccine candidate. Not 
much is known about the Plasmodium PDC proteins and if drug discovery is to progress it 
is necessary to be able to generate protein to investigate the structure and function of the 
complex and also ultimately study the effects of inhibitors.     
 
 
6.1 P. falciparum protein expression and purification  
 
Heterologous expression of P. falciparum proteins is plagued by difficulty, which is why 
obtaining high amounts of soluble proteins required for structural characterisation is often 
challenging or even impossible. Factors thought to cause poor expression include the high 
A/T content (80 %) of the P. falciparum genome and the high number of introns (Gardner 
et al., 2002a). PfE2 contains 10 introns and the A/T content of the mature protein is 73%. 
PfaE3 does not contain introns but has an A/T content of 75 %. P. falciparum also prefers 
to use codons that are rare in E. coli, which can lead to depletion of the host tRNAs and 
halt expression (Saul and Battistutta, 1988; Kane, 1995; Kurland and Gallant, 1996). For 
example, the P. falciparum preferred codons for arginine (AGA/G), isoleucine (AUA) and 
glycine (GGA) are very rarely used in E. coli (Baca and Hol, 2000). A P. falciparum gene 
may also contain Shine-Dalgarno-like sequences resulting in incomplete protein translation 
(Cicek et al., 2013). Both PfE2 and PfaE3 contained several rare codons and PfaE3 also 
contained two Shine-Dalgarno-like sequences. Furthermore, P. falciparum proteins are 
usually larger than those from other species and contain long disordered stretches or loops 
(Pizzi and Frontali, 2001; Aravind et al., 2003). This is the case for both proteins studied 
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here, with PfE2 being about 8 kDa larger than other organisms and PfaE3 being on average 
12 kDa larger. Both proteins also contain longer unstructured loops than their counterparts 
from other organisms.        
 
To obtain recombinant protein in this study, extensive optimisation of parameters was 
carried out including codon optimisation, choice of expression plasmid and E. coli host 
strain, expression temperature and medium, and the amount of IPTG required for induction 
were varied. Regardless, the final protein yields were low but enough to carry out 
meaningful analyses. Average yields from 1 L of bacterial culture were 1.8 mg for His-
rPfE2m, 0.25 mg for His-rPfE2bc and 1.5 mg for His-rPfaE3.  
 
A few large-scale studies attempting heterologous expression of P. falciparum proteins in 
prokaryotic systems have been performed. These had the aim to generate recombinant 
protein for high throughput structural analyses potentially aiding drug discovery. The 
Structural Genomics of Pathogenic Protozoa group (SGPP, University of Washington) 
expressed 1000 P. falciparum open reading frames in E. coli (Mehlin et al., 2006). They 
successfully expressed 33.7 % of the genes but only 6.3 % of these generated soluble 
proteins with yields between 0.9 – 406.6 mg/L of bacterial culture (Mehlin et al., 2006). 
This just emphasises how variable and unpredictable the recombinant expression of 
proteins can be and that expressing P. falciparum proteins is particularly challenging. 
Upon closer analyses, a strong correlation of high isoelectric point (pI) was associated with 
poor expression of soluble recombinant protein; other factors such as size of the 
recombinant protein and greater structural flexibility were also contributing factors for low 
expression levels (Mehlin et al., 2006). The pI of a protein was found to be especially 
important for expression of soluble recombinant proteins. The theoretical pI of His-
rPfE2m, 6.1, falls within in the optimum range for recombinant expression, while both 
His-rPfE2bc and His-rPfaE3 have a high predicted pI of 9.0 and 8.6, respectively, which 
may have contributed to the poor expression levels I found. The pI of a protein is 
influenced by the presence of basic and acidic amino acids and it was shown that proteins 
that expressed well had high quantities of aspartic acid, glutamic acid and histidine and 
low levels of tyrosine, lysine and arginine (Mehlin et al., 2006). All three constructs 
studied here contained only 1.4 to 3.6% tyrosine and arginine residues, but they possessed 
9.9 to 13.2%  lysine residues. On the other hand, they contained few aspartic acid, glutamic 
acid and histidine residues (2.6-5.9 %), apart from His-rPfE2m which contained 7.4 % 
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aspartic acid and 9.1 % glutamic acid. Therefore, proteins with higher levels of acidic 
residues have lower pI values, which could contribute to the better expression levels.     
 
The estimated molecular masses of both His-rPfE2m and His-rPfaE3 (70 kDa and 64.5 
kDa) are in the category of >60 kDa, which may have a negative effect on expression 
efficiency - the SGPP study found that only 20 % of proteins larger than 60 kDa expressed 
at all and of these only 3 % were found to be soluble (Mehlin et al., 2006). This does not 
mean, however, that similar problems cannot be encoutnered with smaller proteins (Mehlin 
et al., 2006) and indeed His-rPfE2bc which has a predicted molecular mass of 34.5 kDa 
also showed a relatively low soluble expression. So the likelyhood is that other factors 
contribute to the poor expression levels I found for the proteins. For instance, PfE2 
contains highly disordered long linkers between the domains and PfaE3 has several longer 
loops between structured elements, all of which could play a role in the poor expression of 
the proteins.  
 
Another consortium (Structural Genomics Consortium SGC, Toronto, Canada), expressed  
400 P. falciparum genes and also assessed expression of orthologues of these from other 
apicomplexan parasites (P. yoelii, P. vivax, P. berghei, P. knowlesi, T. gondii and C. 
parvum) (Vedadi et al., 2007). From a total of 1008 genes, 30.2 % expressed as soluble 
proteins and this study concluded that protein size and pI did not correlate with expression 
levels, soluble expression and sucessful crystallisation of the proteins (Vedadi et al., 2007).  
 
Surprisingly, P. falciparum A/T content and codon bias was not shown to significantly 
affect expression (Mehlin et al., 2006; Vedadi et al., 2007). It could be reasoned that as 
codon optimisation would not change the amino acid sequence of the protein, it would not 
change the pI of the protein, thus it would not affect expression. However, there could be 
an effect of ribosome stalling due to limited availability of required amino acids, which 
could lead to errors and truncated proteins (Zhou et al., 2004; Birkholtz et al., 2008). 
Indeed, I found that truncated expression products were a problem in the expression profile 
of His-rPfaE3, which contained the endogenous gene. However, truncated expression 
products were also seen with the codon optimised His-rPfE2m. Several individual proteins 
have been expressed with better success by either codon optimising the whole gene or by 
co-expressing the gene in an E. coli strain with plasmids encoding for rare tRNAs (Baca 
and Hol, 2000; Zhou et al., 2004; Dobano et al., 2009; Evans et al., 2012). A recombinant 
PfE2m construct with the native sequence was not tested, thus it cannot be said whether 
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codon optimisation improved expression of His-rPfE2m. The codon optimised construct, 
His-rPfaE3-pET-15b, did not express soluble protein as well as the native construct, His-
rPfaE3. This, however, was more likely due to the codon optimised construct including 10 
more amino acids at the N-terminus than the native construct. All or some of the additional 
residues in the codon optimised construct were most likely part of the transit peptide, thus 
affecting the solubility of the recombinant protein. For His-rPfE2m expression with 
Rosetta™ 2(DE3)pLysS, which contains plasmids encoding rare tRNAs, was more 
successful but this was not the case for His-rPfE2bc of His-rPfaE3.  
 
Another method related to codon optimisation is codon harmonisation, which has 
successfully improved E. coli expression of P. falciparum vaccine candidate proteins 
including merozoite surface protein 8 (PfMSP8) (Alaro et al., 2012), the transmission 
blocking vaccine target Pfs48/45 (Chowdhury et al., 2009), liver-stage antigen 1 (LSA-1) 
(Hillier et al., 2005) and FALVAC-1, a recombinant protein encoded by a synthetic gene 
consisting of epitopes from various parasite life-cycle stages (Zhou et al., 2004). The 
frequency of a codon in an organism correlates with the amount of tRNA present, thus high 
frequency codons are translated faster than low frequency ones (Ikemura, 1981). Proteins 
begin their secondary structure formation already within the ribosomal tunnel during 
translation (Thanaraj and Argos, 1996). Therefore, the ribosome pausing at the low 
frequency codons is thought to regulate co-translational protein folding (Komar, 2009). 
Interestingly, high frequency codons are associated with the translation of -helix 
structures, while low frequency codons are preferred by -sheets and loops (Thanaraj and 
Argos, 1996). Hence, the placement of codons within an amino acid sequence is not 
random and codon harmonisation takes this into account. By substituting P. falciparum 
low frequency codons with E. coli low frequency codons and likewise for the high 
frequency codons, ribosomal processing can keep its native rhythm (Komar, 2009). Codon 
optimisation is more drastic and changes all the codons in the P. falciparum sequence, 
which are rare in E. coli, into codons that the host organism “prefers”; thus the ribosomal 
pauses required for correct folding may be lost. Therefore it may be worthwhile to codon 
harmonise the gene sequences encoding the recombinant proteins His-rPfE2m, His-
rPfE2bc and His-rPfaE3, which may have beneficial effects on the degree and levels of 
soluble expression in the prokaryotic system.  
 
Other methods used to improve soluble expression of recombinant P. falciparum proteins 
were to add large, highly soluble proteins as fusion-protein tags at the N-terminus of the 
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protein of interest. Proteins such as glutathione-S-transferase (GST) (Das et al., 2012), 
maltose binding protein (MBP) (Choveaux et al., 2012) or thioredoxin (TRX) (Xiao et al., 
2007) were used with some success.  The success-rate was between 5% and 16% when 
using MBP or GST-tagged constructs for the recombinant expression of P. falciparum 
proteins (Aguiar et al., 2004). In this thesis, expression of the catalytic domain (CD) of 
PfE2 was attempted using a fusion with GST. Expression of GST-rPfE2c improved over 
His-rPfE2bc, however, separation of the target protein, rPfE2c, from the GST fusion 
partner following cleavage of the fusion protein was not achieved. rPfE2c did not elute 
from the GST-FF purification column, suggesting rPfE2c has an affinity to the glutathione 
coated beads or that it interacts or aggregated with the cleaved GST and was thus retained 
on the column. This is not unusual as Tsunoda et al. (2005) also reported difficulties 
following cleavage of a range of fusion tags (GST, MBP, TRX, His-tag) including 
aggregation, degradation, incorrect folding and precipitation of the target protein. 
Therefore, as with the other optimisation methods, expression and purification of P. 
falciparum proteins using fusion constructs is not a universally successful method. In fact, 
a survey of 57 potential drug targets from the WHO TDR Targets database 
(http://tdrtargets.org) showed constructs with His-tags to express better than the other large 
fusion tags (Birkholtz et al., 2008). Thus, initial expression of a protein is worth testing 
first with His-tags rather than the more complex fusion proteins.  
 
In some cases, purification and refolding of recombinant protein from inclusion bodies can 
be achieved to take advantage of the insoluble expression fractions. The target protein is 
often quite pure in the inclusion bodies, high protein concentrations can be obtained and 
protein in inclusion bodies is protected from proteolysis (Jungbauer and Kaar, 2007). The 
major downside is that the correct refolding of the protein following isolation from the 
inclusion bodies using denaturing purification methods may not be successful. Protein 
refolding is a complex process through several intermediate conformations, which can 
aggregate and precipitate (Jungbauer and Kaar, 2007). However, Foth et al. (2005) did 
purify PfE2 CD using denaturing conditions followed by refolding of the protein and they 
obtained catalytically active protein, thus this method can be successful in some cases.   
 
It is apparent that there is no simple solution to optimising P. falciparum protein 
expression in E. coli as there does not seem to be a unified set of parameters applicable to 
all soluble expressed proteins. Size, pI, amino acid composition and protein disorder play a 
role in some of the proteins. Codon optimisation or harmonisation is suitable for some 
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while co-expression with plasmids containing additional rare tRNAs may improve soluble 
expression of others. Expression of P. falciparum proteins with fusion partners can be 
successful in some cases. A recent development improving expression has been the co-
expression the molecular chaperone, heat-shock protein 70, to aid correct folding of the P. 
falciparum recombinant protein (Stephens et al., 2011). To improve the yield of the 
proteins studied here, codon harmonisation and co-expression with molecular chaperones 
is something that could be done in the future. Expression in other organisms such as yeast 
(LaCount et al., 2009) and the baculovirus/insect cell system (Barfod et al., 2006; Withers-
Martinez et al., 2012) could be tried in the future as these have been proven successful for 
a number of P. falciparum proteins. Also the cell-free wheat germ protein expression 
system has been successful in some cases (Iwanaga et al., 2013).  
 
Improving expression yield is not the only aspect that would improve the final amount of 
protein. In this study, protein aggregation and degradation during purification were also a 
major problem. There are several co-solvents that can be added to protein solutions to 
prevent formation of aggregates. Chaotropic agents (e.g. MgCl2, CaCl2) interact with 
peptide groups and hinder protein-protein interactions thus preventing aggregates, while 
kosmotropes (e.g. Na2SO4, MgSO4, NaCl, KCl) help stabilise the native state of a protein 
(Bondos and Bicknell, 2003). Sugars, for example, glycerol can also stabilise proteins 
(Gekko, 1981). The reducing agents dithiothreitol (DTT) and -mercaptoethanol prevent 
formation of unwanted disulphide bonds thus inhibiting aggregation (Bondos and Bicknell, 
2003). Degradation on the other hand can be prevented by the addition of protease 
inhibitors during the protein extraction steps. EDTA is a metal chelator, which sequesters 
metals from metalloproteases, thus inhibiting them. Ideally during purification proteases 
will be separated form the target protein, thus eliminating proteolysis. Eliminating 
degradation due to other factors such as temperature and pH requires trial and error 
optimisation. A lot of aggregation and degradation was seen during purification of both 
His-rPfE2m and His-rPfaE3. This was partially improved by the addition of EDTA and 
increasing the concentration of NaCl. His-rPfE2bc was very unstable and precipitated at 
concentrations higher than 0.7-0.8 mg/ml even with the addition of EDTA, glycerol and 
DTT. All the protein constructs studied here were more stable when stored at 4C than at – 
20C. Further work could be done to potentially improve the stability of these proteins by 
screening several other co-solvents and additives.  
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6.2 P. falciparum dihydrolipoamide acetyltransferase  
 
6.2.1 Homology models of P. falciparum E2 domains show structural similarity to E2 
from other organisms  
 
To gain some insight into the structure of PfE2, homology models of the PfE2 domains 
were made using the I-TASSER server for protein structure and function predictions 
(http://zhanglab.ccmb.med.umich.edu/I-TASSER/, Zhang, 2008; Roy et al., 2010). I-
TASSER was chosen for the modelling as the server ranked first in the 10th critical 
assessment of techniques for protein structure prediction (CASP10) 
(http://predictioncenter.org/casp10/groups_analysis.cgi). 
 
The I-TASSER homology models of PfE2 domains were overall quite similar to structures 
from other organisms as evidenced by the low rms values (0.9-2.5Å). The P. falciparum 
first lipoyl domain (LD1) and the sub-unit binding domain (SBD) are more similar to those 
of the human E3BP, while the second lipoyl domain (LD2) and the catalytic domain (CD) 
were more similar to domains of bacterial counterparts. The residues on the P. falciparum 
SBD differ from those in other organisms, thus mutation studies would be an interesting 
future experiment to decipher which residues are involved in E1 and E3 binding. P. 
falciparum E2 is larger than several of its counterparts from other organisms. This is 
mainly attributable to longer linkers between the domains, especially the linker between 
LD2 and SBD, which is 37-56 amino acids longer than in E2 proteins from other 
organisms.  
 
A trimer homology model of the PfE2 CD was also generated based on the A. vinelandii 
and G. strearothermophilus crystal structures (Mattevi et al., 1993a, Izard et al., 1999). 
Residues that could potentially be involved in intra-trimer interactions were mapped (Fig. 
4-6). These residues are not conserved and most likely form different types of bonds in 
proteins from different organisms. The PfE2 residues in these regions include several 
polar, hydrophobic and charged amino acids that could form hydrogen bonds and 
electrostatic interactions, required to form the trimer structure.   
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6.2.2 P. falciparum E2 does not readily form a large core  
 
As in A. vinelandii and G. strearothermophilus (Mattevi et al., 1992a; Izard et al., 1999), 
P. falciparum E2 C-terminal residues form the 310-helix “ball”, which should interact with 
a “socket” formed in the neighbouring trimer (Fig. 4-7). Based on this observation, the 
protein should be well adapted to form the high molecular mass core as is found for E2 
from other organisms. Interestingly, however, His-rPfE2m and His-rPfE2bc do not seem to 
form the large E2 core readily. Fractionation of recombinant proteins by gel filtration 
resulted in the elution of several high molecular mass proteins, however, these were shown 
by AUC to be aggregates. An SV experiment on a concentration series of His-rPfE2m 
showed a main species with s   = 6.6 ± 0.1 S (33-40% of sample), which is likely to 
correspond to a trimer of the protein. In addition, a minor species with s   = ~10.4 S (4-8 
% of sample) was present at lower concentrations. This species may represent a hexamer 
of His-rPfE2m. However, the expected 24mer or 60mer that E2 of other organisms readily 
form (Willms et al., 1967; Danson et al., 1979; Bosma et al., 1984; Schulze et al., 1991b; 
Stoops et al., 1997; Lessard et al., 1998; Vijayakrishnan et al., 2010) was not detected. The 
only larger forms of His-rPfE2m that were detected were protein aggregates - a total of 31-
67 % of the sample. His-rPfE2bc, on the other hand, contained only one species with s  
= 4.5 ± 0.3 S and no aggregates.  
 
These sedimentation coefficients suggest the main species is a trimer, which was 
confirmed by SE determination of the molecular mass of the main species. This was on 
average 217 kDa for His-rPfE2m (monomer size 70 kDa) and 105 kDa for His-rPfE2bc 
(monomer size 34.6 kDa). Mature-length E. coli E2 core, which forms a 24-mer, has a 
sedimentation coefficient of 23.1 S, while the value for a truncated core with only the CD  
is 17.1 S (Willms et al., 1967; Schulze et al., 1991b). A. vinelandii mature-length and 
truncated CD cores, also 24-mers, have sedimentation coefficients of 20.8 S and 17 S, 
respectively (Bosma et al., 1984; Hanemaaijer et al., 1987). The truncated 60-mer G. 
stearothermophilus core is 27.4 S (Packman et al., 1984). The 60-mer potato mitochondrial 
PDC E2 had a sedimentation coefficient of 28 – 33 S depending on the concentration of the 
protein (Millar et al., 1999). 60-mer mature-length human E2/E3BP core, was 29.3 S, 
while a truncated core consisting of the CD was 27.5 S (Vijayakrishnan et al., 2010). No 
peaks corresponding to sedimentation coefficients as large as these were observed for His-
rPfE2m or His-rPfE2bc.  
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The SE studies, however, indicated that there could be a large core complex present in the 
His-rPfE2m sample. At the two highest concentrations used for this experiment, a 1.33-
1.53 MDa species made up 11-16% of the sample. This larger species could represent a 24-
mer, which theoretically should have a size of 1.67 MDa (based on the amino acid 
sequence). Interestingly, with decreasing concentrations of His-rPfE2m larger proteins 
species were observed with sizes of 2 MDa and 3.7 MDa, which potentially correspond to 
a 30-mer and a 60-mer, respectively. These large molecular mass species, however, were 
not detected in SV studies. One possibility for this could be the high rotor speed (49,000 
rpm) used in these experiments, which would sediment very large molecular mass species 
too fast for adequate analysis. Although, large aggregates with sedimentation coefficients 
above 40 S were seen in SV analyses at this speed as well. 
 
The trend of increasing molecular mass with decreasing concentration seen in the SE 
experiments indicates thermodynamic non-ideality of the protein. The elongated shape of 
His-rPfE2m affects the excluded volume of the protein, which in turn affects how the 
protein packs toward the base of the cell during an SE experiment. This further 
complicates the determination of the true molecular mass of the His-rPfE2m multimers. 
Thus, the stoichiometry of the potential larger core complex is inconclusive and will 
require further studies using alternative approaches.  
 
If PfE2 does in fact form a large core complex, it can be implied that the interaction, at 
least in vitro, is not very strong. The E2 proteins of other organisms form the large core 
structure very readily regardless whether it is investigated using a recombinantly expressed 
protein or a purified native protein (Willms et al., 1967; Danson et al., 1979; Bosma et al., 
1984; Schulze et al., 1991b; Stoops et al., 1997; Lessard et al., 1998; Vijayakrishnan et al., 
2010). The interactions required to form the large core between the E2 trimers involve two 
hydrogen bonds, thus it is a much weaker interaction than the intra-trimer interactions. 
This is thought to facilitate “breathing” of the core for optimum protein dynamics (Zhou et 
al., 2001a). Despite this apparently “weak” interaction, to dissociate the 60-mer E2 core of 
G. stearothermophilus, 2 M guanidine hydrochloride was necessary. After reversing this 
dissociation, the 60 mer reassembled without any precipitation of the proteins and the re-
folded protein retained its ability to bind E3 and was catalytically active (Lessard et al., 
1998). The 24-mer core of E. coli was also disassembled and it regained the correct core 
stoichiometry after refolding (Willms et al., 1967). A factor that could weaken the 
interaction between the P. falciparum trimers is that the “socket” into which the C-terminal 
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310-helix “ball” is inserted, is predicted to be formed by one less residue than in other 
organisms as the helix H3 is shorter than that of E2 proteins from other organisms (Fig. 
4.8). 
 
Low protein concentration was another factor considered, which could affect core 
formation. The highest concentrations at which His-rPfE2m and His-rPfE2bc were assayed 
were 3.5 and 0.5 mg/ml, respectively. However, large complexes in other organisms have 
been observed by SV and electron microscopy (EM) experiments even at concentrations as 
low as 0.1 – 0.8 mg/ml (Willms et al., 1967; Bosma et al., 1984). Thus, the His-rPfE2m 
and His-rPfE2bc concentrations were in a range in which larger cores can form. 
Nevertheless, further studies into the effect of protein concentration on core formation 
could be done in the future. As obtaining a higher concentration of His-rPfE2m is not 
possible, a “crowding experiment” may provide further insights into the structural 
peculiarities of rPfE2m. This would be achieved by expressing the protein with an iLOV-
tag (Light, Oxygen and Voltage), a fluorescent tag that can be spectrophotometrically 
tracked (Gawthorne et al. 2012). This recombinant protein would be mixed with a high 
concentration of another protein, for example, bovine serum albumin, to increase the 
general protein concentration of the solution. It is possible that the high protein 
concentration environment could encourage the interaction of iLOV-rPfE2m trimers with 
each other, hence resulting in the formation of the large protein core.    
 
The A. vinelandii PDC behaves slightly differently to the other complexes. The E2 forms a 
20.8 S core on its own, however, upon binding of E1 and E3 the core dissociates into 18 S 
species, whereas the PDC of E. coli has a sedimentation coefficient of 60 S (Willms et al., 
1967; Bosma et al., 1984). Determining the correct stoichiometry of the A. vinelandii 
complex was not as straight forward, as it was thought for years to be a 32-mer formed of 
eight tetramers (Bosma et al., 1984). Experimental errors in determining the molecular 
mass of the monomer E2 were cited as the reasons for the incorrect stochiometry, which 
was instead found to be a 24-mer by Hanemaaijer et al. in 1987. The smaller building-
block of the core was concluded to be a trimer once the crystal structure was solved 
(Mattevi et al., 1992a). Thus, upon binding of E1 and E3 the A. vinelandii E2 24-mer core 
dissociates into trimers. These trimer PDCs are functional with about 2-fold higher specific 
activity compared with the bovine E2/E3BP 60-mer core (Schulze et al., 1993; Yang et al., 
1997).  
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A small proportion of some E. coli PDC preparations have also shown an enzymatically 
active 19.8 S complex (Danson et al., 1979). Thus, if PfE2 was a trimer and did not form 
the expected larger core structure as other E2 proteins do, the protein still should have the 
ability to interact with E1 and E3 and form a functional PDC. Although the A. vinelandii 
E2 on its own forms a 24-mer core, the interactions were shown to be weaker than in other 
complexes as some dissociation into smaller units occurred even without the addition of E1 
or E3 (Bosma et al., 1984). Interestingly, the stoichiometry of the plant plastid E2 core is 
still unresolved as some dissociation occurs with this complex as well, resulting in broad 
variation in the measured molecular mass of the whole PDC (Camp and Randall, 1985; 
Olinares et al., 2010). It has been suggested, however, that based on the ~ 5 MDa of the 
main PDC species, which is similar to that of the mitochondrial PDC protein, that the plant 
plastid E2 is a 60-mer (Mooney et al., 2002; Olinares et al., 2010).     
 
Whether, in contrast with the trend observed for A. vinelandii, the addition of E1 and/or E3 
encourages PfE2 core formation will need to be assessed in future studies. In bacterial 
complexes it is thought that one E1 or E3 binds one SBD, however, recent studies with the 
human PDC have shown one E1 heterotetramer binds two E2 SBDs and one E3 dimer 
binds two E3BP SBDs (Smolle et al., 2006; Vijayakrishnan et al., 2010). Thus, addition of 
E1 and E3 could crosslink trimers to form a larger complex. Under some conditions the A. 
vinelandii PDC did form a large 52-60 S complex, which is comparable to the 
sedimentation coefficient of the E. coli PDC (Bosma et al., 1984). This large complex was 
only seen in fresh protein preparations after the addition of PEG 6000 or 10 mM MgCl2 or 
with increasing temperature (Bosma et al., 1984). Testing whether  the addition of these 
reagents affects the structure of His-rPfE2m and His-rPfE2bc would be a possibility, while 
increasing the temperature is not an option as both proteins are unstable at room 
temperature.  
 
 
6.2.3 The linker between the P. falciparum E2 CD and SBD is extended  
 
For the first time insights into the solution structure of an E2 trimer consisting of the CD 
and SBD has been obtained. Crystal structures have included only the CD and a portion of 
the linker, which in the bacterial structures extends over the neighbouring monomer in a 
hook-like conformation forming interactions thought to be involved in trimer formation 
(Mattevi et al., 1992a; Izard et al., 1999). In the human EM based CD structure, the linker 
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does not extend across in this manner (Yu et al., 2008b). In the homology model of His-
rPfE2bc, which is based on the bacterial structures, the extension of the linker across the 
neighbouring monomer places the SBD in a position in which interaction with E1 and E3 
would be sterically hindered (Fig. 4-9 and 4-10).  
 
The EOM solution structure of the His-rPfE2bc trimer suggests the presence of a flexible 
elongated linker that does not reach over the neighbouring monomer (Fig. 4-31). This is 
supported by E2 structures obtained from EM studies, where the linker also does not 
extend across the neighbouring monomer but reaches out from the first -helix of the CD 
(Zhou et al., 2001b; Gu et al., 2003; Yu et al., 2008b). From EM studies with G. 
stearothermophilus E2 in complex with E1 or E3, the length between the CD and the SBD 
was determined to be 75 - 95 Å (Milne et al., 2002; Milne et al., 2006). More constrained 
linker lengths of 50 – 80 Å were obtained from EM structures of mature-length human 
E2/E3BP and E1 bound yeast and bovine E2/E3BP (Zhou et al., 2001b; Gu et al., 2003; 
Yu et al., 2008b). The G. stearothermophilus linker is 35 amino acids while the eukaryotic 
linkers are about 40 residues, which if allowing a 3.5 Å length for each residue, could 
stretch up to ~ 122 Å and ~140 Å (Zhou et al., 2001b; Gu et al., 2003). That the observed 
linker length is shorter than this suggests the linker has structured elements, for example, 
the human, bovine and yeast EM structures all have a linker with a bend in it (Zhou et al., 
2001b; Gu et al., 2003; Yu et al., 2008b). The P. falciparum linker between the CD and 
SBD is 31 amino acids long, thus it could stretch up to ~108 Å. Nine of the representative 
EOM models include linkers with lengths of 30 – 45 Å, which compare well to the lengths 
reported for the human, yeast and bovine linkers. Only one of the models had a linker of 60 
Å. This suggests that the P. falciparum linkers have some structure to them as well and, in 
fact, a bend such as the one mentioned above can be seen in the EOM models (Fig. 4-31). 
Also, the estimated s

20,w
0  of 6.9 S for the compact homology model of His-rPfE2bc does 
not correlate with the experimental values. The average estimated sedimentation 
coefficients for the elongated EOM models was 4.6 ± 0.1 S, which does correlate very well 
with the experimental value of 4.5 ± 0.3 S for His-rPfE2bc, thus further validating this 
conformation.  
 
The linkers were not extended in EM structures of truncated cores with only the CD and a 
portion of the linker, thus it was suggested that E1 binding was required to lengthen the 
linker (Zhou et al., 2001a; Zhou et al., 2001b; Yu et al., 2008b). However, the results 
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shown here suggest that merely the presence of the SBD promotes extension of the linker. 
The longer linker lengths (50 - 95 Å) were obtained upon binding of E1, thus movement of 
the linkers seems to be required for PDC assembly and function (Gu et al., 2003). It would 
be very interesting to obtain solution structures for His-rPfE2bc with E1 and E3 to see the 
range of movement of which the linkers are capable of. The EOM structures grouped into 
two types of models, one with the linkers and SBD stretching out on the x/y-axis (Fig. 4-
31A), the other with the linkers pointing upwards on the z-axis (Fig. 4-31B). If the P. 
falciparum PDC functions as a trimer, this movement would not seem to be a problem. 
However, if the protein forms a larger core complex, the most likely conformation would 
be with the linkers pointed upwards in the z-axis, as seen in the E2 EM structures. Any 
other conformation will most likely cause steric hindrance in E1 and E3 binding. For this 
reason it would be interesting to observe the effect of E1 and E3 binding on the 
conformation and placement of the linker and SBD with respect to the E2 trimer.  
 
Some suggestions were made that E1 binds not only to the SBD but also to the CD 
(Schulze et al., 1991a). Interaction of the CD core with E1 would not support the results 
obtained here or the EM structures, as this would not allow the extended conformation of 
the linker (Zhou et al., 2001b; Milne et al., 2002; Gu et al., 2003). A mutation of A. 
vinelandii Arg416 in the CD (numbering based on A. vinelandii E2 sequence) to an 
aspartic acid weakened the binding of E1 and decreased the activity of the reconstituted 
PDC (Schulze et al., 1991a). E1 interaction with the CD, however, was not seen in 
proteolysis studies of the CD (Packman et al., 1984; Schulze et al., 1991b) or in a more 
recent mutagenesis study where Arg416 was replaced by a glutamic acid (Chandrasekhar 
et al., 2013). The role of the A. vinelandii CD-SBD linker was also probed by constructing 
a recombinant protein without the linker (Schulze et al., 1991a). The deletion did not affect 
core formation (Schulze et al., 1991a), thus the linker is not required to extend across the 
neighbouring monomer to form the core. E1 binding was lost, while E3 binding was not 
suggesting different binding sites for the two proteins. This does not mean that E1 
necessarily binds to the CD. The construct was made so that the SBD was still present 
which, without the linker, would be right on top of the E2 trimer, thus it could be that the 
residues required for E1 binding were not accessible. Complete loss of E2 activity was also 
seen in the linker deletion mutant, which is most likely due to the deletion including a part 
of the first -helix of the CD, which may be required for assembly of the E2 catalytic 
domain (Schulze et al., 1991a). In a study where only the A. vinelandii linker was deleted 
but the first -helix of the CD was left untouched, E2 catalytic activity was not lost, 
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neither was core formation (Schulze et al., 1993). The lack of the linker did destabilise the 
trimer causing monomerisation upon E1 binding (Schulze et al., 1993), however, again this 
could be due to the incorrect orientation of the SBD causing steric clashes resulting in 
monomerisation. If there is some interaction of E1 with the E2 CD, this could be a 
transient interaction required during PDC activity for correct substrate channelling. In 
conclusion, the linker does not need to extend over the neighbouring monomer for correct 
complex formation and activity. Thus, the extended linker model seen in this study and 
supported by the EM structures (Zhou et al., 2001b; Gu et al., 2003) is possible.  
 
 
6.2.4 Catalytic activity of His-rPfE2m and His-rPfE2bc is higher than that of human 
E2 
 
The specific activity of His-rPfE2bc (80 ± 4 Abs240mn/min/mg) was 2.7 times higher than 
that of His-rPfE2m (30 ± 0.9 Abs240mn/min/mg) (Table 3-3). This difference may well be 
attributable to the fact that the enzyme preparation (even after purification) of His-rPfE2m 
contains inactive protein aggregates and degradation products, thus resulting in a decreased 
number of functional PfE2 units. A similar difference was seen in A. vinelandii, where the 
truncated E2 CD core activity (117.9 Abs240mn/min/mg) was 1.5 times more active than 
the mature length protein (79.4 Abs240mn/min/mg) (Hanemaaijer et al., 1989; Schulze et 
al., 1991b). Compared with activity values reported by Foth et al. (2005) for the PfE2 CD 
(153.8 ± 16.2 Abs240mn/min/mg), His-rPfE2bc appears to be 1.9 times less active. 
Hanemaaijer et al. (1989b) reported a 1.6 times increase in A. vinelandii mature-length E2 
activity following denaturing and refolding of the purified protein, suggesting some 
incorrect folding of the protein during expression or purification. However, purification 
methods have advanced since the 1980s as now the use of affinity tags has simplified the 
purification of soluble protein without the use of several precipitation steps, which could 
affect correct protein folding. Foth et al. (2005) purified the recombinant PfE2 CD under 
denaturing conditions followed by refolding the protein. This may have removed 
interfering unfolded and aggregated protein species. However, the differences in specific 
activities observed in the two studies (this study and Foth et al., 2005) are not very large 
and may not be significant. However, denaturing purification is something that could be 
tried as several studies have denatured and refolded E2 successfully without losing activity 
or core formation ability (Willms et al., 1967; Lessard et al., 1998; Foth et al., 2005). 
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His-rPfE2bc activity was 4 times higher than that of the human E2 only core, 6.5 times 
higher than that of the bovine E2/E3BP core and 11 times higher than that of the G. 
stearothermophilus E2 core (Yang et al., 1997; Lessard et al., 1998, Table 3-3). The maize 
mitochondrial PDC E2 was the most active of all the organisms mentioned here, as it was 
6.3 and 2.3 times more active than His-rPfE2m and His-rPfE2bc, respectively (Thelen et 
al., 1999). The activity of the plant plastid E2 was measured with an assay different from 
the one used in this study, thus straightforward comparison with His-rPfE2m and His-
rPfE2bc activities is not possible. However, the plant plastid E2 activity values measured 
by following 14C-acetyl-CoA incorporation into acetyl-dihydrolipoamide, were similar to 
those for the human E2 and bovine E2/E3BP core (Yang et al., 1997; Mooney et al., 
1999). The activity of His-rPfE2bc was similar to that of A. vinelandii (Hanemaaijer et al., 
1989). This is interesting as A. vinelandii forms a functional trimer PDC. Apart from the 
maize mitochondrial PDC E2, the activities of both His-rPfE2bc and A. vinelandii E2 are 
higher than those for organisms that function as 60- or 24-mer cores. Also the activity of 
the E. coli E2 is higher than that of the other large core forming organisms, and 
interestingly E. coli E2 can dissociate into smaller functional trimer PDC units (Danson et 
al., 1979). Thus, it could be that if an E2 had to function as a trimer, the activity would 
need to be higher to assure adequate function of the complex. This would give further 
weight to the hypothesis that PfE2 functions as a trimer.   
 
Of the active site residues, His612 (P. falciparum full-length protein residue numbering) is 
the only strictly conserved amino acid. Ser561 is a serine in all other organisms apart from 
G. stearothermophilus, in which it is threonine, a residue with very similar properties to 
serine. His612 and Ser561 are the residues directly involved in the transfer of atoms in the 
catalytic reaction (de Kok et al., 1998). In A. vinelandii Asn614 and Asp508 (A. vinelandii 
residue numbering) form a hydrogen bond in the inactive enzyme, thus preventing CoA 
entering and binding the active site (Fig. 1-11). These residues are not conserved in other 
organisms. In P. falciparum the corresponding residues are Tyr616 and Gly511. In other 
organisms these are an aspartic acid and an alanine or serine, respectively. Whether Tyr616 
and Gly511 are important residues in the P. falciparum active site is something that could 
be further studied by mutational studies. It would be interesting to find out whether Tyr616 
formed a bond with Gly511 or if it in fact interacted with either lysine residue flanking 
Gly511, which would be much more receptive to hydrogen bonding. In any case, activity 
probably is not affected by which residues form the inactive state bond as the variation in 
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these two residues in different organisms does not correlate with their differing activity 
values.         
 
 
6.3 P. falciparum dihydrolipoamide dehydrogenase 
 
The homology model of PfaE3 shows the possible relative positioning of the FAD, NAD, 
central and interface domains (Fig. 4-32). The overall structure is unsurprisingly very 
similar to E3 proteins from other organisms with rmsd values ranging between 1.1.Å for 
the human E3 and 2.2 Å for the A. vinelandii E3. PfaE3 is on average 12 kDa larger than 
its counterparts from other organisms. This extra size does not affect the structured 
elements of the protein as the majority is accounted for by six longer loops (Fig. 4-33).  
 
SV analysis of His-rPfaE3 shows the presence of a main peak with s  = 6.1 ± 0.1 S, 
which accounted for 68-94 % of the protein in the samples studied. SE analysis confirmed 
this to be on average a 120 kDa dimer (His-rPfaE3 monomer size is 64 kDa). For 
comparison, the A. vinelandii E3 had a sedimentation coefficient of 5.9 S, while the values 
for human E3 range between 5.6-5.9 S (Hanemaaijer et al., 1987; Hiromasa et al., 2004; 
Smolle et al., 2006; Brautigam et al., 2009; Vijayakrishnan et al., 2010). A ~4.1 S 
degradation product, with a molecular mass corresponding to a truncated monomer (60-62 
kDa), accounted for 4-18 % of the samples. The degradation was thought to have occurred 
from the C-terminus, thus preventing dimerisation. Confirmation of this could be done by 
creating various PfaE3 constructs truncated from the C-terminus to see how many residues 
are required for dimerisation. In three out of six samples 2-9 % of the sample was 
accounted for by a ~8.8 S species. Following SE analysis to obtain molecular mass, these 
were concluded to be 233-238 kDa tetramers. 
 
The solution structure of His-rPfaE3 shows the structure to be more elongated than the 
homology model based on the crystal structure of E3 from other organisms (Fig. 4.41). As 
the protein is highly conserved the crystal structures are very similar and have Dmax values 
of approximately 110 Å (Chandrasekhar et al., 2013). The Dmax of His-rPfaE3 determined 
from the distance distribution function, p(r), was 133 Å, while the Dmax of the final ab 
initio model was 146-149 Å. An elongated, more flattened E3 with a Dmax of 130 Å has 
also been observed for the human E3 (Smolle et al., 2006). Also, the sedimentation 
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coefficients suggest a less compact and elongated protein as the s  computed for the His-
rPfaE3 homology model was 7.35 S, which is much higher than the experimentally 
obtained values for His-rPfE3 (6.1 ± 0.1 S). Surprisingly, however, the computed 
sedimentation coefficient for the DAMMIF model, 6.8 S, was still higher than the 
experimental value even though the shapes of the models are more elongated. The long 
loops and flexible regions between the domains of PfaE3 could affect protein 
sedimentation and thus lower the experimental sedimentation coefficient. Flexibility of a 
protein can result in an incorrect DAMMIF model leading to the higher computed 
sedimentation coefficient, thus EOM and DMD were used to model the flexible His-tag at 
the N-terminus of His-rPfaE3. This flexible region did seem to account for some of the 
empty space in the DAMMIF model (Fig. 4-44). However, the short 14-amino acid N-
terminus region was not substantial enough to cause a decrease in the computed 
sedimentation coefficient (7.0 – 7.3 S). Thus, the extended and less compact structure of 
His-rPfaE3 could to be due to loops between the domains, which would need to be 
modelled in the future.  
 
The active site of PfaE3 consists of the same conserved residues as in all other organisms; 
the two cysteines (Cys165 and Cys170), His646 and Glu 651 (Fig. 4-34). In the reverse 
reaction, NADH and lipoamide Km and Vmax values for His-rPfaE3 (Table 3-5) were 
comparable with those reported previously (McMillan, 2006). The values are similar to 
those for the P. falciparum mitochondrial E3 (PfmE3) and other organisms (Kim et al., 
1991; Schöneck et al., 1997; McMillan et al., 2005). The kcat of the reverse reaction for the 
apicoplast was determined to be 10 times lower than that for PfmE3 (McMillan, 2006). 
The plant chloroplast E3 was also shown to be 5 times less active than the mitochondrial 
counterpart (Conner et al., 1996). In this study, the Km and Vmax values for the forward 
reaction substrates NAD+ and DHLA were also determined. The affinity of His-rPfaE3 for 
DHLA was 8 times lower than that for the mitochondrial E3, while the affinity for NAD+ 
was about 5 times higher. A 6-fold higher affinity for NAD+ has also been reported for the 
Pisum sativum chloroplast E3 compared with its mitochondrial E3 (Conner et al., 1996). It 
was also shown that, unlike the mitochondrial E3, the chloroplast protein did not show any 
activity with NADP+ (Conner et al., 1996). It was concluded that low NADP+ activity was 
required because, unlike in the mitochondrion, the levels of NAD(H) are lower than those 
of  NADP(H) in the chloroplast stroma, thus requiring higher affinity of the chloroplast E3 
to NAD+ (Conner et al., 1996). Whether His-rPfaE3 is active using NADP+ is something 

20,w
0
Chapter 6 Discussion 
 
 
 
226 
that needs to be tested to further understand the environment in which the apicoplast PDC 
functions.    
 
 
6.4 E2 and E3 gene deletion from P. falciparum 
 
Gene manipulation in P. falciparum is very challenging due to the A/T rich genome 
resulting in difficulty with PCR generation of inserts for the knockout plasmids. Also 
transfection of P. falciparum is of very low efficiency, in the order of 1 in 106 (O'Donnell 
et al., 2002), which makes obtaining transfectants time consuming. The low efficiency is 
likely due to the fact that transfection can only be done with ring stage parasites, thus the 
DNA has to cross four membranes (erythrocyte membrane, parasitophorous vacuole, 
parasite cell membrane, nucleus) before being able to integrate into the genome. In this 
study positive/negative drug selection using the pCC1 plasmid was used to obtain deletion 
of the target gene with double crossover recombination (Maier et al., 2006).  
 
Deletion of PfE2 from P. falciparum was unsuccessful as the correct gene locus was not 
targeted. The PfE2 gene contains 10 A/T rich introns, thus designing the gene deletion 
cassette was very difficult. The pCC1-PfE2 construct was intended to delete 1941 bp 
from the centre of the 3192 bp PfE2 gene. It could be that this deletion was too short for 
specific targeting of the PfE2 locus. Also the flanks used for targeting the gene could have 
been too short for specific targeting of PfE2. Flanks up to 1000 bp could be tried in future 
experiments. However, the failed attempt to delete PfE2 could also be because the gene is 
required for P. falciparum survival and thus could not be targeted. Further attempts to 
delete PfE2 will be made using a different approach with the recently published DiCre 
system, which allows inducible excision of genes from the P. falciparum genome (Collins 
et al., 2013).  
    
The deletion of the PfaE3 was successful, thus the PfaE3 protein is not essential for P. 
falciparum erythrocytic stages implying that PDC is not essential for these parasite stages. 
However, interest in potential other roles of PfaE3 in the parasite warranted further 
investigation of the parasite line. 3D7pCC1-∆PfaE3 showed a growth phenotype, which was 
unexpected. The mutant parasites progressed through their erthrocytic cell cycle slower 
than the WT 3D7 parasites. Also, 3D7pCC1-∆PfaE3 remained highly synchronous for 3 cycles 
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(7 days), while wild type 3D7 parasites lost synchronicity after 2 cycles (4 days). The 
deletion of E1 or E3 in P. yoelii did not affect growth of blood stage parasites in mice (Pei 
et al., 2010). It is possible that experimental differences caused the mild phenotype 
observed here while this was not obvious in the mouse model. This is reminiscent of the 
varying observations of the growth phenotype of a variety of gene deletions in P. 
falciparum and mouse malaria species. The deletion of lipB in P. falciparum resulted in a 
shorter cell cycle phenotype (the mutant parasites progressed about 8 hours faster through 
the intra-erythorcytic cycle than the wild type parasites), which was not seen in the P. 
berghei lipB deletion mutant (Günther et al., 2007; Falkard et al., 2013). Deletion of the 
FAS II enzymes FabI, FabB/F and FabZ did not show any effect on P. falciparum intra-
erythrocytic growth in vitro or P. yoelii growth in vivo (Yu et al., 2008a; Vaughan et al., 
2009). Thus, it could be that the growth phenotype seen in this study (and the lipB study) is 
due to an effect other than disruption of PDC and independent of FAS II. Acetylation is a 
major posttranslational modification, which is involved in and regulates a vast range of 
cellular processes including the cell cycle (Choudhary et al., 2009). Thus, potentially a 
decrease in acetyl-CoA levels followed by reduced acetylation of proteins involved in the 
regulation of the cell cycle could cause the growth phenotype. In any case, the growth 
assay will need to be repeated and further studies on the 3D7pCC1-∆PfaE3 mutant will be 
carried out to better understand the effect PfaE3 deletion is having on the parasites.  
 
Susceptibility of the 3D7pCC1-∆PfaE3 mutant lines was tested against oxidative stressors and 
the FASII inhibitor triclosan. Susceptibility to the oxidative stressors, BSO and paraquat, 
did not differ from that of the 3D7 WT lines. BSO inhibits the glutathione synthesis 
pathway, a major redox balance mechanism in the cytoplasm (Patzewitz et al., 2012) and 
paraquat is a general ROS producer. Thus, reducing equivalents from the apicoplast, which 
is separated from the cytosol by four membranes, would most likely not have a significant 
effect on combating oxidative stress in the cytoplasm caused by these agents. Thus, PfaE3 
does not play a role in oxidative defence of the organelle. A significant increase (P< 0.001) 
in resistance to triclosan was determined in the 3D7pCC1-∆PfaE3 mutants. It has been shown 
that FabI is not the only target for triclosan and that the drug may also have an effect on for 
instance parasite membranes (Paul et al., 2004; Yu et al., 2008a). Why the 3D7pCC1-∆PfaE3 
mutants would be more resistant to triclosan is unclear. Due to time constraints, these 
experiments were done only once, therefore before launching into further speculation, the 
experiments need to be repeated to verify whether the difference is truly significant or not.  
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6.5 Conclusions and future perspectives 
 
Expression of soluble P. falciparum protein is challenging and purification of native or 
recombinant proteins can be taxing due to instability of the proteins or simply the 
availability of sufficient biological materials when working with native proteins. In this 
study several methods were employed to improve expression of recombinant proteins and 
their purification to allow subsequent structural analyses. Plasmodium gene sequences 
were E. coli codon optimised, cloned into various expression vectors, grown in a range of 
E. coli host strains at different temperatures, in different growth media for various time 
periods and at various IPTG concentrations. In addition the length of the expressed 
proteins was varied to improve their expression and purification. Improving purification of 
the recombinant proteins was assessed by supplementing buffers with several additives 
known to prevent degradation and aggregation such as EDTA, glycerol and DTT. Overall, 
this resulted in the successful expression, purification and concentration of the mature-
length P. falciparum E2, His-rPfE2m up to a yield of 1.8 mg//L of bacterial culture. The 
truncated E2, His-rPfE2bc, containing the CD and SBD could be obtained only at 0.25 
mg/L of bacterial culture due to instability of the protein. For mature-length P. falciparum 
E3, His-rPfE3, maximum final yield was 1.5 mg/L of bacterial culture. Due to extensive 
optimisation of expression in the E. coli host performed here, the next steps to improve this 
would be to try other expression systems. These could include expression in yeast, insect 
cells or the wheat germ cell-free system (Barfod et al., 2006; LaCount et al., 2009; 
Iwanaga et al., 2013). It would be interesting to obtain His-rPfE2bc at higher 
concentrations so that crystallisation could be attempted. A more stable mature-length P. 
falciparum E2, which does not aggregate, would enable interesting SAXS studies on the 
mature length trimer to complement results obtained for His-rPfE2bc. Also a more stable 
E3 construct would be useful in crystallisation studies.  
 
The most interesting finding of this study was that P. falciparum E2 does not readily form 
a large 24-mer or 60-mer core as seen for E2 proteins of other organisms. Some indication 
of a larger complex was seen in SE experiments with the mature-length PfE2, however, 
these larger species were not observed in SV experiments. Also, no indication of a larger 
complex was seen with the truncated His-rPfE2bc. Both native and recombinant E2 from 
bacteria, yeast, bovine and humans form the large central core even at concentrations 
below 1 mg/ml and even after denaturing and refolding (Willms et al., 1967; Danson et al., 
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1979; Bosma et al., 1984; Schulze et al., 1991b; Stoops et al., 1997; Lessard et al., 1998; 
Vijayakrishnan et al., 2010). Additional studies need to be done to further probe this. One 
option is to perform a “crowding experiment”, where PfE2 is placed into a high protein 
concentration environment to see whether this would increase the affinity of E2 trimers for 
each other and drive core formation. Another possibility would be to attempt purification 
of native PfE2 from the parasites. This would be difficult as the PDC proteins are 
expressed only at low levels during the erythrocytic stages, thus large amounts of parasites 
are required to obtain sufficient starting material for purification. The Müller lab does have 
an antibody reactive with PfE2, which will be used to immunoprecipitate the protein from 
parasite extracts. Using this protein it may be possible to determine the stoichiometry of 
PfE2 using native PAGE or mass spectrometry. Also EM could be carried out to obtain 
images of the PfE2 core. Another advantage when working with the native E2 protein is 
that the protein may have E1 and E3 bound to it, thus enabling the study of the full native 
PDC complex in structural and kinetic studies. Another experiment that will be performed 
in the future is to assess whether the addition of E3 affects E2 core formation. The effect of 
both E1 and E3 will require the expression and purification of the two E1 subunits. This is 
likely to be complicated by the fact that E1 is formed by two subunits of E1- and two 
subunits of E1-domains, which probably need to be co-expressed to generate the fully 
active and properly folded E1-protein. But if this can be achieved, studies can be done to 
elucidate the whole P. falciparum PDC function. 
 
The lack of large core formation permitted, for the first time, the acquisition of solution 
structural information for an E2 trimer was obtained. The PfE2 SBD is separated from the 
CD by a 30 – 45 Å linker, which correlates well with EM studies that show a 50 – 80 Å 
gap between the CD and bound E1 in the yeast, human and bovine complexes (Zhou et al., 
2001b; Gu et al., 2003; Yu et al., 2008b). The linker in these organisms is approximately 
10 residues longer, which could account for the shorter gap between the P. falciparum CD 
and SBD. Also the binding of E1 or E3 could further extend the linker (Gu et al., 2003). 
This is in contrast to the bacterial crystal structures, where a major portion of the linker 
extends over the neighbouring monomer and is thought to be involved in intra-trimer 
interactions. However, mutation studies have shown that the linker does not need to extend 
over the monomer for core formation or activity (Schulze et al., 1993). Also the 
sedimentation coefficient of His-rPfE2bc supports the extended linker model and not the 
compact homology model based on the crystal structures of E2 from other organisms. In 
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the future it would be very interesting to carry out SAXS experiments with added E1 and 
E3 to see how the linker dynamics are affected.   
 
The first major difference between P. falciparum and human E2 is that the human E2 core 
is formed of trimers comprising two E2 monomers and one E3BP or three E2 monomers 
(Vijayakrishnan et al., 2010; Vijayakrishnan et al., 2011). P. falciparum does not possess 
E3BP and therefore forms trimers with three E2 monomers. A further important difference 
may be the lack of multimer formation beyond a trimer implying that PfE2 may be 
catalytically active as a trimer, which suggests that PDC in the parasite apicoplast has a 
very divergent structure to those of other PDCs. But even if a large multimeric core was 
formed, it still would seem that dissociation into the trimeric building blocks may occur 
readily – thus the structure of the PDC core may well be much less stable than that of, for 
example, the human enzyme. If this were indeed the case, it would lead to exposure of 
protein surface that may be exploited in drug discovery especially as in the human PDC 
equivalent areas would be buried inside the core.  
 
It appears that the PfE2 trimer is more active than its human counterpart, and interestingly 
has an activity similar to that of A. vinelandii E2, which was shown to function as a trimer 
PDC (Hanemaaijer et al., 1989). Whether there is a correlation between higher E2 activity 
and full PDC activity would need to be studied. The A. vinelandii trimer PDC is twice as 
active as the bovine E2/E3BP 60-mer core (Schulze et al., 1993; Yang et al., 1997), thus it 
could be that a trimer P. falciparum PDC would also be more active than its mammalian 
60-mer counterparts. The residues involved in catalytic activity, His612 and Ser561 (full-
length PfE2 numbering), are conserved between the parasite and human proteins. 
However, the two residues thought to be involved in a hydrogen bond to form the inactive 
state conformation, Tyr616 and Gly 511, are an aspartic acid and serine in human E2. A 
drug that would prevent the conformational change required for the formation of the active 
catalytic site in P. falciparum but not in the human enzyme could be a possibility. Residues 
in helix H1 of the E2 CD are also required for correct active site formation (Schulze et al., 
1991a). This is something that could be further studied with mutational studies, as these 
residues are not conserved between organisms and could differ enough to be exploited in 
drug development.  
 
The final interesting difference is the binding of E1 and E3. Human E3BP binds E3 and the 
E2 SBD binds E1. In P. falciparum the E2 SBD binds both E1 and E3. In the P. 
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falciparum SBD homology model the amino acids in the positions of residues known to be 
involved in G. stearothermophilus E1 and E3 binding are very different (Mande et al., 
1996; Jung et al., 2003; Jung and Perham, 2003; Frank et al., 2005, Fig. 4-3, Table 4-1). 
This suggests P. falciparum may have a different mechanism of binding the peripheral 
enzymes. Furthermore, several residues involved in E3 binding to E3BP are very different 
to the P. falciparum residues (Brautigam et al., 2006; Ciszak et al., 2006, Table 4-2). Also 
the E2 amino acids involved in human E1 binding are thought to be similar to the G. 
stearothermophilus residues (Korotchkina and Patel, 2008). Thus, future structural and 
mutational studies of PfE2 binding of E1 and E3 would be very worthwhile as a sufficient 
difference in binding the two proteins could also be exploited in inhibiting P. falciparum 
PDC activity.     
 
As expected, PfaE3 is a homodimer as in other organisms. Its hydrodynamic parameters 
and solution structure showed that the shape of the protein is more elongated and it is not 
as compact as homology models based on crystal structures of E3 from other organisms. 
The more elongated shape of PfaE3 has also been observed for human E3 and is supported 
by SV values obtained for proteins of other organisms (Hanemaaijer et al., 1987; Hiromasa 
et al., 2004; Smolle et al., 2006; Brautigam et al., 2009; Vijayakrishnan et al., 2010). 
PfaE3 is approximately 12 kDa larger than human E3. However, the extra size is 
distributed in loops rather than the structured elements of the protein, thus the homology 
model of PfaE3 actually had the highest similarity to the human protein (rmsd = 1.1 Å). 
Crystallisation of PfaE3 could be attempted with the protein concentrations that can 
already be obtained. PfaE3 is less active than either its mitochondrial counterpart or human 
E3 (Kim et al., 1991; McMillan, 2006). PfaE3 also has a higher affinity for NAD+ than the 
P. falciparum mitochondrial E3 or human E3 (Kim et al., 1991; McMillan, 2006). Whether 
this is something that could be exploited for drug development needs to be assessed in 
further studies. Although designing a drug that would be specific to PfaE3 would most 
likely be difficult due to the high structural similarities not only to the homologous protein 
in the human host but also the structural and functional similarlty of E3 to other NAD(P)H 
dependent FAD disulphide oxidoreducatses (Petsko, 1991; Perham et al., 1996; 
Chandrasekhar et al., 2013). 
 
Much more work will need to be done to characterise the 3D7pCC1-∆PfaE3 mutants and it 
would be interesting to try an alternative strategy to delete PfE2 from the parasites. If PfE2 
is truly essential to the parasite, questions arise why PfE2 is required but PfE3 is not. One 
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possibility could be that another oxidoreductase or a related reducing enzyme was 
substituting the function of PfE3. For example, a glutathione reductase and a glutathione 
peroxidase-like thioredoxin peroxidase have been shown to be targeted to the apicoplast 
(Kehr et al., 2010).    
 
Manipulating the P. falciparum genome is difficult and very time consuming, thus the 
3D7pCC1-∆PfaE3 mutants were obtained only at the very end of laboratory work, and hence 
only a few selected assays were carried out once. The growth assay will need to be 
repeated to verify the interesting growth phenotype. Additionally a growth assay with 
shorter time points over two cycles would be useful to pin point the stage which causes the 
slower growth of the mutant parasites. Also the number of merozoites produced by the 
3D7pCC1-∆PfaE3 mutants compared with the wild type could be counted to see whether the 
lower multiplication rate is due to fewer merozoites being produced. The susceptibility test 
that implies a greater sensitivity to triclosan needs to be repeated. To further probe the role 
of the PDC in the blood stages, the parasites could be grown in media without fatty acids to 
see whether the mutant parasites will survive when fatty acids are not readily available 
from the medium. Targeted metabolomics will be carried out with the mutant parasites to 
study the effects that the deletion of PfaE3 might have on parasite metabolism. It would be 
particularly interesting to assess the levels of acetyl-CoA, and to analyse whether 
compensatory reactions are induced through the removal of the PDC activity.  
 
This study on P. falciparum E2 and E3 has uncovered fascinating aspects of the PDC, 
which could substantially differ from the human complex, thus making the PDC a 
candidate drug target. This work provdes a fantastic starting point and platform from which 
to continue further dissection of not only the interesting stoichiometry and assembly of the 
complex but the role of the PDC in P. falciparum and other Plasmodium parasites.   
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